standard_type,standard_units,count,activity_direction
Potency,nM,4471741,-1
GI50,nM,2612253,-1
IC50,nM,2530782,-1
Inhibition,%,1529105,1
Percent Effect,%,1328366,1
Ki,nM,650568,-1
Activity,,625329,0
MIC,ug.mL-1,608019,-1
Activity,%,560776,1
EC50,nM,487170,-1
INHIBITION,%,339133,1
AC50,nM,232772,-1
IC50,,192954,-1
Kd,nM,179228,-1
Z score,,147592,0
Ratio IC50,,135452,-1
Tissue Severity Score,,128999,0
Ki,,123897,-1
MIC,nM,114529,-1
Ratio,,114411,0
GI,%,101853,1
IZ,mm,90853,1
CC50,nM,89561,-1
T1/2,hr,84488,1
IC50,ug.mL-1,77190,-1
Residual Activity,%,73944,1
FC,,63132,0
Stability,%,53591,1
ED50,mg.kg-1,51862,1
% Control,%,50544,1
LC50,nM,47192,-1
AC50,,45407,-1
TGI,nM,43111,-1
CL,mL.min-1.kg-1,42622,-1
Ratio Ki,,42544,0
Growth Rate,,36972,0
AUC,ng.hr.mL-1,35822,0
Emax,%,35061,1
Solubility,nM,30200,0
F,%,29793,1
LogD,,29075,0
MIC90,ug.mL-1,27769,-1
Solubility,ug.mL-1,26380,0
GI,,26250,-1
MIC50,ug.mL-1,25072,-1
CL,mL.min-1.g-1,24405,-1
Cmax,nM,24217,0
Control DMSO Tubulin Phenotype Different Cells (%),%,22607,1
Population Membrane Permeable-Phenotype (%),%,22607,1
Population Mitotic Cells (%),%,22607,1
Population Mitochondria Different-Phenotype (%),%,22607,1
Control DMSO Pyknosed Nuclei (%),%,22607,1
Population Normal (%),%,22607,1
Control DMSO Mitotic Cells (%),%,22607,1
Population Tubulin-Different-Phenotype (%),%,22607,1
Control DMSO Mitochondria Different-Phenotype Cells (%),%,22607,1
Population Pyknosed Nuclei (%),%,22607,1
Control DMSO Membrane Permeable-Phenotype Cells (%),%,22607,1
Control DMSO Healthy Nuclei (%),%,22607,1
Population Healthy Nuclei (%),%,22607,1
Control DMSO Fragmented Nuclei %,%,22607,1
Population Fragmented Nuclei (%),%,22607,1
Population Apoptotic (%),%,22607,1
Population Hoechst High Intensity Objects (%),%,22607,1
Total Cell Count,,22607,0
Biotransformation,,22306,0
Ratio EC50,,21600,0
Efficacy,%,21569,1
Selectivity Index,,21340,0
Selectivity ratio,,20974,0
Ratio CC50/EC50,,20423,-1
LogP,,20279,0
LUCIFERASE INFECTION ASSAY - IC90,uM,19978,-1
LUCIFERASE EXPRESSION CONTROL - IC50,uM,19978,-1
LUCIFERASE EXPRESSION CONTROL - IC90,uM,19978,-1
LUCIFERASE INFECTION ASSAY - IC50,uM,19978,-1
HEPG2TOX ASSAY - CC90,uM,19978,-1
HEPG2TOX ASSAY - CC50,uM,19978,-1
Delta TM,C,19246,-1
IFI,%,19230,1
MIC,,19032,-1
EC50,,18930,-1
WEIGHT,g,18871,0
Drug metabolism,,16980,0
TIME,hr,16768,1
Delta Tm,degrees C,16667,-1
mortality,%,16386,1
ED50,ug ml-1,16163,-1
EC50,ug.mL-1,15074,-1
Vdss,L.kg-1,14765,0
MIC80,ug.mL-1,14598,-1
Survival,%,14294,1
PPB,%,13695,1
XC50,nM,13587,-1
Tmax,hr,13103,0
Drug uptake,,13005,0
Fu,,12990,0
Ratio CC50/IC50,,12909,-1
%Inhib (Mean),%,12829,1
Drug uptake,% ID/g,12663,1
ED50,uM,12659,-1
pKa,,12609,0
MBC,ug ml-1,12226,-1
Control DMSO Total Cells,,12143,0
Activity,uM,11992,0
T/C,%,11858,1
Selectivity,,11179,0
Control DMSO Growth Rate,%,10464,1
Control DMSO Apoptotic Cells (%),%,10464,1
Control DMSO Total Cells,%,10464,1
% of control,%,10334,1
ED50,umol.kg-1,9751,-1
IC90,nM,9538,-1
Km,nM,9415,-1
Thermal melting change,degrees C,9183,1
PHOS,ug.mL-1,8646,0
BUN,ug.mL-1,8646,0
CHOL,ug.mL-1,8646,0
GLUC,ug.mL-1,8646,0
ALB,ug.mL-1,8646,0
CREAT,ug.mL-1,8646,0
MCV,fL,8645,0
RBC,cells.uL-1,8645,1
HCT,%,8645,1
PROT,ug.mL-1,8645,0
WBC,cells.uL-1,8644,1
MCH,pg,8642,1
HGB,ug.mL-1,8642,1
SODIUM,mEq.L-1,8642,0
POTASSIUM,mEq.L-1,8642,0
Drug metabolism,%,8636,1
Change,%,8629,1
PLAT,cells.uL-1,8626,1
MONOLE,%,8615,1
LYMLE,%,8615,1
BASOLE,%,8615,1
EOSLE,%,8615,1
NEUTLE,%,8615,1
BILI,ug.mL-1,8565,0
Ac50,uM,8340,-1
CLH,uL/min,7772,-1
solubility,,7707,0
Control,%,7387,1
MIC90,nM,7163,-1
%Max (Mean),%,7141,1
Imax,%,7022,1
DIZ,,6847,1
LD50,mg.kg-1,6838,-1
TI,,6751,0
%max,%,6658,1
Reduction,%,6318,1
MED,mg kg-1,6227,1
GI50,ug.mL-1,6197,-1
MFC,ug ml-1,6196,-1
Kb,nM,6004,-1
CC50,ug.mL-1,5696,-1
Activity,ug ml-1,5529,1
TGI,%,5466,1
Activity,g,5225,1
ILS,%,5215,1
GI50,,5186,-1
Intrinsic activity,,5152,1
APTT,s,5112,-1
FICI,,4947,-1
Kd,,4928,-1
ID50,uM,4911,-1
Relative potency,,4872,0
PT,s,4868,0
GGT,IU.L-1,4773,1
ALT,IU.L-1,4773,1
Cl,meq/L,4773,0
CALCIUM,ug.mL-1,4773,0
TERMBW,g,4773,0
LDH,IU.L-1,4773,1
TRIG,ug.mL-1,4773,0
AST,IU.L-1,4773,1
PHOSLPD,ug.mL-1,4773,0
ALBGLOB,,4773,0
ALP,IU.L-1,4773,1
RETIRBC,%,4773,1
MCHC,%,4773,1
pKb,,4772,-1
BILDIR,ug.mL-1,4749,0
ID50,mg.kg-1,4698,-1
FIBRINO,ug.mL-1,4637,0
LogD7.4,,4557,0
Papp,10'-6 cm/s,4553,0
AbsAC40_uM,uM,4490,-1
Vd,L.kg-1,4489,0
MRT,hr,4415,0
Papp,ucm/s,4244,0
TC50,uM,4182,-1
Retention_time,min,4101,0
% of inhibition,%,4072,1
permeability,10'-6 cm/s,4009,0
Selectivity index,,3971,-1
MST,day,3962,1
log2FC,,3941,1
Hepatotoxicity,,3929,-1
MIC>99,uM,3921,-1
MCHC,ug.mL-1,3876,0
ALP,U.L-1,3873,1
ALT,U.L-1,3873,-1
AST,U.L-1,3873,-1
CHLORIDE,mEq.L-1,3869,0
CC50,,3844,-1
-logMIC,,3840,-1
IZ,,3803,1
Papp,10^-6 cm/s,3801,0
CK,U.L-1,3716,0
ID/g,%,3716,1
CLogP,,3694,0
RBA,,3598,-1
Emax,,3564,1
LD50,uM,3511,-1
EC90,uM,3500,-1
LIPASE,U.L-1,3460,0
URATE,ug.mL-1,3459,0
LDH,U.L-1,3438,1
Activity,mmHg,3398,0
CO2,nM,3370,0
ED50,nM,3362,-1
MIC99,ug ml-1,3359,-1
Activity,mg/dl,3357,0
INH,uM,3347,-1
Ke,nM,3343,-1
BASO,cells.uL-1,3331,1
RBA,%,3316,1
Drug uptake,%,3312,1
MONO,cells.uL-1,3307,-1
EOS,cells.uL-1,3307,1
LYM,cells.uL-1,3307,1
MIC50,nM,3301,-1
t1/2,,3256,-1
permeability,nm/s,3246,0
NEUTSG,cells.uL-1,3201,1
ED50,,3181,-1
Intrinsic activity,%,3169,1
Cp,ng/ml,3167,0
Cp,uM,3158,-1
BPR,,3119,0
T/C,,3113,1
RBCNUC,/100WBC,3111,0
ID50,ug ml-1,3106,-1
MCC,nM,2908,-1
CI,,2837,0
LC50,ug.mL-1,2817,-1
permeability,10^-6 cm/s,2781,0
Activity,nM,2774,-1
AbsAC35_uM,uM,2740,
Decrease,%,2725,
Papp,nm/s,2693,
% Ctrl,%,2684,
MBC,uM,2669,
Activity,mg,2630,
RatioGI50,,2624,
MIC100,ug ml-1,2579,
permeability,ucm/s,2572,
Tm,degrees C,2565,
PD50,mg kg-1,2507,
MIC99,uM,2502,
Drug uptake,%ID,2501,
Activity,mm,2493,
Drug uptake,uM,2485,
Toxicity,,2460,
TD50,mg kg-1,2407,
IC95,nM,2406,
% Cell Death,,2400,
Kcat,/s,2366,
MIC80,nM,2358,
Activity_index,,2312,
Relative activity,,2308,
Residual activity,%,2283,
Log 1/C,,2270,
Diet,%,2246,
pD2,,2234,
Protection,%,2221,
MCC,ug.mL-1,2220,
permeability,,2167,
DOSE,mg.kg-1,2131,
CLH,,2117,
Activity,mg kg-1,2054,
Drug uptake,ng/g,2030,
EC90,nM,2016,
pIC50,,2013,
Activity,s,2010,
MIC,10'-2 umol/ml,1986,
Ratio,/M/s,1985,
Activity,pg/ml,1959,
Efficacy,,1949,
Survivors,,1945,
log(1/C),,1938,
log(activity),,1935,
MIC95,uM,1929,
IC90,ug.mL-1,1862,
Survival,day,1843,
pKB,,1832,
Increase,%,1828,
Drug degradation,%,1823,
IC50 ratio,,1786,
max activation,%,1778,
Ratio ED50,,1747,
CL,uL.min-1.(10^6cells)-1,1737,
Cp,nM,1723,
MEC,uM,1714,
PXC50,,1705,
log K,,1698,
Activity,mU/ml,1694,
Activity,ml,1686,
Hit score,,1669,
Activity,pm/min/mg,1663,
ERH,,1654,
Drug recovery,%,1618,
TGI,,1614,
KA,uM,1610,
Kinact,nM,1607,
Motility,%,1597,
SI,,1578,
Inhibition index,,1577,
Delta MST,day,1559,
Drug uptake,nM,1557,
Cytotoxicity,,1555,
IC50 relative,nM,1551,
MIC,ug,1548,
MTD,mg kg-1,1539,
MEC,ug ml-1,1524,
AbsAC35,uM,1489,
log10cfu,,1482,
Papp,,1450,
Log K,,1447,
Ratio IC50/EC50,,1445,
CL,,1441,
Concentration,ug ml-1,1431,
EC,uM,1427,
Potency,,1414,
AUC,,1411,
SUV,,1403,
AbsAC26_uM,uM,1390,
Fold change,,1389,
DC50,nM,1388,
Dose/organ,%,1386,
Activity,equiv,1377,
Concentration,uM,1362,
Displacement,%,1345,
Dose/g,%,1344,
PI,,1336,
Ratio TD50/ED50,,1330,
Rm,,1326,
pEC50,,1312,
MIC=>90,ug ml-1,1301,
Activity,U/L,1281,
deltaT,degrees C,1279,
HC50,ug ml-1,1275,
Activity,mM,1273,
AbsAC40,uM,1268,
ID/organ,%,1260,
Concentration @ Maxi,um,1244,
MBC,,1243,
Activity,ng/ml,1222,
Hepatotoxicity (benign tumour),,1216,
Hepatotoxicity (choleostasis),,1216,
Hepatotoxicity (time to onset),,1216,
Hepatotoxicity (association with vascular disease),,1216,
Hepatotoxicity (successful reintroduction),,1216,
Hepatotoxicity (steatosis),,1216,
Hepatotoxicity (severe hepatitis),,1216,
Hepatotoxicity (animal toxicity known),,1216,
Hepatotoxicity (moderate),%,1216,
Hepatotoxicity (granulomatous hepatitis),,1216,
Hepatotoxicity (moderate),,1216,
Hepatotoxicity (malignant tumour),,1216,
Hepatotoxicity (mechanism),,1216,
Hepatotoxicity (acute),,1216,
Hepatotoxicity (comment),,1216,
Hepatotoxicity (cytolytic),,1216,
Hepatotoxicity (cirrhosis),,1216,
Hepatotoxicity (chronic liver disease),,1216,
Hepatotoxicity (acute),%,1216,
Effect,,1203,
Relative Growth,,1195,
ID50,nM,1191,
BP,mmHg,1187,
K,/min,1164,
CLH,ml/min,1163,
LC50,ppm,1162,
LC50,,1145,
% inhibition,uM,1143,
Response,%,1136,
Cmax,ug.mL-1,1115,
Max,%,1100,
Ratio AUC,,1097,
Inhibition,ug ml-1,1092,
Survival,,1082,
mortality,,1074,
Peff,10'-6 cm/s,1067,
UI,,1063,
Compound recovery,%,1061,
Cytotoxicity,%,1059,
K obs / 1,M-1 s-1,1058,
Conc @ Max Fold Incr,um,1040,
C50,uM,1039,
Activity,bpm,1027,
Growth,%,1026,
Activity,nm,1013,
Activity,nmol,993,
ID50,umol.kg-1,971,
Cures,,970,
Activity,ug,968,
log10CFU/ml,,967,
Inhibition,uM,965,
MSD,day,955,
log Pe,,950,
Drug uptake,ng/ml,942,
Stimulation,%,942,
Injected dose,%,942,
ED50,M,938,
DILI_Concern,,929,
DILI_severity_class,,929,
Flu intensity,,928,
"K(p,uu,brain)",,918,
FIC,,903,
Activity,mm3,902,
Distribution,%,896,
Kp,,896,
logPapp,,893,
HepSE_Combined Scores,,888,
HepSE_liver fatty,,888,
HepSE_hepatic necrosis,,888,
HepSE_cholecystitis,,888,
HepSE_cholelithiasis,,888,
HepSE_cirrhosis,,888,
HepSE_elevated liver function tests,,888,
HepSE_liver function tests abnormal,,888,
HepSE_hepatic failure,,888,
HepSE_liver disease,,888,
HepSE_jaundice,,888,
HepSE_hepatomegaly,,888,
HepSE_hepatitis,,888,
HepSE_bilirubinemia,,888,
ID50,M,877,
Activity,um,870,
NT,,869,
TDI,,858,
Therapeutic index,,850,
Stability,microL/min/mg,847,
Phospholipidosis,,846,
Biodistribution,%,843,
Dose,%,842,
Rf,,840,
logIC50,,834,
MBC>99.9,uM,829,
permeability,%,828,
AD50,mg kg-1,822,
MBC99.9,ug ml-1,815,
LD50,umol.kg-1,810,
Drug uptake,ug ml-1,804,
CD,uM,802,
Imax,,802,
Duration,min,795,
Log 1/D50,,792,
Cp,ug ml-1,788,
MED,,787,
PC50,uM,786,
Activity,mmol/L,783,
RatioLC50,,782,
Log 1/LD10,,776,
MPE,%,770,
Ratio pKi,,767,
Activity,cm,760,
ILS,,758,
MST,,757,
MFC,uM,750,
CL_renal,mL.min-1.kg-1,746,
pKi,,743,
Ratio,%,740,
Activation,%,737,
Potency ratio,,735,
OD,,731,
MBC,10'-2 umol/ml,722,
% residual kinase activity,%,716,
TD50,uM,712,
Injected dose/g,%,711,
DC50,uM,710,
Ka,uM,705,
LD50,ug ml-1,699,
OD,mg kg-1,699,
Concentration,,699,
Reversal,%,699,
pA2,,694,
,,680,
MIC50,,679,
HC50,uM,673,
Compound recovery,,671,
Kinetic_solubility,,670,
ID50,,670,
AC40,uM,669,
Decrease in blood pressure,%,666,
K,,663,
Delta Tm,,662,
MTC,uM,657,
Rmax,%,653,
Delta mean survival time,,649,
k_off,s-1,647,
Activity,umol/L,645,
fT>MIC,%,643,
Activity,log10CFU,641,
Max_Activity,uM,640,
Vmax,%,639,
Kcat/Km,/uM/s,636,
GI,uM,636,
No. of survivors,,636,
Relative binding affinity,,634,
k obs / 1,M-1 s-1,632,
Activity,log10CFU/ml,631,
Activity,day,631,
Activity,U/mg,630,
IP,nM,628,
MPC,ug ml-1,627,
Binding,%,625,
% Inhibition of Control Specific Binding (Mean n=2),%,623,
Reduction,,613,
ED90,mg kg-1,613,
Log 1/MMIC,,612,
MIC90,,611,
Rate of inhibition,%,609,
Animals,%,608,
Delta TC,%,607,
log Ks,,607,
MFC,,606,
Delta MST,,604,
MFC,10'-2 umol/ml,604,
Kinact,/min,601,
Ratio pIC50,,594,
MIC100,uM,588,
Activity,min,588,
Effect,%,581,
CD50,uM,579,
Drug excretion,%,573,
Inhibition (mean),%,572,
HC10,uM,569,
ILSmax,%,568,
CHI,,568,
Variation,%,567,
INH,nM,563,
ID,%,563,
Suppression,%,562,
pCC50,,561,
MIC=>90,uM,561,
LD10,mg kg-1,554,
IA,,551,
Log Ki,,550,
Zone of inhibition,mM,549,
Diuretic activity,,549,
CL/F,mL.min-1.kg-1,547,
Weight change,%,545,
Activity,pmol,545,
Log2 MIC,,543,
Viability,%,541,
Max response,%,534,
No. of cured mice,,534,
LD50,,532,
deltaTm,,532,
deltaG,kcal/mol,532,
EC,nM,529,
ED30,mg kg-1,526,
2PT,uM,517,
GI,ug ml-1,515,
IC90,,514,
AFI,%,512,
MIC>90,ug ml-1,509,
T,degrees C,508,
Log S,,505,
AbsAC1000_uM,uM,505,
Kis,uM,504,
Virus rating,,503,
EDmin,mg kg-1,501,
Kinact,uM,498,
Delta IOP,mmHg,498,
Cp(f),nM,497,
Activity,nmol/min,495,
Activity,U,495,
Log k',,493,
MOTILITY REDUCTION/CYTOTOXICITY,%,491,
LDH Increase - Activity Score,,490,
Composite Activity - Active,,490,
Alkaline Phosphatase Increase - Activity Score,,490,
Composite Activity - Marginal,,490,
GGT Increase - Activity Score,,490,
GGT Increase - Index Value,,490,
GGT Increase - Number of Reports,,490,
LDH Increase - Index Value,,490,
Alkaline Phosphatase Increase - Number of Reports,,490,
Composite Activity - Score,,490,
SGPT Increase - Index Value,,490,
SGPT Increase - Activity Score,,490,
LDH Increase - Number of Reports,,490,
SGOT Increase - Index Value,,490,
SGOT Increase - Activity Score,,490,
Alkaline Phosphatase Increase - Index Value,,490,
SGOT Increase - Number of Reports,,490,
SGPT Increase - Number of Reports,,490,
pGI50,,488,
Activity,IU/L,487,
Activity,ms,487,
Drug metabolism,uM,486,
deltaTm,K,485,
Peff,ucm/s,484,
Mortality,,484,
Occ,%,483,
Ratio Ke,,483,
Activity,mV,483,
Kcat,/min,483,
K ass,l M-1,479,
Activity,ug/g,476,
-log(solubility),,474,
Drug uptake,nmol/g,474,
Concentration,%,472,
Duration,hr,469,
Activity,degrees C,467,
Ratio Ki(app),,466,
deltaCT,,464,
MIC>95,uM,464,
Recovery,%,462,
Locomotor activity,,461,
MBC,mg/L,461,
Cmax,,461,
RLU,,460,
MED,g/acre,459,
Log 1/Ki app,,458,
Drugexcretion,%,457,
Vmax,,457,
% binding,%,454,
IA,%,454,
pED50,,450,
log(ratio),,446,
Ct,ng/ml,444,
Ki ratio,,442,
k3/Ki,M-1 s-1,440,
CLH,%,439,
K app,M-1,439,
TC50,ug ml-1,438,
Radioactivity,%,438,
MIC=>80,ug ml-1,435,
Km,,430,
Remaining,%,429,
K,/M/s,423,
Weight change,g,422,
k_obs,s-1,422,
Increase,,421,
MIC,ug cm**-2,420,
MBEC,uM,420,
RFU,,419,
CL,L/hr,418,
IC80,umol/L,418,
Score,,415,
Activity,micromol/min,415,
CL,%,413,
Phytotoxicity,%,411,
CD50,mg kg-1,410,
MRT(t),hr,410,
No. of animals,,410,
K,/s,410,
In vitro activity,,409,
log(1/MIC),,407,
K app,uM,407,
delta Tm,,406,
delta Tm Staurosporine positive control,,406,
IZ,nm,405,
Activity,nmol/min/mg,404,
LCK,,401,
Permeability,nm s-1,400,
T1/2,,400,
Max_Activity_Concent,uM,400,
Growth Inhibition,%,400,
Anticonvulsant activity,,399,
GI90,ug ml-1,398,
EC50,ppm,397,
Block,%,397,
LD50,ug,395,
AbsAC1,uM,395,
fluorescence,,390,
pD'2,,390,
k_on,M-1.s-1,390,
Biodistribution,%ID/g,387,
Vd/F,L.kg-1,386,
Radiolabel recovery,ngequiv/g,382,
Motility,,380,
Kcat/Km,/s/microM,380,
Cytotoxicity,uM,378,
Heart rate,beats min-1,378,
MFC99.5,10'-2 umol/ml,378,
TGI,ug.mL-1,376,
Injected,%,376,
Paw swelling,mM,375,
CLH,ml/min.g,375,
log(ILSmax),,374,
EC1.5,uM,373,
Solubility ratio,,373,
Ct,nM,372,
kon,Ms-1,372,
Concentration,ug g-1,369,
Cp,,368,
-Log KB,,367,
Optimal dose,mg kg-1,367,
MBC,uM/ml,366,
MIC95,ug ml-1,364,
IG50,uM,363,
Drug uptake,ug/g,362,
IC20,uM,362,
EC90,,362,
Cured,%,361,
FPDc,,361,
Activity,mg dl-1,359,
KE,,359,
Vmax,pmol/min,357,
Drug excretion,,357,
deltaH,kcal/mol,357,
Cmax,ng/g,357,
2aPTT,uM,356,
No. of mice cured,,355,
Hill coefficient,,354,
RUmax,%,354,
Relative affinity,,354,
MIC80,,352,
ED50,ug,352,
Ka,,352,
ED50,mg kg-1 day-1,351,
Cooperativity,,350,
Relative IC50,,350,
Inhibition,mm,348,
SDL,%,346,
MLC,ug ml-1,345,
log(%),,344,
Peff,10^-6 cm/s,344,
Activity,RFU,344,
INH,ug ml-1,340,
Activity,g/dl,339,
MIC>90,uM,339,
ED,nM kg-1,339,
TD50,,336,
MIC95,umol/L,336,
CL,uL/min,335,
Activity,microM/min,334,
Kcat/Km,,334,
Relative potency,%,333,
% Residual activity with Skepinone-L,%,333,
Delta blood pressure,mmHg,332,
MTC,mg kg-1,331,
Distribution of radioactivity,dose g-1,330,
Fa,,329,
IC30,uM,329,
Ka,10'5/M,328,
MPC8,ug ml-1,328,
Release,%,328,
MIC,10'-2umol,328,
Activity,V,328,
k cat,s-1,327,
IC80,ug ml-1,326,
AUC,uM.hr,326,
Radiolabel recovery,ugequiv,324,
Max fall in blood pressure,mmHg,324,
-log(1/MIC),,324,
MBIC50,ug ml-1,324,
PFA,,323,
Change,,323,
k',,322,
Activity,mg/ml,322,
QH,%,322,
Safety ratio,,322,
CTD50,uM,321,
FPD measurement,,321,
Viable cells,%,321,
HR,beats min-1,320,
No. of revertants per plate,,320,
Drug uptake(free),nM,318,
pKa2,,318,
Mean fold stimulation,,318,
Affinity,,317,
Activity,/min,316,
Schizont size,um,315,
ERH,%,315,
Radiolabel recovery,%,314,
IC80,uM,314,
MIC=>80,uM,314,
Activity rating,,314,
Vmax,nmol/min,313,
Inhibition zone,mM,313,
Decrease in SBP,%,311,
CL,ml/min,311,
Fg,,310,
MFC99.9,uM,310,
Max,,310,
Fh,,310,
ED,mg kg-1,309,
Ke,,309,
F_fraction,,308,
Activity,uEq/min,308,
Mean injected dose/g,,307,
-Log C,mM l-1,306,
Activity,mg/L,304,
Cp(f),uM,304,
Inhibition,,304,
PAE,hr,303,
Mean survival time,day,303,
Activity,mm2,303,
Relative activity,%,303,
Permeability,,300,
IZ,mM,300,
pKa1,,299,
MIC99,,299,
Therm_solubility,,299,
MIC,ppm,299,
Kii,uM,298,
log(10^6/IC50),,297,
MBC99.9,uM,297,
CD50,ug ml-1,295,
ED50,10'-1 ug/ml,293,
Kel,/hr,293,
dTM,K,291,
Log 1/M,,291,
Repellency,%,290,
GR80,ppm,289,
VR,,289,
TC50,,289,
Kb,,288,
deltaH,kJ/mol,287,
CCIC50,uM,287,
Drug uptake,kBq/ml,287,
IC100,uM,287,
AUC/dose,uM.hr.kg/mg,286,
LTKB_BD DILI severity score,,286,
Drug metabolism,pmol,284,
EC80,mg/L,284,
Ct,ng/g,284,
EC50,mgAi/L,283,
MBC99.5,10'-2 umol/ml,282,
Drug metabolism,nmol/min/mg,282,
Drug uptake,nmol,282,
Radiolabel recovery,ugequiv/g,282,
PF50,,282,
Activity,umol,281,
% Activity remaining,%,280,
APD95,%,280,
Cell survival,%,280,
pXC50,,279,
EC25,uM,279,
Drug metabolism,nmol/min,279,
IC12,ug ml-1,279,
fAUC,ng.hr.mL-1,279,
ED30,ug kg-1,279,
CC20,uM,278,
pKA,,278,
pKD,,278,
MNCC,uM,278,
MIC=<90,ug ml-1,277,
Solubility,,277,
ED50 ratio,,276,
Diameter of inhibition zone,mM,275,
Activity,mol/mol,274,
Log EC50,,273,
Inhibitory activity,,273,
TD50,ug ml-1,273,
Average IC90,uM,273,
Oral activity,,272,
Cmin,ng/ml,272,
delta logD,,272,
Relaxation,%,272,
ED20,mg kg-1,271,
log(1/I50),,271,
HD50,uM,271,
I.D./g,%,270,
Growth_index,,270,
Complex formation,%,270,
CC90,uM,269,
%max,,268,
MBC90,ug ml-1,268,
EC150,uM,267,
CC10,uM,267,
Drug uptake,ng,266,
Response,,266,
D40,mg kg-1,266,
MABP,mmHg,265,
MBEC,ug ml-1,265,
K,uM,264,
logKi,,264,
Activity,Zone units,264,
DILI positive/negative,,261,
log(RBA),,261,
pKa_B1,,261,
log(1/ID50),,260,
log(43000/Ki),nM,260,
Ka,M-1,260,
Time,,260,
T-C,day,259,
MTD,uM kg-1,259,
Polyamine,%,258,
Fold reversion,,258,
Ratio LC50/IC50,,258,
Activity,umolequiv/umol,256,
MIC,10'-2mmol/ml,255,
fAUC/MIC,,255,
EC50,mg kg-1,254,
Activity,IU/ml,254,
RF,,253,
IOP,mmHg,253,
IC50,mg kg-1,253,
Concentration,ng ml-1,252,
MIC99.9,ug ml-1,252,
GIC50,nM,252,
ID50,ng ml-1,251,
Amnesia reversal,%,251,
BBR,,251,
MIC,ug mg-1,250,
Blood glucose,%,249,
ID50,mM,249,
Fabs,%,248,
Ka,10'6/M,247,
RatioAUC/MIC,,247,
Formation,%,246,
Log IC50,nM,246,
LTS,,246,
deltaG,kJ/mol,246,
Drug uptake,pmol,246,
MBC,mg/ml,246,
ALD50,mg kg-1,245,
Relative Vmax,,245,
Activity,g/L,245,
Kcat/Km,/M/s,245,
TDI,%,244,
fIC50,nM,244,
Kcat/Km,/mM/s,244,
Activity,10'2mEq,244,
MFC,uM/ml,244,
MBIC,uM,243,
ED50,10'-2 ug/ml,243,
EC30,uM,243,
Ke(app),nM,243,
-TdeltaS,kcal/mol,242,
Activity,deltalog10CFU,242,
IC50,ug,241,
ED50,mg/kg/day,240,
ED50,g ml-1,240,
ED50,10'-3 ug/ml,240,
C0,ng/ml,240,
MBC50,ug ml-1,239,
No. of mice,,238,
Activity,pg,238,
fCmax,uM,237,
Activity,micromol/kg/min,237,
MRC,ug ml-1,237,
Diet,,237,
Antagonist potency,,237,
Stability,nmol/min,236,
MEC,nM,235,
MBIC50,uM,235,
Stability,ml/min.kg,235,
MIC,p.p.m.,234,
EC2,uM,234,
EC99,uM,234,
Activity,pmol/min,234,
MNTD,uM,234,
Growth inhibition,,234,
% of engagement,%,233,
Ratio LD50/ED50,,233,
Max inhibition,%,233,
Mean survival days,day,232,
K,10'5/M/s,231,
Body weight,g,231,
Potency,%,230,
ED50,nmol,230,
LC99,uM,229,
Level,,229,
deltaA,,228,
Drug release,%,228,
Decrease,,228,
Toxicity,%,227,
Mole fraction,,227,
Vmax,nmol/min/mg,227,
LC90,ppm,227,
Activity,milliequivalent,227,
Drug degradation,,227,
Binding affinity,,226,
R,%,226,
MED50,mg kg-1,226,
OD,mg kg-1 day-1,226,
Mortality,%,226,
Toxic deaths,,225,
Activity,c.p.m. 50ul-1,225,
Remaining (without cofactor),%,224,
AP,uM,224,
AUC,uM.hr.Kg/mg,224,
INH,min,223,
Kinetic,ug/ml,223,
Max fall in blood pressure,%,222,
pKa_A1,,221,
MEC,p.p.m.,221,
Weight change,,221,
Decrease in blood pressure,,221,
Smax,%,220,
DNAUC,kg.min/L,220,
Drug metabolism,pmol/min,220,
ED25,mg kg-1,219,
Control,,219,
MIC,10'-3micromol/ml,219,
K,M-1,219,
Retention,%,219,
Fall,,219,
Biodistribution,,218,
I,%,218,
D,%,218,
Activity rating,%,217,
Log SP,,217,
Saluretic activity,m equiv 5hr-1 kg-1,217,
Activity,cpm,216,
Activity,U/ml,216,
Activity,CFU,215,
EC90,ug ml-1,215,
LogP app,,214,
Weight difference,g,213,
LED,uM,213,
HC10,ug ml-1,213,
Kic,uM,213,
pK,,213,
Drug metabolism,nM,212,
Antagonism,%,212,
ED50,mM,211,
log Kp,,211,
fCmax,nM,211,
Log RA,,211,
nH,,211,
LD99,uM,210,
MES,,209,
Survivors,%,209,
Agonist potency,,208,
Alpha max,,208,
Residual_activity,%,207,
NI,,207,
Stability,hr,207,
MBIC,ug ml-1,207,
HILLSLOPE,,206,
BOTTOM,,206,
FPD measurement,FPDc,206,
TOP,,206,
logKw,,205,
IC50,molar ratio,205,
Plasma level,ng ml-1,205,
Retention time,s,205,
Hypoglycemic activity,%,204,
Blood pressure,mmHg,204,
Activity,10'-2mm,204,
Mean survival,day,204,
CF,,203,
Weight change,g mouse-1,203,
Parasitaemia,%,203,
Activity,mg/kg/day,203,
Activity,uMequiv/uM,203,
Basal uptake,%,202,
Activity,pg/hr,202,
CL/F,L/hr,202,
deltalog(Tau/KA),,202,
Weight,mg,202,
Resistance index,,201,
Vmax,microM/s,201,
Drug uptake,nmol/mg,200,
Ks,uM,200,
log(RatioIC50),,200,
CLogD,,200,
delta pIC50 wt-mutant,,200,
Log kill,,199,
K,/hr,199,
Drug uptake,ug,199,
K0.5,nM,199,
Acquisition time,s,199,
EC1.5,nM,199,
Taste character,,198,
Activity,MU,198,
Log 1/K,,198,
Glucose normalisation,%,198,
DC50,,198,
K inact,min-1,197,
Survival time,day,196,
k2,M-1 s-1,196,
Activity,10^-2mm,196,
deltalog10CFU/ml,,196,
Dose/organ,,196,
Activity,a.u.,195,
TDS,,195,
AUC,uM,194,
Peff,,194,
Efficiency,%,194,
AD50,,194,
Ct,uM,194,
K,10'-3/s,193,
Change in amplitude response,%,193,
MBC,umol/ml,193,
Relative viability,%,192,
Activity,ml/min,192,
Saluretic activity,m equiv kg-1,192,
RI,,192,
Relative SEAP activity,%,192,
Activity,nmol/g,192,
Activity,/hr,192,
Activity,IU/mg,192,
IZ,%,192,
IZ,Zone units,191,
Activity,ppm,191,
% activity,%,191,
FDI,%,190,
CFU/ml,,190,
fAUC,uM.hr,190,
Fu,nM,190,
Kinact,/s,190,
C10,uM,190,
MBC99.5,10'-2microM,190,
Activity,milliequivalent/kg,190,
RA,,189,
MHC,ug ml-1,189,
Delta A/min,,188,
MHC10,uM,187,
Emetic episodes,,187,
permeability,10'6cm/s,187,
ILS max,,187,
Activity,pg/microg/hr,187,
IZ,mm2,186,
k,hr-1,186,
ED90,gAi/ha,186,
MFC90,ug ml-1,186,
MTD,uM,186,
MFC,10'-2umol,186,
Binding energy,kCal mol-1,185,
Drugexcretion,,185,
MFC,umol/ml,184,
Survivals,,183,
Papp,10'6cm/s,183,
Activity,nmol/mg,183,
Retention time,min,183,
EMR,,183,
HD50,uM kg-1,182,
Max stimulation,%,182,
Log PNalk,,182,
EC50 ratio,,182,
MNEC,ug ml-1,181,
pLD50,,181,
MIC50,mmol/ml,181,
Drug uptake,%IDKg/g,180,
K,nM,180,
AUC,ng.hr/g,180,
MNCC,ug ml-1,179,
PI,%,179,
P,,178,
Activity,ng g-1,178,
IC50 relative,uM,178,
Partition coefficient,,178,
Activity,RU,178,
permeability,10'-7 cm/s,178,
CT,%,178,
k cat,min-1,178,
CC100,ug ml-1,177,
ED50,ppm,177,
Thermal melting change,,177,
IC50,ppm,177,
Activity,mmol,177,
Log 1/T,,177,
max activation,,177,
I50,,176,
AUC/dose,uM.hr,176,
MIC,10'-2micromol/ml,176,
log1/IC50,,175,
IC25,uM,175,
logPeff,,175,
Taq inhibition,,174,
HR,%,174,
Emin,%,173,
pIC25,,173,
Median survival time,,173,
MBC,10'-2micromol/ml,173,
GABA ratio,,173,
Log 1/MIC,,173,
Reversion,%,172,
Growth inhibition,%,171,
AB50,mg kg-1,171,
IC99,nM,171,
GE,%,171,
AUC/dose,nM.hr,171,
Activity,dose ratio,171,
Tissue distribution,,171,
Aggregation,%,171,
EC20,uM,171,
Delta HR,%,171,
Activity,ng,170,
Cell growth,%,170,
Fall,%,170,
EC,ug ml-1,170,
GABA shift,,169,
MPR,,169,
R%,%,169,
HC50,,169,
MFC,umol/L,168,
No. of cures,,168,
Change in BP,mmHg,167,
Geometric mean,,167,
k3/ki,1/m/s,167,
BP,,166,
Average skin reaction,,166,
K,10'5/M,166,
ED90,uM,166,
Average weight change,g,166,
PGI,%,166,
AUC/dose,ng.hr/ml,165,
Drugabsorption,%,165,
RRT,s,165,
Protected,%,165,
Log LC50,,165,
LD50,mM,164,
AbsAC30_uM,uM,164,
FRP,%,164,
Vd,l,164,
Drug metabolism,ng/ml,164,
solubility,uL,164,
MBIC90,uM,164,
K obs / 1,,163,
Normalization,%,163,
log(permeability),,163,
Response ratio,,162,
ID x kg of body weight/g of tissue,%,162,
Vdss,,162,
ED1.5,mg kg-1,162,
MTC,ug ml-1,162,
Analgesia,%,162,
Activity,g/day,161,
Enhancement,%,161,
Index,,160,
&#256;,mm,160,
MFC50,ug ml-1,159,
log10(%HIA +10),,159,
No. of survivals,,159,
pMIC50,,159,
Log IC50,,159,
Resistance factor,,159,
Activity,MT/ha,159,
CFU,,159,
ED50,ng/ml,158,
RIS,%,158,
pTC50,,158,
Log kon,,158,
Affinity,%,158,
Uptake,%,157,
Conversion,%,157,
TCS50,uM,157,
Relative ED50,,157,
Vmax,microM/min,157,
Inhibition,radii mm-1,157,
Drugexcretion,%ID,157,
Proliferative response,,156,
absorbance,,156,
Incorporation,,156,
Iron change,%,156,
Hydrolysis,%,156,
Residual insulin release,%,156,
MISS T/C,,156,
Delta blood pressure,,156,
IC50,%,156,
PT,uM,156,
FDI,,155,
Relative efficacy,,155,
Log kOH-,,155,
Average weight,%,154,
MFC99.5,10'-2microM,154,
Plasma level,uM,154,
Uptake ratio,,154,
Decrease in SBP,,154,
Mean arterial blood pressure,mmHg,154,
MID,ug ml-1,154,
Concentration,M,153,
Peff,nm/s,153,
HACU improvement,%,153,
IC70,ug ml-1,153,
Reduction of live worms,%,152,
Disease control,%,152,
NOAEL,uM,152,
Fold selectivity,,152,
MFC99.9,ug ml-1,152,
Zone size,mM,151,
Neurotoxicity,,151,
Drug uptake,%ID/cc,151,
Cures/total,,151,
Max effect,%,151,
MED,uM,151,
Survival time,,150,
Css,uM,150,
pRA,,150,
P50,mmHg,150,
Culture,%,150,
Activity_index,%,149,
Parasitemia,%,149,
MAP,mmHg,149,
MIC>98,ug ml-1,149,
Survivors at day 4,,149,
Cmin,ug ml-1,149,
Plasma concentration,ng ml-1,149,
Kd,/s,149,
Drug uptake,mg kg-1,149,
Kcat/Km,/mM/min,148,
Emax,uM,148,
LC80,ppm,148,
Vdss,l,148,
Inhibition,nM,148,
logEC50,,147,
RA,%,147,
HF,,147,
Potentiation,%,147,
Log Kd,,147,
Lethality,%,147,
XI50,molar excess,146,
Radiolabel recovery,,146,
Tumors,%,146,
MIC100,,145,
pTGI,,145,
TD50,umol/Kg,145,
Kb,10'5/M,145,
-Log MIC,ug ml-1,144,
Activity,radii mm-1,144,
Mean relative potency,,144,
Kd(app),,143,
Activity,cm2,143,
Swelling,%,143,
EC100,uM,143,
MIC=>95,uM,142,
Delta BG,%,142,
MAD,mg kg-1,142,
MBC,10'-2umol,142,
Recovery A to B (mean),%,142,
Kb,10'6/M,142,
Relative IC50,nM,142,
D10,mg kg-1,142,
Papp A to B (mean),10E-6 cm/s,142,
pDC50,,142,
Concentration,nM g-1,141,
Incorporation,%,141,
GC50,uM,141,
Ratio,/M/min,141,
Activity,mmolequiv/mmol,141,
Radioactivity,%ID/g,140,
SUV,%,140,
Max_Concentration,uM,140,
Activity,umol/Kg,140,
effect,%,140,
BBC,ug ml-1,140,
kHOX,M-1 min-1,140,
HCR,,140,
Activity,ng/L,139,
IC5,uM,139,
CMC,uM,139,
k obs / 1,,139,
pKi(uM),,139,
P50e,mmHg,138,
Drug transport,,138,
log(1/ED50),,138,
CPE index,,138,
solubility,%,138,
Leishmanicidal activity,,138,
Average survival,day,138,
Kinact,min-1,138,
DC50,microg/cm2,138,
HD50,mg kg-1,138,
C/I ratio,,137,
Range,,137,
Activity,mol,137,
Selectivity index,uM,137,
Activity,/m2,137,
V1/2,mV,137,
Effective dose,nM kg-1,137,
Activity,mg Kg-1,136,
LC70,ppm,136,
Uptake value,,136,
Crop_yield,tons/ha,136,
KB,,136,
Kcat/Km,10'6/M/s,136,
Cell Proliferation EC50,uM,135,
Fa,%,135,
CLH,ug/min,135,
Papp,cm s-1,135,
UTC,%,135,
ED40,uM kg-1,135,
IC70,uM,135,
Ki,mM/min,135,
Normal beats,%,135,
Toxic,,135,
No. of toxic deaths,,135,
Heart rate,,134,
Activity,tons/ha,134,
Ratio,uM,134,
kDPPH,M-1 s-1,134,
pH,,134,
PF,,134,
% of activity,%,134,
Log koff,,134,
Change in IOP,mmHg,134,
Cleavage,%,133,
Vmax/Km,,133,
No. of positive cases,,133,
Hypersensitivity factor,,133,
Concentration,ng/mL,132,
Alloste ic enhan er (AE),%,132,
AUC/dose,,132,
Diuretic effect,,132,
ED50,mg 2kg-1,132,
GR50,gAi/ha,132,
MRTlast,hr,132,
AbsAC200_uM,uM,131,
EC200,uM,131,
Specificity,,131,
NE,,131,
T-C,g,131,
MIC,uL/ml,131,
Equieffective dose,mg kg-1,131,
Concentration,mM,130,
k cat/Km,M-1 s-1,130,
Kcat,,130,
Log BR,,130,
TT,s,130,
Selectivity,uM,130,
LC30,mg/ml,129,
FR50,,129,
Activity,10^9/L,129,
MIC99,mM,129,
Activity,CFU/ml,128,
Activity,ng ml-1,128,
ED90,mg/kg/day,128,
MFC,10'-2mmol/ml,128,
MTL,ug ml-1,128,
CRC/CRC0,uM,128,
AUC/dose,hr.Kg/L,128,
Fold increase,,128,
K,10'-2/s,127,
Relative efficacy,%,127,
Decrease in activity,%,127,
Number,,127,
Apoptosis,%,127,
Toxicity ratio,,127,
logFu,,127,
MFC99,ug ml-1,126,
K,10^5/M,126,
Max salt tolerance,,126,
MFC<=99.9,uM,126,
Tumor volume,mm**3,126,
Stability,ug ml-1,126,
ED50,pmol,126,
MCC,,126,
Tlast,hr,126,
MEC,%,126,
Log IC50,uM,125,
Kb,10'4/M,125,
log(1/MLD),,125,
MBP,,125,
Plasma concentration,uM,125,
Relative Potency,,125,
Protection,,125,
p[A50],,125,
Bmax,fmol,125,
Activity,nmol/ml,125,
logP(lung),,124,
ILSmax,,124,
ED80,gAi/ha,124,
Absorption,%,124,
Vdss,mL/min/kg,124,
MBC,10'-2mmol/ml,124,
Enzyme activity,%,123,
Ct,%,123,
NS,,123,
MBC99.9,,123,
Activity,nmol/min/ml,123,
Ki(app),,123,
log10CFU/g,,123,
CLH,L/min,123,
Heart rate,%,123,
HI,,123,
Accumulation,%,122,
No. of tumors,,122,
Distribution (dose/g),%,122,
DIZ,%,122,
MLD,mg kg-1,122,
Log 1/MEC,,122,
Proliferation,%,121,
LD50,nM,121,
Average weight,g mouse-1,121,
Lysis,%,121,
Weight change difference,g,121,
log(1/Km),,121,
TR,,121,
Level,nM (mg of protein)-1,121,
Decrease in Systolic blood pressure,%,121,
Vmax,pmol/min/mg protein,120,
Relative potency,fold,120,
Ki app,,120,
Cmax/dose,nM,120,
MTD,g/acre,120,
K app,,119,
No. of mice protected,,119,
NOAEL,mg kg-1,119,
ILS max,%,119,
Papp,cm/s * 10E6,119,
Activity,mEq/L,119,
CCh,%,119,
AbsAC50_uM,uM,119,
MMC,ug ml-1,119,
Log (1/C),,118,
Dose,uM kg-1,118,
Ratio Ki,nM,118,
KL,nM,118,
No. of animals protected/animals tested,,118,
Lipophilicity,,118,
MBC,umol/L,118,
Kd,10'-3/s,118,
FIC50,,118,
ND50,mg kg-1,118,
IC90,ug,118,
Kis,nM,117,
TD50,mg Kg-1,117,
Toxicity,uM,117,
MBC,10'-3micromol/ml,117,
Log 1/Km,,117,
pA2(app),,117,
Activity,mol/L,117,
Inhibition rate,%,117,
EC25,nM,116,
TC50,mM,116,
Saluretic potency,u equiv,116,
Stimulation index,,116,
Resistance,,116,
ED20,mM kg-1,116,
Drug uptake,ngequiv/g,116,
Log Ki,nM,116,
D50,mg kg-1,116,
MBC,mM,115,
BWD,g,115,
Ratio,10^3/M/min,115,
Excretion,%,115,
Cmin,nM,115,
Change in Cl- current,,115,
Relative amplitude,%,115,
TC50,nM,115,
C50,mM,115,
K,/mM/min,115,
-Log ED50,M acre-1,114,
FIC,ug ml-1,114,
Amount excreted,%,114,
Drug transport,%,114,
Rating,,114,
MCD,mg kg-1,114,
Urine volume,ml,114,
Plasma concentration,ug ml-1,114,
Ratio,M-1 s-1,114,
LC50,mgAi/L,114,
Max response,,113,
MAC,uM,113,
Kcat/Km,/s/M,113,
FC,%,113,
Change in heart rate,%,113,
Delta t,degrees C,113,
Urine volume,ml 6hr-1 100g-1,113,
Cholesterol reduction,%,113,
ED40,mg kg-1,113,
deltalog10CFU,,113,
Hemolysis,%,113,
Activity scale,nM,113,
Papp,10'-7 cm/s,112,
Uptake,%ID/g,112,
Selectivity quotient,,112,
Licking latency,s,112,
Solubility (mean),uM,112,
Susceptibility,,112,
MLD,nmol,112,
Bound,%,112,
Glucose utilization,uM,112,
Max,mmHg s-1,112,
LD99,ug ml-1,112,
AUC/dose,microM.hr/mg/kg,111,
IC100,ng ml-1,111,
Q,uM,111,
mechanism based inhibition,,111,
Entry latency,s,110,
IC80,nM,110,
Activity,umol/min/mg,110,
MIC100,umol/L,110,
MIC>85,ug ml-1,110,
Effective dose,,110,
-Log C,mM kg-1,110,
Lowering,%,110,
pTD50,,109,
Activity,/s,109,
AUC,hr.ng/g,109,
TD50,uM kg-1,109,
SC50,uM,109,
Ratio,/mM/s,109,
pKa3,,109,
Activity,ug/mg/day,108,
Ratio,/uM/s,108,
Taste class,,108,
SMT,s,108,
CMC,mM,108,
Kinact,,108,
Na+/K+,,108,
MGM,,108,
Relative hydrolysis rate,,108,
"K(p,uu,CSF)",,108,
Injected dose/organ,%,108,
Na,m equiv 6hr-1 100g-1,108,
Total iron output,ug kg-1,108,
Safety index,,107,
TPE,hr,107,
IVP,,107,
Time constant,ms,107,
Secretion,%,107,
IC10,uM,107,
Conversion rate,%,107,
Body weight,,107,
Expression,%,107,
Activity,mg/g,106,
Sensitivity,,106,
A50,uM,106,
Cell viability,,106,
Total radioactivity,%,106,
Kcat/Km,10'4/M/s,106,
Kcat/Km,10'5/M/s,106,
LAD,mg kg-1,106,
No. of rosettes/100 Jurkat T cells,,106,
Flu intensity,a.u.,106,
Activity index,,106,
Ratio,nM,106,
kOX,M-1 min-1,105,
Estrogenic potency,,105,
Inhibitory index,,105,
Kiuc,uM,105,
INH,mg kg-1,105,
K,10'4/M,105,
Stability,min,105,
ED,ug ml-1,105,
Wet weight of tissue,nM g-1,104,
LC50,microg/cm3,104,
Activity,disintegrations/minute,104,
Ct,ug/g,104,
T/C x100,,104,
Antifertility potency,,104,
Activity,uEq,104,
Activity,uM.hr,104,
Concentration,ng g-1,104,
deltalogIC50,,104,
C50,nM,104,
k3/Ki,1/Ms,104,
Ratio pKb,,104,
MIC95,uM/ml,104,
MTD,mg/kg/day,103,
log(ratioKi),,103,
Ki,ng/ml,103,
K app,10e-7/M,103,
Log I50,,103,
IR,%,103,
Papp,cm/s,103,
Kcat/Km,10'4/s/M,103,
MBP,mmHg,103,
AD50,ug/kg,103,
Activity,uM/L,103,
ED50,ug injection-1,103,
LC100,uM,103,
Activity,hr,102,
PBI,,102,
IS,,102,
Dose,ug ml-1,102,
Kapp,10^6L/mol,102,
Protein-DNA complex formation,%,102,
Ka,10'4/M,102,
Beta2 duration,min,102,
Tm,Â°C,102,
pI50,mM,102,
Increase in blood pressure,mmHg,102,
MFC,10'-3micromol/ml,102,
permeability,nM/s,102,
Accumulation,,101,
pI50,uM pupa-1,101,
HR,,101,
TPE,,101,
LD10,M kg-1,101,
Serum Ca2+,mg dl-1,101,
ID50 ratio,,101,
P50c,mmHg,101,
Fluorescence intensity,,101,
ED90,,101,
Fm,,100,
No. of cells,%,100,
Dose,,100,
Specific binding,%ID/g,100,
No. of sensitive,,100,
Estrogenic effect,%,100,
MEC,,100,
pKi,uM,100,
Paw swelling,%,100,
Cures/no. of animals,,100,
ED50,ng ml-1,100,
Inhibition zone,,100,
permeability,cm/s,99,
C0,ug ml-1,99,
behavior,,99,
Change in response,%,99,
RE,,99,
MITC95,uM,99,
kinact,min-1,99,
Adhesion,%,99,
Ki,%,99,
K,/M/min,99,
Relative binding affinity,%,99,
Antagonist activity,,98,
Activity,mol%,98,
Average dose per organ,%,98,
IP,uM,98,
Amount of TNF-alpha,%,98,
Increase in IC50,,98,
K,min-1,98,
APDc,,98,
pXC50,M,98,
Agonism,%,98,
Hydrolysis,,98,
Hammett constant,,98,
Delta MAP,%,98,
BPR,%,98,
ED50,10'-4 ug/ml,98,
MES,mg kg-1,97,
log(1/IC50),uM,97,
Log10 cfu,,97,
K,10'-3/min,97,
CL,L/min,97,
PCMA antagonism,,97,
Activity,pmol/mg,97,
IP,%,97,
Urine volume,ml 4hr-1,97,
Benzidine positive cells,%,97,
MTD,,97,
Rate constant,M-1 min-1,96,
Serosal/Mucosal Ca,,96,
MBC,10'-2microM,96,
MIC,10^2umol/ml,96,
Max reversal,%,96,
SD90,mg kg-1 day-1,96,
Stability,uM,96,
MBC,10^2umol/ml,96,
MFC,10'-2microM,96,
K,10'-4/s,96,
Activity,uMequiv,96,
Residual insulin release,,96,
TI50,,96,
XI50,mole fraction,96,
Metabolite level,,96,
Transfection efficiency,RLU (ug of protein)-1,96,
AUC,ug ml-1,95,
Taste,,95,
Sleeping time,min,95,
ED50,mg,95,
Estrogenic effect,,95,
Fold induction,,95,
pka,,95,
kinact,hr-1,95,
Log K',,95,
DA release,%,95,
K,10'6/M/s,95,
ED1.5,,95,
3 log kill,,95,
Activity,mA,95,
Body weight change,%,95,
SVT,%,95,
log(1/BC),,94,
Free,%,94,
Cytotoxicity,ug ml-1,94,
Inhibition,mM,94,
APTT,uM,94,
CCID50,uM,94,
H2O2 prot,,94,
Delta SBP,mmHg,94,
ED20,gAi/ha,94,
IC20,ug ml-1,94,
LD50,ppm,94,
Log 1/D40,,94,
Plaque reduction,%,94,
Drug metabolism,ug/g,93,
Ki,nM l-1 hr-1,93,
D,,93,
IC25,nM,93,
MED=>50,mg kg-1,93,
Average survival (days),,93,
MHC,uM,93,
Drug recovery,,93,
EH,,93,
Diuretic activity,m equiv kg-1,93,
Ratio LD50/IC50,,93,
Lactone,%,93,
Radiation prot,,93,
MGM,uM,92,
APD,-60mV,92,
Max fall in blood pressure,,92,
Max_Delta_Tm,uM,92,
Mean aortic blood pressure,mmHg,92,
AUC/dose,ng.hr/ml/mg/kg,92,
MIC95,,92,
Toxic dose,mg kg-1,92,
Mean,,92,
Blood flow,100ml g-1 min-1,92,
AbsAC50,uM,92,
ED100,mg kg-1,92,
Induction,,92,
Increase in ear thickness,1/100mm,92,
Differentiation,%,92,
Delta G,,92,
NO release,%,92,
Ratio LD50/EC50,,92,
ID50,ug,91,
V,ml,91,
Relative resistance,,91,
pI50,,91,
Papp,10'-5cm/s,91,
K inact,,91,
Excretion Cl-,m equiv,91,
Antagonism,,91,
beta t1/2,,91,
ED50,ug mouse-1,91,
Excretion K+,m equiv,91,
Excretion Na+,m equiv,91,
C20,uM,91,
ED2,mg kg-1,91,
logKA,,90,
Diameter of inhibition zone,,90,
LD50,g/Kg,90,
Increase in life-span,%,90,
ISA,%,90,
Am,%,90,
MIC,microg/cm3,90,
Biodistribution,% dose organ-1 ,90,
Average consumed,g,90,
Excretion,m equiv,90,
Mean excretion of K+,m equiv,90,
Drug metabolism,microL/min/mg,90,
Mean excretion of Cl-,m equiv,90,
Production,%,90,
Mean urine volume,ml,90,
Biliary excretion,%,90,
ED50,micromol/kg/min,90,
Activity,Kg,90,
A10,mg l-1,90,
Mean excretion of Na+,m equiv,90,
INH,mM,90,
ED25,mg kg-1 day-1,89,
REC,,89,
p[A]50,,89,
Activity,% dose (g of tissue)-1,89,
Kapp,uM,89,
Cmax,ug/g,89,
Fluorescence,nM,89,
Vmax,umol/min/mg,89,
IC50,equiv,89,
pK1,,88,
CCTD50,uM,88,
Temperature,degrees C,88,
PDK,,88,
Drug uptake,nmol/min,88,
ED20,ug kg-1,88,
Nuclear cataract,%,88,
MFC,mM,88,
Activity,deltalog10CFU/ml,88,
Metabolism,%,88,
V0,microM/min,88,
ID50,ng min-1 rat-1,88,
K inact/Ki,M-1 s-1,88,
Tmax,,88,
Kinetic constant,,88,
mean log D,,88,
BWD,,88,
Decrease in AP,%,87,
-Delta G,,87,
% of residual activity,%,87,
Activity,10'3/mm3,87,
Relative uterus weight,,87,
Ct,,87,
MIC=>90,mg/L,87,
Ovulating rats,,87,
fCmax,ng/ml,87,
RAC,,87,
Esc loss,%,87,
Kr,/mM/min,87,
Glucose transport,%,87,
% inhibition,nM,87,
Ke,uM,87,
Judgments,,87,
AbsAC90,uM,87,
Diuretic activity,ml,87,
EC200,ug ml-1,87,
Inhibition,ng ml-1,87,
Inhibitory zone,mM,87,
BK,%,87,
Kd,10'-2/s,87,
HC50,mg/L,86,
EC50,ug,86,
Delta APD95,%,86,
Cell viability,%,86,
Mean blood pressure,mmHg,86,
T-C,,86,
Cytotoxicity,U,86,
Revertants/plate,,86,
Activity,ug/mg,86,
No. of rats ovulated,,86,
Metabolism,uM min-1mg-1,86,
Ratio pA2,,86,
Weight difference,,86,
Systolic blood pressure,mmHg,86,
pCC50,uM,86,
Analgesic activity,,86,
Metabolism,,86,
Result,,86,
Therapeutic ratio,,86,
pIC50(app),,86,
CLH(app),uL/min,86,
Protective index,,86,
CL,ug ml-1,86,
Protection index,,85,
Stability,uL/min.mg,85,
Injected dose/g tissue,%,85,
AD50,ug kg-1,85,
Latency,s,85,
log KOW,,85,
fEC50,nM,85,
MEC,mg/L,85,
Antibacterial activity,,85,
Concentration,nM (10e6*cells)-1,85,
Contraction,%,85,
LC90,ug ml-1,85,
TdeltaS,kcal/mol,85,
Brain content,nM ml-1,84,
pA10,,84,
logKb,,84,
IC50 relative,,84,
EII50,,84,
EC100,ppm,84,
MD,,84,
ov. rat/total,,84,
LLR score,,84,
LDH,MU,84,
Change in weight,%,84,
Loss,%,84,
Decrease in blood glucose,%,84,
Stability,uL/min,84,
Relative protection,,84,
Plasma content,nM ml-1,84,
MPE50,mg kg-1,84,
Decrease in blood pressure,mmHg,84,
Binding affinity,nM,84,
DRF,,84,
Change in blood pressure,mmHg,84,
IC100,ug ml-1,84,
Inhibition ratio,,84,
Drugexcretion,mg,84,
S,,84,
Rmax,,83,
Survival ratio,,83,
Survival days,,83,
EC15,nM,83,
Relative JC-1 accumulation,,83,
Average weight change,%,83,
2x APTT,uM,83,
Drug metabolism,nmol/g,83,
Kb,10'7/M,83,
Concentration,nM,83,
k,min-1,83,
logKcat,,83,
Vmax,pmol/min/mg,83,
No. of Colony forming Units,,82,
Drug metabolism,umol/L,82,
ki/Ki,M-1 min-1,82,
PD50,,82,
EC15,uM,82,
K,10'4/M/s,82,
EH,none,82,
Activity,nmol/mg/min,82,
pIC100,,82,
LTC,,82,
Activity,total picomoles,82,
Fibril formation,%,82,
BP decrease,mmHg,82,
Kd,10'-1/s,82,
Vmax,micromol/min,82,
p(1/MIC),,82,
RP,,82,
Level,%,82,
Fmax,%,81,
CL free,,81,
Activity,pmol/hr,81,
logBB,,81,
Extracted,%,81,
Relative activation,%,81,
EC50,microg/cm2,81,
Activity,L/mol/s,81,
MTC,,81,
Relative EC30,nM,81,
Relative amount,%,80,
Lipid level,mg dl-1,80,
Ki'',uM,80,
LC50,ugAi/ml,80,
-log(RatioIC50),,80,
Contraction,,80,
logRA,,80,
IAr,,80,
MABP,,80,
ALP activity,,80,
CMP,,80,
Activity,milli optical density/minute,80,
Biodistribution,%Dose/g,80,
Mycelial growth,cm,80,
Emax,nM,80,
Plasma level,ug ml-1,80,
Log Ki,mM,80,
K,10^4/M/s,80,
ED50,umol/L,79,
LD90,uM,79,
AUC/dose,uM.hr.Kg/mg,79,
EC30,nM,79,
ECS ratio,,79,
logMIC,,79,
Activity,pM,79,
Mean weight,mg,79,
RU,,79,
MBC90,mg/L,78,
DOM,%,78,
TCS50,nM,78,
Kinact,mM,78,
Baseline systolic BP,%,78,
Duration of action,hr,78,
IF,,78,
Mutagenicity,,78,
Activity,/uL,78,
LD90,ug/g,78,
Activity,fmol,78,
Concentration,pg ml-1,78,
SVT,,78,
AA,,78,
MBC50,mg/L,78,
log10CCID50,,78,
Ki/Km,,77,
P,cm s-1,77,
MNTD,ug ml-1,77,
Peak rhGH,ng ml-1,77,
Drug metabolism,pmol/min/mg,77,
RUmax,,77,
Affinity constant,uM,77,
I50,ppm,77,
Binding intensity,,77,
Log Kmemb,,76,
IP,,76,
D50,mg kg-1 day-1,76,
Max decrease in heart rate,%,76,
IC16,uM,76,
K 0.5,nM,76,
TG100,uM,76,
Oral diuretic activity,m equiv [Na+] 5hr-1kg-1,76,
Ratio GI50/EC50,,76,
Kel,/min,76,
Krel,,76,
DIZ,mm/mg,76,
Activity,p.p.m.,76,
EC,,76,
TI rating,,76,
Kapp,10'6/M,76,
Cytotoxicity,ng ml-1,76,
Sleeping time,s,76,
IC200,uM,76,
Decrease in CR,%,76,
Fold resistance,,76,
Inhibitory response,%,76,
K,10'3/M/s,76,
pKa4,,76,
Range,ug ml-1,76,
Antibiotic activity,,76,
MFC100,ug ml-1,76,
Activity,IU,76,
GS,,76,
Activity,10'3CFU/ml,76,
Log potency ratio,,75,
Slope,,75,
scMet,,75,
Degradation,%,75,
Ratio,/uM/min,75,
HSAI,,75,
Duration,,75,
Reversal activity,%,75,
increase in mean survival time,day,75,
Relative affinity,%,75,
DeltaTC,%,75,
Activity,mU,75,
CyD50,ug ml-1,75,
2-DG uptake stimulation,,75,
AUC/dose,nM.hr.kg/mg,74,
ED50,%,74,
K,10'6/M,74,
dTm,K,74,
logS0,,74,
Rate,,74,
Activity,nmol/hr,74,
Zone of inhibition,,74,
MGC,uM,74,
ED10,ug kg-1,74,
T50,min,74,
Growth zone,mM,74,
Cell Proliferation IC50,uM,74,
Log Ki,uM,74,
Cured/treated,,74,
Log [MrI],,73,
Rblood_plasma,,73,
XI50,,73,
FR,,73,
Bmax,pmol,73,
PB,pmol,73,
No. of rabbits convulsed,,73,
Remaining activity,%,73,
K,10'-2/min,73,
Bioreduction,%,73,
Drug uptake,nmol/Kg,73,
TGIR,%,73,
Drug discrimination effect,%,73,
Activity,nM/s,73,
AUC,ng/g.hr,73,
EC40,uM,73,
Hill coefficient (n50),,73,
Activity,pg/mg,73,
CL,ml/hr,73,
K,10^-3/min,72,
Diuretic activity,ml kg-1,72,
Compound_Concentrati,uM,72,
Biodistribution,nM (g of tissue)-1,72,
Serum concentration,,72,
MBC>99.9,umol/L,72,
Blockage activity,,72,
Ratio,U,72,
log(1/MED),,72,
TBPS shift,,72,
Sweetness potency,0-15 scale,72,
Ka,10'5/M/s,72,
Excretion rate,,72,
log(Tau/KA),,72,
pK2,,72,
Saluretic activity,m equiv 6hr-1 kg-1,72,
Death,%,71,
Lw/Bw,,71,
log%Abs,,71,
logPF,,71,
Inhibitor level,,71,
Inflection point,nM,71,
Ka,10^5/M,71,
Plasmaconcentration,ug ml-1,71,
Selectivity index,SI,71,
Mouse behavior activity,,71,
Cr,mg dl-1,71,
Shift,,71,
Stabilty,min,71,
Relative uterus weight,mg,71,
Blood sugar lowering,%,71,
k2,min-1,71,
Log CR,,71,
Concentration,% kg dose g-1,71,
ED30,uM kg-1,70,
GHI,,70,
Ka',,70,
ND,,70,
Glyceamia evolution,%,70,
No. of cures,day,70,
C20 APD95,uM,70,
Resistance,%,70,
Ulcerogenic index,,70,
ED50,g/Kg,70,
AUC,uM.hr/ml,70,
Log cell kill,,70,
KB app,uM,70,
AUC/dose,min.kg/L,70,
LogD6.5,,70,
Binding affinity,%,70,
IC50,% conc,70,
Biodistribution,% g-1,70,
Affinity,nM,70,
Cells,%,70,
Papp,uL/hr/cm2,70,
Stability,nm,70,
Methemoglobin,,70,
UD50,mg kg-1,70,
I0.5,uM,69,
Ratio,10'3/M/s,69,
Survivors / animals tested,,69,
Activity,/M/s,69,
Mortality,day,69,
MFC,mg/L,69,
Kapp,10^3/M,69,
AUC/dose,kg.hr/L,69,
EC30,,69,
UN,mg dl-1,69,
Drug uptake(free),uM,69,
ED50,mM l-1,69,
Log BB,,69,
Delta,%,69,
SS,%,69,
Log A,,69,
Latency,,69,
Diuretic effects,,69,
Change in reaction time,%,69,
LS,%,69,
Inhibitory potency,,69,
AOA,,69,
MIC,microg,69,
Kinact,/mM/min,68,
Activity,ml/kg,68,
Change TC,%,68,
AR,,68,
Drug uptake,ng/mg,68,
Displacement,,68,
% absorbed,%,68,
Log relative k',,68,
Activity,nmol/L,68,
Ka,/uM,68,
Vasorelaxant effect,,68,
Activity,log10CFU/g,68,
Potency,mg kg-1 day-1,68,
Activity,10'6/ml,68,
Convulsion,%,68,
pC1,,68,
Delta G,kCal,68,
Temperature change,degrees C,68,
ID50,umol,68,
ED200,uM,68,
PCA,,68,
CT10,uM h,68,
MID,,68,
Activity,% ID/g,68,
MBEC,,68,
MBC,ug,68,
-Delta G,kCal mol-1,68,
No. of chicks,,67,
Activity,uIU/ml,67,
MFC99.9,,67,
ED150,mg kg-1,67,
Average change in body weight,%,67,
Mean peak APTT,,67,
Activity,M,67,
Activity,mmol/Kg,67,
No. of emetic episodes,,67,
Uterine weight,mg,67,
SP,mmHg,67,
Occ,,67,
Hypothermic effect,,67,
Turnover,ng ml-1,67,
MHC,ug,67,
[3H] concentration,% kg dose g-1,67,
Stability,ml/min,67,
Activity,Da,67,
TC,mg dl-1,67,
Bmax,fM mg-1,67,
EC100,nM,67,
K obs,,66,
-Log ID50,,66,
% recovery,,66,
EC2x,uM,66,
Parasite_Clearance,%,66,
Ratio_Papp,,66,
Drug uptake,ugequiv,66,
delta Log P,,66,
log Pe,cm/s,66,
Edema variation,%,66,
AUC,ug.hr/g,66,
Ratio,/s/M,66,
Growth delay,day,66,
Ki 0.5,nM,66,
BWLmax,%,66,
PFC,,66,
NOAEL,mg/kg/day,66,
MBC90,uM,66,
Urinary recovery,%,66,
Iron output,,66,
Activity,/M/cm,66,
Ratio,M-1 min-1,66,
Weight loss,g,66,
Activity,mol/min,66,
CD100,uM,66,
P50d,mmHg,66,
Delta Vmax,%,66,
log1/Ki,,66,
EC50,%,66,
EC20,nM,66,
Pc,cm s-1,65,
Ulcer incidence,number/group,65,
K2,min-1,65,
Specific binding,%,65,
Serum Ca2+,,65,
K,10'3/M/min,65,
Body weight change,g,65,
No. of deaths,,65,
ED50,mg ml-1,65,
Serum level,mg dl-1,65,
Activity,RLU,65,
Potency_Clk4_uM,uM,65,
Activity,nmol/sec,65,
Kd,min-1,65,
Log kw,,65,
Kieq,nM,65,
logGI50,,65,
Kdiss,/min,65,
Max reduction,%,65,
pKd,,65,
Biological activity,%,65,
Activity,m,65,
LD10,mg kg-1 day-1,65,
CC25,ug ml-1,65,
MDD,,65,
C1.6,mM,65,
Selectivity,zone unit,65,
Systolic blood pressure,,64,
Papp,10'-5 cm/s,64,
Activity,/cm3,64,
Binding affinity,uM,64,
Delta HDL,%,64,
AC3,uM,64,
Toxicity,uM kg-1,64,
Tracer,%,64,
eLog D,,64,
Kbapp,nM,64,
Fraction ionised,,64,
ED100,,64,
Net cell kill,log10,64,
MCC50,uM,64,
Tm,,64,
Residual insulin secretion,%,64,
LD20,,64,
Activity,10^2 mm,64,
Behavioral score,,64,
Inhibition Zone,cm,64,
deltaRm,,64,
CL_renal,L/hr,64,
CC,,64,
LD100,mg kg-1,64,
Relative EC30,,64,
Change in weight,,64,
Log Pe,cm s-1,64,
Discrimination ratio,,64,
Rotarod toxicity,,64,
-TdeltaS,kJ/mol,64,
p24,pg ml-1,64,
log(1/SD90),,64,
Radius of inhibition zone,mM,64,
Stability,ml/min/mg,64,
EC1.5,,63,
ED85,g/ha,63,
Bmax,fmol/mg,63,
Agonist activity,,63,
No. of cells,,63,
Activity,molar ratio,63,
BA,%,63,
Stability,pmol/min/mg,63,
Activity,10'-3/M/s,63,
Ratio IC50,uM,63,
Log activity,,63,
Relative velocity,,63,
-Log KD,,63,
pLC50,,63,
APD75,%,63,
Cl - current change,,63,
K,M-1 s-1,63,
Papp,10^6cm/s,63,
Inhibition uptake,%,63,
Metabolic stability,%,63,
K ass,l uM-1,63,
RUmax,10'2/Da,63,
Imax,mmHg,63,
I ABC,,63,
Activity ratio,,63,
log(1/LD50),,62,
Kdiss,uM,62,
cAMP accumulation,%,62,
Concentration,mg ml-1,62,
PI turnover,,62,
GR50,kg/ha,62,
Delta MAP,,62,
TC,%,62,
Relative velocity,%,62,
K,10'5/M.s,62,
Hydrolysis rate,,62,
Max non-toxic dose,ug ml-1,62,
Activity,log10FFU/ml,62,
Activity,10'9/L,62,
Activity,m equiv kg-1,62,
Ulcerogenic activity,%,62,
Deaths,,62,
Activity,pmol/g,62,
PHA,,62,
pA50,,62,
Log RAI,,62,
log(IA),,62,
ED50,mg mouse-1,62,
CPA,%,62,
permeability,10'-5 cm/s,62,
ED99,ug ml-1,62,
Uterotrophic effect,,62,
MIC=<50,uM,62,
Organ distribution,%,61,
Ka,10^6/M,61,
Stability,uL/min/kg,61,
Log ED50,uM kg-1,61,
Drug metabolism,ug ml-1,61,
Kin,hr-1,61,
AUC,%,61,
Inactivation,%,61,
LD50,microgAi/g,61,
KD/Ki,nM,61,
T/C,day,61,
Alpha E,,61,
Lowering,,61,
Dead cells,%,61,
Effect,mg 100g-1,61,
Tumor weight,g,61,
ED20,,61,
Cmin,mg/L,61,
Papp,nM/s,61,
Significance,,61,
Potency_Clk2_uM,uM,61,
Delta MAP,mmHg,61,
Activity,10^-7/M,61,
ED95,mg kg-1,61,
ISA,,61,
Chemotherapeutic index,,60,
Activity,ugequiv/ml,60,
MG MID,uM,60,
Level,uM,60,
% remaining,%,60,
Activity,10'-3cpm,60,
%AUCextra,%,60,
Vmax,nM min-1,60,
Sensory evaluation,,60,
Absorbance,nm,60,
Activity,10'7mol/J,60,
Potency_Dyrk1a_uM,uM,60,
A0.5,uM,60,
Change in heart rate,beats min-1,60,
IFN,ml,60,
No. of animals protected,,60,
-Log ED50,,60,
Weight,%,60,
Activity,mg/mg/day,60,
ED50,nM mouse-1,60,
Ratio_ATPase activity,,60,
[I],uM,60,
% maximum response,%,60,
Anticoccidial Activity,%,60,
PCA shift,,60,
HYPO,,60,
Drug release,,60,
CC30,uM,60,
SF,,60,
MIC=>50,ug ml-1,60,
pID50,,60,
DAR,,60,
Bmax,fM (mg of protein)-1,60,
Cytotoxicity,nM,60,
Median day of death,,60,
K,10^5/M/min,60,
Latency time,s,60,
LC90,uM,59,
Half duration,min,59,
ED30,,59,
RHT,,59,
Average weight,,59,
kon,nM^-1 min^-1,59,
Change of tumor area,%,59,
koff,min^-1,59,
ED99,mg kg-1,59,
Activity,microg/ml,59,
Effective dose,mg kg-1,59,
Dose ratio,,59,
Fold activation,,59,
log(Kinetic_solubility),,59,
Relative uterine weight,,59,
Erythroid induction,%,59,
CFU,/ml,59,
Other,,59,
Inhibitory diameter,,59,
Total cholesterol,mg dl-1,59,
Relative hydrolysis,,59,
CD,,59,
IE50,uM/L,58,
EC5X,uM,58,
Inhibition ratio,%,58,
dP/dt20,mg kg-1,58,
MLC,uM,58,
Collapse time,min,58,
Body weight loss,%,58,
Cmax,nmol/g,58,
ECmax,,58,
AUC,uM.hr/mg.kg,58,
Log GI50,,58,
AWC,g,58,
UR,%,58,
Cmax/dose,uM,58,
Specific activity,uM min-1 (mg of protein)-1,58,
LD50,mg/L,58,
Glycaemia evolution,%,58,
MED,uM kg-1,58,
Relative growth,,58,
AE Score,%,58,
Potency_Dyrk1b_uM,uM,58,
ED50,g/ha,58,
Estrogenic effect,nM,58,
Level,pM g-1,58,
Tp control,%,58,
Activity,10'-7M,58,
KI_MICROM,um,58,
Stabilty,ml/min.kg,58,
Neuroprotection,%,58,
Activity,fL,58,
Reduction factor,,58,
ACT,%,58,
Relative salidiuretic activity,,58,
Ct,% dose/g,57,
CL,L/Kg,57,
pKi,nM,57,
ED25,uM kg-1,57,
TCID50,uM,57,
AUC Ratio,,57,
Onset,s,57,
Polyamine level,,57,
Max increase,%,57,
LD0,mg kg-1,57,
Mean uterine weight,mg,57,
ID90,uM,57,
Ratio,ug ml-1,57,
Total radioactivity,ug equiv g-1,57,
LBF,%,57,
RPP,%,57,
AUC cytotoxicity,,57,
SI,uM,57,
ED50,microg/cm2,57,
K,10'-5/s,57,
Surviving fraction,,57,
Anti-pent effect,,57,
Max PI,%,57,
Activity,mmHg/s,57,
EC80,ug ml-1,57,
Antiovulatory activity,%,57,
Uterine activity,%,57,
PC,,57,
Kb,M-1,56,
Modification,%,56,
Lipid-soluble radioactivity,,56,
Therapeutic index 99,,56,
pTCD50,,56,
Growth of cells,,56,
Activity,10'6CFU,56,
MDD50,mg kg-1,56,
% Inhibition of Control Values (Mean n=2),%,56,
Kr,/min,56,
ZImax/KZI,mm microL/micromol,56,
IC,uM,56,
Log k,,56,
Deuterium retention,%,56,
EC30,ug ml-1,56,
Vmax,nM/s,56,
Relative stability,%,56,
pRA2,,56,
T99.9%,hr,56,
Uterine weight,,56,
pRA1,,56,
Activity,umolequiv/g,56,
Stimulation,,56,
IZ,mm/mg,56,
T/C,min,56,
ITP,%,56,
Metabolism,pM min-1 mg-1,55,
Reactors/Test group,,55,
permeability,10'-4 cm/s,55,
Antidiuretic activity,mg,55,
AUC/dose,microg.hr/mL,55,
PO2,%,55,
Activity,pA/pF,55,
-log(inh/100-inh),,55,
D50,,55,
ID75,uM kg-1,55,
Log 1/EDMES(2.5),,55,
GC50,,55,
K,10'3/s,55,
K inact,s-1,55,
CD,nM,55,
TAC,mmol/L,55,
pA2,nM,55,
Activity,kcal/mol,55,
NOHA,%,55,
Activity,uM kg-1,55,
ED50,ug ear-1,55,
Log 10 LC50,,55,
NO formation,%,55,
logKa,,55,
Serum total triglycerides,mg dl-1,55,
Removal of microfilariae,%,55,
MTD,ug ml-1,55,
Clearance,ul min-1,55,
Supression,%,55,
Clearance,L/h/Kg,55,
Kinact,/M/min,55,
log(1/D40),,55,
Saluretic score,,55,
ED100,ug,55,
EDMES(2.5),mg kg-1,55,
Log AP,,55,
pC,,55,
STY seizure,mg kg-1,55,
Recovery,,55,
Activity,umol/g,54,
MBEC50,ug ml-1,54,
Drug uptake,ppm,54,
CC25,,54,
Binding energy,kCal M-1,54,
Protected mice,%,54,
pKm,,54,
AUBC,log10CFU/ml.hr,54,
Drug uptake,pmol/mg,54,
ED300,ug kg-1,54,
Kcat/Km,microM/s,54,
log(1/ED30),,54,
Drug metabolism,ng/g,54,
Papp,10^-8cm/s,54,
Relative ID50,,54,
Vmax,uM min-1mg-1,54,
Activity,mmol/g,54,
Concentration,ng (g of tissue)-1,54,
AUC,microM.hr/mg/kg,54,
Biodistribution,dose/organ %,54,
No. of lung colonies,,54,
Log D50,,54,
Median survival day,,54,
Injection dose/g,%,54,
No. of falls,,54,
nHill,,54,
Receptor occupancy,%,54,
Rel Max FI,,54,
Maximal effect,%,54,
Total dose,mg kg-1,54,
Growth Inhibition,mm,54,
Polyamine content,nM g-1,54,
alphaKi,uM,54,
Ct,ug ml-1,54,
Rotation number,,54,
Ka,L/mol,54,
log(10'6/IC50),,54,
Initial activity,%,54,
SUVmax,,54,
Relative inhibition,%,54,
CLH,uL/mg/min,54,
Length,mM,54,
CD50,nM mouse-1,54,
k cat,,53,
LogFC,,53,
Normalized abundances for DMSO,,53,
CS index,,53,
MBC=>99.9,uM,53,
Inhibitory diameter,mM,53,
Behavioral effect,,53,
LD10,,53,
Methemoglobin,%,53,
DOPA accumulation,,53,
Life span,day,53,
KSV,10'4/M,53,
Activity,10^3 /uL,53,
Binding,,53,
Max increase,,53,
Clined screen test,,53,
Vmax(app),/s,53,
MLD,ug ml-1,53,
Relative agonistic activity,%,53,
Delta HR50,beats min-1,53,
IC50,10^2 uM,53,
Turns,,53,
EC95,ug ml-1,53,
Ki,ug ml-1,53,
Ki',uM,53,
Punch weight/MPO activity,,53,
Maximal activation,%,53,
K,/uM/s,53,
Normalized abundances for compound,,53,
MED=>50,,53,
Drug uptake,%ID/ml,53,
CLz/F,L/hr/kg,53,
ED90,gAi,53,
Anti-fighting behaviour,,53,
Drug metabolism,umol,53,
Delta HR50,%,53,
Blood glucose,mg dl-1,53,
Drug degradation,mol%,53,
K,10'6/M/min,53,
IC90,ppm,52,
Incorporation,c.p.m.,52,
Stool output,g (350g of rat weight)-1,52,
Vmax,pM min-1 mg-1,52,
IC50,uM well-1,52,
CD,ug ml-1,52,
Vmax/Km,uL/min,52,
Inhibition potency,,52,
Protective effect,%,52,
K,10^-3/s,52,
K,10'-5/M,52,
GM-MIC,ug ml-1,52,
Activity,degree,52,
Fraction experiencing seizures,,52,
Ratio,10'4/M/s,52,
Kdiss,/s,52,
IC90,uM well-1,52,
Vmax,uM,52,
Kinetic_solubility,Ug/ml,52,
Transactivation,%,52,
Activity,million/mm3,52,
Eye toxicity,,52,
ECmax,uM,52,
Saldiuretic activity,m equiv 6hr-1 kg-1,52,
-Log Kdiss,,52,
Distribution coefficient,,52,
TWI,%,52,
pKp,,52,
SER,,52,
Ks,nM,52,
Delta p,%,52,
EC50,nmol/cm2,52,
Rhodamine-123 accumulation,arbitrary units,52,
Zone diameter,mM,52,
Max/average,,52,
ED50,pM mouse-1,51,
MOT,min,51,
MIC=>50,uM,51,
Zone of stimulation,mM,51,
Relative inotropic potency,,51,
Papp,10'-4 cm/s,51,
Activity,kCounts,51,
Competition factor,,51,
Drug uptake,cpm,51,
Antihypertensive score,,51,
Acceptor activity,,51,
% of Control Agonist Response (Mean n=2),%,51,
Max Achievable Bioavailability,%,51,
ascites volume,ml mouse-1,51,
Weight loss,%,51,
packed cell volume,%,51,
EC,mM,51,
Challenge time,min,51,
Increase in CBF,ml min-1,51,
Activity of control,%,51,
Kcat/Km,10'7/M/s,51,
Vmax,mM/min,51,
Kis,,51,
UI,mm,51,
pIC90,,51,
Responding,%,51,
IC50,p.p.m.,51,
CLH,nmol/min/mg,51,
IC90 mutant/IC90 WT,,51,
cAMP activity index,,51,
% Inhibition of Control Agonist Response (Mean n=2),%,51,
Aneuploidy activty,,51,
K2,uM,51,
Log ESA,,51,
CLH(app),,51,
GT fold stimulation,,50,
Delta pH,,50,
Days,,50,
Rate of O2 consumption,nM min-1,50,
FBP mean score,,50,
MPC,,50,
Avg IC90,uM,50,
Kcat/Km,10'3/M/s,50,
S0.5,mM,50,
Beta-lactamase induction,,50,
GDP ED50,mg kg-1,50,
Log K1,,50,
Ka,10'3/M,50,
logCL,,50,
Reversion activity,%,50,
AbsAC30,uM,50,
FT mean score,,50,
Activity,ng/mg,50,
Survival rate,number of mice,50,
Log 1/ratio,,50,
Systemic effect,%,50,
Ka,10'6/M/s,50,
Modulation factor,,50,
Cp(f),%,50,
Virucidal,nM,50,
Tissue distribution,ug g-1,50,
Activity,nmol/mg.min,50,
CL,uL/ml/kg,50,
Max T/C,,50,
Uptake,nM (mg of protein)-1,50,
pKi,mM,50,
LC95,mg/L,50,
Total excretion,%,50,
Ka,10'-4L/mol,50,
Increase in concentration,uM,50,
Initial blood pressure,mmHg,50,
Blood pressure,%,50,
K,10'-8M,50,
LED,mg kg-1,50,
K,10'4/M.s,50,
BDW,g,50,
Locomotor activity,mg kg-1,50,
T>MIC,hr,50,
Max delta APD95,%,50,
K,10'7/M,50,
Papp,10^7cm/s,50,
C20,ug kg-1,50,
Efficacy ratio,,50,
mequiv of Na+/kg,0-5h,50,
Max,mmHg,50,
BP,%,50,
XI50,uM,50,
pEC100,,49,
Control Uptake,%,49,
APTT,IU mg-1,49,
ka,min-1,49,
RIC50,,49,
Accumulated counts,,49,
Efficacy,nM,49,
Ks/i,uM,49,
MTL,uM,49,
Delta TAO,,49,
BWC,g,49,
Arterial pressure,mmHg,49,
Bmax,%,49,
Turnover,,49,
pTI,,49,
Median life span,day,49,
FA,%,49,
Activity,um/hr,49,
ED2,,49,
ADI,,49,
N,,49,
Antiviral effect,,49,
K,hr-1,49,
Recovered,%,49,
-Log C,,49,
ID50,uM hr-1 kg-1,49,
Mean body weight,g mouse-1,49,
Activity,/ml,49,
KSV,10'4L/mol,49,
Efficacy index,,48,
No. protected/tested,,48,
Activity,CFU/g,48,
LD50,M,48,
MABP change,mmHg,48,
log10FFU,,48,
Glucose rise,mg dl-1,48,
KSV,10'3/M,48,
Ka,nM,48,
Ka,10'7/M/s,48,
GTP shift,,48,
Drug recovery,%ID,48,
Vmax / Km,,48,
Total activity,uM min-1,48,
Pmax,mM,48,
fold selectivity,fold selectivity,48,
Skin tests intensity,,48,
Cmin,uM,48,
ED50,uM l-1,48,
Concentration,uM g-1,48,
Cytoprotective effect,,48,
Binding constant,M-1,48,
Urine volume,ml min-1,48,
MED,ug ml-1,48,
Drug concentration,uM,48,
K Bind,uM,48,
Survival range,,48,
K bind,nM,48,
Potentiation,,48,
K inact,M-1 s-1,48,
Tm shift,degrees C,48,
Diameter,mM,48,
Behavior score,,48,
Baseline,%,48,
Optimal concentration,mM,48,
EC75,uM,48,
AUC/dose,ng/hr/ml,48,
P ABC,,48,
Reversal,,48,
Irritation,arbitrary units,48,
Increase in footpad thickness,mM,48,
Drug uptake,umol/Kg,48,
CLH,min/ml/kg,48,
ED25,,48,
EC99,ug ml-1,48,
CD50,,48,
Specific activity,nM min-1,48,
Inhibitory concentration,ug ml-1,48,
MTD50,mg kg-1,48,
PWT,g,48,
Radioactivity,c.p.m.,48,
IA50,%,48,
Broncho selectivity,,48,
MI0.5,nM,48,
logPm,,48,
MNTD,mg kg-1,48,
Kic,nM,48,
RH,%,48,
FI5,nM,48,
Activity,fmol/min,48,
ECI,%,48,
ED40,,48,
Stability,mg/ml,48,
ED10,mg kg-1,48,
MID,uL/L,48,
Compound remaining,%,47,
Alphax10E,,47,
LD10,mg/kg/day,47,
K0.5,uM,47,
solubility,10^-6 cm/s,47,
Relative Ki,,47,
CL,L/Kg.hr,47,
Mean latency,s,47,
Positive cells,%,47,
Permeability,cm s-1,47,
Activity,IU mg-1,47,
[35S] TBPS shift,,47,
Pgp AbA/analogue ratio,,47,
Vc/F,l,47,
CBF Ratio,,47,
Activity,/mm3,47,
Rectal temperature,degrees C,47,
Response rate,,47,
MIC70,ug.mL-1,47,
Log Ko,,47,
Reactivation,%,47,
Contragestational activity,mg kg-1,47,
ID50,nM ml-1,47,
Growth,,47,
FBF Ratio,,47,
MAC,ug ml-1,47,
cAMP,%,47,
Survival rate,,47,
Mean IC50,,47,
Log Pn,,47,
Stability,pmol,47,
Activity,mmolequiv/L,47,
LMA,,47,
Body weight,%,47,
Activity,uL,47,
Cp,%,47,
permeability,%/hr,46,
Lethal dose,mg kg-1,46,
Relative uptake,,46,
LM,uL/min/mg protein,46,
Vigour_index,,46,
Ataxia,%,46,
Average lesion score,,46,
Variation/Control,%,46,
Log SOSIP,,46,
Log TGI,,46,
MNCC,mM,46,
Log 1/I50,1/M,46,
Log ILS max,,46,
kin,hr-1,46,
MDR ratio,,46,
RD50,mg kg-1,46,
MI50,ug ml-1,46,
Activity,10'6/mm3,46,
REP,%,46,
Ki,ug nM-1,46,
Pm,,46,
Fold-induction,,46,
KB app,,46,
MED20,mg kg-1,46,
EC20,%,46,
Drug uptake,mM,46,
Activity,10'-3mg/ml,46,
Duration of action,,46,
Cell number,,46,
Log M50,,46,
Dose excreted,%,46,
Cytotoxic activity,,46,
Reaction time,s,46,
Delta APD90,,46,
Relative ET-A IC50,,46,
IC15,uM,46,
Active/total cultures,%,46,
C175,uM,46,
Blood sugar lowering,,46,
Activity,nM/mg,46,
Activity,nM/mg*min,46,
PKa,,46,
PFU/ml,,46,
Possible response,%,45,
pEC170,,45,
ED100,ug kg-1,45,
rIC50,,45,
Activity,cm/s,45,
Change in body temperature,degrees C,45,
log(1/CON),,45,
Foci/dish,,45,
Activity,ng dl-1,45,
RAC app,,45,
AUEC,A% min-1,45,
Relative F%,,45,
CAC,uM,45,
ka/Ki,uM-1 min-1,45,
Papp,10^-7 cm/s,45,
Acute electroshock activity,,45,
Delta G,kCal mol-1,45,
Hepatic Extraction ratio,,45,
Level,mg dl-1,45,
Delta MABP,mmHg,45,
LV FRP,%,45,
ED50,10'3nM,45,
No. of animals with liver necrosis,,45,
Antiviral activity,mM,45,
Weight,,45,
OD(540nm),,45,
Drug metabolism,micromol/min,45,
logK(lung),,45,
Drug uptake,ng/ml/g,45,
Vz/F,l,45,
Ka,10'-5/M,45,
Blood level,ug ml-1,45,
Kb,10^4/M,45,
NC,,45,
Tubulin binding,%,45,
LC90,mg/L,45,
Alpha,,45,
Apparent enzyme activity,,45,
Relative Kd,,45,
Kcat,10'5/s,45,
CC25,uM,44,
MBEC50,uM,44,
Administered dose,%,44,
logK(blood),,44,
Inhibition constant,,44,
Decrease in MABP,%,44,
Decrease in QA interval,,44,
Change in blood pressure,delta mmHg,44,
No. of mice survived,,44,
Cells killed,%,44,
ECmax,%,44,
GR,%,44,
log1/CLD50,,44,
Ka,10'7/M,44,
IC20,,44,
Drug degradation,/hr,44,
Fraction cured,,44,
Kcat/Km,10'6/s/M,44,
Virus yield,log pfu ml-1,44,
Immobility time,s,44,
LVP,mmHg,44,
Activity,ug/L,44,
ED50,10'-5 ug/ml,44,
CL,ug/min,44,
CPP,mmHg,44,
Alpha max,%,44,
Change in response rate,%,44,
Reversal type,,44,
Antitumor activity,%,44,
Average weight change,,44,
LD,uM,44,
Ki ss,nM,44,
Level,U l-1,44,
GSH-Px activity,,44,
HD50,ug ml-1,44,
Activity,10'-6M,44,
Mean blood pressure,%,44,
-logKa,,44,
Delta TM,c,44,
Liver weight,mg (g of body weight)-1,44,
pA2/pKB,,44,
MED,mM kg-1,43,
RL,%,43,
KiH,nM,43,
EPMR,,43,
Potential,,43,
CL_renal,ml/min,43,
REA,,43,
fCmax,ug ml-1,43,
R,,43,
Log Kw,,43,
EC5,nM,43,
Inhibition over time,%,43,
pEC90,,43,
TCID50,ug ml-1,43,
deltaS,kJ/mol,43,
Sleeping time,,43,
MNEC,uM,43,
Max inhibition,,43,
Drug metabolism,nmol/mg/hr,43,
pD,M,43,
Influx,nM mg-1,43,
Net log cell kill,,43,
TP,%,43,
ILS30,,43,
log1/CED90,,43,
AUClast,hr.ng/g,43,
GR80,gAi/ha,43,
Behavior,,43,
Activity,micromol/m2/s,43,
Activity,/mM/min,43,
Active dose,mg kg-1,43,
Diuretic activity,ml kg-1 6hr-1,43,
Cmax/dose,ng/ml,43,
Control compound IC50,uM,43,
Recovery time,min,43,
Deoxyribose degradation,uM of MDA mM-1,43,
DR10,mg kg-1,43,
Activity,pg/g,43,
Competition,%,43,
"% Enzyme Activity (relative to DMSO controls, average n=2)",%,43,
Unchanged,%,43,
Median survival time,day,43,
kr,min-1,43,
Ka,10^5/M/s,43,
RSA,%,43,
LT50,ppm,43,
LD5,uM,43,
ED50,mg ear-1,43,
No. of entries,,43,
SP,%,43,
Activity,10'3 /uL,43,
Distribution,% dose g-1,42,
MED>50,mg kg-1,42,
Lethality,dead/total,42,
EC80,ppm,42,
Emax,pM,42,
Activity,ng/g,42,
Radioactivity,nM equiv (mg of tissue)-1,42,
Antihypertensive activity,,42,
AUC,ng/ml,42,
Diuretic activity,m equiv,42,
Urinary volume,,42,
AUC,ng.hr/ml/mg/kg,42,
Capacity,,42,
Uterine weight,g,42,
Cell protein,ug dish-1,42,
ED80,mg kg-1,42,
Compound recovery,10^-9M,42,
ED90,mg l-1,42,
Rise HR,,42,
MLD50,uM,42,
Csat,g dl-1,42,
Csat/Co,,42,
Co,g dl-1,42,
RD500,mg kg-1,42,
MED,M kg-1,42,
Range,day,42,
Max change in blood pressure,mmHg,42,
Separation,,42,
Tremorolytic dose,uM kg-1,42,
No. of cured,,42,
Vdu,ml,42,
ID40,mg kg-1,42,
APD60,,42,
Na+ excretion,,42,
Clast,ng/ml,42,
IT50,min,42,
P (Ei),,42,
Daq,10'-6cm2/s,42,
K,/M,42,
PCY,,42,
Ka,/M/s,42,
No. of shocks,,42,
No. of dead mice,,42,
Loss of righting reflex,,42,
ED35,mg kg-1,42,
Decrease in SBP,mmHg,42,
Bmax,pmol/mg,42,
k cat/Km,10e4 M-1 s-1,42,
NBT positive cells,%,42,
K,10^-4/s,42,
Inhibition,delta A min-1,42,
K+ excretion,,42,
AUClast,,41,
Smax,uM min-1 kg-1,41,
Index,%,41,
pK50,,41,
Pigment binding,%,41,
ED125,uM kg-1,41,
AC200,uM,41,
GI,mM,41,
ED50,M l-1,41,
Fmut,,41,
Cell death,%,41,
-Log IC25,,41,
Kr,M,41,
CAR,,41,
Relative rate,,41,
Relative rate of hydrolysis,%,41,
Log C,,41,
Vmax,nM min-1 mg-1,41,
ID50,mg,41,
MNTD90,uM,41,
Survival rate,%,41,
DNA crosslinking,,41,
Concentration,ug/g tissue,41,
Activity,U mg-1,41,
Antagonistic activity,,41,
WBC,%,41,
MfI,,41,
Migration index,,41,
K,10^5/M/s,41,
IC50,g/ha,40,
ID50,ng/ml,40,
IC70,nM,40,
ID90,mg kg-1,40,
Activity,U/min,40,
Drug uptake,pmol/min,40,
AZT formation,,40,
Drug uptake,nmol/mg.min,40,
Activity,uM min-1 (mg of protein)-1,40,
Tissue concentration,% injected dose g-1,40,
ASF,p.p.m.,40,
In vivo duration,Minutes,40,
Delta ERPc,%,40,
ID50,mM l-1,40,
MIC100,microg/ml,40,
K,mM,40,
Change in BP,,40,
ID50,M l-1,40,
Change in BP,%,40,
MIC=<80,ug ml-1,40,
MP,%,40,
Aspirin formed,%,40,
Zone diameter,,40,
CFU,10'8/ml,40,
Activity,Bq,40,
DD,uM of MDA mM-1,40,
EC12,uM,40,
Body weight reduction,%,40,
MES ED50,mg kg-1,40,
Papp,10^-5cm/s,40,
ED50,umol/cm2,40,
EC25,,40,
Arthritic score,,40,
Biodistribution,ug of B g-1,40,
KSV,10^4L/mol,40,
Reactivity,,40,
Dose,uM,40,
ECmax,nM,40,
Fold activation,%,40,
Luciferase activity,RLU 10s-1,40,
Positive control,%,40,
Serum cholesterol,mg dl-1,40,
Mean no. of revertants,,40,
Cytokine induction,,40,
EC90,pM,40,
Fluorescence Intensity,,40,
GR,,40,
log(1/MIC>90),,40,
Max inhibitory effect,%,40,
Log 1/ID75 (uM L-1),,40,
Dose,ug,40,
ED99.9,mg kg-1,40,
RTV,,40,
RPF,pM nM-1,40,
pKa_B2,,40,
Quantity,mg,40,
ED50,mg l-1,40,
RU,pg/mm2,40,
Ki/KI,M-1 s-1,40,
Kii,nM,40,
LD50,g/ha,40,
ED90,ug ml-1,40,
LD20,mg kg-1,40,
Recovery time,%,40,
"Kpot A,B",,40,
K,10^-2/uM/min,39,
ID50,10'-4M,39,
Decrease in CR,,39,
P24 concentration,ng ml-1,39,
Dead,,39,
IS/AAR,%,39,
Activity,Hz,39,
Oral diuretic activity,u equiv of [Na+] kg-1 hr-1,39,
Infectedmosquitoes,%,39,
I 90,,39,
k,s-1,39,
log Kp,cm/s,39,
Kdiss,10'-3/s,39,
Kp,ucm/s,39,
Vd,ml,39,
Flea,p.p.m.,39,
BCM serum Ca,mg 100ml-1,39,
Activation,,39,
Kp,10^-6 cm/s,39,
FI,,39,
Delta pCa50,,39,
Kq,10'12/M/s,39,
Average dose,ug kg-1,39,
Cp,ng/g,39,
CLint,uL/min/1E6 cells,39,
D150,mg kg-1,39,
k cat/Km,mM-1 min-1,39,
Rate of phosphorylation,,39,
k2,,39,
Analgesia duration,,39,
RSA,,39,
Ka,10'4/M/s,39,
Mean arterial blood pressure,,39,
Activity,nM (mg of protein)-1,39,
Max temperature decrease,,39,
E,,39,
Relative susceptibility,,39,
Topical potency,,39,
MIC,10'-3uM/ml,39,
TBMIC,ug ml-1,39,
Lesion length,mm mice-1,39,
Toxic level,M,39,
Change in body weight,g mouse-1,39,
Vmax,microM/min/mg,39,
Activity,ug (mg of protein)-1,39,
BWC,%,39,
Vmax,nM/mg*min,39,
Na,m equiv 6hr-1 kg-1 (body weight)-1,39,
Suppression,,39,
V,ml 6hr-1 (kg of body weight)-1,39,
delta(V1/2),mV,39,
MAP,,39,
Ratio AUC,%,39,
EC170,uM,39,
Apoptotic Activity,%,38,
D50,10'-5M,38,
Stability,day,38,
ED50,mg/day,38,
Histone_modification,,38,
Inhibition,ug kg-1,38,
x fold,uM,38,
CLH,ml/hr,38,
AUCt,,38,
Binding ratio,,38,
% NO2-,M/M,38,
Activity,/g,38,
Activity,log10PFU/ml,38,
CIC,nM,38,
Activity,kilobase,38,
Activity,nM min-1 mg-1,38,
Change in heart rate,,38,
Acute toxicity,,38,
Binding,(ng of DNA) dish-1,38,
BMF,,38,
Affinity ratio,,38,
K aps,l M-1,38,
Relative luciferase response,,38,
Partition ratio,,38,
PDH active/PDH total,%,38,
Dose/g of tissue,%,38,
RIA,,38,
IC50,mMequiv,38,
DNA binding,degrees C,38,
IC80,,38,
PL,%,38,
MLC,%,38,
x fold,,38,
Onset,hr,38,
I90,ppm,38,
MLS,day,38,
Dose,mg kg-1 day-1,38,
Log PR,,38,
pKapp,,38,
LogPapp,,38,
Lipophilicity,=,38,
No. of animals survived,,38,
LD0,mg,38,
Ct,pmol/g,38,
Vertebral blood flow,,38,
pMIC,,38,
Presynaptic antagonism,,37,
BP change,%,37,
Dose-modifying factor,,37,
Alpha max,uM,37,
C20,uM l-1,37,
H ABC,,37,
INH,mm,37,
Vasoconstriction effect,,37,
DNA cleavage,ug ml-1,37,
QH,,37,
Delta T,degrees C,37,
AD50,uM kg-1,37,
Postsynaptic antagonist,,37,
BSI,,37,
Vmax,deltaOD/min,37,
Inihibition,%,37,
Hyperglycemic activity,,37,
Mu/kappa ratio,,37,
MIC100,umol/ml,37,
Glucose level,mg dl-1,37,
No. of animals exhibiting toxicity / Number of animals tested,,37,
Change in Tm,,37,
AUC,ng.hr/Kg,37,
MED,mg kg-1 5day-1,37,
Kdiss,10'-4/s,37,
Agonist,%,37,
Hmax,,37,
Papp,%,37,
Kreact,s-1,37,
Time,nanoseconds,37,
Activity,PSL/mm2,37,
Test/control survival,,37,
NSB,,37,
log(10'3/IC50),,37,
MTD,mg kg-1 5day-1,37,
AUC/dose,hr.kg.ng/ml/mg,37,
GMMIC,ug ml-1,37,
Tension,%,37,
Drug uptake,mg/L,37,
CT10 ratio,,37,
P50e/P50c,,37,
A1 selectivity,,37,
Delta BG,,37,
Kobs,/min,37,
Delta HR,beats min-1,37,
Stability,% ID/g,37,
No. of mouse protected,,37,
Fu,uM,37,
Max delta MAP,mmHg,37,
Max delta HR,beats min-1,37,
FaFg,,37,
G30,,37,
EC10,nM,37,
K2,nM,36,
-log(1/EC50),,36,
Inhibition_index,,36,
Optimal dose,mg,36,
Exp Inhib Constant,,36,
Activity,Counts,36,
Decrease in AP,,36,
Polyamine,pM g-1,36,
Reversal ability,,36,
C,uM,36,
Pressure,mmHg,36,
K,10^-2/s,36,
k,,36,
K,mM/min,36,
Relative toxicity,,36,
Initial rates,,36,
Incorporation rate,c.p.m. hr-1,36,
SC50,ug ml-1,36,
Enzyme level,U l-1,36,
log1/activity,,36,
Activity,g%,36,
Survival increase,,36,
pEC0.5,,36,
Pc,nm s-1,36,
Degradation rate constant,hr-1,36,
Activity,10'-5/ml,36,
nNOS activity,%,36,
Sensitized animals,,36,
IG,%,36,
logLD50,,36,
Inhibition,pM of cAMP min-1 mg-1,36,
30 day survival / total,,36,
Relative inhibitory potency,,36,
% Inhibition of Control Values,%,36,
36Cl- uptake,,36,
IC,ug ml-1,36,
ID50,mg/day,36,
koff,1-s,36,
RVR,,36,
ED95,p.p.m. in feed,36,
Ct,% ID/g,36,
SD,min,36,
Kb,10^5/M,36,
SI,beats min-1,36,
Activity,umol/hr,36,
Log 1/ED50,,36,
Tubulin polymerization ratio,,36,
Log 1/LD50,,36,
MEC,mg l-1,36,
Log M,,36,
Log k'w,,36,
Amax,pmoles,36,
MBIC50,,36,
Uptake at C50,,36,
Cross linking,%,36,
G index,,36,
TI,uM,36,
Delta cpm x10e-3,,36,
ED90,p.p.m.,36,
Formation of NO2-,nM,36,
AUC/dose,ug.hr/mL/mg/kg,36,
Ki,10^2 uM,36,
EC1000,nM,36,
IC25,umol/L,36,
Dose,rd mCi-1,36,
fCmax,mg/L,36,
Vmax,mAU/min,36,
Delta/kappa,,36,
RBA ratio,,36,
MIC50/MIC90,,36,
Activity,/mmol/min,36,
Plasma GH release,ng ml-1,36,
Rate,%,36,
fpIC50,,36,
Delta pKi,,36,
Maximal non-toxic dose 50,ug ml-1,36,
Intrinsic Toxicity,,36,
Change of body weight,%,36,
CMR,,36,
AUC/dose,nM.hr/mg/kg,36,
BNa,%,36,
MSD,,36,
Activity,nmol/g tissue,36,
Thymidine shift,,36,
Vmax,pmol/mg/min,36,
CL,nmol/mg.min,36,
IA50,equiv,35,
LC50,microg/cm2,35,
Weight gain,%,35,
ED50,10'-6 ug/ml,35,
2x aPTT,uM,35,
LD50,microg/cm2,35,
ED40,ug kg-1,35,
Volume,l hr-1,35,
LD90,ppm,35,
Vmax/Km,microL/min/mg,35,
Drug metabolism,nmol/mg/min,35,
Average tumor volume,mm**3,35,
pAlpha,,35,
Kcat/Km,/uM/min,35,
LED,mgP kg-1,35,
Cellular reversion,%,35,
Loss of righting reflex,%,35,
Drug uptake,fmol,35,
Log 1/ED40,,35,
Change from Control (LV dp/dt),%,35,
Cmin,umol/L,35,
Log TCID50,,35,
ID50,10'-5M,35,
solubility,ml,35,
Log ED50,,35,
IT100,min,35,
k cat/Km,mM-1 s-1,35,
Average turns,,35,
p alphaKa,,35,
pKHB,,35,
AFI,,35,
fT>MIC,hr,35,
CT50,uM,35,
LOAEL,uM,35,
CLH,10^-6uL/min,35,
AUC,ng.hr.kg/mg/ml,35,
Ratio,1/Ms,35,
Activity,mg ml-1,35,
MTD50,ug ml-1,35,
Exhibiting turning,%,35,
Activity,RFU min-1,35,
MD,mg kg-1,35,
MF,%,35,
Activity,/nmol,35,
Motor activity,,35,
Plasma glucose,mg dl-1,35,
Protected,,35,
ED50,M kg-1,35,
Tumor response,%,35,
Mean survival time,,35,
ED50,mg 4kg-1,35,
Minimal dose,ug ml-1,35,
Ratio,/mM/min,35,
Cholesterol,mg 100ml-1,35,
TMP.decrease,degrees F,35,
McPhail index,,35,
Agonist activity,%,35,
AbsAC0.39_uM,uM,35,
Decrease in IC50,,35,
SBP,mmHg,35,
ED50,umol,35,
MPC4,ug ml-1,35,
Activity,beats min-1,35,
FSC recovery,%,35,
MIC,U ml-1,35,
MTD,umol/Kg,35,
Seizure score,,35,
ERP,%,35,
Incidence,,34,
Ea,kJ/mol,34,
Selectivity ratio S3/1,,34,
No. of retches,,34,
Cardio selectivity,,34,
Activity,10'7No_unit,34,
% of selectivity,%,34,
IC75,uM,34,
Caco-2 Papp,cm s-1,34,
Duration,s,34,
Cell cycle analysis,,34,
OD,ug kg-1,34,
KOX,M-1 min-1,34,
Phosphorylation rate,uM,34,
Flu intensity,%,34,
Currents,%,34,
MED,mg,34,
Loss of cells,%,34,
Log k' w,,34,
TN,uM min-1,34,
TAR,,34,
Log KAT,,34,
TMED50,mg kg-1,34,
Activity A,uM kg-1,34,
MFC,ug,34,
Rate constant,min-1,34,
CL,ml/mg/kg,34,
dP/dt,mmHg s-1,34,
Agonistic activity,,34,
dP/dt max,,34,
Control current,%,34,
SH level,uM g-1,34,
T50,hr,34,
Parent compound,%,34,
Delta Gsolv,kCal mol-1,34,
Bapp,,34,
Stabilty,ml/min.Kg,34,
Ki low,nM,34,
ER,,34,
Range of survival days,,34,
Cells in metaphase,%,34,
rf50,,34,
E 1/2,,34,
Delta Fmax,%,34,
AUC/dose,nmol.hr/L,34,
C0,uM,34,
CTS,,34,
AUCt,ng/g.hr,34,
Rolipram activity,%,34,
Synergy,fold,34,
Ka,10'3/M/s,34,
RC50,uM,34,
Retention_index,,34,
Activity,10'5U/mL,34,
Death,,34,
K,10'7/M/min,34,
K,10'4L/mol,34,
K,1/s,34,
Cytotoxic concentration,M,34,
PI metabolism,%,34,
K cat,1/sec,34,
Serum level,,34,
Jump latency time,s,34,
Kill at C50,%,34,
Survival median,,34,
BA,,34,
Change of SBP,%,33,
inhibition of control,%,33,
TG,mg dl-1,33,
GI90,nM,33,
Change of CF,%,33,
KT,,33,
Specific index,,33,
BP decrease,%,33,
Pm,10^-5 cm/min,33,
cGMP content,pmol/mg protein,33,
Ka,10^4/M,33,
Saluretic potency,u equiv min-1,33,
-Log 1/Kb,,33,
Cytotoxiciy,,33,
Edema,,33,
Plasma insulin,ml,33,
Change of HR,%,33,
L/CE,%,33,
Symptoms,,33,
No of monkeys,,33,
dP/dt,max,33,
Functional profile,,33,
Polyamine level,nM,33,
Selectivity coefficient,,33,
No. positive cases/tested,,33,
MUD,mg kg-1,33,
ED80,ug/kg,33,
Maximum test concentration that did not exhibit cytotoxicity,uM,33,
TdeltaS,kJ/mol,33,
Ks,M,33,
Change of CO,%,33,
Cmax/dose,nM.kg/mg,33,
Stereotypy score,,33,
Kapp,10^-6/M,33,
Change of DBP,%,33,
AC50,%,33,
Drug uptake,nmol/ml,33,
Duration of action,min,33,
LC50,ug,33,
Efficacy,uM,33,
Tlag,hr,33,
ED Arec,mg kg-1,33,
K1,nM,33,
Tm shift,Â°C,33,
Change in systolic pressure,mmHg,33,
ED30,uM,33,
SC50,,33,
Accumulation coefficient,,33,
Cytokinetic response,,33,
HVA control,%,33,
PDD50,ug ml-1,33,
Vmax,U/mg,33,
Total score,,33,
Activity,uV,33,
K,/nM/min,33,
K ass,l mol-1,33,
MI100,ug kg-1,33,
Activity in animals,%,33,
SRR,,33,
Clearance,,33,
Activity,umol/mg/min,33,
Ratio,1/uM*sec,33,
IW,,33,
Relative inhibition index,,33,
Phospholipidosis as % of positive control,%,33,
permeability,10^-7 cm/s,33,
permeability,uM,33,
RBF,,33,
CL,hr.Kg/L,33,
IM,,33,
Ratio,/uM,33,
tR,min,33,
CLH,umol/min/mg,33,
AUC,nmol.hr/g,33,
RT50,min,33,
DNA cleavage,,33,
Inotropic effect,,33,
Reverse transcriptase activity,,32,
Survivors / treated,,32,
AUC N,mM hr dose-1,32,
TD50,nM,32,
TAC,U,32,
SRR,%,32,
Stability,nmol/min/mg,32,
Activity,/day,32,
Cmax,ng/mg,32,
SPF,,32,
Temperature,,32,
Activity,umol/L/min,32,
Treated cells,,32,
EC95,nM,32,
Max drop,%,32,
MRT,,32,
GI90,uM,32,
No. of circlings,,32,
IC5,nM,32,
CI,ml min-1 kg-1,32,
Ionotropic activity,mg,32,
Anticonvulsant Activity,,32,
Repression,%,32,
Cytostatic activity,%,32,
pkB,,32,
Relative rate of hydrolysis,,32,
log10 TCID50,,32,
EC0.01,uM/A unit/min,32,
Ratio,10'3/M/min,32,
Recovery,mg,32,
DA response,%,32,
Activity,cm3,32,
Active dose range,mg kg-1,32,
pIC50(calc),,32,
1/IC50,,32,
pGC50,,32,
logKd,,32,
ED25,ug kg-1,32,
Activation time,%,32,
dP/dt,%,32,
Weight change at nadir,,32,
Vmax,/min,32,
Viscosity,,32,
AUC,nM,32,
Vdss/F,L.kg-1,32,
UI,%,32,
Cp,ng.Eq/ml,32,
Cp,nmol/ml,32,
ED50,molar ratio,32,
Licking latency,,32,
RLU,%,32,
Permeability,cm hr-1,32,
RBA2,,32,
Ka,10^6/M/s,32,
OD,nm,32,
Kq,10'12L/mol/s,32,
RBA1,,32,
Activity scale,,32,
Activity,mAU,32,
Drug degradation,uM,32,
RLU/well,,32,
MEC,mM,32,
Log B/F,,32,
Drug recovery,ngequiv/g,32,
Oral diuretic activity,u equiv of [Na+]  kg-1,32,
KiL,nM,32,
Kin x10e3,hr-1,32,
Plasma lipids,mg dl-1,32,
EC10x,mM,32,
HC20,uM,32,
DD,uM,32,
RC10,uM,32,
Activity,10^-10.mol/mg/min,32,
Log 1/IC50,mM,32,
Kcat,10'6/s,32,
CL,ml.min/kg,32,
CC25,umol/L,32,
Drug uptake,umol/L,32,
%,,32,
Activity,pmol/ml,32,
HDL-C,mg dl-1,32,
Ka,10^7/M,32,
No. of platelets,%,32,
MRF,,32,
IC30,nM,32,
Cell viability,uM,32,
MIC=>95,ug ml-1,32,
Occ50,uM,32,
KA,nM,32,
Dry weight,%,32,
MLD,,32,
No. of positive animals,,32,
Activity,nmol/umol,32,
Cell no/dish,,32,
K ass,M-1,32,
CD50,nM,32,
CIC95,,32,
Plasma GH,ng ml-1,32,
Activity,pmol/L,32,
Organ weight,mg,32,
C50,,31,
Log 1/MIC (mM L-1),,31,
Cleavage,ug ml-1,31,
ID50,umol/L,31,
Analgesic activity,%,31,
Activity,10'3CFU,31,
VT50,min,31,
UVAPF,,31,
Delta FC,%,31,
pEC15,,31,
SSC,,31,
Max hypotension,%,31,
Max possible effect,%,31,
Ca2+ transport,,31,
Survivors at day 9,,31,
Cured animals,,31,
Kcat/Km,uM/hr,31,
K,m equiv 6hr-1 kg-1 (body weight)-1,31,
Locomotor activity,uM kg-1,31,
Collateral index,,31,
Drug metabolism,nmol,31,
Relative PT,,31,
K,10^-2/min,31,
LogD5.0,,31,
solubility,mg,31,
Urinary output,ml,31,
Ka,min-1,31,
Uterine wet weight,,31,
Kcat,10^5/s,31,
Vd,ml/cm3,31,
Change from control,%,31,
LC95,mgAi/L,31,
LD90,J cm**-2,31,
Potentiation,nM mg-1,31,
Volume,,31,
Hypothermic effect,degrees C,31,
LD90,ug ml-1,31,
Vmax,nmol/mg.min,31,
EC100,ug ml-1,31,
AUC/dose,ug.hr/ml,31,
FSC,,31,
Metabolic stability,,31,
Activity,uM g-1,31,
MIC50,%,31,
DHP-I susceptibility,,31,
K1/2,uM,31,
Max collateral index,,31,
Time above IC50,hr,31,
MLC,,31,
Dissociation constant,,31,
MLD50,ug ml-1,31,
Tail vein toxicity,,31,
Tail flick latency,s,31,
Binding site preference,,31,
FL-1,,31,
Binding stoichiometry,,31,
MTC50,ug ml-1,31,
RBF,ml min-1,31,
G30,%,31,
permeability,pmol/s,31,
MIC100,nM,31,
Cl-,m equiv 6hr-1 kg-1 (body weight)-1,31,
MFC,mg/ml,31,
EC0.25,,31,
Treatment period,,31,
EFTPC,nM,31,
NG ratio,,31,
-Log activity,,31,
No. of nonpregnant/treated,,31,
K,%,31,
Spont activity,Counts 10min-1,31,
-Log IC50,,31,
Delta G,%,31,
Fluorescence activity ratio,,31,
Crel,,31,
log1/S,,31,
MIC+/MIC-,,31,
SOD activity,mM,31,
Delta ERP,%,31,
Accumulation,nM (mg of protein)-1,31,
In/Fi,,30,
Efflux ratio,,30,
Recovery time,,30,
Electrolyte excretion,uM sample-1,30,
Brain level,nM g-1,30,
Dec,%,30,
Cell cycle,nM,30,
PTZ protection,%,30,
Cardiac force,,30,
Ki50,uM,30,
Immobility,%,30,
Max decrease,,30,
Cp,mg/L,30,
T/C 1,,30,
Least dose,mg kg-1,30,
BP increase,mmHg,30,
ED85,mg kg-1,30,
Max delta FRP,%,30,
Max decrease,%,30,
Activity,cps,30,
Change in Tm,degrees C,30,
Kcat(app),/min,30,
Tumor size,,30,
Residual activity,,30,
Residual secretion,%,30,
Relative binding,%,30,
permeability,10'-9meter/s,30,
PD50,nM,30,
Papp B to A plus inhibitor (mean),10E-6 cm/s,30,
Activity,c.p.m. min-1 mg-1,30,
Recovery A to B plus inhibitor (mean),%,30,
CC75,uM,30,
Activity,uL/ml,30,
Phorbol displacement,uM,30,
DLS Concentration,uM,30,
Papp B to A (mean),10E-6 cm/s,30,
Phototoxic effect,,30,
FICI80,,30,
Efflux ratio plus inhibitor,,30,
-Log K,,30,
Papp A to B plus inhibitor (mean),10E-6 cm/s,30,
Skin reaction,,30,
Recovery B to A plus inhibitor (mean),%,30,
ID (per g of organ),%,30,
Drugexcretion,umol/min/kg,30,
Activity,IU ml-1,30,
Effect,mg dl-1,30,
CC10,ug ml-1,30,
Recovery B to A (mean),%,30,
Non-HDL-C,,30,
Max CF response,%,30,
T/V,,30,
KF,,30,
LC50,microg/mL2,30,
Ke,/min,30,
Stability,nM,30,
Activity,10'1AU.min,30,
pIC50,uM,30,
Assembly,%,30,
Max stimulation,,30,
LD50,10'-3 mol/L,30,
Drug uptake(free),,30,
KD',M,30,
Activity,ug/min,30,
LAD,M l-1,30,
Mean day of death,,30,
K,10'3/M,30,
KSV,,30,
MIC>90,10'-4M,30,
TC,,30,
Mean no. of shocks,,30,
pGI50,M,30,
Basal inhibition,%,30,
VAR,,30,
K,10'5/Ms,30,
-Log KB,%,30,
2aPTT,,30,
ED30,ug,30,
Log KA,,30,
Ki/KI,,30,
TC25,uM,30,
Activity,u equiv min-1,30,
Differential,,30,
No. of counts,uM kg-1,30,
Log CFU,,30,
HDL-C,,30,
MSIC,ug ml-1,30,
log(M50),,30,
EC100,mg/L,30,
TD50,mmol/Kg,30,
MPE,,30,
VERP,ms,30,
K rel,,30,
T-cell inhibition,,30,
Vmax,abs/min,30,
Speed of induction,,30,
Log sweet/bitter,,30,
GM,,30,
A2 selectivity,,30,
ED30,nM,30,
NT,mg kg-1,29,
Mutagenicity,revertants plate-1,29,
RV,%,29,
Cell growth,,29,
Nr/N,,29,
Stability,nmol/min/kg,29,
Body weight gain,g day-1,29,
NCC,%,29,
Antibody stimulation,,29,
SubMIC,uM,29,
Average peak Concn.,ug ml-1,29,
Concentration in serum,ug ml-1,29,
Viable cells,*10e-5,29,
Ka,10^-6/M,29,
Peff,10'-7 cm/s,29,
Maximal efficacy,%,29,
Net log kill,,29,
pKi ratio,,29,
Feed efficiency,,29,
-Log K0.5,,29,
Activity,kDa,29,
Feed consumption,g day-1,29,
Ka,10'3/M/min,29,
CFU,10'5/ml,29,
Activity,mgequiv/mmol,29,
Vz,l,29,
BFU,,29,
Relative change,%,29,
Mean enhancement of binding,,29,
EC200,nM,29,
Delta mV,,29,
MBP,ug kg-1,29,
Activity,pmol/mg/min,29,
ED15,ug kg-1,29,
Log Ki,D4,29,
No. of errors,,29,
Activity,10'8CFU,29,
Reversible,%,29,
MI,,29,
RM,,29,
Top1 cleavage activity,,29,
Total cholesterol,mg 100ml-1,29,
IC50,10^-9mol/L,29,
EC>90,uM,29,
Glucose normalisation,,29,
BPR,ml/g,29,
K cat,s-1,29,
Max dose,mg kg-1,29,
PGE2 Level,ng ml-1,29,
Lethality,,29,
Max contraction,%,29,
fEC50,uM,29,
RHR,,29,
Compound recovery,ng/g,29,
T/C min,%,29,
Contractility,%,29,
pC3,uM,29,
Toxicity zone,mM,29,
CLH,uM/ml,29,
Rate constant,,29,
ED 50,mg kg-1,29,
Activity,%ID,29,
Cp,pmol/ml,29,
KA,M-1,29,
ED ratio,,29,
CLIP,,29,
Increase in concentration,pmol/mg prot.,29,
pLADY,,29,
Cmin,,29,
pMIC,M l-1,29,
RIA,%,29,
Antimalarial activity,,29,
Enhancement,,29,
LambdaZ,hr,29,
Vmax,nmol/mg/min,29,
deltaH,J/mol,28,
Inverse relative potency,,28,
EC90,mg/L,28,
Optimal dosage,mg kg-1 dose-1 day-1,28,
LC100,ppm,28,
Ki,10'3/M/min,28,
Ataxia,mg kg-1,28,
Antiviral index,,28,
Cure rate,%,28,
No. of tumours,,28,
CL/F,ml/min,28,
IC30,ug ml-1,28,
Blood level,Counts min-1 0.2ml-1,28,
Mean log concentration ratio,,28,
LC100,ug ml-1,28,
Blockade,%,28,
Worm reduction,%,28,
Ratio,Io/Eo,28,
FICI,nM,28,
LC50,ng/cm2,28,
AUC N,uM hr dose-1,28,
TdeltaS,J/mol,28,
Organ weight ratio,,28,
Mydriasis,%,28,
Effect,day,28,
FSC,%,28,
Heart rate,min-1,28,
Edema ratio,,28,
Synergy,,28,
Arrhythmias times,,28,
No. of rats,,28,
IC30,,28,
CL/F,mL/min,28,
ICmax,ug ml-1,28,
RI,%,28,
TDI,/min,28,
MTD,mg Kg-1,28,
Content,ug (g of tissue)-1,28,
deltaG,J/mol,28,
pLADM,,28,
Cure,,28,
Delta P50,,28,
TN,M min-1 M-1,28,
P50e / P50c,,28,
APD50,ms,28,
pED50,uM kg-1,28,
Activity,10'3/M/s,28,
K2,M-1 min-1,28,
CL,ml/kg.min,28,
A-selectivity,,28,
Ka,10^4L/mol,28,
Ae,%,28,
Adjusted Ki,nM,28,
No. of cultures active/total,,28,
MET,,28,
k cat/Km,,28,
Active dose range,mg kg-1 day-1,28,
Relative inhibition,,28,
MIC,g,28,
CLH,uL/ml,28,
Tumors with CR,%,28,
solubility,10'-3mol/dm3,28,
CTL activity,,28,
Plasma glucose,mg 100ml-1,28,
VCR accumulation,,28,
LogK-IAMex,,28,
LC50,umol/dm3,28,
Tumor-free,survivors/total,28,
Drug metabolism,mmol/L,28,
EC50,mol%,28,
n50e,,28,
Ep,mV,28,
Saldiuretic activity,,28,
Kapp,/M/s,28,
Kel,hr-1,28,
T/C,survivors/total,28,
Max effect,mmHg,28,
pKred,,28,
LD,mg kg-1,28,
Drug metabolism,uM/L,28,
RFU,%,28,
Optical density,,28,
Cat score,,28,
Aggregates,%,28,
Anti-uterotrophic effect,,28,
Grip score,,28,
Lowest effective dose,mg kg-1,28,
Kb,10^6/M,28,
Activity,nanoampere,28,
ISC,%,28,
Actvity,mmHg,28,
Mitotic index,,27,
Myoblasts with parasites,%,27,
Saline control,%,27,
Muscarinic agonist index,,27,
Monoamine level,pg mg-1,27,
K ass,10e6 l M-1,27,
Survival after 10 days,,27,
Activity,microM/min/mg,27,
Activity,micrometer/day,27,
Na,,27,
Delta IC,%,27,
IC50,uL,27,
Na+ excretion,m equiv kg-1,27,
No. of pos rxns,,27,
Delta BP,%,27,
No. of animals responding/animals receiving drug,,27,
Delta G,kCal M-1,27,
Specific activity,nM min-1 mg-1,27,
NOEC,uM,27,
AUC/dose,pmol.hr/ml,27,
AUC/dose,pmol.hr/g,27,
Ratio,10'5/M/s,27,
PD2,,27,
T>IC50,hr,27,
Activity,pM (10e6*cells)-1,27,
pNF,,27,
Toxicity Survivors,,27,
MCT,s,27,
Reversibility ratio,,27,
MABP,delta mmHg,27,
IC50,10^3nM,27,
ED50,mmol/L,27,
VF,%,27,
log1/GI50,,27,
2PT,,27,
CLH,microM/min,27,
Total turnings,,27,
Kb,10'-4L/mol,27,
ID84,M,27,
Tox50,uM,27,
AdoMetDC,%,27,
p nMED,,27,
Ka,10^3/M,27,
Kact,nM,27,
KSV,/M,27,
MED50,,27,
% activity remaining,%,27,
MED,ug,27,
CF C20,uM,27,
Ka,1/Ms,27,
Long-term survivors,,27,
Parasitaemia,,27,
Activity,nmol/hr/mL,27,
Rate of hydrolysis,nM min-1 mg-1,27,
MPO release,ug ml-1,27,
Amount of cross-linked protein,(ug of cross-linked protein) (mg of protein)-1,27,
Vmax,M s-1,27,
EC150,nM,27,
Volume of ascrit fluid,,27,
LD50,umol/L,27,
LD90,,27,
ID (per g of tissue),%,27,
ID16,M,27,
Vmax,/s,27,
Plasma level,nM,27,
Plasma selectivity,,27,
Plasma level,mg ml-1,27,
Kinact,10'-3/s,27,
solubility,ppm,27,
Log K2,,27,
Cave,uM,27,
Kq,10'13L/mol/s,27,
Average survival days,,27,
Analgesic efficacy,%,27,
DD,,27,
dp/dt,mmHg s-1,27,
Kd,10^-1/s,27,
ED25,M,27,
Change,mmHg,27,
Vd,,27,
Pm,nm/s,27,
CC100,uM,27,
kinact,M-1 s-1,27,
T-C/C,%,27,
Weight gain,,27,
Activity,USP-U/mg,27,
K inact/Ki,M-1 min-1,27,
FRP C20,uM,27,
MTD,uM day-1 kg-1,27,
AUC/dose,ng.hr/ml.mg,27,
Activity,nM (10e6*cells)-1,27,
Max delta,%,27,
SSAT,%,27,
pCF,,27,
pKi1-pKi2,,27,
Differentiated cells,%,27,
Kcat,10'3/s,27,
E1/2,,27,
AUC,ug.hr/kg,27,
TG100,,27,
Cardiotoxicity,,27,
Log Kobs,,27,
Ki,/M/s,27,
ascrit,,27,
Zone of inhibition,uM,27,
ODC,%,27,
Log 1/EC50,uM,27,
Weight loss,,27,
HYPO,mg kg-1,26,
LD100,,26,
Staining potential,,26,
Alloste ic enhan er (AE),,26,
Lowest effective concentration,p.p.m.,26,
Vmax,milli optical density/minute,26,
LT50,hr,26,
LD50,mg kg-1 i.p.,26,
Antitumor activity,,26,
LDL cholesterol,mg 100ml-1,26,
Potency,uM kg-1,26,
Heart rate,delta beats min-1,26,
Toxic dose,uM,26,
Surviving factor,%,26,
Serum Mg2+ level,,26,
Diuretic activity,ml g-1,26,
Activity,um/min,26,
Activity,ug/kg,26,
GT rate,nM min-1 (mg of protein)-1,26,
CLH,mL.min/g,26,
Activity,uM (g of spores)-1,26,
Total cells,ml,26,
Activity,V/s,26,
PC100,uM,26,
Activity,pmol/min/mg,26,
Fabs,,26,
Cp,umol/L,26,
Occupancy,%,26,
Activity,mole fraction,26,
Potency_Clk3_uM,uM,26,
Liver weight,g,26,
DNA relaxation,,26,
Drug metabolism,ug/kg,26,
Selectivity,Ratio,26,
Radioactivity,,26,
Pleural fluid,ml,26,
Etopic beats,%,26,
TT,uM,26,
Antibiotic resistance,,26,
Natriuretic activity,uM g-1,26,
Plaque accum,,26,
ED50,10'-7 ug/ml,26,
Fm,%,26,
Ventricular rate,beats min-1,26,
Coronary flow,,26,
Stability,months,26,
HDL cholesterol,mg 100ml-1,26,
Log beta3,,26,
RHA,%,26,
Alpha-cholesterol,%,26,
Alpha-adrenolytic activity,,26,
Ratio,/min/microM,26,
Potency,IU mg-1,26,
Lactone production,,26,
Phorbol displacement,,26,
EC125,uM,26,
AP50,ng ml-1,26,
Min lytic concentration,uM,26,
Km,/s/microM,26,
AUClast,%,26,
cAMP production,pM min-1 well-1,26,
Activity,mg/day,26,
MNTD50,ug ml-1,26,
Transcriptional activation,,26,
Activity,nM/min,26,
K aff,,26,
Radiolabel recovery,ngequiv/ml,26,
KSV,10'5L/mol,26,
ICD,,26,
IC50,10^-5 uM,26,
log(PB),,26,
EC68,uM,26,
K inact/Ki,,26,
Improvement,,26,
AFC50,mg/ml,26,
pAI50,,26,
ID50,10'-7M,26,
AE activity,%,26,
Kd,10'-4/s,26,
KH,nM,26,
Inhibitory activity,nM,26,
Ka,10'8/M/s,26,
K,10'-7/s,26,
Kb,10'3/M,26,
Body temp change,degrees C,26,
ID80,mg kg-1,26,
MTD,mM kg-1,26,
Rate constant (k),Ie3 M-1 s-1,26,
f(Cave),nM,26,
Ki,M-1,26,
Rate,mg of protein,26,
K1,min-1,26,
Bmax,pM (mg of protein)-1,26,
Kaliuretic activity,uM g-1,26,
Kapp,/M,26,
tox/total,,26,
CCCT,uM,26,
Ca2+ antagonism,,26,
Catalepsy,%,26,
log(1/ED80),,26,
Sinus beats,%,26,
Optimal dose,ug kg-1,26,
CLH,microL/min/g,26,
V,,26,
MA,%,26,
No effect dose,mg kg-1,26,
Stability,ml/min/g,26,
Day of first positve reaction,,26,
Change in cholesterol,%,26,
Speed of performance,,26,
HC10,ug.mL-1,26,
Unaltered compound,%,26,
PTD50,mg kg-1,26,
DAP,%,26,
Residual peptide,%,26,
DC50,mg/L,26,
R.I,,26,
Kif,nM,26,
Triglycerides,M,26,
Sp St,%,26,
V,%,26,
Triglycerides,mg 100ml-1,26,
MED,g,26,
Papp,10'-6/cm,26,
Activity,g/m,26,
Residual contractile activity,%,26,
Mitotic index,uM,26,
K,10'7/M/s,25,
MAC,,25,
GR50,ppm,25,
Kcat,10^-3/s,25,
GSH,%,25,
MIC75,uM,25,
Velocity,%,25,
Log K-1,,25,
Count/h,,25,
Calcium release,,25,
log1/S0,,25,
Change in WBC,%,25,
CTE,uM,25,
Uptake/Binding ratio,,25,
CD90,mg/kg/day,25,
MDL50,uM,25,
Tumor number,,25,
k2/Ki,M-1 s-1,25,
Tumor mass,g,25,
KSV,10^4/M,25,
Mean life extension,,25,
Food intake,g mouse-1 day-1,25,
deltaH,,25,
Delta blood pressure,mM,25,
Drug uptake(free),%,25,
CPM,,25,
Kcat,%,25,
GI99,ug ml-1,25,
CMC,mmol/L,25,
EC150,,25,
Biodistribution,ug equiv/g,25,
LC90,mgAi/L,25,
Biological evaluation,,25,
T/C untreated,,25,
ED30,ug/kg,25,
APTT,,25,
K ass,M-1 s-1,25,
T inh,s,25,
Drug response,%,25,
K aff,M-1,25,
Mean graph mid point,,25,
Kis,mM,25,
Rate response,min-1,25,
Ki,min-1,25,
ED20,uM kg-1,25,
Binding selectivity,,25,
Binding activity,c.p.m.,25,
Relative maximum,,25,
Relative enzyme activity,,25,
Excess zone radius,mM,25,
Potency,nM kg-1,25,
E2 response,%,25,
Erythema,,25,
Protected/Tested,,25,
Epileptogenicity,,25,
QH,ml/min.kg,25,
Activity,/mm2,25,
Occ50,nM,25,
solubility,g,25,
Papp,nm s-1,25,
Fold selective,,25,
K,10'-2/hr,25,
Cardiotoxicity,nM,25,
IC50,/uM,25,
pKa_A2,,25,
Injected (dose/g),%,25,
AUCt,ng.hr/g,25,
Min oral dose,mg kg-1,25,
Activation (% of control),%,25,
Activity,log10IU/ml,25,
Inhibition (% of control),%,25,
ED99,,25,
Ratio,mg dl-1,25,
CD50,mg/kg/day,25,
MET,umol/min/mg,25,
MI0.5,uM,25,
Total tumors,,25,
pAFC50,,25,
ED5,mg kg-1,25,
Survival,months,25,
Activity,10'6PFU/ml,25,
HSF,ml,25,
Clast,ug ml-1,25,
% recovery,%,25,
PTZ seizure,mg kg-1,25,
Ileal activity,uM,25,
permeability,10^6cm/s,25,
Peff,10'-5cm/s,25,
Relative tumor growth,,25,
Increase in dP/dTmax,%,25,
Activity,10^6 /uL,25,
BWL,%,24,
LC20,uM,24,
Drug transport,pmol/cm2/hr,24,
Verapamil index,,24,
BIC,ug ml-1,24,
Kd,10^-2/s,24,
Kd,/uM,24,
pA2 - pA10,,24,
Kapp,mM,24,
Kapp,10^-7/M,24,
Beats/min,,24,
KSV,10'-4L/mol,24,
Astrocyte reversal,%,24,
Ka,10'8/M,24,
Drug uptake,pmol/L,24,
kOH,M-1 min-1,24,
Activity,EU/ml,24,
Activity,pg/L,24,
MTC,M,24,
VDR affinity,%,24,
P50,%,24,
P50,Torr,24,
Activity,Miller_unit,24,
TC50,M,24,
PTD50,mg,24,
T/C-CQ,,24,
T/C 41,,24,
Phototoxicity,,24,
Sweetness potency,,24,
Activity,10^4/M/cm,24,
Precursor inhibition,%,24,
Biodistribution ratio,,24,
K'a,,24,
deltapKi,,24,
K,10^6/M/s,24,
LD50,M kg-1,24,
Actvity,ngAoxigen/min/mg of RLM,24,
fVdss,L/Kg,24,
LD50,ng,24,
Vmax,10'-3uM/min,24,
Antiinflammatory Activity,%,24,
MG-MID,uM,24,
fAUClast,hr.ng/ml,24,
Level,pM min-1,24,
Vmax,uM s-1,24,
Vss/F,l,24,
Substrate specificity,uM min-1mg-1,24,
Log TA98,,24,
AIDH activity,nM min-1,24,
Lysis diameter,mm,24,
MED,mg Kg-1,24,
pC60,uM kg-1,24,
Cmax/dose,uM.kg/mg,24,
AUC,%ID/g/hr,24,
MBIC90,ug ml-1,24,
apE,,24,
Ae,a.u.,24,
Kinact,10'-4/s,24,
k obs / 1,M-1,24,
% nucleotide present,%,24,
% turnover,%,24,
pKact,,24,
-log(1/MED),,24,
-log(1/MKC),,24,
Intrinsic activity,pmol,24,
pED40,,24,
Decrease in Systolic blood pressure,,24,
Suppression ratio,%,24,
Activity,10'12/L,24,
Oncostatic index,,24,
ED75,mg kg-1,24,
Aggregation response,,24,
Mean % growth (n = 2) for 0.01 ÂµM probe concentration,%,24,
MIC=>80,mg/L,24,
Activity,c.p.m.,24,
Activity,cells ml-1,24,
Occ90,nM,24,
No. of axonal points,,24,
Number,millions,24,
No. toxicity/tested,,24,
Time,hr/ha,24,
No. of sensitive animals,,24,
Delta C urate / delta C insulin,,24,
No. of mice receovered,,24,
EC37,uM,24,
Formation of erythema,,24,
Frequency,,24,
EC90,mM,24,
ED,uM,24,
Ca2+ current,mV,24,
ERP,ms,24,
Ratio,/min.mg,24,
Edema,ml,24,
Cardiac depression,%,24,
Cage leaving,,24,
CC90,ug ml-1,24,
EC50 iGC,nM,24,
IC10,mM,24,
ED50,10'-8M,24,
FI,%,24,
Enzyme inhibition,%,24,
Tissue distribution,%,24,
Femoral blood flow,,24,
New tumors,,24,
AUC/dose,micromol.hr/L,24,
Net accumulation,,24,
Ratio,l s-1 M-1,24,
AUCt/dose,hr.ng/ml.mg,24,
Cumulative dose,,24,
Schizont size,,24,
Activity,/nl,24,
Reduction in RBS,%,24,
Ref I oncostatic index,,24,
Rel max,,24,
Cmax,ng g-1,24,
Relaxation,,24,
Substrate activity,c.p.m.,24,
Others,%,24,
INH,ug,24,
Selectivity ratio S3/2,,24,
Urinary glucose excretion,,24,
Mean % growth (n = 2) for 10.0 ÂµM probe concentration,%,24,
NADPH oxidation,nM min-1 (mg of protein)-1,24,
MLC,umol/ml,24,
Mean score,,24,
Change systolic BP,%,24,
Transport inhibition,%,24,
Mean % growth (n = 2) for 100.0 ÂµM probe concentration,%,24,
Mean no. colonies,10e4*cells,24,
Mean % growth (n = 2) for 1.0 ÂµM probe concentration,%,24,
Tritium release,%,24,
Rm,%,24,
Delyse,%,24,
Activity,mol/L.sec,24,
Mean % growth (n = 2) for 0.1 ÂµM probe concentration,%,24,
Plasma concentration,,23,
Papp,10e-6 cm s-1,23,
FBP,,23,
Palpha,,23,
PGI,,23,
PMA,%,23,
FPT,,23,
Optimal dose,mg kg-1 day-1,23,
Activity,10^12/L,23,
Fapp,%,23,
Plasma-E2 concentration,pg ml-1,23,
Emax,meter/s,23,
Q50,uM,23,
RD500,,23,
Ratio,/min/M,23,
Ratio Ki,uM,23,
"Emax,diss",%,23,
CLT50,uM,23,
MIC,ug disk-1,23,
Activity,uM/g,23,
Gated current,,23,
Activity,ugequiv,23,
No. of crosses,,23,
No. of transfers,,23,
DHP-I stability,,23,
Mean hemagglutination titers,,23,
Delta HR,,23,
IC50,10^-7mol/L,23,
EC,mg kg-1,23,
Cell survived,day,23,
Distribution,,23,
Dopamine release,%,23,
EC40,nM,23,
EC60,uM,23,
Drug metabolism,%ID,23,
Drug uptake,umol,23,
Dose interval,hr,23,
Caspase induction,,23,
CL free,uL/min,23,
Change MAP,%,23,
Change of body temperature,degrees C,23,
Delta RM,,23,
KA,10'6/M,23,
Organ weight,g,23,
MIC>98,,23,
MIC>99,,23,
Activity,nmol.hr/g,23,
Activity,nM min-1 (mg of protein)-1,23,
MTD50,,23,
Increase in volume,ml min-1,23,
Imax,uM,23,
Influx Ki,uM,23,
ED90,mg kg-1 5day-1,23,
INH,10'4L/mol/s,23,
S.I,,23,
kOH-,M-1 s-1,23,
ED200,mg kg-1,23,
ka,/hr,23,
ED50 Ratio,,23,
AC10,uM,23,
2x PT,uM,23,
ED80,uM/g,23,
AI,,23,
ED90,uM kg-1,23,
Ki,Ratio,23,
pC2A,uM,23,
AUC,ug hr uM-1,23,
TOX,,23,
AUCmet/AUCp,%,23,
SD90,mg kg-1,23,
Tumor volume,,23,
"pEC0.5,diss",,23,
ED,,23,
Vmax,uM min-1 (mg of protein)-1,23,
ED50,mg kg-1 5day-1,23,
AZT formation,%,23,
"median survival time, days",,23,
MED25,mg kg-1,23,
Kinact,10^-4/s,23,
MCC50,,23,
Insulin release,,23,
Intinsic activity,,23,
Intrinsic_solubility,,23,
K,/mM/s,23,
Blood level,uM ml-1,23,
KSV,10'5/M,23,
Kcat/Km,/min/mM,23,
Ki,10'5/M/min,23,
AbsAC0.54_uM,uM,23,
Hydrogen peroxide degradation,,23,
Ka,10'9/M,23,
CL,min/ml/kg,23,
LC50,umol/g,23,
LD50,mg/kg/day,23,
Antilipid peroxidation,%,23,
HSF release,ug ml-1,23,
Log,,23,
Log EC50,nM,23,
Log10ED50,,23,
Acute toxicity,%,23,
LC50,ug/g,23,
X1(50),,22,
IC50,10^-8mol/L,22,
Covalent binding,,22,
VERP,,22,
IC2x,uM,22,
logSI,,22,
HIA,%,22,
ED75,uM kg-1,22,
Activity,kC/sec,22,
No effect dose,mg,22,
ED90,nM,22,
Ulcer score,,22,
IC50,milliequivalent,22,
Excretion,ml,22,
Accumulation counts,,22,
Toxicity,ug ml-1,22,
ED50,uM/L,22,
EC10,uM,22,
Mutagenicity,%,22,
bwc,g,22,
kon,10e3* M-1 s-1,22,
kn,M-1 min-1,22,
EC50,g/m2,22,
Ep,V,22,
Mean vesicle score,,22,
Vrel,,22,
Vmax/Km,/min,22,
Physical dependence capacity,,22,
AUC,AU.min,22,
Ke ratio,,22,
Ki,M-1 s-1,22,
Median T/C,day,22,
Kinact,10'3/s,22,
BEI,%,22,
DC50,pM,22,
Activity,10'3No_unit,22,
RBA,g,22,
BW loss,%,22,
Max intensity,turns min-1,22,
Remaining,,22,
Platelet aggregation,uM,22,
DNA,ug,22,
Gastric toxicity,,22,
Permeability coefficient,cm s-1,22,
solubility,mg/g,22,
Rate of decomposition,(nM of drug) min-1 ml-1,22,
ECmax,ug ml-1,22,
permeability,uL/hr/cm2,22,
CTL activity,M,22,
CV dose,mg kg-1,22,
LC50,g/m2,22,
Recovery time,mg kg-1,22,
Mean time to seizure,s,22,
Absorption,,22,
Median T/C,,22,
IG50,,22,
MITC95,nM,22,
Cp(f),ng/ml,22,
Max IOP reduction,mmHg,22,
LD90,ug/kg,22,
SI,%,22,
SD50,mg kg-1 day-1,22,
LD50,uM/L,22,
Cytocidal activity,%,22,
Ka,/M,22,
Log 1/D125 (L1210) (mM kg-1),,22,
pI50,M l-1,22,
E/Emax,%,22,
Increase in plasma amylase,IU ml-1,22,
TFS,%,22,
T decrease,degrees C,22,
CT10,uM hr-1,22,
Anesthesia duration,min,22,
pEC200,,22,
Intestinal toxicity,,22,
TGI correlation coefficient,,22,
Optimal dose,,22,
T>MIC,%,22,
Log APA,,22,
Observed log APA,,22,
Log 1/conc (mM min-1 L-1),,22,
Thymidine uptake,c.p.m. (mg of protein)-1,22,
Incidence,N,22,
GI80,uM,22,
LED100,mg kg-1,22,
TC50,umol/L,22,
PR,,22,
Log potency,,22,
k0,M-1,22,
Cell number,%,22,
fEC50,mM,22,
log(1/LC50),,22,
AI50,,22,
deltaS,cal/mol.K,22,
Minimal bacteriostatic concentration,,22,
GI20,uM,22,
c90,uM,22,
c30,uM,22,
FA,,22,
Cmax/dose,kg/L,22,
No. resp animals / Total,/ 7,22,
Life span,,22,
K,uM-1,22,
Solubility,%,22,
PDE inhibition,,22,
K,10^-6/s,22,
Activity,M g-1,22,
K,10^-4/min,22,
Bmax,,22,
Mean activity counts,,22,
Decrease in QA interval,ms,22,
Amount,ml,22,
DIZ,mm3,21,
ED25,ug,21,
Metabolic stability,mg ml-1,21,
Metabolism,pM min-1,21,
Distribution,pM mg-1,21,
-Log KA,,21,
Activity,10'5/ml,21,
-Log IC50,uM,21,
Final average tumor weight,mg,21,
LH level,ng ml-1,21,
Activity,10'4Meq,21,
CT50,ug ml-1,21,
pKb,nM,21,
Kapp,10'4/M,21,
Deaths/total,,21,
Apoptosis,,21,
ED delta20,nM kg-1,21,
EC99,,21,
Change in entry latency,s,21,
Ataxia,,21,
Thrombus weight,mg,21,
Log TA100,,21,
MED,mg/kg/day,21,
MED,mg kg-1 day-1,21,
pC25,,21,
Log delta (1/T2),,21,
SI,ug ml-1,21,
INH,Miller_unit,21,
Gain,%,21,
MST increase,,21,
K,10'-7M,21,
Serum lipoprotein cholesterol,,21,
Average,%,21,
Ka,10^4/M/s,21,
K,u equiv kg-1,21,
koff,,21,
Paw weight increase,%,21,
Kcat,10'-3/s,21,
Solubility,g,21,
RTW,%,21,
Mean number of parasites,,21,
GII50,,21,
Prejunctional antagonist potency,,21,
d tox,,21,
Supression,,21,
K calc,M-1 s-1,21,
Modification of hemoglobin,%,21,
Range of death,day,21,
MIC,%,21,
Survivor increase,,21,
POT,nM,21,
pC60,,21,
CL,nmol/min/mg,21,
RTW,,21,
Decrease in MABP,mmHg,21,
Absolute turn angular/3 min,,21,
Passivity,mg kg-1,21,
Ka,10'8/M/min,21,
Eggs,%,21,
Protected/tested,,21,
kOH,M-1 s-1,21,
Ka,10'4L/mol,21,
Retention ratio,,21,
CT10,mM hr,21,
Activity,10'6dpm,21,
Mean survival days,,21,
AI recovery time,min,21,
LED,,21,
Edema inhibition,%,21,
Activity,turns hr-1,21,
AUC,ugequiv/l.hr,21,
Incidence of RBC decrease,,21,
ED delta5,nM kg-1,21,
Log 1/ID50,,21,
NEA,,21,
Prejunctional agonist potency,,21,
Optimal dose,uM kg-1,21,
Relapses,,21,
Creatinine,mg 100ml-1,21,
AUC,hr,21,
Weight,mg dl-1,21,
Change HDL -C,%,21,
Pmax,%,21,
HTD,mg kg-1,21,
Picoequivalents of amine/10e6 cells,,21,
Animal death,%,21,
Activity,um2,21,
CV,%,21,
Bmax,nM,21,
HD100,uM,21,
Activity,umol/ml,21,
Symptom initiation,%,21,
Log K' IAM,,21,
CI,uM,21,
K,/min/microM,21,
BT,,21,
Kcat/Km,10'5/s/M,21,
Initial average tumor weight,mg,21,
Rate,pM,21,
Log K3,,21,
logC50,,21,
BUN,mg 100ml-1,21,
Log 1/D125 (mM kg-1),,21,
Reflex,mg kg-1,21,
TG,%,21,
TGD,day,21,
ED99,mg Kg-1,21,
logCC50,,21,
Activity,um3/um2,21,
Vmax,uM min-1,21,
ID/g tissue,%,21,
Vc,l,21,
ICmax,uM,21,
V0,/s,21,
IC99,ug.mL-1,21,
Total lysis,uM,21,
No. effective,,21,
Hill slope,,21,
Delta pEC50,,21,
MPE50,,21,
Na,u equiv kg-1,21,
Log MBC,,21,
Cell cycle,,21,
Testes weight,mg,21,
ED50,mg/ml,21,
Cmax/SS,uM,21,
ID/brain,%,21,
Activity,/cm2,21,
MTD,mg,21,
Toxicity,mg kg-1,21,
Platelet aggregation,%,21,
No. of escape failures,,21,
Total turns,,21,
Drug degradation,nmol/min,21,
C20 FRP,uM,21,
Potency index,,21,
IC100,,21,
Postjunctional antagonist potency,,21,
CD90,mg kg-1,21,
Kd,10^2 uM,21,
LogIC50,,21,
Postjunctional agonist potency,,21,
Treated,,21,
Stabilty,microL/min/mg,20,
Ip,,20,
Lipid peroxidation,%,20,
K,10'6L/mol,20,
ED25,mM,20,
K,10^4/M,20,
Photo-cross-linking of DNA,,20,
Serum HDL-cholesterol,%,20,
Average No. of metastasis,%,20,
AUCt/dose,ng/mL.hr,20,
-ln K,,20,
Complex_formation,deltaA.10^4nmol-1,20,
Survivors alive/total,,20,
Survivors at day 8,%,20,
Kapp,10'5/M,20,
T max,nM,20,
Serum cholesterol,%,20,
Serum LDL-cholesterol,%,20,
Kcat/Km,/s/mM,20,
Serum concentration,hr,20,
Recovered radioactivity,%,20,
Time constant T1,ms,20,
Activity,nM mg-1,20,
Complex formation,,20,
Brain concentration,ng g-1,20,
Activity,K/uL,20,
Drug uptake,pmol/g,20,
K50,M,20,
Papp,10'-8cm/s,20,
Kb,ug kg-1,20,
ED15,mg kg-1,20,
Activity,/s/microM,20,
Intrinsic efficacy,,20,
Log AC50,uM,20,
Log Y,,20,
-TdeltaS,,20,
PI hydrolysis,%,20,
Increased life span,%,20,
p[BH+50],,20,
Toxic level,mg kg-1,20,
Activity,day of onset,20,
Average,,20,
Dead/total,,20,
2DG uptake,uM,20,
LD50,p.p.m.,20,
Mean HR,beats min-1,20,
MTD,uM/g,20,
Diameter,nm,20,
S50,mM,20,
No. of mice effected/No. of treated,,20,
Mean LAF,ml min-1,20,
Mean RBF,ml min-1,20,
-Log EC20,,20,
Kb,10'4L/mol,20,
Log K delta,,20,
Total counts,,20,
Activity,10'-2/hr,20,
Urinary Na+,m equiv,20,
IC50,ug/g,20,
pLADm,,20,
Degree of resistance,,20,
Ka,/hr,20,
Pw,,20,
Time constant T2,ms,20,
ED15,ug,20,
DP,%,20,
Respiratory frequency,r.p.m.,20,
Activity,nM ml-1,20,
Ka,10'7/M/min,20,
Average onset,min,20,
Change in cAMP,%,20,
Activity,mmol/ml,20,
Tumor weight,mg,20,
Residual binding,%,20,
Turns/first hour,,20,
MAPD90,ms,20,
Removal,%,20,
Drug metabolism,% ID/g,20,
TBPS IC50,uM,20,
Selectivity,A1/A2A,20,
MDL50,,20,
QTc interval,ms,20,
IC50,10^-4microM,20,
MBC90,,20,
Kr,,20,
ED (1mV),ug kg-1,20,
IC50,kJ m**-2,20,
Urine volume,ml kg-1,20,
Highest active dose,mg kg-1,20,
MMC,uM,20,
CLH,uL/ml.millig,20,
HD50,,20,
deltaG,,20,
FPG correction,%,20,
Activity,pg ml-1,20,
AUC,mg hr-1 kg-1,20,
increase in RFU,%,20,
Vc,ml,20,
MLD,umol,20,
HVA level,%,20,
Epidermal thickness,,20,
I/C,,20,
Cardiac frequency,beats min-1,20,
BHIA50,,20,
k2'',min-1,20,
Concentration ratio,,20,
Activity,nmol/ml.min,20,
CLH,ug/min/mg,20,
CL,uL/ml.millig,20,
Vmax,cm-1,20,
Analgesic effect,%,20,
Activity,umolequiv/L,20,
Ratio,1/sM,20,
Actual duraction,min,20,
Activity,g/m2,20,
Kp,10'-6 cm/s,20,
Mortality inhibition,%,20,
AFC50,ug ml-1,20,
I50,molar excess,20,
Flow rate,ml min-1 100g-1,20,
Ki,10'4/M/min,20,
Vmax,pmol/hr,20,
APD90,ms,20,
Ki,/M/min,20,
CLH,ml/mg/kg,20,
Activity,ng/hr,20,
Distribution,fM mg-1,20,
Control,ug kg-1,20,
CTF,%,20,
Delta latency time,s,20,
ID99,ug ml-1,20,
CS50,uM,20,
CQ,uM,20,
ED10,mM,20,
ED3,mg kg-1,20,
Log II50,,20,
Effective molarity,M l-1,20,
CI,l hr-1 kg-1,20,
Selectivity,nM,20,
Vmax,nM/min,20,
Hemodynamic change,%,20,
NSR,,20,
RCI,,20,
Activity,pmol/mg/hr,20,
Min effective dose,,20,
Vmax(app),pmol/min,20,
Ca2+ transport S/M,,20,
Km,ug ml-1,20,
CL,/uM/min,20,
MIC=>90,,20,
k2',min-1,20,
dTagg,K,20,
RC50,ug ml-1,20,
Water consumption,ml,20,
Change non HDL-C,%,20,
Rate of formation,pM min-1 (mg of protein)-1,20,
No. of metastases,,19,
Antagonist effect,,19,
ClT,ml min-1,19,
Catalase rate,uM of O2 min-1,19,
Log CDGH,,19,
Log ED50,mM kg-1,19,
Log CDQR,,19,
Activity,log10ng/ml,19,
Analgesic efficacy,,19,
Average inhibition,,19,
Survivors at day 15,%,19,
HI,%,19,
kon,M-1-s-1,19,
Cation influx,,19,
ActiveConcentrationI,uM,19,
Decrease in RFU,%,19,
[EOP']infinity/[EOH]infinity,,19,
Drugabsorption,,19,
Level,ng ml-1,19,
Ki high,nM,19,
Cmax/dose,nM/mg/kg,19,
Activity,N,19,
PFU,,19,
PG,%,19,
Smax,ul min-1 kg-1,19,
Basal,(fM of GTP-gammaS bound) (mg of protein)-1,19,
GTP-gammaS index,,19,
Kinact,10^5nM,19,
Inhibition activity,uM,19,
Activity,min-1,19,
ERP3,,19,
Max aggregation response,,19,
TVI,%,19,
CT2,uM,19,
Activity,millimeter/min,19,
Activity,ml min-1,19,
ED0,gAi/ha,19,
log KOA,,19,
CT1,,19,
log Pe,10^-3cm/min,19,
ED50,nM min-1 kg-1,19,
permeability,10'-8cm/s,19,
ED25,microg/cm3,19,
Max effect,,19,
1/kobsd-ka,min,19,
Disease control,,19,
Concentration,ug (g of wet tissue)-1,19,
permeability,10'-6/cm,19,
permeability,10'-5cm/s,19,
EC50,mol/g,19,
MNTC,uM,19,
pLADy,,19,
Max,(fM of GTP-gammaS bound) (mg of protein)-1,19,
Change in weight,g,19,
MTD,ug/kg,19,
CMC,ug ml-1,19,
Combination_index,,19,
pKinc,,19,
ERP1,,19,
TT,,19,
PKC,uM,19,
Occ50,mg kg-1,19,
Urine osmolality,mOsmol kg-1,19,
LD50,10'-3M,19,
Kinetic,,19,
FOC,,19,
Relative stability,,19,
fCmax/MIC,,19,
Selectivity factor,,19,
K+ Ion content,,19,
Kapp,10'7/M,19,
Max hemorrhage,,19,
K+/Na+ ratio,,19,
Cytotoxic endpoint,uM,19,
Decrease,degrees C,19,
ke,hr-1,19,
Activity,mU/mg,19,
MID,ug,19,
Average seizure score,,19,
LC99.9,mg/L,19,
Approx. lethal dose,,19,
Cmax_[GH],ng ml-1,19,
Binding competition,mean counts,19,
Prolongation,%,19,
increase in mean survival time,,19,
deltaS,J/mol.K,19,
Relative protection,%,19,
Drug uptake,microM,19,
LED100,,19,
IC50/IC50,,19,
PT,,19,
Change in systolic BP,%,19,
Skin uptake,uM,19,
Kr,uM,19,
MIC,ug/disk,19,
Tumor uptake,uM,19,
Treated cells,%,19,
Ratio,10'6/M/s,19,
Change in body weight,%,19,
Activity,g/cm2,19,
Vdss,L/hr/kg,19,
IC12,nM,19,
Corr,%,19,
Viability,,19,
CFC20,uM,19,
AUC,mmHg hr-1,19,
Kdiss,,19,
ILS30,mg kg-1,19,
Improvement,%,19,
Cp(T),uM,19,
C100,uM,19,
Tested/Control,,19,
Incidence,%,19,
Na+ ion content,,19,
Kq,10^12/M/s,19,
AUC,mg/dl,19,
CFU,10^4/ml,19,
ILSmax,mg kg-1,19,
Number,%,19,
Horizontal activity,Counts min-1,19,
INH,ppm,18,
Ex-vivo screening,,18,
Cp,ug/L,18,
GID75,mg m**-2,18,
Activity,/millimeter,18,
Nature,,18,
Kp,s-1,18,
A/B ratio,,18,
CLH(app),uL/min/mL,18,
Muscarinic receptor affinity,,18,
Q1/2,mM,18,
AUC,ug/hr.kg,18,
GSH level (mg),%,18,
C24,ug ml-1,18,
Kinact,/hr,18,
Colony formation,%,18,
MRP,,18,
Kiuc,,18,
Activity,10'6CFU/g,18,
Activity,delta mmHg,18,
IE,%,18,
C50,umol/L,18,
2*APTT,uM,18,
Control response,%,18,
DT,hr,18,
Mean survival in days,,18,
MI20,nmol/L,18,
Polyamine pools,%,18,
Dissociation ratio,,18,
Mydriasis,,18,
MED,ug kg-1,18,
Cpss,ng/ml,18,
Vmax,10^-8mol/s,18,
LD50,10'-5M,18,
EC50,uM kg-1,18,
permeability,ng/cm2/min,18,
Differential affinity,,18,
Max lowering,%,18,
[GSH],nM (10e6*cells)-1,18,
Na+ excretion,ml kg-1,18,
Rate of oxidation,,18,
Kdiss,10^5/M/s,18,
AUC,ug.hr/mL/mg/kg,18,
Activity,10^-9No_unit,18,
Ratio,Ratio,18,
Activity,delta mV,18,
Ratio,[Na+]/[K+],18,
Kd,l M-1,18,
Triglycerides,mM l-1,18,
Tt,k,18,
Ratio Cmax,,18,
GOF,,18,
permeability,um/s,18,
Mean no. of lung colonies,,18,
Cave,nM,18,
EC80,%,18,
Transport rate,M hr-1,18,
permeability,mN/meter,18,
Drug metabolism,uM/min.mg,18,
Efficacy,mg kg-1,18,
CL,nl/min,18,
Activity,mg%,18,
LD10,mg m**-2,18,
Histamine level,,18,
CC,ug ml-1,18,
Phagocytosis,,18,
Ka,10'5L/mol,18,
Activity B,uM kg-1,18,
Time constant,s,18,
Partial remission,%,18,
ED50,microg/cm3,18,
IC85,uM,18,
Relative ODN uptake,,18,
AUC,ugequiv.hr/g,18,
Conversion dose,mg kg-1,18,
Acc. counts,,18,
Med tumor weight,mg,18,
Activity,nm/s,18,
LD100,%,18,
Thymolysis,,18,
ED100,microg/cm3,18,
ERP observations,,18,
FBF,,18,
Imbalance,,18,
Prodrug reduction,%,18,
Relative molar potency,,18,
Kn,M-1 min-1,18,
Dmax,,18,
Kobs,/hr,18,
GR50,g/ha,18,
Kon,s-1,18,
IC50,10'-5g/L,18,
Rate,nM,18,
Hemolytic activity,%,18,
Rate of decrease,%,18,
ED10,gAi/ha,18,
Affinity constant,,18,
Extremes treated,,18,
Vmax,V s-1,18,
GI50 ratio,uM,18,
Net dry weight,mg,18,
permeability,10^-5 cm/min,18,
Vmax,mM s-1,18,
Inactivation,,18,
k1,s-1,18,
Controls,%,18,
Duration of block,min,18,
Delta Vmax,,18,
LC50 ratio,uM,18,
Efficacy,pM,18,
Stability,nmol/mg/min,18,
Chemotactic index,,18,
pK1a,,18,
AUClast,ng.hr/g,18,
Binding,pM 30min-1 (mg of DNA)-1,18,
FIC50,nM,18,
Activity,pM of drug (10e6*cells)-1,18,
Mortality,day of death,18,
LD50,J/cm2,18,
Drug metabolism,pmol/min/ug,18,
Metabolic turnover,%,18,
Log Pc18,,18,
Brain level,pM g-1,18,
Cell size,,18,
No. of counts,,18,
KD app,uM,18,
GHmax,ng ml-1,18,
Log LD50,,18,
SD90,mg/kg/day,18,
Min antiviral concentration,ug ml-1,18,
CT5,uM,18,
Activity,HAU/ml,18,
CC50,10^2 uM,18,
AUC metabolite/AUC radiolabel,%,18,
Cholesterol,mM l-1,18,
TD90,ug ml-1,18,
Antimalarial activity,%,18,
Decrease in MAP,%,18,
Insulin secretion,,18,
AUC,min.g.nM/mg,18,
Vmax,(nM of H202) min-1 (ug of protein)-1,18,
Bmax,pM mg-1,18,
ED25,uM,18,
Min effective dose,mg kg-1,18,
dP/dt,nM,18,
TGI ratio,uM,18,
CT3,,18,
Cured/Infected,,18,
CE37,uM,18,
Aggregation,mg kg-1,18,
K app,1/min,18,
Selective toxicity,,18,
AUC,nM hr ml,18,
Drug uptake,pmol/min/mg,18,
CE logK',,18,
pMED,,18,
EC100,,18,
fIC50,uM,18,
Vd/F,L,18,
K eff,M-1 min-1,18,
Serum corticosterone,ug ml-1,18,
Activity,pixel,18,
Uncut DNA,%,18,
Drug level,ug ml-1,18,
TT,ug ml-1,18,
krel,,18,
Binding activity,,18,
Intact,%,18,
fCmin,mg/L,18,
1/IC50,/uM,18,
Antiemetic activity,%,18,
Drug metabolism,ng,18,
Glucose correction,%,18,
Blockade,,18,
Response,mmHg,18,
Slow binding,,18,
max Delta Vmax,,18,
EC5,ug ml-1,18,
Activity,ng/uL,18,
pK1d,,18,
MTS,day,18,
Cell no,,18,
TCID50,/ml,18,
G2/M,%,18,
MFED,mg kg-1,18,
pK1b,,18,
Initial rate ratio,,18,
MBC99.99,ug ml-1,18,
Stability,cpm,18,
fAUC/dose,uM.min,18,
Anticonvulsant dose,mg kg-1,18,
Initial_rate,deltaA.10^4nmol-1.min-1,18,
Onset of action,min,18,
Stability,ml/min.Kg,18,
Stomach,%,18,
Stability,pmol/mg/hr,18,
K,M,18,
V0,RFU/s,18,
Mean day appearance of lesions,,18,
MBC90,mg/ml,18,
Stability,weeks,18,
Fold_activity,,18,
No. of lung metastasis,,18,
MBC50,mg/ml,18,
ED50,2mg kg-1,18,
Intrinsic activity,nM,18,
Activity,U (mg of protein)-1,18,
Uterine activity,mg,18,
pED50,ug,18,
Survival treated,,18,
Iron excretion,%,18,
ALD50,g/Kg,18,
EC20,,18,
Iron excretion,mg kg-1,18,
Locomotor activity,Counts,18,
P,M l-1,18,
Optimal dose,mg uM kg-1,18,
Macrophage cytotoxicity,%,18,
Log 1/LD50 (mM kg-1),,18,
Activity,fold,18,
deltaH,cal/mol,18,
Change in conflict,%,18,
Urinary excretion,ml kg-1,18,
Activity,mg/cm3,17,
Kcat/Km,10'8/M/s,17,
ED90,mg kg-1 day-1,17,
MLC50,uM,17,
CLH,ug/ml/min,17,
Rats blocked,%,17,
Pigment induction,,17,
Antiovulatory activity,,17,
Efficiency,,17,
Delta F75,M l-1,17,
Toxicity day survivors,,17,
LTS,%,17,
K,10^3/M/s,17,
K,10'2/min,17,
Survival,min,17,
Ratio,uL/min,17,
Vmax,nmol/sec,17,
Emax,mg kg-1,17,
Dose,nM,17,
Kiuc,mM,17,
Deaths/total,%,17,
Decrease in Bmax,,17,
kOX,,17,
DNA cleavage activity,,17,
Kinact,10'6nM,17,
DNA,%,17,
Drug responding,%,17,
CL_renal,mL/min,17,
Km,/s,17,
Vmax / Kmax100,,17,
KmH,uM,17,
NR,,17,
Ki,10'6/M/min,17,
kHOX,,17,
Clearance,ml hr-1,17,
Synergy EC50,nM,17,
Drug uptake,umol/g,17,
Fraction of accumulated 86Rb remaining.,,17,
LD99,,17,
Mean response/min,,17,
Effective concentration,uM,17,
Activity,ug/dl,17,
AUMC,hr.hr.ng/ml,17,
Swimming activity,,17,
P2 uptake,,17,
FS-SIF,mg ml-1,17,
LDL oxidation,%,17,
No. of deaths/mice injected,,17,
influx_CL,ml/min.Kg,17,
Cp,% ID/g,17,
KA,10'6L/mol,17,
Activity,(fM of O6-MeG removed) (mg of protein)-1,17,
Synergy,nM,17,
IC10,ug ml-1,17,
Ccellular,ug of B (g of cells)-1,17,
ED50,(mg/kg)/day,17,
Activity,g/Kg,17,
K,10^6/M,17,
Cmax/dose,ug/mL/mg/kg,17,
Antipapilloma activity,%,17,
PD50,ug ml-1,17,
Ct,ng/mg,17,
Liver cholesterol,mg g-1,17,
efflux_CL,ml/min.Kg,17,
deltapIC50,,17,
K,10'9/M/s,17,
Sterilized,%,17,
Drug uptake(free),ug ml-1,17,
ED50,10'-12 ug/ml,17,
Load,%,17,
Activity,pA,17,
Max T/C,%,17,
Activity,nM/min/mg,17,
TC25,,17,
TFS,,17,
Time,microsec,17,
AQ,,17,
Time,%,17,
C,nM g-1,17,
EC50,umol/Kg,17,
AUC,ug hr-1 g-1,17,
G-protein activation,,17,
MABP,%,17,
Mean IC70,ug ml-1,17,
GI50/EC50,,17,
Cp max,ng ml-1,17,
ED50,mg/kg.day,17,
Thromboxane B2 (TxB2),pg 0.1ml-1 500x10^3,17,
EC50,ug/kg,17,
APD95,ms,17,
GABA current,%,17,
GDP ED50,,17,
GSH level,,17,
KD50,ug/g,17,
Optimal dose,mg kg-1 injection-1,17,
ID50,mg/ml,17,
Toxicity,hr,17,
ID50,ug min-1 kg-1,17,
EA,,17,
Intrinsic activity,uM,17,
ED50,uL,17,
ED50,10'-8 ug/ml,17,
Uptake,nM g-1,17,
"Log Pe,max",,17,
Cr release,%,17,
MHC,,17,
Time constant T3,ms,17,
Gastric emptying,%,17,
Log Po,,17,
Agonism,IU mg-1,17,
Activity remaining,%,17,
Relative lipophilicity,,17,
Day 9-RTV,%,17,
Hydrophobicity index,,17,
Cytotoxicity,mM l-1,17,
No. of animals protected / no animals tested,,17,
30 days survivors,,17,
Remains,%,17,
Permeability,nM hr-1 cm**-2,17,
Concentration,g dl-1,17,
Parasites,%,17,
Ka,/s/microM,17,
KR,uM,17,
Worm movement inhibition,%,17,
KDs,uM,17,
Day 22-T/C,%,17,
MDR,,17,
Drug uptake,mg/ml,17,
Tlag,min,17,
GR20,ppm,17,
TC lowering,%,17,
Relative daunomycin accumulation,,17,
pCD,,17,
Mean log GI50,M,17,
Increase in dP/dt max,%,17,
CPE50,uM,17,
ToxD/Surv,,17,
Drug metabolism,mg kg-1,17,
MEC,ug/g,17,
CMC,,17,
permeability,10^-5 cm/s,17,
Hypnosis duration,min,17,
LC50,mg kg-1,17,
K obs / 1,uM-1 s-1,16,
Stretches,,16,
ED2sec,mg kg-1,16,
Inhibition of damage,%,16,
Analgesic,%,16,
Difference,%,16,
Non-HDL-C,%,16,
Log t1/2,,16,
Toxic level,,16,
Serum metabolite,mg dl-1,16,
ED300,uM kg-1,16,
CT-luci TAR,T/C,16,
Serum triglyceride,mg dl-1,16,
pK3,,16,
Specific Displacement,%,16,
Specific activity,Ci mM-1,16,
EC50rel,uM,16,
Spreading,%,16,
Stability,pmol/min,16,
Cell kill,%,16,
K,10'8/M,16,
K,10'5L/mol,16,
Toxic dose,,16,
Insulin release,ng/islet/h,16,
E max,%,16,
Infarct,%,16,
ILB,,16,
Normal,mmHg,16,
Survival median,day,16,
LED,mM,16,
Selectivity,%,16,
Amount delivered,pg ml-1,16,
Maximal relaxation,%,16,
Log KH,,16,
Log KL,,16,
TI,%,16,
Decrease in the QA interval,ms,16,
Inflamed,mmHg,16,
Increase in dP/dtmax,%,16,
Tensile strength,g cm**-2,16,
Amount of Acotine used,,16,
Incidence_count,,16,
Inactivation time,min,16,
Amount excreted,,16,
IZ,U,16,
Drug metabolism,%/min/pmol,16,
Time to max. inhibition,hr,16,
Tissue/Blood ratio,,16,
Total binding,%,16,
Cmax,Î¼g/mL,16,
E,mV,16,
Suppressive dose,mg kg-1,16,
EC50,10'8pM,16,
Activity,U/g,16,
Survivors / total,,16,
CL,ug/min/mg,16,
FC50,uM,16,
fAUC,,16,
MIC>80,ug ml-1,16,
Cholesterol Concentration,mg dl-1,16,
Fu,ng/ml,16,
Median survival,day,16,
Fluorescence intensity,a.u.,16,
MIC,ng,16,
Activity,nanoseconds,16,
Activity,ng (g of tissue)-1,16,
Effect on polyamine pools,,16,
MET,%,16,
HC10,,16,
NM,,16,
k1,M-1 s-1,16,
Activity,pmol/ug,16,
Fluorescence,nm,16,
Vmax/Km,ml/min,16,
A50,nmol,16,
Activity,mMequiv/mg,16,
A,ug (g of abscess)-1,16,
Kcat,10'-3/min,16,
MIC>99,ug ml-1,16,
ER max,mM,16,
Activity,mU/L,16,
Activity,mmHg/min,16,
Survivors at day 30,,16,
K,10'-4/nM/min,16,
Original amplitude,%,16,
ED50,10'-7M,16,
Organ weight,,16,
Carbohydrate,ug,16,
Ionization,%,16,
Concentration,mg kg-1,16,
MTT reduction,%,16,
Activity,log10PFU,16,
A0,,16,
CLH,mg/min/mL,16,
Activity,ug/100mg of tissue,16,
k,se-1,16,
Efficacy,ug ml-1,16,
CLH,l/min/mg,16,
MNTD,umol/L,16,
MNCC,nM,16,
k',min-1,16,
AD,mM l-1,16,
AB50,,16,
[Ca2+] variation,,16,
Binding inhibition,%,16,
No. of canine,,16,
BUN,mg dl-1,16,
Unbound,%,16,
Delta Gm,,16,
No. deaths/treated,,16,
Vmax,optical density/minute,16,
ED80,,16,
MBEC90,uM,16,
Uptake,,16,
Control value,g dl-1,16,
E/Eref,,16,
Activity,equiv/uM,16,
Virus rating,VR,16,
Tumor growth,10e3mm,16,
ED90,mg Kg-1,16,
Dose/ml,%,16,
AUC,nmol.min.g-1,16,
MBC,umol,16,
ACT,,16,
C24,ng ml-1,16,
No. total,,16,
Relative intrinsic activity,,16,
LC60,mgAi/L,16,
LC90,,16,
Dependency,,16,
LC95,uL/L,16,
Acute tolerability,,16,
CFU,10^3/ml,16,
Peak deltaMAP,mmHg,16,
Ulcerative index,,16,
Cave,ng/ml,16,
EDmin,,16,
HF ratio,,16,
CI50,,16,
ID50,nmol/ml,16,
Hematotoxicity,%,16,
Activity (mg),%,16,
HR,mmHg,16,
Tp,min,16,
CTS increase,,16,
Transport rate,nM min-1 mg-1,16,
CC50/EC50,,16,
AUC,uM h kg/mg,16,
HT50,%,16,
Viability,mM,16,
Vmax,nM s-1,16,
Vmax,pM min-1,16,
ED90,(mg/kg)/day,16,
MAT,hr,16,
IC50/[E],,16,
AUC,nmol/g.hr,16,
IC,nM,16,
MDD50,,16,
Relative value,,16,
Heart weight,g,16,
Peak deltaHR,beats min-1,16,
EC90/MIC,,16,
B,ug (g of abscess)-1,16,
Kin,/s,16,
Activity,10'6 /uL,16,
KiAH,nM,16,
Colony_count,,16,
Ca2+ reduction,,16,
RTP,%,16,
Radioactive constituents,%,16,
Probability,,16,
Pressor activity,mg,16,
Average score,,16,
Potentiation,uM kg-1,16,
Drug metabolism,umol/ml,16,
Rate of hydrolysis,,16,
Ke,/M,16,
Activity,10^3/mm3,16,
Kr,10^-3/min,16,
Kd,10^3nM,16,
Activity,/mmol,16,
Plasma cholesterol,mg dl-1,16,
Reduction in virus titer,%,16,
LC10,ug ml-1,16,
Drug metabolism,uM/Gy,16,
EC95,mg/L,16,
Activity,10'-4/min,16,
Rate constant,k hr-1,16,
Rs,uM min-1 kg-1,16,
Remaining rate,%,16,
Cmax,min,16,
Remaining ratio,%,16,
Cleavage rate,nM min-1 mg-1,16,
Resistance reversal,,16,
ED20,nM kg-1,16,
Response,min,16,
Max cAMP,%,16,
Ka,1/M.sec,16,
Retention_time,,16,
Change in IC50,fold,16,
Drug metabolism,uL/min,16,
SC200,,16,
Apoptosis index,,16,
Apoptotic activity,,16,
Cell protein in untreated control,%,16,
K2,,16,
LC50,uL/L,16,
Papp,10'-6nanometer/s,16,
Activity,FU/min,16,
KB,uM kg-1,16,
Relative esterase susceptibility,,16,
k obs / 1,1/M 1/s,15,
AUC/dose,ng/mL.hr/(mg/kg),15,
Hypoglycemic activity,mg kg-1,15,
pAH50,,15,
pAD,,15,
MAC,mg/kg/day,15,
Total number of entries,,15,
Ka,10'2/M,15,
Cp,mg/ml,15,
CLH,mg/min/microL,15,
Hemispheres reduction,,15,
Activity,mmolequiv,15,
Log 1/Th+200,,15,
Proliferation,,15,
T/C (ratio of treated to control),%,15,
TI,Ratio,15,
Activity,uA.cm^-2,15,
RMP,mV,15,
Accumulated counts/30 min,,15,
MTX equivalent,mg kg-1,15,
FE,,15,
Weight changes,g,15,
Cholesterol,ug,15,
deltaOD,/min,15,
Tumor volume,cm*3,15,
B50,M,15,
C10,mM hr,15,
Weight change,g mouse-1 on day 8,15,
IC50,M ml-1,15,
Extent of skin lesions,cm**2,15,
-Log concentration,M l-1,15,
AUCt,ng.min/g,15,
Kapp,10'-5/M,15,
Drug uptake,ug/L,15,
Activity,M-1 s-1,15,
Kact,uM,15,
Tonic seizures,%,15,
Cytotoxicity,mM,15,
INH,10'-3M,15,
Remaining compound,%,15,
K app,nM,15,
p alpha,,15,
Rate constant,M-1 s-1,15,
Dose,mg ml-1,15,
Hx shift,,15,
HC30,mg/ml,15,
Cp(f),ug ml-1,15,
T50,nM,15,
T/C survival days,,15,
Animals cured,%,15,
Clp,ml.min-1,15,
EC95,uM,15,
K,1/Maa,15,
Analgesia duration,min,15,
Inhibitory effect,,15,
Average tumor volume,,15,
Kinact,10'4/M/s,15,
Log K'W,,15,
Cp(f),,15,
Activity,mMequiv,15,
Log 1/B+1,,15,
Log 1/B.5,,15,
Log 1/B+100,,15,
Body weight change,BWC,15,
Cmax,ng.hr/ml,15,
CL free,%,15,
CGI,nM,15,
AP,,15,
Decrease in fighting,%,15,
Average survival time,day,15,
pEC50 diss,,15,
RBI,,15,
Delta HDL-C,%,15,
pD2,M,15,
Crop_yield,kg/ha,15,
Insulin-sensitizing activity,%,15,
T/C 1.2,,15,
Optimal dose,mg uM kg day-1,15,
CHI,%,15,
Co,uM,15,
Activity,mS/cm,15,
cpm,,15,
RVR ED15,ug kg-1,15,
3H-TdR incorpolation,c.p.m.,15,
Fresh weight,ng g-1,15,
Communicating cells,,15,
Preventive_index,,15,
E50,uM,15,
Kq,10^12L/mol/s,15,
Decrease RVR,%,15,
Kcat/Km,L/mmol/s,15,
Survival,weeks,15,
Change in rat blood sugar,%,15,
No. of cells,ml,15,
Vm/Km,,15,
Mineral apposition rate,mm day-1,15,
Reduction in movement,%,15,
Vd/F,l,15,
Ratio,10^5/M/s,15,
ED85,ng ml-1,15,
MOT,,15,
Ratio,10^3/M/s,15,
Vmax,RFU/min,15,
Drug recovery,umol,15,
I50,ppb,15,
P50d/P50c,,15,
Vz,,15,
GI,nM,15,
Food intake,g,15,
Succeeded/tested,s,15,
Ratio CC50/IC50,10'4No_unit,15,
Kq,10^13L/mol.s,15,
No. of entries,%,15,
WLC PRA,,15,
Alkylation,%,15,
Activity,ug disk-1,15,
Efficacy,picometer,15,
Amount bound,M g-1,15,
Spent time,hr,15,
Stability,yr,15,
Stability,%/hr,15,
Average change in weight,%,15,
Kcat,10'-4/s,15,
CR,,15,
Ae,%ID,15,
Kcat/Km,10'2/M/s,15,
VCT,,15,
PD50,mg Kg-1,15,
Antidiuretic activity,,15,
Blood glucose level,,15,
2x APTT,,15,
Drug metabolism,ml/min.kg,15,
ED80,uM kg-1,15,
Activity,/10'2cm3,15,
GI25,nM,15,
ID50,umol/kg/hr,15,
No. of suncus vomited,,15,
AERP,,15,
CLogD7.4,,15,
C8h,uM,15,
Log concentration,,15,
Triglyceride correction,%,15,
Metabolite levels,,15,
Cell proliferation,%,15,
MPE,mmHg,15,
Scavenging activity,%,15,
GTP-gamma35S bound,%,15,
-Log I50,,15,
LD95,mg kg-1,15,
Activity,FU,15,
Metabolite levels,ug,15,
Cures,survivors/total,15,
CL_renal,ml/hr,15,
Kcat/Km,10^6/M/s,15,
Log2,,15,
Activity,mJ/m2,15,
S,Dilution factor,15,
Activity,uM of MDA (mM of deoxyribose)-1,15,
Activity,RLU/mg,15,
IC100,nM,15,
Activity,Angstrom,15,
CF,%,15,
Plasma concentration,nM,15,
Relative differentiating activity,,15,
EC40,mM,15,
No. of living cells,,15,
ED40,nM kg-1,15,
NBT positivity,%,15,
EC25,ug ml-1,15,
CMC,umol/L,15,
fIC50,,15,
Effectiveness,%,15,
Gastric concentration,ug g-1,15,
Root_galling_index,%,15,
Max agonist response,%,15,
Rmax,RU,15,
MFC,mg l-1,14,
Kd1,nM,14,
K,10'-4/min,14,
NLCK,,14,
Ratio,10^6/M/s,14,
Growth delay (T-C/C),%,14,
Reduction,mg kg-1,14,
AI50,nM,14,
Concentration,M l-1,14,
Rate max,beats min-1,14,
Histopathology,,14,
Dose range,mg kg-1,14,
Survivors at 24 h,,14,
Rate of inhibition,s-1,14,
Activity,ml/min.Kg,14,
Ratio,10^4/M/s,14,
Kdapp,nM,14,
Increase in blood pressure (P/R),%,14,
Positive,%,14,
Kdiss,10'-2/s,14,
Hypotensive activity,mmHg,14,
K,10'-6/M,14,
Hypocotyl length,cm,14,
Dissociation rate constant,1/S,14,
ALP Level,U l-1,14,
GI,square millimeter,14,
Vdss,ml,14,
deltaTm,hr,14,
Net grain counts,,14,
Kd,1/s,14,
Lipid peroxidation,,14,
Erythema induction,,14,
K,10'3/uM/s,14,
Blood urea nitrogen,mg 100ml-1,14,
EC100,mg ml-1,14,
Kt,uM,14,
Ct,hr.fmol,14,
Cmax,hr.fmol,14,
Log Pmic,,14,
Cl,mg ml-1 kg-1,14,
Plasma histamine,ng ml-1,14,
Reactivity,%,14,
Therapeutic index,ug ml-1,14,
IC,mM,14,
Activity,10'-10mol/min,14,
k3,s-1,14,
30 day survivors,,14,
PB,pmolequiv,14,
Net turns/min,,14,
Liver TG,mg g-1,14,
Subcut score,,14,
Reduction,mg,14,
Reduction,hr,14,
AUC,nM.hr.kg/mg,14,
No. of dogs used,,14,
Complete remission,%,14,
No. of dogs reverted,,14,
Free complex,%,14,
Ouabain,ug kg-1,14,
No. protected/ No.dosed,,14,
I75,gAi/ha,14,
AUC c,,14,
Vmax,nM hr-1 mg-1,14,
Mean decrease,%,14,
Lethal dose,p.p.m.,14,
MBC=>99,ug ml-1,14,
ECLT,min,14,
C/P,,14,
fAUC/MIC,hr,14,
Adjuvant effect,,14,
kc,10e-3 1/s,14,
Log change,,14,
Activity,ul min-1,14,
Activity,uM/day,14,
IC20,nM,14,
Ki,10'6/M,14,
Stain index,,14,
ED6,mg kg-1,14,
PEI,%,14,
EC10,ug ml-1,14,
Change,uM,14,
Activity,uM min-1,14,
Pigmentation capacity,,14,
Average body weight change,%,14,
ED50,10'-7mol/cm2,14,
Activity,pmol/min/ug,14,
Vmax,nM hr-1 (10e6*cells)-1,14,
Experimental DPM,,14,
Infectious virus,ffu ml-1,14,
K,10^3/M/min,14,
Amount,nM (mg of protein)-1,14,
K,10^6/M/min,14,
Plasma ALT at 24 h,mU ml-1,14,
Therapeutic effect,%,14,
MCCD,mg kg-1,14,
Bullatacin index,,14,
Nitric oxide,%,14,
Equilibrium OD340,,14,
Increase over control,%,14,
Increase in plasma lipase,IU ml-1,14,
Increase in DPM,(mg of protein)-1,14,
Activity,10'-5OD/s,14,
Potentation,,14,
Kr,10'-3/min,14,
Thermodynamic solubility,ugA/ml,14,
Stability,nmol,14,
Duration of reversal,min,14,
TPO,%,14,
VM,pM min-1,14,
Kcat/Km,10'-3/microM/s,14,
CCh,,14,
Time,10'3s,14,
EI,,14,
NADH oxidation,uM min-1mg-1,14,
Activity,pmol/min.mg,14,
Photosensitization,,14,
PD50,mg/kg/day,14,
T/C corr,%,14,
C1.3,uM,14,
K,10'-1/min,14,
dose BP/BP,,14,
No. of males fertile,,14,
Emax,mM,14,
Radiation equivalent,,14,
Blood glucose,mM (l of whole blood)-1,14,
Activity,nM g-1,14,
Delta TC,,14,
fCmax,,14,
No. of males mated,,14,
k2,10e-3 1/s,14,
G0/G1,%,14,
Sp Max,%,14,
ID50,nmol,14,
AUCt,nM/ml.hr,14,
Activity,L/s,14,
Max decrease in blood pressure,mmHg,14,
MIC,umol/uL,14,
Relative level,,14,
Decrease in Bmax,%,14,
Activity,IU/dl,14,
MIC,ug m/L,14,
GSTCP activity,,14,
k-2,10e-3 1/s,14,
ID50,ng,14,
DNA cleavage,%,14,
Toxicity related death,,14,
CT10,mM-hr,14,
AUC,mg kg-1,14,
Max MBP,mmHg,14,
EDmin,uM kg-1,14,
Kinact,10^-3/s,14,
Vmax,nmol/min/mg protein,14,
Ko,min-1,14,
Relaxed DNA,%,14,
Relative t1/2,,14,
-Log Sw,,14,
LWI,%,14,
MID log LC50,M,14,
Tonic-clonic seizure,,14,
K NBP,s-1,14,
RT,min,14,
TCID50,ml-1,14,
GOT Level,U l-1,14,
LD0,,14,
No. of mice dead/day died,,14,
Drug metabolism,pmol/hr,14,
K app,min-1,14,
K H,s-1,14,
ED15,uM kg-1,14,
Max relaxation,%,14,
k,M-1 min-1,14,
log10PFU/ml,,14,
Vmax(app),pmol/mg.min,14,
Of control,%,14,
POT vigilance,,14,
LD10,mM,14,
No. of writhings,,14,
pXI50,,14,
Drug uptake,ml/min/mg,14,
gammaCMC,mN/meter,14,
Agonistic activity,%,14,
Peak time,min,14,
Kid,uM,14,
Control relaxation,%,14,
Pcaco2,cm s-1,14,
KDMPC,M-1,14,
Activity,10'7/ml,14,
Antimicrobial activity,,14,
IC60,nM,14,
Serum triglyceride,%,14,
Body weight change,g (100g of body weight)-1,14,
GPT Level,U l-1,14,
Serum stability,,14,
No. of plaques,,14,
Bilurubin Level,mg %,14,
UD,mg kg-1,14,
Prolactin control,ng ml-1,14,
Edema density,,14,
CAR,MPK,14,
Prolactin treatment,ng ml-1,14,
ED33,mg kg-1,14,
Maximum response,%,14,
AUC p,,14,
No. of males cohabited,,14,
deltaA,nm,14,
LD50,ug/mg,14,
Inhibition potency T/II,,14,
Inhibitory activity,uM,14,
Vmax,uM min-1 mg-1,14,
Drug uptake,ug base equiv/g,14,
Activity,uS,14,
Parasites no. per 100 Myoblasts,,14,
Max increase in coronary flow,%,14,
Log rate constant,M-1 s-1,14,
KI',uM,14,
Tumor weight,%,14,
Ka,10'-6/M,14,
LD50,10'-6M,14,
APA,mV,14,
Max tolerated dose,mg kg-1,14,
Emax,mV,14,
Myoblast with parasites,%,14,
HVA level,ug g-1,14,
5-HT syndrome,,14,
TC90,umol,14,
B(DPB),%,14,
TC50,umol,14,
Kidney weight,,14,
K obs,uM,14,
Change in blood flow,,14,
C20 APD95,,14,
ED50,uM site-1,14,
Lysis area,mm.mm,14,
Vmax / Km,nM min-1 mg-1 mM-1,14,
LD50,mg/ml,14,
MI50,uM,14,
Tumor growth delay,day,14,
Fungicidal,ug ml-1,14,
Tumor burden,mg,14,
Abdominal fat,g,14,
No. of scratches,,14,
Activity,(ng of PGE2) (mg of protein)-1,13,
ED70,mg kg-1,13,
Vagal response,,13,
MBC>99.9,,13,
Kcat/Km,/min/microM,13,
Vmax,c.p.m.,13,
Max delta BP,mM,13,
MEC,%w/v,13,
AUC,nM/ml,13,
Regression response,%,13,
Enhancement ratio,,13,
Kcat/Km,10'2/s/M,13,
Ratio,/min,13,
Excreted,%,13,
Kq,10'11/M/s,13,
NOAEL,ng/ml,13,
Reduction in virus yield,pfu/ml,13,
LBF,ml/min,13,
Vmax,pmol,13,
Kr,mmol/min,13,
Ki,s-1,13,
KB app,nM,13,
VOLSYN,,13,
Change in cholesterol,,13,
IC25,,13,
MBIC=>90,ug ml-1,13,
LBF,L/min,13,
Kdiss,10^-3/s,13,
RBP,%,13,
MNTD,mg/kg/day,13,
Radioligand bound,%,13,
ED100,nM,13,
Hormonal activity,,13,
Photolysis,,13,
IC20,10'-5M,13,
EC50,Ke nM-1,13,
BMD,mg/cm3,13,
Ratio,10^4/M/min,13,
Cmax,mg kg-1,13,
Kup,ml/min/g,13,
Kd,s-1,13,
Kt,,13,
Ks,mM,13,
MST,%,13,
AD50,nmol,13,
Ratio,mg/L,13,
Equilibrium,ug/ml,13,
Caco-2 permeability,,13,
Kd,10^-12M,13,
Vm,10'-4m3/mol,13,
Kd,10^-3/s,13,
Drug deaths,,13,
Parasitemia,,13,
MED10,mg kg-1,13,
QT interval,ms,13,
ED2,ug kg-1,13,
k'',s-1,13,
Chlorine uptake,,13,
Km/Kcat,,13,
MED98,mg kg-1,13,
RSA tR,min,13,
Agonism,,13,
Ki int,uM,13,
Activity,10'9CFU/g,13,
EC99.9,uM,13,
MRD,V s-1,13,
MAP,%,13,
RHA,,13,
AUC,hr/mL,13,
CL,ml/kg.hr,13,
increase in response,%,13,
S,%,13,
AUMCt,hr.hr.ng/ml,13,
Ki',mM,13,
Average weight change,mg kg-1,13,
Transcriptional activity,%,13,
Logit_p(conc),,13,
Ki/(Km/Kcat),,13,
B/P,,13,
RFU,a.u.,13,
Root_galling_index,,13,
KDNB,,13,
IC>80,,13,
Ka,10'-4/M,13,
CMI,mg l-1,13,
Ka,/mM,13,
Emax,ms,13,
SB,%,13,
p10 MIC,nM,13,
ln Kp,,13,
LD50,mg,13,
Tumor inhibition ratio,%,13,
LD50,mg kg-1 day-1,13,
LD50,mg/m2,13,
Effective dose,uM kg-1,13,
Behavioral response,,13,
DNA fragmentation,,13,
MED50,mg,13,
Average tumor volume,T/C,13,
AERP,ms,13,
Activity,mg l-1,13,
Protective Index,,13,
E100,M,13,
Effectiveness,,13,
Activity,mg/g DW,13,
Log tumor cell kill,,13,
Weight change on day 5,%,13,
ED50,mpk/d,13,
Cmax,ug g-1,13,
CL,ml/min.g,13,
Blockade duration,min,13,
Shutdown time,min,13,
MIC,umol/cm3,13,
deltaA,%,13,
Serum level,ug ml-1,13,
K,10^-5/s,13,
ILS (T/C),%,13,
Optimal dose,mg uM kg-1 day-1,13,
C120/ED50,,13,
TT,min,13,
AUCt/dose,nM.hr,13,
Cmax,uM-1 kg-1,13,
Migration,%,13,
Induction,fM,13,
K,/min/nM,13,
Log 1/IC90,,13,
Activity,degreeC.hr,13,
Occ50,ng/ml,13,
Effective concentration,,13,
Amine formed,ug,13,
Max SBP,mmHg,13,
ID50,umol/cm2,13,
K,10'-4/M/s,13,
Change in temparature,degrees C,13,
Drug uptake(free),ng/g,13,
I50,gAi/ha,13,
Survivals,%,13,
Spontaneous motor activity,,13,
Alpha Ki,M,13,
ED50,m equiv [H+] l-1,13,
Cures,%,13,
Lesion_Clearance,%,13,
TO,min,13,
Increase in HR,%,13,
ED50,kg/ha,13,
ID50,uM ml-1,13,
PDI,%,13,
Length,mm rat-1,13,
Log cfu/g,,13,
ED50,gAi/ha,13,
P value,,13,
ST,s,13,
Activity,pmolequiv/mg,13,
Body weight loss at nadir,%,13,
K,10^8/M,13,
T,min,13,
TPI,%,13,
ED50,M mouse-1,13,
K bind,,13,
Inotropic potency,nM kg-1,13,
Delta ED50,mg kg-1,13,
Exploratory activity,,13,
Rate,nM min-1 (10e6*cells)-1,13,
D,10'-10m2/s,13,
Relative bioavailability,,13,
BEI,kDa-1,13,
HC5,ug ml-1,13,
Peroxidase rate,uM of ABTS min-1,13,
Rate constant,hr-1,13,
log10LT50,,13,
LC50,ugAi/L,13,
Negation,%,13,
Necrosis response,%,13,
ln Kt,,13,
Relativity,,13,
Wet weight,mg,13,
Peff,10'-4 cm/s,13,
ED90,mg/kg.day,13,
Hepatic necrosis in survivors,,13,
AUC,SUV.min,13,
Differentiation activity ratio,,13,
Ki,10^5/M,13,
LC90,ugAi/L,13,
Duration time,hr,13,
Max enhancement,,13,
Relative stimulatory activity,%,13,
Hill coefficient,nH,13,
Cell permeation,nm s-1,13,
EC40,,13,
Activity,mg.min/dL,13,
Ip score,,13,
ID95,nM,13,
MTD,mg/m2,13,
Fmax,,13,
K HOX,,13,
fAUC/dose,nM.hr/mg/kg,13,
MTX ratio,,13,
K OX,M-1 min-1,13,
MIC,U/ml,13,
LVEDP,mmHg,13,
Absorbance,,13,
Radioactivity level,ml,13,
CL,ml.Kg/min,13,
Relative florescence,,13,
Rate,delta OD340 min-1,13,
Urine/bile,,13,
kR,uM,13,
Cell Proliferation AC50,nM,13,
Basal,%,13,
Tissue levels,ug ml-1,13,
Age,d,12,
Myristoylpeptide,%,12,
CFU,10^9/ml,12,
TVR,mmHg ml-1 min-1 g-1,12,
CFU,10^8/ml,12,
Amount of Ouabain used,,12,
log10PFU,g,12,
Dose (urinary recovery),%,12,
Infarct volume,mm**3,12,
Volume,ml,12,
IC50,ug well-1,12,
Cholestrol levels,g l-1,12,
[3H] TdR uptake,c.p.m.,12,
Vmax,pM hr-1,12,
Weight gain or loss,%,12,
Activity,ucat/L,12,
No. of mice protected/tested,,12,
Urinary level,mg,12,
Activity,micrometer,12,
Brain penetration index,%,12,
Vaginal activity,,12,
Neostigmine reversal,,12,
Concentration,nM min-1 (mg of protein)-1,12,
Ibuprofen,%,12,
Bronchoalveolar lavages,,12,
Time in flight,%,12,
Adjuvant activity,,12,
mBP(delta),%,12,
IC35,nM,12,
Tissue concentration,uM,12,
Viscosity,%,12,
Mortality range,day,12,
Activity,fmol/g,12,
logt1/2,,12,
BsI,%,12,
Ae,umol,12,
Activity,cm s-1,12,
Activity,micromol/s,12,
CLp,L.h-1.m-2,12,
Cmax/dose,kg.ng/ml/mg,12,
IC50,pmol/L,12,
Total acid output,%,12,
Activity,(ng of TXB2) (mg of protein)-1,12,
No. of animals protected/number of animals tested,,12,
Lesion length,mm rat-1,12,
Catalyptic action,,12,
Excretion,mg kg-1,12,
Stability,%ID,12,
LC30,ug ml-1,12,
Average colony count,,12,
Phosphorolysis,,12,
Kcat,10'-1/s,12,
LC50,mg/cm2,12,
Ct,pmol/ml,12,
AUC,hr.sec,12,
LC50,ng,12,
Relative binding potency,,12,
Spermatogenic index,,12,
PDC,,12,
Kb app,uM,12,
Effect,pM (10e6*cells)-1,12,
Relative growth,%,12,
MFI,,12,
TOC ED50,M,12,
Unchanged tracer,%,12,
AUC,g.hr,12,
Log PI,,12,
ME increase,nM min-1 mg-1,12,
N/T,,12,
INH,%/min,12,
GPGB tension,g,12,
INCC50,uM,12,
Mean day of death for total dead,,12,
Log k'o,,12,
Degranulating activity,,12,
Urine volume,,12,
Urinary volume,ml kg-1 5hr-1,12,
GPI,nM,12,
No. of animals alive,,12,
EC20,ng ml-1,12,
Urine Na+,m equiv,12,
logK-IAMex,,12,
Urine K+,m equiv,12,
Urine,ml,12,
ASAT levels,IU/l,12,
Adduct formation,,12,
UB,,12,
Activity,uM min-1 mg-1,12,
Tumor/liver ratio,,12,
HV interval,,12,
Activity,log CFU,12,
C5a max,%,12,
Logit bioavailability,,12,
Transacylation rate,,12,
Vmax/Km,pl/min,12,
Vmax(app),%,12,
AUC/dose,hr.microg/ml,12,
CITH,,12,
Cmax_unbound,nM,12,
TDI,uM,12,
Specific activity,dpm,12,
TLm,ug ml-1,12,
MHC,mg/ml,12,
EC30,M,12,
Vmax/Km,uL/min.mg,12,
HR(delta),%,12,
MTD,(mg of CPT) kg-1,12,
AUC,hÂ·fmol/million cells,12,
Tumor/blood ratio,,12,
Log [-8],,12,
Cp,nmol/L,12,
Log K,M-1,12,
AUC,pM ml-1,12,
Cmax normalised,(ug/ml)/(mg/kg),12,
No. of pits,,12,
TOX/TEST,,12,
Tumor cure,%,12,
IC50H,nM,12,
Na+ excretion,m equiv 5hr-1 kg-1,12,
UR,,12,
Vmax / Km,10^-9 L min-1,12,
MAO deamination,%,12,
Activity,nM stent-1,12,
M50,%,12,
Vmax/Km,uL/mg/min,12,
NRD,mg/kg/day,12,
Change in cell number,%,12,
CQ,,12,
IC90,ug well-1,12,
Dopamine level,ng mg-1,12,
TI,TD50/MIC50,12,
Log Ka,,12,
EC,uM 15min-1 mg-1,12,
Mean,pM mg-1,12,
Log Phep,,12,
V0,microM/s,12,
Total,%,12,
MDL,day,12,
CL,mg/ml/kg,12,
Tmin,hr,12,
Activity,cm/min,12,
Threshold active dose,mg kg-1,12,
CC10,mg/L,12,
av,,12,
Thyroid status,nM l-1,12,
logPc,,12,
Log [-5],,12,
C0,mg/L,12,
Log [-6],,12,
Log [-7],,12,
Mean duration,min,12,
Counts/30 min,,12,
ED70,,12,
No. of animals with damage,,12,
Activity remaning,%,12,
GT rate,,12,
AUC normalised,((ug.h.ml-1)/(mg/kg),12,
HbS solubilized,%,12,
IC10,umol/L,12,
MES/TEST,,12,
Control growth,,12,
OSAV,%,12,
VI30,%,12,
Observed at,ug ml-1,12,
Cmax(app),uM,12,
Vmax,10'-4deltaA/s,12,
OD,/hr,12,
O2 production,%,12,
Log Pmw,,12,
cAMP content,pmol/mg protein,12,
ERP (delta),%,12,
Cp,ug base equiv/g,12,
Relative inhibitor potency,,12,
Tubulin polymerization,%,12,
Average activity,,12,
RAP,,12,
Osmolality,mOsmol kg-1,12,
Crop_yield,%,12,
DNA photo-crosslinking,,12,
T free,ns,12,
Kel,L/hr,12,
Diuretic activity,m equiv [Na+] 5hr-1kg-1,12,
DNA single strand breaks,rad equiv,12,
T bound,ns,12,
lesions,,12,
kinact/Ki,M-1 s-1,12,
Mean value,,12,
Analgesic response,,12,
Log 1/E100,,12,
Potencymean,ng g-1,12,
T/A,,12,
TAC,%,12,
T/C,mg kg-1 injection-1,12,
Rate,ka/Ks,12,
Activity,10'-9PFU/ml,12,
Intensity of erythemia,,12,
Ki,M-1 min-1,12,
Activity,10e-4 K s-1,12,
k cat/Kuncat,,12,
K app x10e-7,M-1,12,
Max release,%,12,
Peak concentration,ug ml-1,12,
pSI,,12,
Residual contractile activity,,12,
%R,%,12,
MIC>90,,12,
LD20,mg/ml,12,
MNTD70,uM,12,
Absorption,ng ml-1,12,
Ka,10'4/Ms,12,
Response,RU,12,
Metabolic rate,pM min-1 (mg of protein)-1,12,
MIC98,uM,12,
Min concentration,ug ml-1,12,
Ratio CC50/IC50,10'5No_unit,12,
Cmax,pmol/g,12,
Emesis,,12,
Iron excretion,ug kg-1,12,
Acetaldehyde,nM (mg of protein)-1,12,
Kd2,nM,12,
Protonated,%,12,
Drug uptake,PSL/mm2,12,
D50,uM,12,
EC30,mgAi/L,12,
Ratio,/s/microM,12,
Quantity,pM mg-1,12,
Activity,no. of living cells (10E3) /mL,12,
Clp,,12,
Protective activity,%,12,
QTc delta,%,12,
Bmax,fM assay-1,12,
Complete spontaneous reversal,,12,
QH,L/hr/kg,12,
Activity,10'-8M,12,
Drug metabolism,%molar,12,
QT,ms,12,
Macrophage activation,,12,
Kb,10'3L/mol,12,
DAP,,12,
Kq,10'5/M,12,
RVmax,,12,
Max intensity,,12,
Cell cycle fraction,%,12,
Activity,10'3/cm2,12,
T1/2 increase,%,12,
Mean tumor volume,cm*3,12,
Potency vs EKC,,12,
RPP,mmHg beats min-1,12,
Progressed tumors,%,12,
Activity,10'5/cm'3,12,
Ki,10'-4/M,12,
deltaS,J/mol/K,12,
Rate,beats min-1,12,
DIZ,cm2,12,
RH/RL,,12,
Kic,,12,
Optimal dose,%,12,
Change,hr,12,
Rate of decomposition,,12,
ED,ug/kg,12,
Peak current,%,12,
Formaldehyde,nM (mg of protein)-1,12,
LV dP/dTmax(delta),%,12,
Max. activation,%,12,
L-T3,%,12,
Kcat/Km,10^4/M/s,12,
Effect,mmHg,12,
Mean relative surviving fraction,,12,
Reducing activity,%,12,
PC50,,12,
LAD,,12,
Static tumors,%,12,
Anticoagulant activity,uM,12,
log S,M/m3,12,
MIC80,%v/v,12,
LD80,ug/mg,12,
AC,,12,
Regiospecificity,,12,
Stability,ng/ml,12,
Ct,nmol/g,12,
Relative Bioavailability,,12,
CL_renal,,12,
Plasma corticosterone,ng ml-1,12,
Cmax,hr,12,
K 0.5,uM,12,
Relative effect,,12,
PL-017 shift,,12,
EC5,uM,12,
Drug metabolism,ug/L,12,
Relative intensity,,12,
AH interval,ms,12,
Extraction,%,12,
Average No. of metastasis,,12,
Latency,min,12,
Kapp,10'-7/M,12,
Activity,Torr,12,
Excretion,m equiv 4hr-1,12,
Ratio IC50/EC50,uM,12,
ALAT levels,IU/l,12,
Plasma lipid level,mg dl-1,12,
-log(1/AD50),,12,
Plasma levels,ug ml-1,12,
Activity,10'-2k/min,12,
Activity,pmol/s,12,
Platelet aggregation,,12,
Excretion,% of dose,12,
LC90,ug,12,
Drug metabolism,pmol/ml,12,
ED25,mM kg-1,12,
pKapy,,12,
Change in MST,,12,
LD90,ng/ml,12,
hSlo current,%,12,
Conc_plasma,uM,12,
Slope of Schild plot,,12,
K diss,s-1,12,
Activity,M min-1 (M of enzyme)-1,12,
SC,mg dl-1,12,
Kapp,,12,
Acid output,u equiv of [H+] 2hr-1,12,
Activity,10^6/ml,12,
Baseline,,12,
AH interval,,12,
Peff,10^-7 cm/s,12,
Concentration,% dose g-1,12,
Relativity,c.p.m. mg-1,12,
k,10e-3 min-1,12,
K L,,12,
K obs / 1 1/Ms,,12,
Activity,AUC units,12,
LH concentration,mU ml-1,12,
KSV,L/mol,12,
Fecal recovery,%,12,
Fe removed,%,12,
Activity,mg m-1,12,
Falling,%,12,
SBP decrease,%,12,
K+ excretion,m equiv 5hr-1 kg-1,12,
Rise HR,%,12,
ED25,10'-5M,12,
Serum TG,mg dl-1,12,
K-1 decrease,%,12,
AUDPC,,12,
LD50,uM/ml,12,
Activity,KA,12,
pKabz,,12,
CLH,/hr,12,
FIC index,,12,
Enhancement,uM,11,
BGL,%,11,
Vmax,deltaA/min,11,
Log,%,11,
Activity,millimeter/sec,11,
Rating,beats min-1,11,
Average weight gain,g,11,
Ke,/hr,11,
deltaS,cal/mol/deg,11,
kHO,M-1 s-1,11,
cAMP production,pM min-1 mg-1,11,
Brain/Plasma,,11,
HAR,,11,
AUCED90,ug.hr/ml/day,11,
Ca2+ binding protein,ug (100mg of duodenum)-1,11,
TG,,11,
10E2 k1,min-1,11,
Inflammation units,,11,
Kn,M-1,11,
AUC/dose,ng.hr/ml/mg,11,
MIC,pug ml-1,11,
Prolonged ARP,%,11,
Activity,uA.cm'-2,11,
EC50,ng/g,11,
Kii,mM,11,
Drugexcretion,ug,11,
Vmax / Km,mM-1 min-1,11,
G Index,,11,
MED99,MKP,11,
Kdiss,10^-2/s,11,
CLu/F,L/hr/kg,11,
Vp/F,l,11,
Hgb levels,g dl-1,11,
Kdiss,10'-5/s,11,
T-cell binding,%,11,
EC25,mM,11,
TD100,uM,11,
LD90,mg/L,11,
MAC,mg/L,11,
[EA],uM,11,
Substrate specificity,,11,
AUClast/dose,nM.hr,11,
CPE50,ug ml-1,11,
pI50,M,11,
ND,mg kg-1,11,
AD50,nM mouse-1,11,
Change of predose,%,11,
MED,%,11,
Others,,11,
Ca2+ elevation,nM,11,
7-day weight change,%,11,
Activity,mm3/day,11,
Minimum Tmax,h,11,
K,1/Ms,11,
K,1/M.sec,11,
AUC,microM/L.hr,11,
CGI,,11,
Clp,ml min-1,11,
Log 1/ISA,,11,
Log 1/Kd,,11,
Ca2+ flux,,11,
Hind-paw lick latency time,s,11,
Log P',,11,
Activity,10'-6mg/kg,11,
K,10'-5/M/s,11,
Activity,10'7log10CFU/ml,11,
Ratio_EC50,,11,
AUC/dose,hr.ng/ml,11,
CT,,11,
fAUC/dose,microg.hr/mL,11,
Vmax,AU/min,11,
Vss,,11,
Vmax,10^4M,11,
cAMP,pM well-1,11,
Ks,,11,
Vz,ml,11,
Distribution ratio,,11,
rK,,11,
2x TT,uM,11,
A2,nM,11,
Platelet count,ul,11,
Diuresis,ml kg-1,11,
K,10^-5/M,11,
Stability,uL/mg/min,11,
f(Cave),uM,11,
Change of size,%,11,
Ca2+,mM l-1,11,
IC10,ng ml-1,11,
IC10,nM,11,
CL,microM/min/mg,11,
No. of dead animals,,11,
Ileal activity,,11,
Log Pion,,11,
Plasma level,pg ml-1,11,
Max.stimulation,%,11,
Delta mmHg,,11,
Mean volume of hind paws,,11,
AUC,mmHg.hr,11,
Response,min-1,11,
Kq,10^13L/mol/s,11,
K,10^-4/M,11,
Protein interaction energy,kCal M-1,11,
NOEL,mg kg-1,11,
log10cfu,/ml,11,
Control period,,11,
MED90,MKP,11,
Psychotropic Effect,,11,
KiL,uM,11,
Inhibition activity,,11,
Mean rate constant,,11,
Ki',,11,
ClC95,nM,11,
KmL,uM,11,
Drug metabolism,10'-5/s,11,
T1/29,min,11,
EC15,,11,
Log 1/delta/Ca,,11,
Ki slope,uM,11,
Ratio Ki,10^-4No_unit,11,
Mean tumor volume,,11,
KiA,uM,11,
TI50,uM,11,
Km,10^4M,11,
pFe3,,11,
TI,hr-1,11,
dP/dt,,11,
Vmax,pmol/uM/min,11,
Maximum Tmax,h,11,
Decrease in heart rate,beats min-1,11,
Bmax,cpm,11,
Rotorod,,11,
AHV,%,11,
Activity,10'-3M,11,
Relative inhibitory activity,,11,
AUC,ng.hr/ml/mg,11,
Cell Proliferation EC70,uM,11,
S/T,,11,
Aberrant cells,%,11,
Vasodilatory rate,%,11,
Vascular relaxation,%,11,
Binding affinity,spec bound mg-1,11,
SBP change,%,11,
Kcat/Km,/min/M,11,
No. of vomiting episodes,,11,
Activity,uM/micrometer/s,11,
FR10 control,,11,
Drug period,hr,11,
FR10 treated,,11,
Degradation ratio,,11,
Low,%,11,
Kcat(app),/s,11,
Tlast,min,11,
No. of rats with 5-HT syndrome,,11,
CD90,,11,
K,microM/min,11,
E2,%,11,
Alkylating activity,,11,
Max delta BP,mmHg,11,
SC200,nM,11,
Kcat,10^6/s,11,
AbsAC0.47_uM,uM,11,
Ca2+,%,11,
No. of implants/pregnancy,,11,
Ulceration,%,11,
Papp,10-6 cm/s,11,
Cells,,11,
Delta Ca,mM,11,
Exclusion parameter,,11,
Vbeta,l,11,
Binding site fraction,,11,
Translation,,11,
Drug metabolism,ppm,11,
Phosphor,%,11,
Tumor cure,,11,
D/P,,11,
Activity,pM of citrulline min-1 (mg of protein)-1,11,
Log geometric mean,pfu mg-1,11,
Phosphorolysis,%,11,
Apoptotic index,,11,
Tubulin polymerization,,11,
ED100,mg/kg/day,11,
VFT,mA,11,
Relative agonist activity,,11,
ED50,ug min-1 kg-1,11,
ED80,mg,11,
Count,,11,
IPA,,11,
Relative agonistic activity,,11,
KPCB,M-1,11,
%hepatic blood flow,%,11,
Med tumor area,mm**2,11,
amount in urine,%,11,
Tmax,uM,11,
Counts,min-1,11,
Tolerance,,11,
ID50,nM (mg SR protein)-1,11,
KIs,M,11,
CT10,,11,
Lesion frequency,%,11,
Fluorescence intensity,%,11,
Blood AcH,uM,11,
ED20,gAi,11,
Fluoroscence,%,11,
ED20,nM,11,
SF50,uM,11,
%T>MIC,%,11,
Kb,L/mol,11,
CLH,nmol/min,11,
Activity,KgAi/ha,11,
Agonist effect,%,11,
LC50,ppb,11,
LD90,g/ha,11,
K-1,min-1,11,
AUC,uM h/mpk,11,
2aPTT,nM,11,
Extent,,11,
Relative cytotoxicity,,11,
AUMC,ug/ml.hr^2,11,
Relative concentration,,11,
ICL50,uM,11,
ABBC,log10CFU/ml/hr,11,
ED60,mg kg-1,11,
Active dose range,mg uM  kg-1 day-1,11,
INH,/M/s,11,
Relative rate metabolism,,11,
log1/CMC,,11,
LC90,mg/ml,11,
AUCt,ug/g.min,11,
Relative phosphorylation,,11,
Mice with lesions,,11,
Serum level,ug dl-1,11,
K cat,1/S,11,
AUC,uM hr l-1,11,
ED30,nmol/Kg,11,
Papp,10'-6cm/min,11,
Tox50,ug ml-1,11,
KA,10'7/M,11,
K1,10e-3 min-1,11,
IC50,ug/mol,11,
Activity,IU/g,11,
Pe,10e-6 cm s-1,11,
% of effect,%,11,
Resorbing implants,%,11,
CLH,microM/min/mg,11,
"pKa,2",,11,
AUC,ngequiv.hr/g,11,
"pKa,1",,11,
No. of mice alive,,11,
Max CF response,,11,
Arthritis scores,,11,
CT10 ratio,air/N2,11,
Papp,10'-2 cm/s,11,
Atttacks,%,11,
Cells arrested,%,11,
General activity,,11,
Max suppression,%,11,
K',abs/time,11,
K''IAM,,11,
MI50,,11,
Untreated control,%,11,
Selective index,,11,
Release,,11,
Change in No. of trophozoites x 10E-5,,11,
[A],uM,11,
IC50,umol/Kg,11,
Glucose,%,11,
EC50,ug.cm'-2,11,
Collapse time,s,11,
CLH,ml/(min.mg),11,
Liver weight,mg 10g-1,10,
% of growth rate,%,10,
Log P16,,10,
A50,,10,
INH,10'-5 mol/L,10,
Max tolerated dose,mg kg-1 day-1,10,
Log,k,10,
PKa2,,10,
PKa1,,10,
CPM x1000,,10,
Log sensitivity,,10,
Tissue/Plasma Ratio,,10,
[I] for Km',uM,10,
Induction,%,10,
C10 N2,uM,10,
MTD,mM,10,
Substrate metabolized at 1hr,%,10,
Vmax/Km,10'6/min,10,
Concentration,nM min ml-1,10,
INH,ng/ml,10,
Activity,KA Units,10,
CMpH,,10,
Alpha-lipoprotein cholesterol,mg dl-1,10,
Activity,nM min-1 ml-1,10,
ED37,uM,10,
INH,mole fraction,10,
CL,ml/min/m2,10,
Occ50,ng/g,10,
Delta RBF,%,10,
C20,,10,
GMS activity,,10,
Ctt2,uM,10,
Survivors / total,%,10,
K,10'-9M,10,
cKi,nM,10,
K ass,,10,
Sigmap,,10,
Si,,10,
INH,10'-4 mol/L,10,
Min lethal dose,mg kg-1,10,
Serum total cholesterol,mg dl-1,10,
Cp(T),ng/ml,10,
Activity,pmol/uL,10,
PB,pmolequiv/mg,10,
CL,nmol/mg/min,10,
Iron mobilization,%,10,
TOC ED50,,10,
Mice,%,10,
K,10'4No_unit,10,
Infected erythrocytes,%,10,
Suppression of parasitemia,%,10,
Mice,,10,
Amount of metabolite,nM ml-1,10,
A50,ug,10,
Frel,,10,
Inflection point,,10,
AUC,ug.ml-1,10,
cAMP increase,%,10,
Stability,nM/min,10,
TD50,ng/ml,10,
Max reduction in mean arterial pressure,mmHg,10,
Vmax,nmol/mg,10,
Ae,,10,
VRT,hr2,10,
Dose/g tissue,%,10,
Log 1/GI50,,10,
Mice In. / Fi.,,10,
ED50,mg/m2,10,
P50d/P50c,mmHg,10,
Substrate,uM,10,
Antiviral activity,nM,10,
K,M/s,10,
TMSW,%,10,
ED50,ug day-1 kg-1,10,
Drug uptake,pmol/mg/min,10,
A50,mg kg-1,10,
FaFg,%,10,
K12,hr-1,10,
A/Ad,,10,
K Bapp,uM,10,
Jss,nM hr-1 cm**-2,10,
AUC,uM min l-1,10,
Induction number,,10,
TTO,min,10,
Survival,hr,10,
O2 consumption,%,10,
clogP-logP,,10,
PTZ,,10,
Induced convulsion,number convulsed,10,
Body weight In. / Fi.,g,10,
pH1/2,,10,
ED50,U ml-1,10,
Binding activity,uM,10,
KD2,uM,10,
Maximal decrease in IOP,,10,
GTPase Activity,,10,
KD1,uM,10,
LD99,mg/ml,10,
TCID50,,10,
Tp,,10,
T>MIC90,hr,10,
TGI50,mg kg-1,10,
APTT,ug ml-1,10,
K21,hr-1,10,
A50,nM,10,
CL/F,,10,
Stability,ppm,10,
CLblood,mL/min/kg,10,
Inhibition effect,,10,
Spleen weight,g,10,
AUC/dose,nM.hr/mg,10,
Log TCID50/mg,,10,
Intrinsic actvity,,10,
Stability,mmol/min,10,
Initial mean arterial pressure,mmHg,10,
Time constant T4,,10,
Brain concentration,nM kg-1,10,
pC30,,10,
Z,%,10,
Inhibition type,,10,
ED25,nM,10,
Change in body weight,g,10,
K,10'8/M/s,10,
Amount,%,10,
Analgesic efficacy compared to morphine,%,10,
No. of untreated cells,%,10,
Intensity,%,10,
Amount,pM (10e6*cells)-1,10,
FT50,hr,10,
Activity,Counts 30min-1,10,
Specific binding,fM mg-1,10,
Concentration,nM ml-1,10,
ST,min,10,
CL/F,L/min,10,
TC50,10'4nM,10,
Bmax,disintegrations/minute,10,
Decrease in mean arterial pressure,%,10,
Distribution percent,,10,
K,10^4/Ms,10,
pC25,uM kg-1,10,
No. of tumors/mouse,,10,
Onset,min,10,
CT10,uM,10,
K13+K23,hr-1,10,
Free,,10,
Liver weight,g 100g-1,10,
Oxygen uptake,nM min-1,10,
Serum cholesterol,mg %,10,
EC50,ug/g,10,
Log 1/E50,,10,
Max vasoconstriction,,10,
K,10'3/mol,10,
pI,,10,
-Log alpha,,10,
Drugabsorption,nM,10,
Log k GSH (s-1),,10,
Transacetylation rate,nM/mg*min,10,
TC25,ug ml-1,10,
Fold activation,uM,10,
ED5,ug,10,
Spleen weight,mg,10,
MTT,s,10,
Drug metabolism,ml/min/g,10,
Cp,ngequiv/ml,10,
Activity,mU m l-1,10,
Triglyceride level,mg dl-1,10,
Fold shift,,10,
Transactivation,fold,10,
alphaKi,nM,10,
Level,ug of tissue,10,
Inhibitory potential,,10,
Function,,10,
ID50,quanta,10,
C/I,,10,
MIC,ug m1 l-1,10,
PCR cure rate,%,10,
Analgesic efficacy compared to epibatidine,%,10,
K,10^7/M/s,10,
I50,ug,10,
HA release,,10,
Vss,L.m-2,10,
Cell toxicity,uM,10,
RD1000,mg kg-1,10,
kinact,s-1,10,
Average latency,%,10,
R50,uM,10,
k3,min-1,10,
MNTD,ug,10,
Emax,fmol/mg,10,
MFC99.5,,10,
CA,%,10,
CA activity,%,10,
Recovery,min,10,
k3/k1,M-1 s-1,10,
log2(ratio),,10,
Concentration,uCi ml-1,10,
ED99,mg/kg/day,10,
Emax,log10CFU/ml,10,
k cat/Km,uM-1 s-1,10,
Drug uptake,nmol/hr,10,
HMGR activity,,10,
LD50,10'-4M,10,
Gastric lesion score,mM,10,
permeability,ng/uL,10,
DNA alkylation,%,10,
BBC50,uM,10,
% bound,none,10,
D,10^-7cm2/sec,10,
B,%,10,
NTD,mg kg-1,10,
MA,,10,
Activity,10'6No_unit,10,
HD50,umol/L,10,
Activity,ug mouse-1,10,
Rel potency,,10,
DNA alkylation,,10,
CL_Ratio,%,10,
HV interval,ms,10,
k2c,min-1,10,
Tumor weight,,10,
Drug uptake,a.u.,10,
Dose per organ,%,10,
MED,umol/Kg,10,
Tumor half growth,,10,
Activity,AU.min,10,
CLH,ng/ml,10,
M.A.D,ug kg-1,10,
Vmax,pmol.min.mg-1,10,
Km x10e3,hr-1,10,
EC>90,nM,10,
Km',uM,10,
MFC>99,ug ml-1,10,
Parasitemia clearance after immunosuppression,%,10,
Arterial pressure,% mmHg min,10,
60-day survivors,,10,
IAR,,10,
MNCC,,10,
Pka,,10,
Response unit,umol/L,10,
Heart weight,mg 10g-1,10,
logCMC,,10,
Delta coronary flow,,10,
Activity,10'-2/min,10,
Max fall in IOP,mmHg,10,
Km,10'5mM,10,
Ki,10'1/M,10,
Activity,pM of cGMP (min)-1 (mg of protein)-1,10,
Mean increased life span,%,10,
Mean inhibition,%,10,
BAT weight,g,10,
Cytoplasmic vacuolization,,10,
Aqueous solubility,,10,
R%,,10,
R/S ratio,,10,
Rice stem length,cm,10,
Parasite suppression,%,10,
MBC99.5,,10,
ACT,uM,10,
Kcat/Km,10'3/s/M,10,
MAC reduction,%,10,
Concentration_Plasma,nM ml-1,10,
Carboxylase activity,dpm,10,
Activity,fM ml-1,10,
Vmax,uM min-1 g-1,10,
D50,quanta*10e-18,10,
Ka,10'5/s/M,10,
Parasitemia clearance after treatment,%,10,
Activity,nM.min,10,
permeability,10'-6cm/min,10,
M-agonist index,,10,
Relative ionotropic activity,,10,
Kp,cm hr-1,10,
FC,10'5No_unit,10,
Delta LV,,10,
Ka,10^3/M/s,10,
permeability,day,10,
MyristoylCoA,%,10,
Max delta HR,%,10,
Writhes,,10,
rIC50,nM,10,
Accumulation,ug ml-1,10,
EC50,10^3nM,10,
CI,mg/kg uM h,10,
METD,%,10,
ED 50,uM,10,
Emesis_Cmax,uM,10,
Mean graft survival,day,10,
k'/k'+1,,10,
Concentration,pmol/10E6 cells,10,
Cellular uptake,uCi ml-1,10,
Delta heart rate,,10,
Gellar cook activity,,10,
MED,nM,10,
Residual activity,c.p.m.,10,
Mean effect,mg,10,
Kcat,10'-2/s,10,
Clonazepam,%,10,
Kcat,10^-4/s,10,
Phosphorylating activity,pM min-1 assay-1,10,
Acid output,u equiv hr-1,10,
NOAEL,,10,
lnK,,10,
Uptake selectivity,,10,
Kp,10^-3cm/min,10,
permeability,ml/min,10,
Relative ability,,10,
kA-,M-1 s-1,10,
Relative activity,c.p.m.,10,
Relative seminal vesicle weight,,10,
Radioactivity level,%,10,
Ki,10^3nM,10,
Cellular uptake,pCi cell-1,10,
k'o,M-1 s-1,10,
Activity,um2/s,10,
Kbapp,mM,10,
DNA unwinding concentration,uM,10,
CTP,mg/L.hr,10,
k2 / Ki,M-1 s-1,10,
Rate max,,10,
Average,uM,10,
ED100,mg kg-1 day-1,10,
Delta MABP,%,10,
IC50,mmol/Kg,10,
Drug uptake,10^-2microM,10,
EC80,nM,10,
Ratio,M/s,10,
Horizontal screen,number passed,10,
kAH,M-1 s-1,10,
Catalepsy score,,10,
MEC,mg/ml,10,
LC80,,10,
Vmax,10'5mmol/min/mg,10,
Cytotoxicity index,,10,
Kapp,10^5/M,10,
k2',M-1 min-1,10,
Growth rate,%,10,
Kb,/M,10,
k/K,M-1 s-1,10,
Active/total,,10,
Relative influx,,10,
LC50,ug/sq.cm,10,
EC50,M 50ul-1,10,
Kd1,uM,10,
Rating,hr,10,
BK,,10,
Max protection,%,10,
Kd2,uM,10,
Efflux Ki,min-1,10,
Kdiss,10^3/M/s,10,
DeltaTC,,10,
Vmax,IU mg-1,10,
Uterotropic activity,,10,
rb,,10,
Vmax,U/ms,10,
Post drug blood pressure,mmHg,10,
Post Antibiotic Effe,hr,10,
Kq,10'4/M,10,
V0,pmol/min,10,
Pa,,9,
Activity,microM/s,9,
Cytotoxicity,M dm-3,9,
AFC50,ppm,9,
Activity,pM min-1 (mg of protein)-1,9,
K2,1/M*s,9,
Gastriculcer index,,9,
Concentration,ug ml-1 ml-1,9,
pA2,%,9,
Contractility,,9,
EC25,%,9,
Ka,10^4/Ms,9,
Mutation frequency,,9,
LD10,mg/m2,9,
Responders,,9,
AUG,ng ml-1 hr-1,9,
Activity,microg/cm2,9,
LogD5.5,,9,
fT>MIC,,9,
Scavenging Activity,%,9,
STY seizure,,9,
Cells sickled,%,9,
Pc,,9,
Decay-time constant,ms,9,
CC50,%,9,
C50,ug ml-1,9,
NonRGS-EC50 (uM),uM,9,
Ka,10^8/M,9,
K x10e-5,M-1,9,
Unwinding,,9,
Peak effect,,9,
Acetylcholine level,uM,9,
Cmax,ng/kg,9,
ABC,mmHg hr-1,9,
ED30,mM,9,
Relative thymus weight,mg 100g-1,9,
pMLD,,9,
pKa5,,9,
[ALP]max,UI l-1,9,
IC50,uM tube-1,9,
K obs,M-1 s-1,9,
Ka,10'3/M.s,9,
Degree of activation,fold,9,
K+ output,uM kg-1,9,
Toxic/total,,9,
Geometric mean,M,9,
Permeated,%,9,
No. pregnant/mated,,9,
PT extension,nM,9,
IC50,mol,9,
Mean survival,time day-1,9,
Papp,10'-6cm/s,9,
Sensitisation,,9,
C0,nM,9,
Activity,mg.equiv,9,
PRL,ng ml-1,9,
Acid secretion,,9,
Weight change at nadir,%,9,
Resting potential,mV,9,
Ka,10'10/M,9,
Max blood pressure fall,%,9,
ED300,nM,9,
Log ratio,,9,
F/dose,%,9,
fIC30,nM,9,
KA,10^3/M,9,
fIC20,nM,9,
Chelator,%,9,
IC50,min,9,
AT1 affinity,nM l-1,9,
Total peripheral resistance,mmHg ml-1 min-1,9,
Activity,A570 min-1,9,
MTC50,mg kg-1,9,
Change TC,,9,
Connectivity density,mm**-3,9,
SEC50,M,9,
Urine output,ml kg-1,9,
Bleeding time,min,9,
Min ED,mg kg-1,9,
Cutaneous toxicology score,,9,
Simulation,%,9,
Permeability coefficient,,9,
ED50,ug/Kg/min,9,
Total activity,,9,
No. partial,,9,
SUV,g/ml,9,
SC50,mM,9,
k cat/Ki,M-1 min-1,9,
ED6,,9,
FRE,,9,
INH,10'-4/min,9,
Active dose range,,9,
Glucuronidation,nmol/min/mg,9,
First adverse effect,,9,
CLH,ml/kg,9,
AHA,delta mmHg,9,
No. of mice surviving >6 months,,9,
Max change,%,9,
Activity,M kg-1,9,
INH,IU/mg,9,
Mu/delta ratio,,9,
K A,M-1,9,
COF,c.p.m. (mg of protein)-1,9,
ED40,10^-5 mol/L,9,
C10 air,uM,9,
E,%,9,
Kcat,10'-5/s,9,
ED200,nM,9,
IC50,10'-4nM,9,
Median,day,9,
Contractility,mmHg s-1,9,
No. of ferrets,,9,
[LDH]max,UI l-1,9,
Distribution,l kg-1,9,
Rs,ul min-1 kg-1,9,
Vd,kg-1,9,
OD max,mg,9,
MBIC,mg/ml,9,
Time constant T4,ms,9,
Lag time,min,9,
Ae,% ID/g,9,
INH,10'5L/mol/s,9,
Relative adrenal weight,mg 100g-1,9,
Latency time,%,9,
Area,mm**2,9,
KT4,M-1,9,
CT50,mM,9,
MNTD,,9,
Abrasion score,,9,
Kapp,10^-3/hr,9,
Social interaction,,9,
Binding Decrease,%,9,
Smax,nM min-1 kg-1,9,
Drug uptake,pg,9,
NADH oxidation,nM min-1,9,
Kbapp,,9,
IC50,10^-10mol/L,9,
Binding competition,%,9,
PKB,,9,
Kbb,,9,
INH,10'-8M,9,
AUCt,ng/ml,9,
E,-V,9,
Acute toxicity,M dm-3,9,
Activity,nM min-1 (10e-6*cells)-1,9,
K,10^5/M.s,9,
Max binding,%,9,
Approx. pKa,,9,
MIC90,%v/v,9,
Tissue area,mM,9,
permeability,mole fraction,9,
LD50,ug fly-1,9,
KSV,10'3L/mol,9,
Delta,,9,
LC100,ng/ml,9,
ID25,mg kg-1,9,
Tumor free survivors,,9,
Vasodilation,,9,
k2/KI,nM-1 min-1,9,
No. of strains,,9,
Binding activity,%,9,
Flaking score,,9,
Content of cell cycle,%,9,
Drug uptake,mg/g,9,
ST/CB ratio,,9,
Activity,microg/cm2/h,9,
Secondary response,,9,
MTC50,uM,9,
k2,10e3 s-1,9,
AUC,uM L,9,
ERH,min,9,
AUC,nM.hr/L,9,
Duration time,,9,
PDD50,,9,
Kcat/Km,10^-6 microM/s,9,
Activity,Amax nM-1,9,
Rs,nM min-1 kg-1,9,
Vz/F,ml,9,
logPi,,9,
Vdss/dose,L/Kg,9,
Corpora lutea,,9,
AUCt,hr/ng.ml,9,
Lung weight,g,9,
ID50,10'-6 mol/L,9,
PDR,,9,
Reduction of heart rate,%,9,
Max delta,uM,9,
K,L/mol/s,9,
Motor activity,Counts,9,
Vascular accumulation ratio,,9,
Cp,ng/mg,9,
IC>80,uM,9,
Activity,pmol/mg.min,9,
Drug uptake,micromol/min,9,
Reaction,%,9,
RD500,ug rat-1,9,
Onset seizure,,9,
APD70,ms,9,
CL,ul.min.nmol-1,9,
Vmax,uM/min,9,
Activity,log10/ml,9,
Ca2+ serum,,9,
TAI,,9,
Marrow area,mM,9,
KL,uM,9,
2x aPPT,uM,9,
Summation MABP,,9,
AD50,nmol/kg,9,
Kq,10^12/M,9,
I / E100,,9,
MDH Reactivation,%,9,
Therapeutic index,%,9,
Anticonflict activity,,9,
Derived trabecular thickness,uM,9,
Chronic TI,,9,
K,10'3L/mol,9,
dP/dt max,mmHg s-1,9,
Onset time,min,9,
Maximal binding,,9,
Ionotropic activity,,9,
MED100,mg kg-1,9,
Vmax,umol/mg/min,9,
Propioaldehyde generated,uM,9,
Production,ng 2hr-1,9,
Hemolysis,,9,
Decrease in pressure,mmHg,9,
AUC/dose,ng.hr/g/mg/kg,9,
VmaxH,pmol/min,9,
Activity,10'4log10CFU/ml,9,
Na,uM,9,
Activity,10'5log10CFU/ml,9,
deltaG,cal/mol,9,
AP,mV,9,
Emax,ug,9,
Cmax/dose,ng/mL/(mg/kg),9,
Inhibition (at concentration M),%,9,
Animals dead,,9,
Vmax,uM hr-1 mg-1,9,
RF,delta beats min-1,9,
pEC99,,9,
Activity,10^-6No_unit,9,
DA utilization,,9,
Pt,cm s-1,9,
Therapeutic efficacy,,9,
Mortality number,,9,
Increase in CBF,,9,
DSB,,9,
K,10'2/M/s,9,
ODC activity,(nM of CO2) hr-1 (mg of protein)-1,9,
Acute TI,,9,
PD50,mM kg-1,9,
Ratio,/min/mM,9,
Dose,mg,9,
Potency,MU,9,
EC80,uM,9,
EC37,ug ml-1,9,
Cmax normalised,nM.kg/mg,9,
Vehicle control,%,9,
Volume of urine,ml,9,
MPC/MIC,,9,
Recovered in urine,%,9,
Tetramer,%,9,
Ratio,10'-4No_unit,9,
Formation,,9,
k0,s-1,9,
K,10^-6/M/s,9,
Postdrug,ug kg-1,9,
AC30,uM,9,
Kq,10^4/M,9,
Reaction time,hr,9,
Control death day,,9,
Hypotension,%,9,
Activity,gAi/ha,9,
K,10'5/s,9,
MDD,mean day of death,9,
MPR,%,9,
K,10'6/uM/s,9,
DeltaTm,,9,
logMEC,,9,
Fold reduction,,9,
Fold_reduction,,9,
Implants,,9,
I50,10'6mol/L,9,
SubG0,%,9,
Activity,10'-8mol/L,9,
Ratio,L/min/umol,9,
ED80,umol/Kg,9,
K,10'8/M/min,9,
Threshold concentration,uM,9,
Body temperature,%,9,
Immobility time,%,9,
Cp/dose,nM,9,
Range of deaths,day,9,
Activity,millimeter/mg/ml,9,
Na+ inactivation,,9,
ECAUC0.2,,9,
solubility,mg kg-1,9,
Amylase stimulation,max,9,
ED50,10'-8mol/cm2,9,
khydr,min-1,9,
Inhibition,(nM of H202) min-1 (ug of protein)-1,9,
K,1/M,9,
Range of survival,,9,
T1/2,%,9,
Clast,ng/g,9,
DOM,,9,
Clonic seizures,,9,
Rate of rotation,,9,
EC1000,uM,9,
deltaS,cal/mol,9,
Antiamnesic activity,,9,
No. of animals,%,9,
EC50,M kg-1,9,
Amplitude,mV,9,
Ki,app,9,
Occ50,mg Kg-1,9,
Minimum single dose,mg kg-1,9,
Mean change,mM,9,
TD50,micromol/kg,9,
LD50,10'-1 ug/ml,9,
Periosteal mineralizing surface,%,9,
Cytotoxic concentration,,9,
Clast,uM,9,
CL,mL/min,9,
logI50,,9,
K,/nM/s,9,
Control tumor volume,,9,
Eicosanoid production,pM 2hr-1,9,
Primary response,,9,
DD,uM mM-1,9,
K,/ms,9,
Na+ restoration,%,9,
Infection score,,9,
Activity,uL/min,9,
Ki,10e2 M-1 s-1,9,
Na+ output,uM kg-1,9,
Oral duration,hr,9,
Maxi-K current,,9,
Creatinine_CL,ml min-1 kg-1,9,
Kel,,9,
ED97,mg kg-1,9,
kobs,/min,9,
RBA,h/min,9,
t1/2lambda,hr,9,
Log GTI,,9,
DNA damage,10e7 exchanged dCps (ng of DNA),9,
AUC(app),uM.hr,9,
HR,delta beats min-1,9,
TE50,,9,
TDI,10'-4/min,9,
Kinase activity,pM min-1*ml-1,9,
Vmax(app),M/min,9,
Inhibitory rate,%,9,
Vmax(app),mM/min,9,
ED50,fmol,9,
tz,hr,9,
MTS50,ug ml-1,9,
Average weekly weight change,%,9,
HHP,mg,9,
Endosteal mineralizing surface,%,9,
Emax,hr,9,
Body weight gain,mg,9,
TC50,uM/ml,9,
EC30,M kg-1,9,
Directly measured thickness,uM,9,
Rate,nM min-1 (nM of cytochrome P450)-1,9,
A50,mM kg-1,9,
Rate of death,%,9,
Increase in concentration,,9,
ED50,10'-9 ug/ml,9,
CLz/F,ml/min.kg,9,
Keq,,9,
Endosteal eroded surface,%,9,
Cmax,ugequiv/g,9,
Predrug,ug kg-1,9,
Pregnant,%,9,
AUC,micromol.hr/L/mg/kg,9,
TW,,9,
PD50,mg kg-1 day-1,9,
K,10'-1/s,9,
Activity,nmol/mg/hr,9,
MIC,10^3nM,9,
selectivity,,9,
DC,,9,
Inhibition,c.p.m./Abs,9,
Tumor uptake,uM kg-1,8,
ID40,,8,
CAT activity,,8,
Tt,,8,
ID50,10'-6M,8,
Tumor area,mm**2,8,
K5,1/min,8,
Tumor response,,8,
K6,s-1,8,
CAC,mM,8,
K6,1/min,8,
AUMC,hr2.ng/ml,8,
K2,10e-3 min-1,8,
Brain level,pM forebrain-1,8,
Cmax normalised,(ng/mL)/(mg/kg/day),8,
Triglyceride level,,8,
Cp,nmol,8,
ID50,ng/kg,8,
K1,M-1 min-1,8,
KA,M,8,
Severity,,8,
Ct,ug,8,
Bmax1,%,8,
K,10^7/M,8,
Turnover,%,8,
T/C max,%,8,
K,/day,8,
AUMC,ng.hr/ml,8,
C10,nM,8,
CC30,nM,8,
AUC,pM kg-1,8,
K-2,min-1,8,
ID95,uL/L,8,
Stability,%Idose,8,
Scavenging Activity,,8,
Total cholesterol,mg kg-1,8,
AUC,ug.min/g,8,
Selectivity,uM s-1,8,
Drug uptake,uL,8,
K m,uM,8,
Tissue level,ug ml-1,8,
Selectivity rating,,8,
ITI activity,,8,
ITP,,8,
Tidal volume,ul,8,
Cumulative amount,ug,8,
Tidal volume,%,8,
Therapeutic index,mg kg-1,8,
Increase (Emax),%,8,
Increase in LD50,%,8,
Serum concentration,nM l-1 hr-1,8,
Increase in blood pressure,%,8,
E/Emax,,8,
Tc,uM,8,
AUEC,%,8,
ID50,uL/L,8,
K,10^4No_unit,8,
Cytotoxity,%,8,
Ct,pmol,8,
AUC,0-24hr,8,
K DMPG,M-1,8,
TAD,%,8,
K DMPC,M-1,8,
AUC/dose,ng.hr.kg/ml.mg,8,
Smax,,8,
K,s-1,8,
K,pM,8,
Blood clearance,ug ml-1,8,
IC50/[E],nM milliunit-1,8,
Urinary excretion,ug,8,
CC50%,ug ml-1,8,
XL50,uM,8,
Wet weight,g,8,
T,uM,8,
Basal control,%,8,
Glucuronidation rate,nM min-1 mg-1,8,
Relative metabolic rate,,8,
Weight at term,g,8,
WBC x10e-3,ul-1,8,
Vz/F,(mg/kg)/(ug/ml),8,
Vss,l hr-1 kg-1,8,
Volume of air,ml,8,
Control of P-450 marker,%,8,
HCMV yield,pfu/ml,8,
Vocalization time,s,8,
Ct,ng,8,
Interferon response,ml,8,
Drugexcretion,ug/g,8,
TC90,uM,8,
AUCt,ngequiv.hr/g,8,
T,,8,
AUClast/dose,uM.hr,8,
AUClast/dose,ng.hr/ml/mg/kg,8,
K,10'-5/nM/min,8,
Survivors,N/total,8,
Ct,nmol/Kg,8,
Survival ratio,%,8,
Survival extension,,8,
Cmax,ug,8,
Supressive effect,ug ml-1,8,
K,10^-6M,8,
Blood glucose,mM l-1,8,
Brain level,ug weight-1,8,
Jmax,pmol/min,8,
K,min,8,
K app ratio,,8,
Du,,8,
AUC normalised,((ng/mL).hours)/(mg/kg/day),8,
Skin response,,8,
AUC normalised,(umol.h/L)/(mg/kg),8,
TGI50,ug kg-1,8,
Skin scaling,,8,
K alkyl,s-1,8,
Boron concentration,ug g-1,8,
Inhibitory concentration,mM,8,
Kcat/Km,10'-2/microM/s,8,
FICI50,,8,
fAUC,nM.hr.kg/mg,8,
pD2,uM,8,
ED30,MPK,8,
Ki.c,,8,
Ki(1.8x10e-11),M,8,
CT,ms,8,
ROR,%,8,
RP,mV,8,
-ln (MIC),,8,
RRI,,8,
Activity,10'5No_unit,8,
ED50,10'-3mmol/kg,8,
Activity,10'4 /uL,8,
pEMR,,8,
ED50,mg kg-1 (day in diet)-1,8,
ED50,ug ear-1 dose-1,8,
Ki,mg/ml,8,
Ki,kcat/Km,8,
DFMBMD,mg/Ecm,8,
ED50,mg/kg/hr,8,
ED50,10'-5M,8,
Carbonyl group,,8,
KiH,uM,8,
ED25,mg/kg/day,8,
tRNA peak exclusion,%,8,
Ca2+ elevation,,8,
Kinact,10'5/M/s,8,
QT interval,,8,
Kd,10^-5/s,8,
ED70,uM,8,
BPR,10'-3/hr,8,
Eudismic ratio,,8,
HD10,ug ml-1,8,
fCmin,nM,8,
Drug uptake,RFU,8,
fAUC/dose,microM.hr/mg/kg,8,
Fever response,degrees C,8,
k obs / concentration,,8,
ADD,s,8,
Contractility (LV dP/dt),,8,
FICI90,,8,
k x10e-3,min-1,8,
k2,min-1 M-1,8,
Reduced BP,%,8,
Receptor occupied,%,8,
Cellular uptake,pM ul-1,8,
k-1,s-1,8,
Ratio of depolarizing activity,,8,
Activity,10'-3dpm,8,
k3/ki,M-1 s-1,8,
Extension,%,8,
Activity,/uM,8,
Drug uptake,cpm/uL,8,
Fg,%,8,
D-2,%,8,
Reduction in TG,%,8,
CLH,g/ml/min,8,
Quenching,%,8,
R+V,90 min,8,
rT3 Production,pM tube-1,8,
ka,L/hr,8,
Ratio CIC95/IC50,,8,
Kd,10^-6/s,8,
Enantiomeric composition,%,8,
Emax,pg/ml,8,
ED50,ng,8,
log10CFU/ml/day,,8,
EDmax,uM kg-1,8,
ED50,nmol/mouse,8,
DC50,ug ml-1,8,
Activity,10'1/mm2,8,
ED50,pg/ml,8,
Rate,nM min-1,8,
Khydrol,s-1,8,
CMT,uM,8,
Kel,h-1,8,
EC50,pmol/L,8,
pA2,mg,8,
Ke naloxone,nM,8,
2TT,ug ml-1,8,
molecular ellipticity,deg.cm2/dmol,8,
Rate of reduction,uM min-1mg-1,8,
max inhibition,%,8,
2x APTT,nM,8,
EC50,ucm,8,
EC50,ppb,8,
Kd,10^1 uM,8,
Emesis,vomiting/tested,8,
Kina,min-1,8,
Kd,10^5/s,8,
Activity,10'6/M,8,
permeability,pmol/min/cm2,8,
permeability,microg/cm2/h,8,
permeability,a.u.,8,
permeability,10'-7nmol/cm2/min,8,
RBC x 10e 3,ul-1,8,
Calculated Ratio,,8,
Kii,,8,
RBI,%,8,
ED25,10'-8M,8,
Change,beats min-1,8,
Ratio I/P,,8,
ED50,mpk day-1,8,
pBBB,10'-6 cm/s,8,
Edema,ul,8,
Kdiss,1/s,8,
AAL,,8,
ABBC,log10CFU/ml.hr,8,
Effective dose,mg,8,
Ratio,10^5/s/M,8,
Cmax_metabolite,ng/ml,8,
ABC,,8,
Concentration,ug/10e6 cells,8,
log Pe,cm2/sec,8,
Ratio,uL/min/pmol,8,
HD10,uM,8,
Specific activity,ukat kg-1,8,
Stabilty,hr,8,
Amount incorporated,M (M of tubulin)-1,8,
Activity,10^3No_unit,8,
Max delta FC,%,8,
Activity,mM-1,8,
Activity,OD/mm2,8,
Plasma level,,8,
NADH oxidized,nM min-1,8,
Log TCI,,8,
Plasma half life,min,8,
Max weight loss,%,8,
Drug metabolism,mmol/L/hr,8,
Plasma concentration,uM l-1,8,
MBEC90,ug ml-1,8,
PC95,ug,8,
Dose modification,,8,
PC50,ug,8,
Log PTA,,8,
Average proportion,,8,
MBC99,uM,8,
No. of killed or paralyzed,,8,
Max delta MABP,mmHg,8,
Lipoprotein level,%,8,
Latency time,,8,
Damage score,,8,
Density,mg/cm3,8,
Log effect,,8,
Platelets x10e-3,ul-1,8,
Activity,mutants (10e4*survivors)-1,8,
Activity,g/ml,8,
Level,ug ml-1,8,
Dose normalized clearance,ml/min.kg,8,
LDL-C,%,8,
Activity,ng/dl,8,
Activity MABP,%,8,
Atherogenic index,,8,
Activity,microL/min/kg,8,
LD app,mM kg-1,8,
Activity,nmol/mg.hr,8,
Koff,M-1,8,
Antiuterotrophic activity,,8,
LC99,ug ml-1,8,
LC95,ug ml-1,8,
LH,,8,
Antitumour activity,,8,
PT,nM,8,
Activity,pg/ml/hr,8,
LD100,uM,8,
Median retension latency,,8,
Affinity,M-1,8,
Diffusion,%,8,
Max delta FRP,,8,
Activity,uM ml-1,8,
Krelative,,8,
Delta F,%,8,
Level,units/mL,8,
Activity,10^5/ml,8,
MIC,10^-3mM,8,
MPD,ug kg-1,8,
Dobs,,8,
M/T,,8,
Change in LV dp/dt,%,8,
MAC,mg/ml,8,
Activity,mmHg.hr,8,
Cholesterol,%,8,
NSR survival rate,,8,
Log K'w,,8,
Progesterone production,ng 2hr-1 (10e5*cells)-1,8,
Cleavage,M,8,
Delta APD90,%,8,
Kinact,10^6nM,8,
Oligo modified,%,8,
Arrhythmia score,,8,
Mean time to seizure,,8,
Latency to step through,s,8,
Km,/uM,8,
Cholesterol level,mg dl-1,8,
LD50,%,8,
Mean response,,8,
Mean pit size,um2,8,
Max fall in MAP,mmHg,8,
Papp,10'-6cm/s2,8,
Delta I/I,mV,8,
MTD,%,8,
LD50,mg kg-1 (day in diet)-1,8,
Of HDL-C,%,8,
HDL cholesterol,mg kg-1,8,
Change in MABP,%,8,
MED,ug/kg,8,
Of non-HDL-C,%,8,
Papp,cm min-1,8,
DW,,8,
No. of axonal branch points/cell,,8,
Delta FFA,,8,
Pm,10'-5 cm/min,8,
Drug metabolism,mol,8,
Activity,pmol/million cells,8,
Log cfu/g of tissue,,8,
MDA content,uM (g of tissue)-1,8,
No. of pits/slice,,8,
DT50,day,8,
LD50,umol/ml,8,
Prolonged VRP,%,8,
Drug metabolism,nmol/ml,8,
Proportion of survivors,,8,
Apparent binding constant,M-1,8,
LD40,uM,8,
Onset of block,min,8,
Protection,nM,8,
MHC,umol/L,8,
NSVT,mg kg-1,8,
No. of protected/tested,,8,
LD90,p.p.m.,8,
Mean total resorption,um2,8,
LD50,umol,8,
Property,,8,
LDL cholesterol,mg kg-1,8,
Papp e-6,cm s-1,8,
MID,mg kg-1,8,
IC40,nM,8,
Ka,10^3/M.s,8,
Vmax,nmol/hr/microg,8,
Drug uptake,nmol.hr/g,8,
Reversion,,8,
Revertant colonies per plate,,8,
Cavg,pg/mL,8,
IC0,ug ml-1,8,
IC05,ug ml-1,8,
IC12,ug,8,
AUC,nM.hr/mg/kg,8,
Vd,L,8,
IC27,uM,8,
Rotations/10 h,,8,
Vmax,nmol,8,
Counts/30,min,8,
V0,,8,
V/K,,8,
Uterotrophic activity,,8,
Drug uptake,nmolequiv/g,8,
Uterotonic activity,IU mg-1,8,
KDss,M,8,
Cmax normalised,(umol/L)/(mg/kg),8,
Cysteine reaction,min-1,8,
Vm,%,8,
CFU,10'4/ml,8,
I/IC50,,8,
HSA shift,,8,
Active culture,%,8,
GR50,nM,8,
GR10,gAi/ha,8,
Km/Ki,,8,
HDL-C change,%,8,
Vmax(app),pmol/min.mg,8,
GTP-gammaS Index,,8,
HPB,,8,
AUBC,log10CFU/ml,8,
[Ca2+] increase,,8,
dp/dt(max),%,8,
Free C,nM,8,
Frequency,%,8,
Frequency,beats min-1,8,
Relative Potency Ratio,,8,
Activity,%Idose,8,
delta logP,,8,
GDPactivity,nM min-1 mg-1,8,
CL,uL/min/pmol,8,
cholesterol level,mg dl-1,8,
cAMP production,N,8,
CL,nmol/min,8,
APTT,nM,8,
BW,%,8,
CL,ng/ml,8,
alkaline phosphatase activity,U l-1,8,
aPTT,uM,8,
GID75,mg/m2,8,
I/E,,8,
Kcat,pmol/min,8,
CGI,uM,8,
Drug metabolism,nmol.min,8,
LT50,min,8,
Microsomal stability,pg min-1 (mg of protein)-1,8,
Log P/(100-P),,8,
Activity,ng/mL.hr,8,
Mean reaction,,8,
LSD,%,8,
Max uterine weight,mg,8,
Dose elevation,mg kg-1,8,
Max lowering MABP,mmHg,8,
Delta mean blood pressure,,8,
Activity,Kcal/kg/day,8,
Activity,nM/hr,8,
Normal weight gain,%,8,
Diffusion analysis,,8,
Diazepam antagonism,,8,
Delta logS,,8,
Antilipid peroxidation,,8,
DeltaCp,kcal/mol/K,8,
Morphology,,8,
Oxidation rate,,8,
Delta K,,8,
Km(unbound),uM,8,
Highest nontoxic dose,mg kg-1 (day in diet)-1,8,
Max fall,mmHg,8,
MBBC,ug ml-1,8,
Permeability,*10e6,8,
MST,hr,8,
Drug metabolism,ug,8,
Hypermotility,,8,
Drug uptake,ng/kg,8,
Activity,um3,8,
Ka,10'9/M/min,8,
Reserpine hypothermia,,8,
Ac,uM,8,
Deiodination,%,8,
Binding,M of drug (M of BSA)-1,8,
Human potency,MU,8,
CL(app),uL/min,8,
Binding,dpm mg-1,8,
Hyperactivity,%,8,
Ka,10'2/M/s,8,
CFU,10^6/ml,8,
Restoration,%,8,
Relative to DA,%,8,
Cocaine,%,8,
CFU,10^2/ml,8,
Ka,10'-5/M/s,8,
Vmax,M-1 s-1,8,
Vmax,M min-1 mg-1,8,
Drug degradation,pmol/min,8,
Ka,10'-2/M,8,
Level,mequiv/L,8,
Vmax,cpm,8,
Hypocalcemic activity,IU mg-1,8,
Block time,ms,7,
K app,M-1 s-1,7,
Repellency,,7,
AUCt,nmol.hr/g,7,
Cell saturation,pM (10e5*cells)-1,7,
Phospholipidosis_MEC,,7,
LD90,mg/ml,7,
Average survived,day,7,
Ka,10^1/Ms,7,
Change,mg kg-1,7,
Kcat,10'4/s,7,
Activity,10^3/ml,7,
AUMC,ug/ml.hr'2,7,
Activity,%/mmol,7,
LD10,mg/me2,7,
Kin,10^-4ml/g/s,7,
Platelet,10e6 ul-1,7,
ED50 mg/kg,,7,
Activity,%.min,7,
K',,7,
Pupil size,mM,7,
Damaged area,%,7,
Avoidance time,s,7,
Activity,10'8CFU/ml,7,
LD84,mg kg-1,7,
Kapp,/hr,7,
Rate of reduction,nM min-1 mg-1,7,
Unreacted drug,%,7,
Repolarization time,,7,
LC20,ug ml-1,7,
Lactate produced,nM hr-1 (mg of worm),7,
Drug metabolism,nanomol/min,7,
Kq,10'5L/mol,7,
Proconvulsant action,,7,
DNA binding,M-1,7,
Activity,10^-3/min/uM,7,
Lambda-em,nm,7,
Profile,,7,
Lambda-ex,nm,7,
Acceleration,,7,
Drug metabolism,mol%,7,
Resowing,%,7,
Kcat/Km,10'-5/M/s,7,
Papp,10^-5 cm/s,7,
S50,umol/L,7,
SF50,nM,7,
IC50 reduction,%,7,
Group toxicity,,7,
Activity,fg,7,
Activity,uU/ml,7,
IC60,uM,7,
Mutation frequency,10e6 F,7,
Drug degradation,nmol/J,7,
Melanotropic potency,,7,
AUC,uM hr-1 ml-1,7,
NTD50,mg kg-1,7,
ID50 mg/kg,,7,
E0,,7,
Change in tidal volume,ul,7,
CO,mM,7,
Uterotropic effect,,7,
MTD,mpk,7,
Cmedia,ug of B/ml,7,
Writhing number,,7,
AUC,cm2,7,
CNS activity,,7,
k',s-1,7,
Mean aortic flow,ml min-1,7,
Ba,%,7,
ID30,uM,7,
MAP,delta %,7,
MBEC99.9,ug ml-1,7,
IC50,ppm g dm**-3,7,
IC50,10^-2microM,7,
IC50,nM/unit,7,
2aPTT,10'-3M,7,
AUC,ng.min/g,7,
fAUC,ng.hr/g,7,
Vss,L,7,
Cmax normalised,microM/mg/kg,7,
Delta MA,hr,7,
Delta heart rate,beats min-1,7,
logD IAM,,7,
EC50,uL/L,7,
NO2- (mol/mol),%,7,
Activity,m/3h,7,
CLtotal,ml s-1,7,
Vomiting frequency,,7,
Vagus,delta %,7,
CL,mg/min/kg,7,
Vbeta,L/hr,7,
IC30,10'-6M,7,
Change in dP/dt,%,7,
Activity,mgequiv/g,7,
Perturbations,,7,
Stability,microM/min,7,
Ka,M,7,
Ka,/mM/s,7,
Papps,cm s-1,7,
Apparent_pKa,,7,
Ka,1/M*1/S,7,
D2 duration,min,7,
Km(app),,7,
K,10^-8M,7,
Drug recovery,g,7,
Rn,,7,
Kcat/Km,10^-5/nM/s,7,
Activity,10'3log10CFU/ml,7,
Drug uptake,nmol/mg/min,7,
Absolute ratio,,7,
Lethality,mg kg-1,7,
Plasma glucose level,mg dl-1,7,
Kun,s-1,7,
Antidiuretic,mg,7,
Lethal toxicity,,7,
LAL test,,7,
Ka,/s,7,
K,10^4/M/min,7,
Kinact,1/min,7,
Activity,10'4/M/s,7,
Dead/treated,,7,
Retention,,7,
Cmax,ngequiv/g,7,
CMV yield,pfu/ml,7,
Activity,10'7CFU/g,7,
K,10^7/M/min,7,
Drug uptake,nmol/L,7,
KII,M,7,
Ratio,10'6/M,7,
Level,ug g-1,7,
KSV,10^3/M,7,
Activity,10'-3 mol/L,7,
KH,uM,7,
Drug metabolism,pmol/mg.hr,7,
BPI,%,7,
Ratio,10'2/s.M,7,
PFC/spleen,,7,
K,10^-5/M/s,7,
DTT inhibition,,7,
Receptor binding,,7,
KSV,10^5/M,7,
DBP-20,ug kg-1,7,
Production,,7,
Kcat/Km,10^7/M/s,7,
Spread,%,7,
Saftey margin,,7,
Spontaneous activity,,7,
Drug responding,,7,
AUCt/dose,nM.hr/mg,7,
Kii,uM kg-1,7,
Kapp,/s,7,
Kapp,10'-2/s,7,
Drug uptake,mmol/Kg,7,
Relative substrate velocity,%,7,
Saq,,7,
LDH release,%,7,
Decrease,mM,7,
Binding intensity,%,7,
Kb,10^6L/mol,7,
Ka1,,7,
"Kd,app",nM,7,
Relative rate of decomposition,(nM of drug) min-1 ml-1,7,
Antiuterotropic effect,,7,
Radiolabel recovery,ug ml-1,7,
Ka(T4),%,7,
Relative potency,M,7,
Cure,%,7,
KdH,uM,7,
DNA peak exclusion,%,7,
K3,min-1,7,
Permeability coefficient,nm s-1,7,
LC50,umol/dm'2,7,
Ki 0.5,,7,
Kd,1/Ms,7,
Lesion index,mM,7,
S50,uM,7,
PTZ seizure,,7,
K Bind,nM,7,
Selectivity ratio,%,7,
LLR msad,mg kg-1,7,
Relative liver weight,%,7,
Radiolabel recovery,ng/g,7,
LD95,microg/cm2,7,
Kb,10'4No_unit,7,
Activity,10'5AU/sec,7,
Drug metabolism,nmol/J,7,
Cmax,%,7,
KdL,uM,7,
Activity,10'5/mm3,7,
Ratio CC50/EC50,10'3No_unit,7,
LD,uM kg-1,7,
Kb,10'8/M,7,
Glucose uptake,nM hr-1 (mg of worm),7,
Ulcer index,,7,
ED50,uM g kg-1,7,
Duration of immobility,,7,
AUC/dose,uM.min.kg/mg,7,
Anti-infectious effect,,7,
Max intensity,rotations min-1,7,
AUC/dose,uM.hr.mg/kg,7,
sigmaH,%,7,
Max lowering,,7,
ED,mg,7,
Oxygen consumed,nM min-1,7,
Log 1/ED30,uM kg-1,7,
T max,,7,
rel ko,,7,
T.I.,,7,
Drugabsorption,ug/g,7,
K,/uM/min,7,
Clast,nM,7,
T/C (survival),%,7,
Change in respiratory frequency,%,7,
TD50/ED50,,7,
Max rev,%,7,
Boron incorporation,ug/10e6,7,
Incidence of occlusion,,7,
Free radical scavenging,%,7,
Mitogenic effect,,7,
sigmaL,%,7,
Change in tidal volume,%,7,
AUC/dose,min.ug/ml/(mg/kg),7,
Log rate,,7,
Max Uosm,mOsmol kg-1,7,
AUC/dose,min.uM,7,
Change in respiratory frequency,beats min-1,7,
Log IC50,%,7,
AUC/dose,hr.nM,7,
Iron clearence,ug kg-1,7,
permeability,umol/cm2/hr,7,
Fu,ng/g,7,
Max efficacy,%,7,
Light transmission,%,7,
Decrease in No. of avoidence responses,%,7,
AUClast,ng.min/g,7,
K,10'6/s/M,7,
Stroke volume,ul,7,
EC90,ng/ml,7,
K,10'4/M/min,7,
AUClast,hr.nmol/ml,7,
ECAUC0.2,uM,7,
GID75,mg/me2,7,
C/T,,7,
Log Dmax,,7,
cell kill activity,,7,
ED250,,7,
-Log KD50,,7,
Depression,%,7,
fIC90,uM,7,
ED25,ug/kg,7,
Log Ki,%,7,
ED5,ug ml-1,7,
k act,M-1 s-1,7,
Infarct volume,mM,7,
Induced frequency,,7,
k cat,-1/min,7,
Increased life span,,7,
Cp(f),mg/ml,7,
EC30,10'-7M,7,
Brain/Blood concentration,,7,
Offset time,min,7,
TDI,/min/M,7,
FLT,%,7,
AUC ratio,,7,
cAMP,,7,
pA2-pA10,,7,
kH,s-1,7,
C0,,7,
pIC30,,7,
pEC20,,7,
ED50,10'-4M,7,
AE activity,,7,
ODC Activity,(nM of CO2) 30min-1 (mg of protein)-1,7,
ED50,10'-9M,7,
[Ca2+] variation,nM,7,
Time to offset,min,7,
ClB,ml min-1,7,
Time to onset,min,7,
EC50,umol/g,7,
Tissue swelling,ul g-1,7,
Amount formed,pM,7,
Activity,millimeter/hr,7,
ATP content,pM (mg of protein)-1,7,
Zone of stimulation,,7,
Pyrogenic effect,,7,
CLH,micromol/min,7,
INH,10'-6 mol/L,7,
ILS40,mg kg-1 day-1,7,
Log net cell kill,,7,
Cp,pmol,7,
Drug metabolism,/min,7,
CLH,L/hr,7,
ED25,10'-7M,7,
Change in mean aortic flow,%,7,
CFU,10^5/ml,7,
MED,(mg of base) 20g-1,7,
"kC,U",hr-1,7,
HR,delta %,7,
MED,mpk,7,
Vmax,pM s-1 mg-1,7,
CIC IC50,nM,7,
Concentration of max response,,7,
CIC90,,7,
MED,uM.kg/diet,7,
Vmax,pmol/s,7,
Vmax,rel,7,
Vmax,uM min-1 unit-1,7,
Vmax,ug/min.kg,7,
Delta I,%,7,
Vmax,nM min-1 (mg of protein)-1,7,
Hydrolysis,nM min-1 mg-1,7,
Activity,omegacm2,7,
Activity,nmol/hr/L,7,
IC100,umol/L,7,
CLint,uL min-1 mg-1,7,
AD50,MPK,7,
Nephrotoxicity,mg dl-1,7,
Nephrotoxicity,ng ml-1,7,
pCB50,,7,
Catalepsy,,7,
pM,,7,
CBF-ID75,ug kg-1,7,
AUC,s,7,
k1,min-1,7,
ED50,ug embryo-1,7,
WBC,10e3 ul-1,7,
Agonist,,7,
Concentration,ug of B g-1,7,
Vd/F,,7,
Erythema intensity,,7,
MEC,mg ml-1,7,
Emax,uM kg-1,7,
AUC,min,7,
CFU,10^7/g,7,
Vmax/Km,uL/min/U,7,
AUC,microM/hr/mg,7,
CFU,10^7/ml,7,
Vmax/Km,uL,7,
Delta HR,min-1 hr-1,7,
Concentration,ug rat-1 hr-1,7,
MBIC80,ug ml-1,7,
MPC,uM,7,
GABA agonism,,7,
IE1,eV,7,
Melanotropic activity,,7,
CPI,mN/meter,7,
Antagonist activity,ug min-1 kg-1,7,
Fh,%,7,
ClM,ml min-1,7,
Jss,ug/cm2.hr,7,
G1,%,7,
Max delta BP,,7,
Activity,mmol/min/mg,7,
HCMV yield reduction,pfu/ml,7,
Irreversible binding,,7,
Change in stroke volume,%,7,
Modification of adsorbed drug,%,7,
Iron mobilized,%,7,
Creatinine_CL,ml/min,7,
ED20,ng,7,
Viral titer,PFU.mL-1,7,
Intrinsic vasorelaxation,M,7,
T>EC99,hr,7,
MPE,mg kg-1,7,
Max contractile force,,7,
Efficacy,number ul-1,7,
Vmax,1/min,7,
Virus yield reduction,,7,
CL_renal,ml min-1,7,
Median life span,,7,
Activity,ng/kg/day,7,
CFU,10'3/ml,7,
MCD,mg/kg/day,7,
Vm,uM min-1 (mg of protein)-1,7,
I50,%,7,
CL,mg min-1 kg-1,7,
A50,umol/Kg,7,
CL_renal,ml s-1,7,
CLb,%,7,
Hypnosis potentiation,%,7,
Volume,ml 4hr-1,7,
NOAEL,ug/L,7,
Vmax,U/min,7,
AUC,ml/min.kg,7,
HC50,10'-5M,7,
k2,m M-1 hr-1,7,
Volume,ml 2hr-1,7,
Bmax2,%,6,
Cr secretion,%,6,
Activity,Ratio,6,
Bmax,fM g-1,6,
Synergy with methicillin,,6,
rapp,,6,
T>EC50,hr,6,
Irritation of eyes,arbitrary units,6,
Blood/Plasma ratio,,6,
IogP,,6,
Avoidance response,,6,
EC90,mg kg-1,6,
Latency,ms,6,
Slope,mutants ug-1,6,
Log 10 cell kill,,6,
Iron binding,m equiv kg-1,6,
Protein content,%,6,
Activity,RFU/min,6,
K,10'6/M.s,6,
Stability,pmol/ml,6,
Bmax,MFU,6,
Stability,nmol/g,6,
Intrinsic efficacy,%,6,
Cell growth,number of cells ml-1,6,
PC95,ug ml-1,6,
Blood pressure,,6,
AUClast,nmol/hr/L,6,
PC50,ug ml-1,6,
Antibody titer,,6,
Static remission,%,6,
t1/2,%,6,
PCP activity,cysts g-1,6,
K,10^-5/nM/s,6,
Anticonulsant activity,%,6,
PCoct,,6,
t,ns,6,
Cell no./dish x10E3,,6,
Ear thickness,uM,6,
T>fEC50,hr,6,
Drug uptake,pg/mg,6,
Bmax,uM,6,
Cmax,pmol.hr/g,6,
Specificity,%,6,
Concentration,ul,6,
Reversibility,,6,
Drug metabolism,nmol/L,6,
%PFU,%,6,
IC50(app),,6,
rate constant app,min-1,6,
log(1/C50),,6,
KA,nm,6,
Aggregation,,6,
Km,nmol/mg,6,
BP,mM,6,
QT,,6,
IC50,ucm,6,
Activity,W,6,
Spermidine concentration,nM (10e6*cells)-1,6,
AUC/dose,ng/mL.hr,6,
K,10^5/Ms,6,
LambdaZ,/hr,6,
Max platelet response,,6,
Cmax,ug/kg,6,
Latency to exit,,6,
Antagonism effects,,6,
Activity,Momega,6,
Kinact,/ms,6,
Average turns/first 15 min,,6,
Anti-fXa activity,%,6,
Cmax,ug/hr,6,
scMet,mg kg-1,6,
T-C,days (optimal dose)-1,6,
Crop_yield,g,6,
Crop_yield,Kg,6,
K,10'-1/hr,6,
Level,ng g-1,6,
Thyroid status,ng ml-1,6,
Kinact,10^-2/min,6,
Duration of plateau,min,6,
Immunosupressive activity,%,6,
% of inhibition or stimulation,%,6,
C,ug ml-1,6,
Thr uptake,,6,
Threshold current,nA,6,
Amount,pM,6,
K bind,uM,6,
AUCt/dose,microM.hr/mg/kg,6,
Activity,U/uM,6,
ODC activity,(nM of CO2) 30min-1 (mg of protein)-1,6,
Thymidylate shift,,6,
Activity,Kb M-1,6,
Selectivity ratio,nM,6,
Activity,KA/dl,6,
PRCF,,6,
Depletion,%,6,
Therm_solubility,g,6,
Effect,pM g-1,6,
permeability,10'-4 cm/min,6,
OMNI med,mg kg-1,6,
AUC,nmol.hr,6,
Antigen p24 content,ng ml-1,6,
TCT,s,6,
permeability,umol cm2/hr,6,
TD50,mg,6,
Kdiss,10'-1/s,6,
LZ,/min,6,
Inhibitory activity ratio,,6,
PIC seizure,mg kg-1,6,
Kin,uL/g.min,6,
Boron in media at 0h,ug of B/ml,6,
AUC/dose,Kg.mg.hr/L.mg,6,
Decrease of SBP,mmHg,6,
Bitter taste intensity,0-15 scale,6,
Body temp drop,degrees C,6,
AUC 1/T1,s-1 min-1,6,
Culture negative,%,6,
Log MrI,,6,
Antitumor activity,g,6,
K,10^-7M,6,
Kinact,M/s,6,
Survival,number,6,
AUClast/dose,hr.ng/ml,6,
Activity,U l-1,6,
A50,M,6,
Ratio,10'3/M.s,6,
K,10^2/M/s,6,
K,10'-7/hr,6,
K,10^3/M,6,
AUClast/dose,mg.hr/ml,6,
K,10'-6M,6,
P ratio,,6,
K,10'-6/s,6,
Susceptibility,nmol/mg protein/h,6,
Css,ng/ml,6,
Denaturation rate constant,min-1,6,
PPB,pmolequiv/mg,6,
Drug metabolism,10'-2/hr,6,
Cell aggregates,,6,
Temperature decrease,degrees F,6,
Serum glucose,mg dl-1,6,
Cp(T),nM,6,
K inact,10e-3 s-1,6,
Testosterone,,6,
Testosterone,ng ml-1,6,
Log Palk,,6,
Increase contractility,%,6,
Occ50,,6,
EMax,,6,
Activity,10^2CFU,6,
Max dV/dt,V s-1,6,
Incorporated,%,6,
Antiproliferative effect,uM,6,
Activity,million,6,
Time over 100ng/ml,hr,6,
Binding constant,,6,
Log k,hr-1,6,
AUCt/dose,min.kg/L,6,
Time to peak tension,min,6,
K inact/Ki,uM-1 min-1,6,
Log d50,nM,6,
K obs x10e2,min-1,6,
DMF,,6,
Cmax,umol/Kg,6,
Cp,ug,6,
Binding constant,l M-1,6,
Topoisomerase-I activity,,6,
Total DPM,,6,
Total binding,pCi mg-1,6,
Kiuc,nM,6,
pKinact,,6,
Pancreatic response,,6,
C50,M,6,
Activity,cmH2O/ms,6,
Log beta,,6,
Secretion,uM hr-1 kg-1,6,
Score,%,6,
IFN,,6,
AUC,uM.h. kg/mg,6,
C24,,6,
LDL,ug mg-1,6,
Trabecular no.,mM-1,6,
Toxic level,mg ml-1,6,
RCI,%,6,
Cmax,ng/mL.hr,6,
LDH release,MU,6,
Mean log GI50,,6,
RD100,mg kg-1,6,
Alpha 50,molar fraction,6,
Tumor volume,%,6,
Max respose,,6,
Total radioactivity,,6,
Trabecular thickness,nm,6,
ROI,,6,
CC50,ppm,6,
Transport rate,uM min-1 g-1,6,
K1,M-1 s-1,6,
Prolongation effect,,6,
Transcriptional activation,%,6,
Drug degradation,10'-8mol/min,6,
E1/2,mV,6,
ID50,mg ml-1,6,
No. of writhes,,6,
Change of hemoconcentration,,6,
No. of spikes,,6,
Activity,10'6/100microL,6,
ID50,fmol,6,
Activity,J,6,
K1,uM,6,
Triglycerides,mg dl-1,6,
CLH,uM/min.mg,6,
Body temperature drop,degrees C,6,
Loss of inactivation,%,6,
ED250,umol/Kg,6,
Agonistic effect,%,6,
Trans,%,6,
No. of shocks accepted/5 min,,6,
K2,s-1,6,
Tumor growth delay,,6,
Derived trabecular number,mM,6,
Tumor growth inhibition,%,6,
ID/organ,,6,
Activity,eggs/g,6,
ID/g femur,%,6,
No. of relapses,,6,
SSAT,pM min-1 mg-1,6,
Tumor size,mM,6,
M2/M1 index,,6,
SR,,6,
Change in MAP,%,6,
Activity,nm s-1,6,
E max,,6,
Kq,10^13/M/sec,6,
ILC,%,6,
MAP,beats min-1,6,
U osm,mOsmol kg-1,6,
pKH,,6,
Kd,ug ml-1,6,
ED300,ug ml-1,6,
AUC,pM hr-1 g-1,6,
Km,mg/ml,6,
ED50,(ug of misoprostol) kg-1,6,
"KCS, APP",uM,6,
RC50,umol/ml,6,
AUC,ng.hr.kg/ml/mg,6,
CAI activity,,6,
Death dose,mg kg-1,6,
MBEC2,uM,6,
Adduct formation,%,6,
Activity,AU/mm,6,
Papp,ucm,6,
EAUC50,hr.ng/ml,6,
AUC,pmol.hr/g,6,
Agonist activity,IU mg-1,6,
SMT,,6,
IC50,nmol/mg,6,
No. of mice dead,,6,
SD50,mg kg-1,6,
RRT,,6,
SC50,%,6,
IC50,nA,6,
-TdeltaS,cal/mol,6,
Ulcer index,mM,6,
CC90,,6,
ED50,10'-10M,6,
Time of licking,s,6,
KA,,6,
CBF increasing activity,%,6,
pKL,,6,
SNA,%,6,
MBIC,,6,
Efflux,uM,6,
AUC,nM.hr/g,6,
AUC,ng.eq.h.ml-1,6,
V0,10^-8M/s,6,
LD50,pmol/g,6,
IC50,10'-4g/L,6,
VLDL,ug mg-1,6,
Cdyn,%,6,
No. of infected cells,%,6,
k3,min-1 M-1,6,
VT50,,6,
CCID50,mM,6,
Concentration,mg dl-1,6,
Agonist index,,6,
MABP change,,6,
AUC,u-1 hr-1 ml-1,6,
Non-HDL-C,mg dl-1,6,
RC50,,6,
KNBP,min-1,6,
EC50,mh/kg,6,
RT activity,%,6,
RRT,mean,6,
IC20,10'-7M,6,
Vdss,L/hr,6,
Rmax,mM,6,
log(activity),/ml,6,
Aberrant cells,,6,
1/MIC,L/mg,6,
Approximate colony formation unit,(g kidney)-1,6,
Egg reduction,%,6,
Vd,%,6,
Cell survival,,6,
Cell,%,6,
No. of foci per dish,,6,
"S20,w",Svedberg,6,
-log(1/HC50),,6,
Cytochrome loss,,6,
Slope,g dl-1M-1,6,
Papp,umol/L/s,6,
Onset for sleep,min,6,
Ka,10'-6/M/s,6,
Ka,10^2/Ms,6,
Vmax,pM,6,
Na+ ratio,,6,
Hepatocyte stability,uL/min/10e6 cells,6,
Vmax,nmol/min/U,6,
Radioactivity,nM equiv (ml of urine)-1,6,
ED50,mg kg-1 4day-1,6,
Change in hematology,,6,
Reduction of IOP,mmHg,6,
Activity (umol/g.of liver 75.min),%,6,
Vmax,amol/cell.min,6,
Change in FVR,%,6,
C10 air/C10 N2,,6,
CLup,ml/min,6,
Radioactivity,nM equiv mg-1,6,
Kapp,/min,6,
CI75,,6,
I,M,6,
CI95,,6,
I,uM,6,
COI,%,6,
Remaining at 40 min,%,6,
Vmax,pmol/min/pmol,6,
Accumulation counts,Counts,6,
Nitrite,uM,6,
LD0,uM kg-1,6,
Ka,10^6/Ms,6,
Vmax,nM min-1 g-1,6,
Activity,units/assay,6,
Ka,10^9/M,6,
MED,ug/L,6,
Vmax,ug/ml/min,6,
Developed tension,%,6,
pC20,,6,
Blood loss,mg kg-1,6,
Fibers/preparations,,6,
fAUC/dose,nM.hr,6,
Mean ED50,mg kg-1,6,
CL free,L/hr,6,
Relative Km,,6,
deltaG,degrees C,6,
Kcat/Km,/M/min,6,
Relative Fluorescent Unit,,6,
Drug uptake,kBq/cm3,6,
Free fraction,%,6,
Activity,/10'3mm'-3,6,
Ke,10'7/M,6,
fAUClast,hr.nM,6,
deltaS,cal/mol/K,6,
deltaT,,6,
Formation,pM/10e9,6,
CL free,uL/min/nmol,6,
Kq,10'11L/mol/s,6,
Average for skin reaction,,6,
Kcat/Km,10'-4/uM/s,6,
Ke,10'6/M,6,
Distribution of excreted Fe,%,6,
Rate of turbidity change,,6,
Min effective dose,ug kg-1,6,
AD50,pM,6,
Fluorescence,a.u,6,
Flu intensity,RU,6,
EC50,uM.hr,6,
Final plasma concentration,nM,6,
CL/F,ml/hr,6,
Activity,m equiv l-1,6,
Plaque inhibition result,,6,
Midpoint dose,mg kg-1,6,
Cardiac output,ml min-1,6,
Plasma,ug ml-1,6,
BPI,,6,
Concentration,uM 100ml-1,6,
CLz/F,ml/hr/kg,6,
fKi,nM,6,
Relaxivity,mM-1 s-1,6,
Hypochromic shift,%,6,
Fallen/treated,,6,
Relative threshold dose,,6,
Relative uterotrophic activity,,6,
Abortion,%,6,
Area,AU mm-1,6,
Bathochromic shift,nm,6,
Ratio,10'-5/M,6,
Ratio CC50/IC50,10'3No_unit,6,
Control of growth,%,6,
Cmin,fmol,6,
pD2 app,,6,
Retraction time,s,6,
Rat fertility,%,6,
VmaxH,pmol/min/g,6,
Convulsion threshold,mg kg-1,6,
Activity,umol/mol,6,
Activity_index,mg/g,6,
LD,Gy,6,
Peak radioactivity in blood,% injected dose cm**-3,6,
Basis motility,,6,
Cellular uptake of boron at 16h,ug of B (g of cells)-1,6,
LD,ppm,6,
K H,,6,
Volume,uM,6,
Reverse potential,,6,
Ka,/uM/s,6,
Activity,um3/um2/day,6,
Periosteal mineral apposition rate,mm day-1,6,
Vmax/Km,10'3ml/min,6,
Volume,ml min-1,6,
Conversion rate,,6,
Cellular content,pM (10e6*cells)-1,6,
Caverage,uM,6,
Peak inhibition,%,6,
Vmax rel,,6,
ks,min-1,6,
HDT,mg kg-1,6,
Activity,10'2/M,6,
MED90,mg monkey-1 day-1,6,
LD50,10'-2 ug/ml,6,
Neurite bearing cells/total cells,%,6,
Acetylation,%,6,
Ka,10'5/Ms,6,
Ka,10'4/M.s,6,
EC1000,umol/L,6,
Kq,10'13/M/sec,6,
Nitrate,uM,6,
Vmax,mM min-1,6,
Binding,fM uterus-1,6,
Vmax/Km,U/mg/uM,6,
Response,mg kg-1,6,
Respiratory system resistance,,6,
Hydrolysis,nM min-1,6,
No. cured/total,,6,
Cells positive,%,6,
Ratio,ng/mg,6,
Net Swelling,,6,
Vmax,delta A/min,6,
Activity,kU,6,
Activity regained,%,6,
CFU/g,,6,
ED50,nM day-1 kg-1,6,
AUC,mM.min,6,
Parasite_Clearance_time,hr,6,
Residual RR activity,%,6,
Nephrotoxicity,,6,
50% naproxen formed,%,6,
Radioactivity,nM equiv (ml of blood)-1,6,
Vmax,mmol/min/mg,6,
Absorbance,%,6,
Resting potential,-mV,6,
CFU,10^8/g,6,
MED,(mg of base) kg-1,6,
1/krel,,6,
High,%,6,
Hexobarb ST,min,6,
MIC70,uM,6,
CL,mL/min/m2,6,
CL/F,uM.hr,6,
CL,uL/mg/min,6,
Modification of hemoglobin,,6,
BUN_CHANGE_BY,%,6,
d50,nM,6,
GABA enhancement,,6,
Drug uptake,mg,6,
Relative Selectivity,,6,
MLD,pmol,6,
GRI,,6,
Average ratio,,6,
Cleavage rate,uM min-1 g-1,6,
Relative binding,,6,
ED50,ug mg-1 kg-1,6,
[I],mM,6,
p24,ng ml-1,6,
Ep2/2,mV,6,
Concentration,pM (10e6*cells)-1,6,
cpm/million cells,,6,
GFR,ml min-1 kg-1,6,
Ratio Ki,10^-5No_unit,6,
CL,uL/ml,6,
Permeability,Papp* 10E6 cm/s,6,
Relative permiability,,6,
WBC_CHANGE,%,6,
MFC>99,,6,
GSH,uM g-1,6,
pA1,,6,
Fungicidal concentration,uM,6,
GH peak,ug l-1,6,
GH AUC 0-180,ug min l-1,6,
MIC,mg,6,
logD,pH7.4,6,
Kq,,6,
Change in sensitivity,,6,
Molar primaquine Index,,6,
Cellular growth,%,6,
Relative analgesic potency,,6,
Drug mol/base pair,,6,
Growth Index,,6,
Ctau,ng/ml,6,
Antinociception,%,6,
ED100,ppm,6,
Occlusions,,6,
Change in TC,%,6,
Occ80,mg kg-1,6,
TPO(max),%,6,
Decrease in tone,,6,
Amount of [3H]thymidine,c.p.m.,6,
Active dose range,mg uM kg-1 day-1,6,
Max delta APD95,,6,
CLm,l hr-1,6,
Cell no./dish x10E5,,6,
Inhibition tumor index,%,6,
TC50,10'5nM,6,
Lag time,s,6,
3D PSA,,6,
Change in TPR,%,6,
Cminss,nmol/g,6,
Druguptake/dose,nM/mg/kg,6,
Inhibition,uM kg-1,6,
Relative amplitude,,6,
LC50,mg,6,
Kcat,10'-2/min,6,
MIC,10'-6mmol/L,6,
GI50,%,6,
GI25,uM,6,
Mortality,number of descendants/number of tested,6,
Virus yield,ffu ml-1,6,
VRT(t),hr2,6,
Virus titer,pfu/ml,6,
K app,uM-1,6,
AUC units,,6,
K aff,nM,6,
K alkyl,,6,
K app,1/M,6,
Clp,ug hr ml-1,6,
Block,,6,
Rate,pM min-1 (g dry weight)-1,6,
MRTlast,min,6,
Distribution,% dpm,6,
CLH,10'-6uL/min,6,
D2 selectivity,,6,
graft survival,day,6,
MSC,ug ml-1,6,
Activity,mV/ms,6,
FPTase activity,fM ug-1 min-1,6,
logED50,,6,
AD99,mg kg-1,6,
Reduction,beats min-1,6,
k cat,M-1,6,
Kcat/Km,10^5/M/s,6,
AE,%,6,
ED90,mg/kg,6,
CLH,microL/ml/min,6,
Kw,min-1,6,
Distribution,% dose organ-1 ,6,
Excretion,mg dl-1,6,
k2,s-1,6,
Ratio_[3H]:tubulin,,6,
Activity,pM (2*10e6*cells)-1,6,
Vz,uL/g,6,
Cmax,mg Kg-1,6,
Median tumoral volume,cm*3,6,
k x10e3,min-1,6,
Drug uptake,cpm/mm2,6,
k+2,s-1,6,
FACO Activity,%,6,
k+2/k,M-1 s-1,6,
k-1 app,hr-1,6,
Reaction rate,,6,
Change in tumor area,%,6,
Ext AUC,%,6,
Exploration motility,,6,
k2,M-1,6,
Recovery rate,%,6,
Plasma insulin,pM l-1,6,
k obs / concentration,M-1 s-1,6,
Average,c.p.m.,6,
GST activity,nM min-1 (mg of protein)-1,6,
Cz,ng/ml,6,
Relative dissociation rate,,6,
Relative metabolic stability,,6,
Glycine antagonism,,6,
Zone size,,6,
Kapp,10'6/M/s,6,
NO release,,6,
MHPG_SO4,ug g-1,6,
Rat turning,%,6,
Growth rate,uM,6,
ka,/min,6,
Khydrol,,6,
NED,mg kg-1,6,
Membrane integrity,%,6,
Mean arterial blood pressure,%,6,
Cmax/dose,,6,
Relative response,%,6,
Weight,(mg of prostate) (100g of body weight)-1,6,
Kb,10'-4/M,6,
APD75,ms,6,
mequiv of HCl,,6,
k_elim,hr-1,6,
CR,%,6,
Ratio IC50,10'4No_unit,6,
Kb,10'5L/mol,6,
Control cell number,%,6,
Mitotic index,nM,6,
Kb,10'-5L/mol,6,
Rate of hydride transfer,s-1,6,
Gastric score,,6,
Drug uptake,microL/min/mg,6,
Kb,10'4mol/L,6,
Xi50,,6,
Extent of DNA binding,,5,
MHC10,,5,
MI0.5,,5,
Drug uptake,ug/kg,5,
Kinetic_solubility,10'-5mg/ml,5,
Ki_app,nM,5,
K beta,nM,5,
Excreted,,5,
Kinetic_solubility,10'-4mg/ml,5,
EC50,10^2 uM,5,
K+ excretion,ml 6hr-1 100g-1,5,
Epoxide formation,nM,5,
Epinephrine level,,5,
Exudate volume,ml,5,
Ki1,uM,5,
Kix,mM,5,
K+2,min-1,5,
Kic,mM,5,
K0.5,10'-5M,5,
KH,s-1,5,
Binding affinity,M-1,5,
Ki2,uM,5,
EC50,uL/ml,5,
Drug uptake,%ID.m^-2,5,
Activity,pM 10min-1,5,
Activity,pM hr-1 mg-1,5,
Enantioselectivity coefficient,,5,
Challenge dose,,5,
MIC,10'-4/M,5,
ICA,,5,
MIC,mg kg-1,5,
Emin,,5,
Log DSF,,5,
ID50,mg ear-1,5,
MIC=<90,,5,
Amount Recovered in urine,mg,5,
Helicity,%,5,
C8h,,5,
Change in TC,,5,
Log Pe,,5,
ID50,10'-8M,5,
Log Pcyc,,5,
LMA,%,5,
Log Ko/w,,5,
Hepatic cholesterol,mg g-1,5,
Hepatic triglyceride,mg g-1,5,
CI,%,5,
CC100,,5,
Change in blood flow,%,5,
Log IC50,log(1/M),5,
Lambda-z,L.h-1,5,
Antifungal activity,%,5,
Anesthetic effect,%,5,
CL,ml/mm/kg,5,
CL,nL/pmol/min,5,
Inhibition,mg kg-1,5,
MIC,ug l-1,5,
K inact/Km,M-1 s-1,5,
Drug uptake,uM.hr,5,
KA,uM kg-1,5,
Kobs,/ms,5,
B-A/A-B,,5,
K,10'10/M/s,5,
Km/Kcat,uM s-1,5,
K,10^6/Ms,5,
Kobs,,5,
MFC90,mg/L,5,
EC50,10'11PFU,5,
Blood level,,5,
FRS50,uM,5,
Drug uptake(free),ng/ml,5,
Kpol,s-1,5,
K,10^-4/M/s,5,
CL/F,ug/ml.hr,5,
MED99.9,mg kg-1,5,
K,10'4/s,5,
K,10'4/Ms,5,
Bmax,disintegrations/min,5,
CL/F,mg kg-1,5,
Flu intensity,10^9/s/cm2,5,
K,10'-6/M/s,5,
LambdaZ,min,5,
EC90,ppb,5,
Remission,%,5,
Vmax,umol,5,
Vmax / K,,5,
Vmax(app),microM/s,5,
Vmax/Km,ml/min/mg,5,
CL,ml/min.mg,5,
Peff,10'-3cm/min,5,
CLH,mg/min/g,5,
CL/F,(mg)/(ug/ml)/hr,5,
MIC99.9,,5,
MFED,,5,
Activity,pmol/(s.cm2),5,
Activity,pmol/Kg,5,
Efficiency,uM-1 s-1,5,
K+2/Ki,uM min-1,5,
KNBP,s-1,5,
K,nmol/min,5,
K,10^8/M/min,5,
Food intake,,5,
Food intake,%,5,
Ks,10'5/M,5,
MEC,ug,5,
Isometric contraction,%,5,
Fraction Recovered in urine,%,5,
Initial heart rate,bts min-1,5,
ME,%,5,
Inhibitory ratio,%,5,
Inhibitory activity,%,5,
MD,%,5,
GI50,10^4M,5,
Inhibition of increase in weight,%,5,
Brain concentration,,5,
Brain concentration,mM,5,
Inhibition at 5nM,%,5,
Brain concentration,nM,5,
Actual duraction,,5,
LC50,%,5,
Kr,s-1,5,
Hypoglycemic activity,,5,
ED100,nM kg-1,5,
Animals affected,,5,
Carbamoylating activity,,5,
ED200,,5,
Max agonist activity,%,5,
Ki,/nM,5,
BC,uM,5,
ED delta,mg kg-1,5,
ED50,mg/L,5,
ED50,uM.hr,5,
MNTD>75,uM,5,
Kd,10'-8/s,5,
Max activation,%,5,
Kapp,10'3/M/s,5,
ED50,10'-4umol/ml,5,
Kapp,10'8/M,5,
CS50,ug ml-1,5,
ED50,mg kg-1 dose-1,5,
Kcat,10'-3/hr,5,
Activity,nanometer2/sec,5,
ED10,M,5,
Kb,mg kg-1,5,
ED100,ug ml-1,5,
Max APD90 (delta),%,5,
ED,ug,5,
Ka,l mol-1,5,
Blood urea nitrogen,,5,
MLC,mg kg-1,5,
LD100,ug ml-1,5,
IOP lowering,mmHg,5,
Bicarbonate level,,5,
Ka,10^10/M,5,
Liver weight,g (100g of body weight)-1,5,
Ca2+ antagonistic activity,%,5,
VmaxL,pmol/min/g,5,
Drug uptake,%Idose/kg,5,
BUI,,5,
Ka,10'5/M.s,5,
ED30,mg/kg/day,5,
Kb,10^4L/mol,5,
Max Achievable Bioavailability,,5,
Dilation,,5,
Keq,uM,5,
Carbonyl group,nM mg-1,5,
Ka,10'5/uL,5,
Khd,,5,
MTD,mg/day,5,
Max fall in IOP,,5,
Kb,10'9/M,5,
EC95,ppm,5,
BAV,%,5,
Behavioral syndrome,,5,
Kcat/Km,/M/hr,5,
MRTV,,5,
Ke,10'5/M,5,
Kh,min-1,5,
ED50,Ug/ml,5,
BP decrease,,5,
EC80,,5,
Ki,1/M.s,5,
Kd,10^-4/s,5,
Lysis time,min,5,
INH,umol/Kg,5,
INH,pM,5,
LD50,10'-3 ug/ml,5,
LD/ED80,,5,
C0,ng/L,5,
ISC,,5,
C0,ug/L,5,
IPol,nM,5,
IG50,ug ml-1,5,
C20 FRP,,5,
HTS data,,5,
LDH,,5,
Animals affected,%,5,
Log AC50,,5,
I,,5,
I,mM,5,
Animals with palpable tumor,,5,
CFU,10'6/ml,5,
Lesion score,,5,
Log 1/KL,,5,
IC50,liposomes ml-1,5,
I40,uM,5,
I50 M,,5,
Log 1/I50,,5,
I80,mM,5,
CFR rating,,5,
Drug metabolism,microM/min/mg,5,
Liver CH levels,,5,
Liver TG,,5,
Liver cholesterol,mg (g of tissue)-1,5,
LD,g/Kg,5,
CL,ml/hr/mg,5,
C 8 h,uM,5,
Loss of affinity,,5,
INH,10'-7M,5,
INH,10'-5M,5,
LD100,ppm,5,
INCC50,nM,5,
C10APD90,uM,5,
Drug degradation,a.u.,5,
HD100,ug ml-1,5,
EC20,M,5,
Drug degradation,pmol/min/mg,5,
Ambulation score,,5,
C2,ug g-1,5,
IL-1 production,pg ml-1,5,
IP+SC score,,5,
Impaired,%,5,
IP3-sensitive Ca2+ stores,%,5,
Agonist response,,5,
Infected,%,5,
MBEC80,ug ml-1,5,
Adrenal uptake,,5,
LC90,mg,5,
Average 14-day MGR,mm**3 day-1 ,5,
Gated current,%,5,
MBC50,uM,5,
Increase in [Ca+2],nM,5,
MBC100,,5,
C,mg ml-1,5,
Peff,10^-6nanometer/s,5,
CLu/F,ml/min.kg,5,
Activity,10^6No_unit,5,
Cp,pg/mg,5,
No. of guinea pigs protected,,5,
Correlation coefficient,,5,
Uptake,fM cell-1,5,
Cl,ml mg-1 kg-1,5,
No. of rats displaying DA syndrome,,5,
Cp,microM,5,
Tm,K,5,
Decrease,mmHg,5,
Total binding inhibited,%,5,
Cp,uM.hr,5,
AUC,ug h/g,5,
Cp,pmol/g,5,
AUCt/dose,ug.hr/mL/mg/kg,5,
Toxic effect,,5,
Decrease in hypothalamus norepinephrine,%,5,
AUC,uM min uM-1,5,
No. survived,,5,
AUC,uM hr ml-1,5,
SWo,,5,
Transport,pM min-1 (mg of protein)-1,5,
No. of virus free mice,,5,
Activity,deltalog10pfu/g,5,
No. of survivors/total,,5,
Ts,degrees C,5,
AUMC,microM.hr^2,5,
Tubulin,,5,
Activity,dyn/cm,5,
Papp,um/s,5,
No. of invaded cells,,5,
S-phase,%,5,
Covalent binding,%,5,
Uterus effect,,5,
Cross reaction,%,5,
T inh,,5,
Decrease in CVR,%,5,
Activity,N/mm,5,
Specific radioactivity,Ci/M,5,
T1/2 h,,5,
T2,hr,5,
T3,%,5,
Decrease in heart norepinephrine,%,5,
PD50,umol/Kg,5,
Thy-1 expression,,5,
Time constant T3,,5,
Cp,ug.hr/ml,5,
SGPT activity,units/mL,5,
No. of openarm entries,,5,
AUC,nmol/g/min,5,
SGOT activity,units/mL,5,
No. of new tumors,,5,
AUC,nmol/g.min,5,
Ulcer index,mm,5,
Delta CPP,mmHg,5,
No. of mice without tumors,,5,
UD50,,5,
SDL,,5,
Uptake rate,nM min-1 cm**-2,5,
AUMCt,ng.hr/ml,5,
No. of lung lesions,,5,
Ratio,10'5/M/min,5,
Stability,pmolequiv/mg,5,
Mean no. of days post-infection to death,,5,
s-GPT level,Karmen units,5,
Protection,day,5,
Delta weight,,5,
Max potentiation,%,5,
Max protection,,5,
Max protective effect,%,5,
% of activity remaining,%,5,
RBC,10e6 ul-1,5,
% release of nitric oxide,uM uM-1,5,
Activity,ml/cm3/min,5,
Compound recovery,hr,5,
Activity,ml/cm3,5,
Max score,,5,
pKR+,,5,
Max tolerated dose,uM kg-1,5,
Progressed remission,%,5,
Max. potentiation,%,5,
DBP/UP ratio,,5,
Ratio,/s/mM,5,
Maximal change,%,5,
Positive paws,%,5,
Concentration,ug kg-1,5,
Ratio,10'2/M/s,5,
Ratio,1/M.sec,5,
Ratio,10'-7No_unit,5,
88Y-serum,%,5,
Activity,log10RLU,5,
Mean log LC50,,5,
s-GOT level,Karmen units,5,
QH,L/hr.Kg,5,
Prodrug remains,%,5,
Clonic seizures,%,5,
Concentration,ml,5,
1/Vmax,deltaA/s,5,
1/n,,5,
MeAIB uptake,,5,
Activity,10'3/ml,5,
DFM,mg/cm2,5,
Change of weight,%,5,
2 x APTT,uM,5,
Pressor response,%,5,
pEC5,,5,
Concentration,ng day-1,5,
Rate of formation,nM (mg of protein)-1,5,
Rate of formation,pM min-1,5,
2PT,10'-3M,5,
Mean blood pressure,mM,5,
p value,,5,
mortality,day,5,
2X PT,uM,5,
Concentration,pmol/10E9 cells,5,
Concentration,pmol/E109 cells,5,
max Delta Vmax,%,5,
Rate,nM-1 min-1 (mg of protein)-1,5,
Maximal activation,,5,
Concentration,dpm,5,
pIC35,,5,
t1/2,ml/min.kg,5,
solubility,mg/uL,5,
Oxytocic activity,U mg-1,5,
pK4,,5,
AUC/dose,uM.hr/mg,5,
Responding,,5,
Residual amine (ee),%,5,
Rescued neurons,%,5,
Negative ionotropic activity,%,5,
Negative chronotropic activity,%,5,
Absolute,%,5,
AUC,/hr,5,
Activity,mM hr-1,5,
Relative antitumor activity,,5,
DR20,ug kg-1,5,
Plasma total cholesterol,mg dl-1,5,
Plasmaconcentration,nM,5,
Ratio IC50/EC50,10'5No_unit,5,
Platelet count/ul,,5,
Ratio EC50,microM,5,
ka,/uM/min,5,
kinact,,5,
Ratio AUC,ml/g,5,
k cat/Km,uM-1 min-1,5,
kn,,5,
lambda-z,L.h-1,5,
Ratio,min-1,5,
ABD50,mg kg-1,5,
Ratio,10^6/M/min,5,
log(1/MEC),,5,
AAC,deltalog10CFU/ml.hr,5,
Activity,10^-8No_unit,5,
Ratio,10^2/M/s,5,
Partition coefficient,min,5,
Delta H-V,ms,5,
Ratio,ml/g,5,
Vmax,area/min/mg,5,
Activity,10^6/mm3,5,
AUC/dose,umol/l.hr,5,
Vmax,pmol/min/ug,5,
Acquisition time,,5,
Peripheral restriction index,,5,
Activity,mAU ml-1,5,
Vz/F,(mg/kg)/(uM),5,
Relative rate,%,5,
Relative loss of potency,,5,
Activity,mJ,5,
Weight difference,T-C,5,
Vr,ml,5,
X,min,5,
Na+ excretion,ml 6hr-1 100g-1,5,
Necrosis,,5,
AV block,,5,
Vdss,ml/min.kg,5,
Virucidal,,5,
Virus inactivation,%,5,
Activity,g/mm,5,
AUC,min.sec,5,
Vm,uM min-1mg-1,5,
Vm rel,%,5,
No. of avoidance,,5,
Accumulation,nM g-1,5,
Vmax,M min-1,5,
Retention time,,5,
Activity,10^-7No_unit,5,
AUC,hr.kg.ng/ml/mg,5,
Plasma MIC,ug ml-1,5,
Oligo shifted,%,5,
AUC/dose,hr.kg.ug/ml/mg,5,
AUC/dose,M.hr.kg/mg,5,
Sleep ratio,,5,
TED,nM kg-1,5,
TG 2X lag,uM,5,
TC,uM,5,
Of dose excreted,%,5,
TPE,toxicity,5,
AUCt,pmol.hr,5,
AUC ED50,mg kg-1,5,
Serum T4,ug dl-1,5,
AUC 100,mg kg-1,5,
PPM,,5,
AUC,umol.hr/kg,5,
Observed relaxivity,mM-1 s-1,5,
Therm_solubility,%,5,
Cp(f),umol/L,5,
Observed [pt],mM (mg of protein)-1,5,
AUC/dose,nM/hr,5,
AUC/dose,ng.hr.kg/mg/ml,5,
Activity,Pmol,5,
Sterility,%,5,
Substrate efficiency,%,5,
AUCED90,uM.hr/day,5,
Activity,meter/s,5,
Surface involvement,%,5,
PD200,umol/Kg,5,
PI turnover,%,5,
AUClast,pmol.hr/g,5,
TD,uM,5,
AOC,mmHg.hr,5,
TC50/IC50,,5,
aPTT,,5,
[I] 0.5,uM,5,
Delta S-H,ms,5,
Activity,10^5No_unit,5,
Phospholipidosis,uM,5,
Phospholipidosis_index,,5,
Reduction in AUC,,5,
Morbidity,%,5,
Molar potency,,5,
Phosphorylation,%,5,
Mitotic figures,,5,
damage reduction,%,5,
AOC,,5,
fEC50,ng/ml,5,
No. of escape failure,,5,
Vd,ml/min.kg,5,
A2,10'-8M,5,
fNOAEL,uM,5,
DTH,mM,5,
Vdss,Not_given,5,
fCmax,nmol/g,5,
Reduction in respiratory volume,ml,5,
fAUC,nmol/g/min,5,
Activity,/cm,5,
Cmax/dose,umol/L,5,
M/NTT,,4,
No. of rats with lesions,,4,
Delta latency time,,4,
Concentration,nM (g of tissue)-1,4,
No. of mice infected /total,,4,
CL,ml/min/hr,4,
Acute lethal toxicity,,4,
Adrenochrome formation,,4,
Change in volume,%,4,
CL,ml/min/nmol,4,
[3H]-uptake,,4,
ED50,pM,4,
MBIC50,mM,4,
Concentration,ng mg-1,4,
Activity,nmol of MDA/mg of LDL,4,
Activity,ngequiv,4,
ED50,uM mouse-1,4,
Zone reduction,%,4,
Delta ERP,ms,4,
ATP content,pM mg-1,4,
Adrenochrome formation,nM min-1 (mg of protein)-1,4,
Changes in dynamic compliance,Cdyn,4,
Catalase,mg of protein,4,
Activity,mg/mm3,4,
M2/M1 Index,,4,
CL,ml min-1,4,
Vz/F,(mg/kg)/(ng/ml),4,
Cmin,ng,4,
MND,14-21 day,4,
pA2,IU mg-1,4,
AUC,10^4nM.min,4,
2aPTT,mM,4,
CL,min.kg/L,4,
ED50,dp/dt,4,
AUC,fmol,4,
ED50,mg kg-1 hr-1,4,
CL,ml.min-1,4,
Changes in airway resistance,RL,4,
Glucose uptake,uM mg-1,4,
1/kmax,min,4,
Aggregation ratio,,4,
AUC,hr.%ID/ml,4,
Cmin,mg/dl,4,
Drug Conc (LDL),ug ml-1,4,
Water intake,ml 20min-1,4,
MRTinf,hr,4,
MBC,mmol/L,4,
CREAT_CHANGE_BY,%,4,
Drug Conc (serum),ug ml-1,4,
AUC,hr.nmol/ml,4,
pEC50,nM,4,
Gross morphology,,4,
Vz/F,g,4,
Gastric damage,%,4,
k cat,ms-1,4,
Mean paw diameter,mM,4,
CLH,ug ml-1,4,
kon,,4,
Consumption,%,4,
NMDA effect,%,4,
Dose,M kg-1,4,
increase in temperature,,4,
Emax,deltalog10CFU/ml,4,
k eff (rel),,4,
Molar content,Molecules (LDL particle)-1,4,
Food intake,g kg-1,4,
F1/2,,4,
Erythema formation,,4,
k3',L (M min)-1,4,
EC50,10'-7mol,4,
k2/Ki,nM-1 min-1,4,
MI50,umol/L,4,
Activity,uM/hr,4,
k2,mM-1 min-1,4,
AD50,ug ml-1,4,
Activity,uM/kg,4,
k2,10e-3 s-1,4,
External nucleoside,nM g-1,4,
No. of WDS/60 min,,4,
AD50,mM kg-1,4,
F3/4,,4,
MFC50,,4,
ko,min-1 s-1,4,
Glucose,mg day-1,4,
NADH oxidation,uM min-1,4,
pAh,,4,
Activity,mg/uM,4,
pBBB,,4,
pBBB,10'-3cm/min,4,
Affinity constant,M-1,4,
deltaTCID50,,4,
Formation of compound,nM,4,
Formation of NO3-,nM,4,
MIC,ug/mg,4,
ki/Ki,M-1 s-1,4,
kinact,1/min,4,
k eff,M-1 min-1,4,
Emax,ng ml-1,4,
NB,,4,
Activity,mIU/ml,4,
ADP formation,%,4,
k cat/Km,m M-1 min-1,4,
Activity,mIU/L,4,
EC50,mg,4,
Cholesterol content,,4,
k cat/Km,%,4,
kirr,s-1,4,
Activity,uL/L,4,
Concentration_urine,ug ml-1,4,
2aPTT,ug ml-1,4,
K,10'6/Ms,4,
Activity,kcps,4,
Functional selectivity,,4,
Activity,10'1/M,4,
Swimming activity,T/C,4,
Pm,10e-5*cm/min,4,
Activation,fold,4,
Drug recovery,uM,4,
Po/w,,4,
Polyamine,,4,
Polyamine,nM (mg of protein)-1,4,
Survival range,day,4,
K,10'2/mol/s,4,
K,10'2/s,4,
AUClast,hr.nmol/g,4,
Acid titer,m equiv l-1,4,
Activity,10^1pg/ml,4,
K,10'3No_unit,4,
Kapp,10'-3/s,4,
AUClast,min.ng/g,4,
Ki,10'3/M/s,4,
Cmax,uM.kg/mg,4,
K,10'5/M/min,4,
Drug recovery,ug ml-1,4,
Post anitbiotic effect,,4,
Drug uptake,ml/g,4,
K,10'5No_unit,4,
IC20,10'-6M,4,
Synaptic site,,4,
Cmax,ug/10^6 cells,4,
Cmax,uM.hr,4,
Pressor activity,,4,
Relative to control,%,4,
FBA,((mmol/day)/100g),4,
Cmax,nM l-1 hr-1,4,
Stability,pmol/mg,4,
Activity,10'9uL,4,
AUClast,ug.hr/g,4,
K,10^-7/s,4,
Kp,nM,4,
Potentiation inflection point,nM,4,
Stability,ng/ml/hr,4,
K,10^3(1/Ms),4,
Acid output,u equiv 2hr-1,4,
K,10'-3M,4,
K,10^4L/mol,4,
Ki,10'7/M/min,4,
Pressor response,IU mg-1,4,
Pressor response,mmHg,4,
Cmax,pmol/10^6cells,4,
DNA on filter,,4,
Behavior response,,4,
Primary tumor weight,mg,4,
Prodrug reconversion,%,4,
K,10^-1/M/s,4,
Clones,%,4,
Subcutaneous score,,4,
Activity,U/dl,4,
Activity,mmHg hr-1,4,
MEC,ng/ml,4,
dP/dt,1/Pmax,4,
CL,nM/min,4,
CL free,uL/hr/10^6cells,4,
Activity Score,,4,
ALT,U l-1,4,
ALT.,U l-1,4,
Fraction,,4,
5-HTP accumulation,ug g-1,4,
Fraction change,%,4,
ED90,umol/Kg,4,
Cmax_tumor,uM,4,
Activity in animals,,4,
Cartilage space,,4,
Dose converted,%,4,
AMPA effect,%,4,
Fraction of Liver Blood Flow,%,4,
dP/dt,1/Pmax s,4,
2x TG,uM,4,
Carotid Flow Decrease,%,4,
Fu,ug ml-1,4,
Median day of survival,,4,
CMC,10'-3 mol/L,4,
MEC,M,4,
delta Log P50,,4,
No. of animals protected / no animals tested,300mg kg-1,4,
Activity,hr-1,4,
IC20,10'-4M,4,
Activity_index,mg kg-1,4,
2TT,uM,4,
GDP activity,nM min-1 mg-1,4,
ED50 mg/animal/day,,4,
MDS,,4,
MLC50,%,4,
MLD,g/Kg,4,
ED50 / ED50 (taxol),,4,
CL,uL/min.ml,4,
ED50,umol/kg.min,4,
CL,pmol/min/mg,4,
Cmax/dose,microM/mg/kg,4,
c.v,,4,
CL,ng.hr/ml,4,
Cmax/dose,kg.mg/L.mL,4,
No. of animals protected / no animals tested,100mg kg-1,4,
GI90,M,4,
ED50,ugAi/ml,4,
2PT,ug ml-1,4,
Activity,inches,4,
Actual clearance,ml min-1 kg-1,4,
Displacement of DP,,4,
ED50,ug rat-1,4,
EC30,10'-6M,4,
ARP,m/M,4,
NAD+ level,%,4,
CI25,,4,
Monocation species,%,4,
CLH,min/mL,4,
P,uM,4,
Activity,U/g.Hb,4,
IC12,,4,
Vdss,L/m2,4,
%,%,4,
CFU,%,4,
Drug metabolism,L/mol/min,4,
ED,U mg-1,4,
rel T,,4,
CV,,4,
Hydroxyproline release,ug ml-1,4,
% change,%,4,
Hypokinesia,Counts,4,
Cmax/Tmax,,4,
Log A50,,4,
Max response,uV,4,
Optimal dose,mg.kg/inj,4,
Antagonist,,4,
Antagonist activity,pA2,4,
qKD,uM,4,
I/M ratio,,4,
Vmax,10'4OD/sec,4,
Vmax,10'-5 uM/s,4,
Depolarisation,mV,4,
Oral duration,,4,
Activity,ml/s/g,4,
Ca2+ flux,nM mg-1,4,
Max effect,Counts 10min-1,4,
Virucidal,uM,4,
pKx,,4,
Occ ED50,mg kg-1,4,
Vmax,pMl hr-1,4,
Amount of TXB2 formation,ng ml-1,4,
CTC50,M,4,
Cmin(84hr),pg/mL,4,
CTE,,4,
Vmax,microM/microg/sec,4,
ED10 HR,,4,
Vmax,mAU/min/uM,4,
Ventricular MAPD90,ms,4,
Competitive protection,,4,
Velocity,uM min-1mg-1,4,
Oxidation,uM min-1,4,
solubility,/mM,4,
Max dose,mM kg-1,4,
Convulsions,%,4,
IC0.2,uM,4,
Cooperative effect,,4,
Oxygen consumption rate,nM min-1,4,
ECAR,%,4,
Venom,%,4,
Control vomits,,4,
Velocity relative to ATP,,4,
Caco-2 permeability,% hr-1,4,
Max contractility,%,4,
Vmax,/RU/s,4,
Alkylating activity,10e3*k,4,
-Log Ki,,4,
ED5,nM kg-1,4,
Mean activity,uM,4,
Drug degradation,nmol/min/mg,4,
Log10 reduction,,4,
Mean body weight,%,4,
ED50,10'-14 ug/ml,4,
Conc_plasma,ng ml-1,4,
Change of area,%,4,
CT10,uM hr,4,
Lysis time,,4,
Log inhibition,,4,
Log10CCID50/g,,4,
VmaxL,pmol/min,4,
-Log IC50/IC50,,4,
CT50,,4,
No. of uptake sites,,4,
ED50,10'-6M,4,
Mean axonal area,,4,
Vss,kg-1,4,
Vss,l,4,
Lung weight,mg,4,
ED50,10'-5umol/ml,4,
Activity,10^-2No_unit,4,
Vmax/Km,%,4,
HC90,ug ml-1,4,
Activity,ml/kg/hr,4,
HC5,,4,
Activity,mmol/m2/s,4,
MTD ratio,,4,
Erosions,,4,
Drug degradation,ug ml-1,4,
AUC,hr/L.kg,4,
Amnesia reversal,,4,
Albumin,mg 100g-1 24hr-1,4,
MTA,,4,
ED300,,4,
Vmax / Km,ml min-1 kg-1,4,
Drug dissolution,%,4,
No. of survivors,%,4,
ED30 DBP,,4,
Volume change,%,4,
MTD,ug/kg/day,4,
pKa6,,4,
CL,L/hr/1.73 m2,4,
Growth response,%,4,
CL,mg/ml/g,4,
Agonistic potency,%,4,
Vomits,,4,
CL,mg/kg/min,4,
Vmax(app),pmol/min.ml,4,
EC5x,uM,4,
Control retches,,4,
Vmax,pmol/min/10^6cells,4,
Maximal decrease in IOP,mmHg,4,
Activity,l kg-1,4,
Activity,pS,4,
EOS inhibition,%,4,
Change in foot-licking latency,%,4,
A,%,4,
Activity,pM/mg,4,
Food,g rat-1 day-1,4,
MEC50,uM,4,
deltalog10CFU,/ml,4,
ALB_CHANGE,,4,
log10cfu,mg,4,
Activity Factor,,4,
CLd,L/hr,4,
NOAEL,mgAi/L,4,
AB,%,4,
Effective concentration,nM,4,
fc max/MIC,,4,
Dose,mg mouse-1,4,
AC50,ug ml-1,4,
fIC90,ug ml-1,4,
fIC90,nM,4,
log Kp,ucm/s,4,
fIC50,ug ml-1,4,
Concentration in Brain,nM,4,
Fecal weight,g,4,
Naproxen produced,uM,4,
Fold stimulation,,4,
Feces,%,4,
ft1/2,,4,
AD50,%,4,
ka/kr,,4,
kaKr/kr,M,4,
N20 formed,nM,4,
Change in spermatogenesis,,4,
FC,log10RLU,4,
kb,M-1 min-1,4,
FC,uM,4,
FD,%,4,
Emax,bpm,4,
EC50,10'-2ppm,4,
f %t > MIC,,4,
MED,mg/L,4,
CLint,,4,
Cholesterol level,mg g-1,4,
Activity,mU.nmol/h,4,
CL/F,L.h-1,4,
Fmax,pg/ml,4,
MED,nmol,4,
EPS MED,mg kg-1,4,
EPS,,4,
CL/F,(mg/kg)/(ng/ml)/hr,4,
Activity,pfu/ml,4,
CL(app),L/hr,4,
Dose,nM kg-1,4,
AG80,%,4,
Vmax,pmol/min/g,4,
Vmax,pM U-1 min-1,4,
Cmin_PBMC,pmol/10^6cells,4,
CHOL_CHANGE,,4,
permeability,10^-5cm/s,4,
Of rats turning,%,4,
CFU-GEMM,%,4,
Vmax,nM hr-1 (mg of protein)-1,4,
Max uterotonic response,%,4,
Decrease in mean arterial pressure,,4,
AUC,microg.hr/mL.g,4,
Analogue level,pM (10e6*cells)-1,4,
Occ90,mg kg-1,4,
Vmax,uM/hr,4,
Vmax,nM/min/mg,4,
CT50,day,4,
Change in blood pressure,,4,
Haptoglobin,g l-1,4,
Vmax,uM min-1 ml-1,4,
Log [-9],,4,
Mean,nM hr-1 mg-1,4,
CL,%ID/cc,4,
Log [-10],,4,
Mean,%,4,
MTD/ TGI50,,4,
Heart weight absolute,g,4,
partition_ratio,,4,
Vmax,nmol/ mL h,4,
NRD,,4,
CL/F,g/min,4,
fEC50,,4,
Ferret emesis,,4,
CL/F,ml.min-1,4,
MED50,ug ml-1,4,
fCmax,ug/g,4,
Dose,nM min-1 kg-1,4,
CL/F,mg/(ng/ml)/min,4,
Activity,units ml-1,4,
MED100,,4,
Activity,mU ml-1,4,
Fluid,ml rat-1 day-1,4,
pH dependence,,4,
Mass index,%,4,
MBC100,ug ml-1,4,
ED15,,4,
Mass index,mg/10g body weight,4,
MTT,min,4,
ED15,mg kg-1 i.d.,4,
Desensitisation,%,4,
% of NO release,,4,
Vmax,nmol/min/ug,4,
Occ90,nmol/g,4,
AUC,mg/L,4,
Activity,milliosmole,4,
Drug uptake(free),nmol/L,4,
Selectivity ratio,Ratio,4,
Kq,/M/s,4,
UD50,uM kg-1,4,
AUC,ng.hr,4,
Decrease in MAP,,4,
Ratio,10^-4/uM/min,4,
Antibody response,,4,
DA stim,%,4,
Liver concentration,nM kg-1,4,
Activity,10'-6 cm/s,4,
Vc/F,,4,
Vc,kg-1,4,
PAE,day,4,
Kd,kcal/mol,4,
Vbeta,,4,
Vasopressor activity,U mg-1,4,
IC37,uM,4,
Vasodilatory rate,,4,
Vasodilation,%,4,
Cortex_Clearance,ml s-1 (10e4*g)-1,4,
PB,uM,4,
Lipid peroxidation,nM MDA (mg LDL)-1,4,
Activity,RFU/ug/min,4,
Vacuole response,ng ml-1,4,
IC50,10'-10 uM,4,
Limiting t1/2,min,4,
IC50,10'-8mg/ml,4,
IC50,10'5mM,4,
IC50,10^2 nM,4,
Ratio IC50,10^2No_unit,4,
PG,,4,
AUC,nmol.hr/kg,4,
IC50,mg.min/m3,4,
Urine,%,4,
Anticonvulsant,,4,
AUC,ng/mL.kg,4,
Urinary recovery,,4,
PD50,uM kg-1,4,
IC50,nM kg-1,4,
Urea Nitrogen Concentration,mg dl-1,4,
Cp,cps,4,
EBD20,mg kg-1,4,
Ratio,10'7/M/s,4,
AUC,nmol/L.min,4,
Activity,M/uL,4,
Ratio,10'6/M/min,4,
Kdiss,10'-5M,4,
Ratio CC50/EC50,10^2No_unit,4,
Unmetabolized,%,4,
Lesion,%,4,
Antidiuretic activity,IU uM-1,4,
Ratio CC50/EC50,10^3No_unit,4,
Ratio CC50/EC50,10^4No_unit,4,
Antidiuretic activity,U mg-1,4,
IC50,umol/dm3,4,
PFC/splleen,,4,
Ratio,ml/min/uL,4,
Level of cGMP,pM,4,
AUC,ng ml-1,4,
ID30,ug,4,
Apoptosis induction,%,4,
Brain lesion,mm,4,
C24h,uM,4,
Drug metabolism,pg/ml/min,4,
ID80,micromol/kg/min,4,
Papp,10'-8m/s,4,
ID95,uM,4,
Recovery,dpm ml-1,4,
Ratio,/min/nM,4,
Tubulin content,pM mg-1,4,
ID50,%,4,
Tumor free/total,,4,
C50k,mg/L,4,
Kd',M,4,
PHOSLPD_CHANGE,,4,
IC70,,4,
Lactose production,uM mg-1,4,
Ratio,10'2No_unit,4,
Activity,L/min,4,
CC50,10'3ug/ml,4,
UI,mm2,4,
Activity,10'-4AU/sec,4,
IC75,nM,4,
UD50,umol/Kg,4,
Receptor state,,4,
C5a affinity,%,4,
IC50,10^-1microM,4,
Kd,10'-5/s,4,
IC50,10^-6 mol/L,4,
Ratio,nmol/g/uM,4,
Kd,10^5/M/s,4,
Ratio IC50,10^3No_unit,4,
DA/NE ratio,,4,
Cp,nmol/g,4,
Antiviral selectivity,,4,
Rats turning,%,4,
Activity,Karmen,4,
Cp,ng.hr/ml,4,
LH,ng ml-1,4,
Ratio,1/M 1/s,4,
Papp,10'-3cm/min,4,
Drug metabolism,nmol/hr,4,
C70,uM,4,
Tremorolytic dose,,4,
Activity,10'-7 ug/ml,4,
PVCs,number min-1,4,
Activity,1/s,4,
LDH release,,4,
Antiviral activity,,4,
Transport,%,4,
Ulcer Index,,4,
AUC,uM h/(mg/kg),4,
Activity,10'-5AU/sec,4,
Ratio,10^-3/min/uM,4,
Ratio (Ci/Ce),,4,
Ke,10'8/M,4,
Papp,nM s-1,4,
Kcat/Km,10'4/Ms,4,
AUC,ug .h/g,4,
Total infarct volume,mm,4,
LD50,mmol/L,4,
Reduction in prostate weight,%,4,
Reflex,,4,
IMPDH activity,(nM of XMP formed) hr-1 (mg of protein)-1,4,
Activity,AU.min/L,4,
Relative,g %,4,
Relative Bioavailability,%,4,
Cytochrome loss,%,4,
ILS days,%,4,
C10,air/N2,4,
LC99,mgAi/L,4,
Kcat,10'-4/min,4,
BG,mM,4,
Increase in HR,,4,
Kcat,1/s,4,
LC95,ppm,4,
Kbapp,10'-8M,4,
Test,,4,
Permeability,10e4*cm min-1,4,
Permeability,AB cm/s,4,
C12h,ng g-1,4,
Total protein,mg 100g-1 24hr-1,4,
Increase in life-span,,4,
Kq,/kM/s,4,
Ke,10'4/M,4,
LD16,mg kg-1,4,
AUC,ug/g.hr,4,
Tm(app),degrees C,4,
Paraparetic mice,%,4,
INH,ugequiv,4,
Activity,10e-6*s cm-1,4,
Cleavage rate,nM U-1 hr-1,4,
LD50,10'-4M/ml,4,
Cell Survival,%,4,
Tm,hr,4,
LD50,10'-7M,4,
Papp,cm'-6/s,4,
Activity,10'-8mol/kg,4,
Papp,10^-6/cm,4,
Activity,10'-7mol/L,4,
Total urine activity,%,4,
Reduction in EOS count,,4,
Total uptake,,4,
Total tritium,%,4,
Total release,%,4,
Total rate,g-1 min-1 ml-1,4,
Total rate,1/min,4,
ILS (mg/kg),%,4,
DC50,mM,4,
Brain uptake,%,4,
Drug uptake,IU/ml,4,
Thylpositive cells/spleen,%,4,
Time constant T2,,4,
Kcat,mM,4,
Time constant T1,,4,
Drug uptake,mBq,4,
Duration of seizure,min,4,
IUP,,4,
Relative TS,%,4,
IVR,beats min-1,4,
Atrial MAPD90,ms,4,
Thymidine reversal,,4,
Peak effect time,min,4,
Thylpositive cells,%,4,
Kcat,uM,4,
Peak striatal uptake,,4,
Peff,%,4,
Activity,%/hr,4,
Relative activity of AChE,,4,
Thermogenesis,%,4,
Thermogenesis,,4,
Augmentation,%,4,
BG reduction,%,4,
IR,,4,
LD90,ug,4,
IH50,uM,4,
DBP change,%,4,
Activity,10^9(p/s)(uW/cm^2),4,
Kb,10^5L/mol,4,
LC50,10'-3ppm,4,
Drug metabolism,ug/ml.hr,4,
Duration,day,4,
Tail flick,%,4,
Permeability rate,nm s-1,4,
Relative efficiency,,4,
TRIG_CHANGE,,4,
AUC glu,mM min,4,
Average body weight,g,4,
Drug mobility,,4,
Infertility activity,,4,
Inhibition,M,4,
Active,,4,
Time of half inactivation,min,4,
Rate change,%,4,
LC50,10'-1ppm,4,
TMED,mg kg-1,4,
Percent remaining,%,4,
Penetration,,4,
Kcat/Km,/nM/s,4,
C,ng/mL,4,
Passivity,,4,
Activity,(nM of vector) (ug of DNA)-1,4,
Activity,(nM of CO2) hr-1 mg-1,4,
Rate of oxidation,nM min-1 ml-1,4,
Antihypertensive activity,mmHg hr-1,4,
Activity,AU/L,4,
LV dP/dtmax,%,4,
Plasma half-life,hr,4,
AUMClast,hr.hr.ng/ml,4,
Ka,1/M,4,
RT50,,4,
KA,mM,4,
KA,mM-1,4,
DL50,mg kg-1,4,
Ka,10^5L/mol,4,
Ka,10^6/M.s,4,
Ka,L/hr,4,
Internalisation,%,4,
Ksolv,hr-1,4,
Average latency,,4,
Binding,nM,4,
Ks app,uM,4,
Average lung weight,mg,4,
Intraperitonal score,,4,
Plasma insulin,uUnits ml-1,4,
Plasma integral,uCi min ml-1,4,
Creatinine_CL,mL/min,4,
Ks,10^5/M,4,
Ks,10^4/M,4,
Plasma levels,nM,4,
T3/4,,4,
Irreversibility,%,4,
RC10,,4,
Challenge dose,cells mouse-1,4,
T2,,4,
Activity,10'6uL,4,
AUPAP,%,4,
AUMCt,hr2.ng/ml,4,
SDS,mg/kg,4,
Response value,uM kg-1,4,
Retention_time,hr,4,
K0.5,,4,
Activity,10'7/M/s,4,
Activity,10'3kdyun/cm3,4,
Drug transport,ug/g,4,
Saluretic activity,,4,
AUMC,%,4,
K1,mM,4,
SHR,,4,
Axonal regeneration rate,,4,
AUMC,hr.hr.ug/ml,4,
ST elevation,delta mV,4,
Kin,uL/sec/g,4,
Retches,,4,
SPAV3,nM,4,
KA,10'5/M,4,
AUMC,ug.hr/g,4,
Activity,10'6CFU/ml,4,
Kimut/Kiwt,,4,
Challenge time,,4,
Ks,10'6/M,4,
Plasma magnesium_CHANGE_BY,%,4,
Ki(app),mole fraction,4,
Body temperature,degrees C,4,
Relative initial slope,,4,
Plasma cholesterol,mM,4,
Basal binding,%,4,
Initial concentration,%,4,
TCI,%,4,
Drug uptake,microg/g,4,
AUC/dose,min.ug/ml,4,
AUC/dose,mmol.L/hr,4,
DTH,,4,
TC50,mg/m3,4,
L/CE,,4,
Plasma concentration,pg ml-1,4,
Inhibitory binding,%,4,
TC50,10^3uM,4,
Drugexcretion,uM,4,
Plasma glucose,mM,4,
T-cell,nM,4,
DC50,nmol/L,4,
AUClast,ng.hr,4,
Stability,um,4,
Drug uptake(free),nmol/g,4,
Kq,10'-12/M/s,4,
Drug uptake,ml/min,4,
UD50,%,4,
AUC/dose,mg.hr/ml,4,
AUC/dose,hr.kg.L,4,
Cytotoxicity IC50,uM,4,
Intima area,10e3 um2,4,
Plasma triglyceride,mM,4,
T1,,4,
K,/M/hr,4,
T/C min,,4,
Critical concentration,ug ml-1,4,
Relative phosphorylation rate,,4,
T/C (d),%,4,
AUC/dose,nmol.hr,4,
T.P.L,ng ml-1,4,
Ks,/hr,4,
Average max,%,4,
Insulin release,ng/islet/1h,4,
KOH,M-1 s-1,4,
Kr/kmax,M-min,4,
Insulin release,%,4,
TGI50,,4,
Drug uptake,mgequiv/ml,4,
Cp(f)max,nM,4,
Basal GH,ng ml-1,4,
Relative initial rate,,4,
Drug uptake,10'-8mol,4,
TEWL,,4,
Rate,nM min-1 (unit XOD)-1,4,
Inhibition period,hr,4,
Activity,10'5/M/s,4,
Prodrug remains,,4,
Ki/K'i,,4,
Selectivity index,%,4,
Cmax,ng/ml/mg,4,
Punishment test msad,mg kg-1,4,
AUCt/dose,hr.Kg/L,4,
AUCt/dose,hr.kg.ng/ml/mg,4,
Kinact,10^3nM,4,
Brain content,nM g-1,4,
Drug transport,nmol/hr.cm2,4,
Activity,10'7CFU,4,
K inact/Ki,mM-1 min-1,4,
Drug uptake,%Idose,4,
AUCt/dose,ng.hr/g/mg/kg,4,
AUCt/dose,ng.hr/ml/mg/kg,4,
K inact,hr-1,4,
Drug uptake,pmol/mm3,4,
K'i,uM,4,
Ka,10'3L/M,4,
AUCt/dose,uM.hr,4,
Kinact,10'3/M/s,4,
Drug uptake,pmol/ml,4,
Ka,10'6/M/min,4,
Absorption,u equiv min-1,4,
Serum creatinine,,4,
Serum creatinine conc,mg dl-1,4,
Km app,,4,
Ki,10e3* M-1 s-1,4,
Kinact,min,4,
Specific activity,pM hr-1 (mg of protein)-1,4,
LT99.9,hr,4,
UC50,uM,4,
Rotorod index,ROI,4,
Kd,10'6/M,4,
IC95,,4,
LV,dP/dtmax,4,
Ratio of stimulation,,4,
ICmax,%,4,
PP2A Selectivity,,4,
Ratio,10'-3umol/min,4,
Tumor size,mg,4,
ID/g,,4,
ID100,ug/kg,4,
DNA damage,,4,
Kd,10'3/s,4,
Cz,ug/L,4,
Inhibition rate,,4,
LC30,,4,
AUCt/dose,mg.hr/ml,4,
Ka,10'6/M.s,4,
K diss,uM,4,
K inact,1/min,4,
Responder,%,4,
Serum conc,uM,4,
Biological activity,,4,
AUCt,hr.ng/g,4,
Ratio of dose,,4,
AUCt,min.ng/L,4,
KB,s-1,4,
Binding,ug g-1,4,
KA effect,%,4,
KSV,10^5L/mol/s,4,
Activity,10'6/M/s,4,
RD50,uM,4,
Drug uptake,nmol.min,4,
Cmax,ng/hr,4,
Cyclase stimulation,%,4,
KSV,10'6/M,4,
KiH,fM,4,
KSV,10'5L/M,4,
Activity,10'4CFU/ml,4,
Binding potency,,4,
Ring immobility,%,4,
Binding activity,fM mg-1,4,
Ki',nM,4,
KD hydro,mM,4,
SA,uM,4,
KDs,,4,
Ki'',nM,4,
S/Cereb Ratio,,4,
Rmax,uM,4,
Binding affinity,1/M,4,
K,L/mol,4,
Drug uptake,ngequiv/ml,4,
S/CX Ratio,,4,
AUCt/dose,uM.hr.Kg/mg,4,
Drug uptake,ng.hr/ml,4,
K,l mol-1,4,
AUCt,ug.hr/g,4,
Solubility,mg kg-1,4,
Activity,mmHg/L.min,4,
Activity,10'9/s/cm2,4,
Kkmax,/hr,4,
AUCt,nmol/g.hr,4,
Skin thickness,,4,
K app x10e6,M-1,4,
Remains,,4,
Sign free dose,mg kg-1,4,
KSV,/uM,4,
Ka,10^3(1/Ms),4,
Renal clearance,ml min-1 kg-1,4,
K cat,1/min,4,
Residue fraction,%,4,
DNA fraction,,4,
K bind,M,4,
Ki,10^4/M,4,
Bleeding time,s,4,
Severity mean,,4,
AUCt,pmol.hr/g,4,
Renal clearance,ml min-1,4,
Serum prolactin level,mg ml-1,4,
LED,ng/ml,3,
MEC1.5,nM,3,
LOAEL,mg kg-1,3,
Ki,TS,3,
PSA,%,3,
MTD,g/Kg,3,
Activity,10'3cm,3,
Difference in retention time,min,3,
Activity,microm2/micrometer/d,3,
LPS,min,3,
DDT msad,mg kg-1,3,
LRR,min,3,
Activity,nM min-1 unit-1,3,
Activity,10'5CFU,3,
BAT,g,3,
Activity,umol/min/ml,3,
Paw weight,mg,3,
Activity,ng.hr/ml,3,
Activity,um3/um2/yr,3,
Paw edema,%,3,
NOAEL,nM,3,
RBA data,,3,
LD20,uM,3,
Clp,kg-1 hr-1,3,
NaCl concentration,M,3,
LDL,%,3,
Ki app (inact),nM,3,
Cp(f)ss,uM,3,
TD50,microM/Kg,3,
Paralysis,min,3,
AUC/dose,microg.min/mL,3,
Cp/dose,nM/mg/kg,3,
TCS50,,3,
GD200 [d],%,3,
TC90,ug ml-1,3,
GAG,%,3,
Injected dose,,3,
Ratio,10^7/M/s,3,
K,mol/L/min,3,
Mobilization,%,3,
Activity EC50,uM,3,
Activity (nmol/mg.of protein. min),%,3,
Papp,10-6 cm s-1,3,
Na+ excretion,mg kg-1,3,
RNA fraction,,3,
MED,ng,3,
RPE,,3,
MST,months,3,
Palmitoyl-CoA oxid,uM min-1mg-1,3,
Negation,,3,
Papp,10^-5 cm/min,3,
Activity,kN/m2,3,
B incorporation,ug,3,
MTD/8,mg kg-1,3,
PD100,mg/kg/day,3,
PD'2,,3,
Cl,,3,
Ki,10'-16M,3,
Drug uptake,10'-7M,3,
MEC,10'-5M,3,
Delta t,,3,
Kf,s-1,3,
Keq,M-1,3,
Kel,min-1,3,
PAR,mg kg-1,3,
PAO activity,pM min-1,3,
No. of dead mice,mg kg-1,3,
P7.4,,3,
Kel,1/min,3,
Drug metabolism,mg.equiv,3,
MTX equivalent,,3,
No. of depolarizations,,3,
Activity in animals,mg kg-1,3,
Drug metabolism,ml/min/mg,3,
PPB,uM,3,
Bone mineral density,mg/cm3,3,
Drug uptake,%Idose/L,3,
Maximum inhibition,%,3,
Level,mg ml-1,3,
Dose,mg uM (kg of body weight)-1,3,
MTD/4,mg kg-1,3,
DLBT,mg kg-1,3,
RC50,10'-1mg/ml,3,
B/P ratio,,3,
Activity,EU/mg,3,
Mean index,,3,
RD1000,,3,
Mean increase in survival,day,3,
KiH,pM,3,
Mean free plasma concentration,nM,3,
KiH,,3,
Papp,nmol/sec,3,
Dioxygen uptake rate,uM min-1,3,
MED10,,3,
Cleavage,,3,
Apoptotic cell,%,3,
Activity,Counts/minute,3,
LS,min,3,
RW,min,3,
Activity,10'-9M,3,
Delta plasma cholesterol,%,3,
MTD/2,mg kg-1,3,
Ki,10'4/M/s,3,
Drug uptake,10'-2microM,3,
GFR,ml min-1,3,
TGIR,,3,
Bone mineral density,mg/cubic cm,3,
Inhibition,nmol,3,
AE,,3,
Blood lactate,mM,3,
K,10^5L/mol,3,
Spleen weight,,3,
EC50,10'7pM,3,
Fold_increase,,3,
Cmax_PTH,pM,3,
Food intake,g day-1,3,
Brain level,uM,3,
Brain levels,,3,
TSH/chol,,3,
GSH,,3,
TRAP staining,,3,
AUC glu reduction,%,3,
TPR,mmHg ml-1 min-1 kg-1,3,
TPR,%,3,
Inflection point,nm/s,3,
Infusion rate,ug min-1 kg-1,3,
T/C x100,mg kg-1,3,
GR50,KgAi/ha,3,
GR activity,mU mg-1,3,
TMED50,,3,
GIC50,uM,3,
Blood lactate,mg dl-1,3,
AUCt,g/hr,3,
Conduction,mm/m/s,3,
Specific activity,uM min-1 (ug of protein)-1,3,
PPB,nM,3,
Consumption,g day-1,3,
K Tm,M-1,3,
K amine,M-1 s-1,3,
Skin Graft Survival,,3,
k0,min-1,3,
K ass,10E3*1/M*1/s,3,
k2,d se-1,3,
CLH,uL/min/pmol,3,
EC50,10^3 uM,3,
AUCt,hr.nmol/g,3,
k cat,M-1 s-1,3,
Specific incorporation,c.p.m. (mg of melanin)-1,3,
K,10^8No_unit,3,
K,10^-8/s,3,
Stability,mol%,3,
Stability,mmol/min/mg,3,
K,10^3/min,3,
Stability,mg/g,3,
Stability,degrees C,3,
K,10^4/M.s,3,
FPGS activity,nM hr-1 mg-1,3,
Cp(f)/dose,ng/ml,3,
Inhibition,units ml-1,3,
Druguptake(free)/dose,ng/ml,3,
AUC first treatment,,3,
delta pKa,,3,
Fu,nmol/g,3,
Carnitine acetyl transferase,mg of protein,3,
deltaH,10^4cal/mol,3,
deltaH1,cal/mol,3,
EC300,uM,3,
T>MIC,min,3,
Ion enhancement,,3,
Iron clearence,,3,
Fraction cleared renally,%,3,
T4,ng ml-1,3,
deltalog10CCID50,,3,
T1/2 regen,s,3,
T1/2,min-1,3,
AUC/dose,ng/(hr.mL.mg.kg),3,
Inotropic potency,,3,
dPT,nM,3,
Cp(f)max,ng/ml,3,
dP/dt20,,3,
GI90,,3,
APTT,min,3,
TED,microg/cm2/h,3,
TDS ratio,,3,
Cpss,ug ml-1,3,
TC50,10'3nM,3,
Cpss,nM,3,
Duration of anesthesia,min,3,
TTO,,3,
TWI,,3,
GSH reactivity,,3,
Imax,nM,3,
Duration of increase in SLA,min,3,
AUC,uh ml-1,3,
Weight difference,%,3,
Glucose level,ml d-1,3,
Improved,,3,
Therapeutic indices,TI,3,
Glucose level,m equiv l-1,3,
AUC total,,3,
Glucose level,g dl-1,3,
Glucose level,g day-1,3,
Weight reduction,%,3,
CL,ml/kg,3,
Brain uptake,nM g-1,3,
Zinc finger reactivity,RFU min-1,3,
GST activity,mU mg-1,3,
AUC Npo,uM x h/dose,3,
Druguptake/dose,nM,3,
AUC second treatment,,3,
Activity,10'3/min,3,
MFC50,mg/L,3,
Net log change in tumor burden,,3,
Ratio,10^3/s/M,3,
Protected mice,,3,
Kis,uM/L,3,
NAD+ content,,3,
Activity,10'8CFU/g,3,
MLC,ppm,3,
NAD+ content,%,3,
Kinetic_solubility,uL,3,
NADH content,,3,
Protection ratio,,3,
MUD,,3,
Activity (umol/mg.of protein. min),%,3,
Drug metabolism,10^-3L/mol/min,3,
Affinity state 1,%,3,
Kdiss,10'-6M,3,
Degrees Centigrade,degrees C,3,
MBC<=99.9,mM,3,
Activity,bpm.hr,3,
Analgesia,,3,
Lysozyme release,%,3,
Activity,cmH2O,3,
Ratio,10^1/M/s,3,
Max jumping rate,%,3,
Kdiss,10^-4/s,3,
NAD content,M (M of enzyme)-1,3,
NAD,%,3,
Kiso,,3,
Activity,uM/min/uL,3,
Kinact,10'5nM,3,
QTc Interval,ms s-1,3,
LD,ug/kg,3,
Activity,nmol of acetaldehyde(AcH) oxide per minute per mg of protein,3,
Qmax,%,3,
Activity,10'7/g,3,
Protective ratio,,3,
Average IOP,mmHg,3,
Mechanistic reference,,3,
Dosage,ug,3,
Km,10^3/M,3,
Perturbations,%,3,
Average food intake,g mouse-1 day-1,3,
Activity,pD2,3,
Activity,mg.min/L,3,
Prolactin release rate,ng mg-1 hr-1,3,
LC5,ng/ml,3,
Phospholipidosis_MEC,uM,3,
MGDH GI50,,3,
Prolonged VRP,,3,
Kkin,M-1,3,
Prostaglandin E2 level,%,3,
Activity,10'-7No_unit,3,
Affected animals,%,3,
Day of vaginal opening,,3,
Derived trabecular number,mM-1,3,
Log A,s-1,3,
Drug degradation,hr,3,
Loss,,3,
Margin before onset of hypokalemia,,3,
Activity,ml/hr,3,
Log Poct C,,3,
No. of protected animals/total,,3,
Ratio,10'5/s/M,3,
Margin before onset of tachycardia,,3,
Ke,10^-6M,3,
Max response,delta mmHg,3,
Alpha c,,3,
MAC,uM/L,3,
Oligo shifted,,3,
Activity,dB,3,
MBC50,,3,
Onset of block,,3,
Ouabain dose,ug kg-1,3,
P/D,,3,
Activity,a.u.L/mol.cm,3,
Ke,L/hr,3,
Locomotion,cm,3,
Kdiss,10^4/M/s,3,
Nucleic acids,mg mg-1,3,
Max aggregation,,3,
Animals protected,,3,
Oxygen consumption rate,,3,
Affinity state 2,%,3,
Decreased_triglyceride,,3,
MAD,,3,
Overt behavoiur,,3,
Activity,cps/nM,3,
Oxidation rate,nM min-1,3,
Activity,nM (nM of NOS),3,
Decrease in exit latency,%,3,
Occlusions,ug min-1 kg-1,3,
Lowering activity,%,3,
Log 1/EC50,,3,
Drug degradation,%molar,3,
No. of occlusions,,3,
Max displacement,%,3,
Oxidation rate,uM min-1,3,
Aggregate,%,3,
Amount of unreacted substrate,,3,
Max T/C,mg kg-1,3,
BMD,mg cm**-2,3,
Activity,10'-6microL,3,
Activity,ms/s1/2,3,
Max effect,s,3,
LD,,3,
Day of death,,3,
MEC,nmol,3,
Production,pM (mg of protein)-1,3,
Activity,uM J-1,3,
Kq,10'-5L/mol,3,
Kq,10'-4L/mol,3,
Plasma half life,hr,3,
Activity,10^-10M,3,
Average sample intake,mg kg-1 day-1,3,
Delta TG,%,3,
Plasma clearance,ml min-1,3,
Mortality threshold,mg kg-1,3,
Distribution,l,3,
Pregnancy index,,3,
Plasma TG,mg dl-1,3,
MIC,10'-1nmol,3,
DR2,ug min-1 kg-1,3,
Motor activity,Counts hr-1,3,
Activity,pKi,3,
Plasma Insulin,pM l-1,3,
Motor activity,accumulated counts 30min-1,3,
Presumed drug-related deaths,,3,
Kobs,/M/s,3,
Activity,mM kg-1,3,
MIC,(ug of base) ml-1,3,
Ko,/M,3,
Plasma TC,mg dl-1,3,
Activity,ng/min,3,
Activity,um/s,3,
PL,,3,
LT99.9,min,3,
LUI,%,3,
Activity,10'3/M,3,
Radioactivity,nCi g-1,3,
Activity,Kg/hr.m2,3,
MTD,mmol/Kg,3,
Activity,kg/ha,3,
Neutrophils,%,3,
Mean AUC,,3,
Activity,10'10CFU,3,
Choline uptake,pM (4 min)-1 (mg of protein)-1,3,
LD100,microg/cm2,3,
Lactone,,3,
Activity,10'2log10CFU/ml,3,
Clearance,mg kg-1 uM-1 hr-1,3,
No. cured,,3,
Learning time,s,3,
Activity,Mequiv,3,
PEI,,3,
Lesion coverage,,3,
Lesion coverage,%,3,
MEC,10'-6M,3,
MI50,nM,3,
Cholesterol,mg dl-1,3,
Kinact,10^-2/s,3,
Activity,10^-4No_unit,3,
Kq,10'11L/mol,3,
Activity,uL/g/min,3,
Activity,mN/meter,3,
DR2,,3,
Km,pmol/uL,3,
Activity,pIC50,3,
LC20,,3,
Mean total plasma concentration,nM,3,
NADH oxidn,uM min-1,3,
Protein,mg ml-1,3,
Permeability,cm (10e3*hr)-1,3,
Activity,ug kg-1,3,
Kinact/Ki,mM-1 min-1,3,
Activity,mEq/dL,3,
Activity,10'7CFU/ml,3,
Kinact,10^4/M/min,3,
Periosteal mineral apposition rate,%,3,
Mean ulcer index,mM,3,
Activity,nmol/mg LDL,3,
Change in myocardial conduction,,3,
QH,ml/min.Kg,3,
LC25,ng/ml,3,
Peff,10'-8cm/s,3,
Plasma_[5-FU],nmol/mL,3,
MIC,ug/sq.cm,3,
Kq,10'13L/mol,3,
MIC50,%v/v,3,
Potency,mg,3,
Dose,mM kg-1,3,
Kq,10^11/M/s,3,
Activity,10^3CFU/mg,3,
DOPAC concentration,nM g-1,3,
DOPAC,,3,
Activity,10^3CFU/ml,3,
Activity,pmol/min.ug,3,
Pleural volume,ml,3,
Ct,umol/L,3,
DOPA level,ug g-1,3,
Post anitbiotic effect,hr,3,
Kq,10^12L/mol.s,3,
Delta TG,,3,
Activity,pmol adducts/mg DNA,3,
Kreact,,3,
Min plague Inhibitory,%,3,
Ks,10^3/M,3,
Activity,pgequiv/ml,3,
Kreact,min-1,3,
Kq,10'6/M,3,
Mineralizing apposition rate,mm day-1,3,
K Tm,,3,
Ka,10'9/M/s,3,
Smax,uM min-1 g-1,3,
SI,ml beat-1 kg-1,3,
EC70,nM,3,
Active dose,,3,
pKic,,3,
Ka,/min/nM,3,
ED50,ug hr-1 kg-1,3,
2PT,mM,3,
Conc_brain,uM,3,
CMC,10'-4M,3,
mean % of control,%,3,
([I]/[S]0.5),,3,
max activation,ug ml-1,3,
2*APTT,,3,
Activity,/M,3,
permeability,10'-5cm/hr,3,
EC50,nmol/Kg,3,
CO,%,3,
permeability,10^6m/s,3,
Drug uptake,pg/ml,3,
Kapp,10^4/M,3,
Eff,%,3,
permeability,min,3,
CLd/F,L/hr,3,
SHR delta blood pressure,dec,3,
Rotational behavior,turns hr-1,3,
KSV,10'-4/M,3,
Kbapp,10'-9M,3,
Cytotoxic effect,%,3,
ED30,nmol/kg/day,3,
EC60,nM,3,
ED15,nmol/kg/day,3,
ED85,,3,
ED15,nM day-1 kg-1,3,
KD,,3,
CMC,10'-2 mol/L,3,
Cyotoxicity,,3,
Ka,10'3L/mol,3,
ED200,ug,3,
log(1/IC50),,3,
AURC,hr,3,
Kc,nM,3,
Ability,%,3,
Abolition,,3,
Cmax_unbound,mg/L,3,
nKa,M/M,3,
Reversing activity,,3,
D,10'-6cm2/s,3,
p24 synthesis,ng ml-1,3,
Cmax,microg.hr/mL,3,
n,,3,
Kd,/M/s,3,
ED10,uM kg-1,3,
Activity,(mM of AZT) (mg k-carrageenan)-1,3,
Kact,/min,3,
pKa app,,3,
ED50,nmol/kg/day,3,
A,,3,
SD50,mg/kg/day,3,
Kcat/Km,10'1/s/M,3,
ED100,uM,3,
CLp,L.h-1,3,
EC80,ng/ml,3,
Reduction in AUC,%,3,
Reduced_parasitemia,,3,
Kcat/Km,10^3/M/s,3,
Eosinophils,%,3,
Relative substrate velocity,,3,
K,10'3/M.s,3,
K diss,10E-2*1/s,3,
Toxicity (deaths),%,3,
Transfection activity,RLU (mg of protein)-1,3,
AUC,uM h/dose,3,
ID50,pg,3,
Traction test,score,3,
Trabecular thickness,,3,
HVA,,3,
Trabecular no.,,3,
pKa value,,3,
88Y-serum,,3,
Drug uptake,g,3,
KA,10'3/M,3,
permeability,nanometer/sec,3,
Cmin ss,nmol/L,3,
Reaction rate,nM hr-1,3,
ED1/3,,3,
Residual activity,nM,3,
KA,10'4/M,3,
Ka,10^-6/M/s,3,
permeability,ug,3,
CPCC,,3,
AUMC,ng/mL.hr'2,3,
EC50,p.p.m.,3,
KB,10'4/M,3,
EC50,pH,3,
Kcat/Km,10^6/s/M,3,
Activation Factor,,3,
Binding,dpm,3,
Kcat/Km,/s,3,
CLtot,ml hr-1,3,
log10cfu/day,,3,
ED50,pmg kg-1,3,
EF200,,3,
Basal activity,%,3,
ED80,nM,3,
Drug uptake,mg Kg-1,3,
HSF activity x10e2,ml,3,
Ratio,hr,3,
Ratio plasma concentration/IC50,,3,
ED5,,3,
Kd,10'7/M,3,
Drug uptake,SUV.min,3,
Drug uptake,min,3,
pD10,,3,
Activity,10'-4/s,3,
Kd,10'5/s,3,
Drug uptake,pmol/OD,3,
Emax,mg/dl,3,
Bacterial growth,,3,
Emax,mg/kg/day,3,
ED5,mg Kg-1,3,
ED50,L/ha,3,
ED50,10'-15 ug/ml,3,
solubility,min,3,
EC99,nM,3,
ka,,3,
EC50,mM kg-1,3,
% Inhibition,"%,%",3,
ED50,10'-6umol/ml,3,
t1/2ss,hr,3,
Serum TSH,ug 100ml-1,3,
kr,min1 M1,3,
K1,pM,3,
AUIC,%.hr,3,
ED35,uM kg-1,3,
AUCt,ng.hr2/ml,3,
ACT,s,3,
EC90,(mg/kg)/day,3,
Efflux,%,3,
AUEC,%.hr,3,
pkb,,3,
Ratio_liver/blood,ng/ml,3,
K5,,3,
Ratio IC50/EC50,10'4No_unit,3,
AUMC,microg.min/mL,3,
koff,*10e6/s,3,
Cellular concentration,nmol,3,
proof of principle,,3,
K-1,hr-1,3,
Activity,10'-2nmol,3,
ED37,,3,
Binding constant,1E4/M,3,
rate constant app,M-1 s-1,3,
kred,M-1 s-1,3,
Elevation of threshold,%,3,
Behavioral observation,,3,
EC50,mg kg-1 day-1,3,
Ratio,mM-1s-1,3,
Emin,nM,3,
2x TG,,3,
Ratio,g/cm,3,
Acetylcholine release,%,3,
ki/Ki,,3,
Selectivity index,ug ml-1,3,
Ratio CC50/EC50,10'4No_unit,3,
Ka,M/M,3,
Kd,10^5/M,3,
Competition,,3,
kel,hr-1,3,
K6,,3,
Ka,10E3*1/M,3,
Ratio_tumour/plasma,,3,
Kcat,nmol/min,3,
ED60,uM,3,
Activity,%/min,3,
CMC,10'-4 mol/L,3,
KI50,M l-1,3,
Kcat,10^-2/s,3,
Binding,pCi mg-1,3,
KHOX,M-1 min-1,3,
Cmax_unbound,ug ml-1,3,
pA2,uM,3,
ED80,mg/ml,3,
S/N,,3,
% Inhibition of Control Specific Binding,%,3,
AC_50,uM,3,
pIC50(mM),,3,
Activity,10'-5M,3,
Caco-2 A-B,cm s-1,3,
k_2,s-1,3,
Kd,uL/OD/min,3,
Empty,%,3,
Activity,10'-6 ug/ml,3,
kR,min,3,
Kd Error,uM,3,
kONOO-,M-1 s-1,3,
Kact,,3,
K inact,uM,3,
Cell plating efficiency,%,3,
sigmaSH,%,3,
Cmax,ng/mg prot.,3,
Ratio IC50,10'3No_unit,3,
Activity,10'-4nmol,3,
CR2,block/treat,3,
Drug uptake,nM/g,3,
Ratio EC50,nM,3,
CL_Ratio,,3,
Emax,s,3,
ECmax,pM,3,
Relativity,%,3,
Vmax / Km,FU min-1 uM-1,3,
Cumulative urine volume,,3,
HDL,%,3,
AUC,g/hr,3,
CI,l kg-1,3,
E2:E1,,3,
CAC,,3,
AUC,nmol/hr,3,
Homovanillic acid concentration,nM g-1,3,
Vmax,10'-4umol/min/U,3,
IC50L,nM,3,
AUC,ng/g,3,
Vmax,10'-5deltaA/s,3,
IC50,nmol/Kg,3,
I.D./g tissue,%,3,
Vmax,FU uM-1,3,
Cp,g,3,
CC50,U/mg,3,
CC50,10^4 uM,3,
Vmax,RFU/s,3,
Conversion,,3,
AUC,nmol/100.000â¯cells x h,3,
Unbound plasma,%,3,
Cp,g/ml,3,
Vmax,deltaA/s,3,
Hours above EC90,,3,
AUC,nmol/g,3,
AUC,uA.cm'-2,3,
ICL5,uM,3,
Control survivals/total,,3,
IC50,ml,3,
IC30,10'-7M,3,
Vdss,mg/ng/ml,3,
Vdss,ml/hr.kg,3,
Vasopressor responses,,3,
IC10,,3,
Coronary flow,%,3,
AUC,ng,3,
Varea,,3,
CC50/IC50,,3,
Vmax,10'-3OD/min,3,
Histamine release,%,3,
Tumor weight reduction,%,3,
AUC,microM/mg/kg,3,
Hind-paw lick latency time,,3,
Vmax,min uM-1,3,
Vmax,min-1,3,
AUC,pmol,3,
AUC,microM.hr.kg/umol,3,
Vmax,nM/mgM,3,
IC80,ng/ml,3,
Tumour_[5-FU],nmol/g,3,
AUC,mg/dl.hr,3,
Ulceration,mg kg-1,3,
Thrombin time,s,3,
IC2x,,3,
K cat/Kinact,,3,
Bmax,nmol,3,
Css,mcg/mL,3,
K,10'-5M,3,
AUC/dose,uM.hr/mg.kg,3,
Susceptibilty Ratio (Liver/Intestine),,3,
CL/F,(mg/kg)/(ug/ml).hr,3,
Css,nM,3,
Survivals / total,,3,
AUCED90,,3,
CL/F,L/Kg,3,
Survival time,hr,3,
AUCED90,microg.hr/mL,3,
AUCED90,uM.hr,3,
ft1/2,hr,3,
EC50,10'-4 ug/cm2,3,
Threshold value,mg kg-1,3,
K SH,,3,
Concentration_plasma,microM,3,
Specific activity,nM Pi min-1 (mg of protein)-1,3,
AUCt,nM/ml.min,3,
Solubility,mg,3,
FC,10'6No_unit,3,
ID90,ug ml-1,3,
T max,uM,3,
K,10'-13/s,3,
Fold stimulation,%,3,
EC50,10'-3mol%,3,
K,10'6/s,3,
IC20,10'-8M,3,
Survival,10'5CFU/ml,3,
AUClast,nM.hr/L,3,
Superoxide anion,mM,3,
Succeeded/tested,,3,
Femur weight,%,3,
EC50,%molar,3,
EC50,(mg/kg)/day,3,
Stoichiometry,,3,
Stimulations,%,3,
CL(%Q),%,3,
Ct,nM/g,3,
K,10^-1/s,3,
Stability,uL/ml,3,
K,10^-3/M/min,3,
K,10^-3/M/s,3,
Consumption,ml d-1,3,
Survival extension,%,3,
fAUClast,nM.hr,3,
EC5,,3,
AUCED90,ug.hr/ml,3,
Vdss,mL,3,
Fana,,3,
Vdss,g/Kg,3,
Hematocrit,g,3,
Heart weight,,3,
HDL,ug mg-1,3,
HDL,,3,
Thromboxane B2 level,%,3,
Grip strength,g,3,
Vz,mg/ng/ml,3,
C1.6,,3,
Vz/F,,3,
C1,ml min-1 kg-1,3,
Time in light,%,3,
EC200,ng/ml,3,
C0/dose,umol/L,3,
C0,umol/L,3,
Walking behaviour,%,3,
Vmax/Km,nmol/min.uM,3,
Time constant,,3,
Graft survival,day,3,
CL,ml kg-1,3,
AUC,hr.fmol,3,
Thymus weight change,g,3,
Glutathione levels,umol/g tissue,3,
Glutathione,nM mg-1,3,
C ss,ng/mL,3,
Helicity,,3,
Vmax,pmol/mg.min,3,
CL,microL/ml/min,3,
C90,nM,3,
ID95,mg/ml,3,
EC10,M,3,
Toxic index,,3,
HR/chol,,3,
CL,10'-6uL/min,3,
CL,L/hr/m2,3,
CL,g/hr/kg,3,
Vmax/Km,U/min/nM,3,
Heart beat,beats min-1,3,
ID50,mg/kg/day,3,
ID50,mg kg-1 hr-1,3,
CL,% ID/g,3,
ID/thyroid,%,3,
Tumor growth,%,3,
ID25,mg kg-1 p.o.,3,
Tumor free survival,,3,
ID30,mg kg-1,3,
Tumor burden,,3,
Tumor,number,3,
CIT,ml min-1 kg-1,3,
Cp,ng,3,
Vmax,pmol/OD/min,3,
Vmax,pmol/h,3,
Vz,mg kg-1,3,
AUC,mg.hr/kg,3,
C10,mM,3,
VDR affinity,M,3,
IC50,10'5pM,3,
I90,g/ha,3,
IC50,10^-5 mol/L,3,
I80,uM,3,
Vm,,3,
Cp,microg/ml,3,
IC50,10^-6 uM,3,
Uterine weight effect,,3,
Uterine weight,mg cm-1,3,
Vm,uM,3,
I50,(ug of base) ml-1,3,
IC50,10^3 uM,3,
AUC,ng/10^6â¯cellsâ¯Ãâ¯hr,3,
Cortical infarct volume,%,3,
AUC,mmol/L,3,
IC5,ug ml-1,3,
Ventricular relative refractory period,ms,3,
Vd,ml/min.Kg,3,
Vd,ml/hr.kg,3,
CD90,uM,3,
Vss,L/hr,3,
AUC,nM.hr/ml,3,
IC12,uM,3,
Counts of rotation,turns hr-1,3,
IC50,mg Kg-1,3,
IC,,3,
Tmax,mg/L,3,
C120,uM,3,
Total no. of turns,,3,
IC50,10'-3g/L,3,
Vmax/Km,uL/OD/min,3,
Total liver weight,g,3,
CL,mL/mg/kg,3,
HC50,mM,3,
Total coenzyme,%,3,
Total cells,number ul-1,3,
Topical irritation score(0-21),,3,
Tmin,,3,
HC50,10'-4M,3,
Tmax,%,3,
Tumor incidence,%,3,
Vss,L.kg-1,3,
C100,,3,
INH,mg/L,3,
Uterotrophic effect,%,3,
CL,mg/ng/ml/hr,3,
Hepatic extraction,,3,
Tumor latency,day,3,
Activity,10'5/M,2,
AUMCt,ug/ml.hr^2,2,
Rotational behavior,,2,
Cmin,ng/dL,2,
Clp,mg min-1 kg-1,2,
Rotorod index,,2,
AUMCt,ug/L.hr,2,
Rs,uM min-1 g-1,2,
Drug uptake,%ID/cm3,2,
Central selectivity,,2,
ED50,10'-9mol/cm2,2,
Kiact,min-1,2,
Activity,10'5CFU/ml,2,
Activity,nM/ml,2,
KHOX,,2,
DI50,ppm,2,
ED50,gAe/L,2,
1-logKi,,2,
Rlung,% delta,2,
MRT(t),min,2,
Activity,microA,2,
Kic,10'-7M,2,
Activity,microM/g,2,
SD,,2,
SD200,uM kg-1,2,
KB,10'5/M,2,
Activity,nanometer,2,
SD80,mg kg-1,2,
AUMCt,mg/L.hr,2,
pEC50,%,2,
Drug uptake,pM,2,
"S20,w",,2,
CS50,mA,2,
Mean duration,hr,2,
CPmax,uM,2,
ED50,nM hr-1 kg-1,2,
Kidney VDR,fM (mg of protein)-1,2,
K0.5,10'-4M,2,
Mean day survival,day,2,
Cmax,ng/hr/ml,2,
AUMClast,hr2.ug/g,2,
SF50,,2,
AUMClast,hr.hr.ug/ml,2,
Kieq,pM,2,
MPO release,,2,
AUMC,ug/L.hr,2,
Activity,ng ml-1 hr-1,2,
CPM,%,2,
pChange,%,2,
AUMC,ug.hr/ml,2,
1/Ki,M-1,2,
Kin,10'-2/min,2,
CPD50,mg kg-1,2,
K5,hr-1,2,
Drug transport,ug/hr,2,
Kin,ml/min/g,2,
K0.5,mM,2,
K4,min-1,2,
K3,M-1 min-1,2,
RBA,M,2,
Kin,uM,2,
pBBB,microL/min/g,2,
AUMC,mg.hr/L,2,
K2,1/M,2,
ED50,ng/kg,2,
Kin x,hr-1,2,
AUMC,hr.hr.ng/g,2,
pBBB,%,2,
Activity,ng/cm2,2,
K1,1/M,2,
Kinact,/us,2,
Saldiuretic activity,pM equiv kg-1 6hr-1,2,
Activity,10'5PFU,2,
Complete survival dose,mg kg-1,2,
KD1,nM,2,
Ratio,microM/s,2,
pMIC,ug ml-1,2,
Activity,10'-5 ug/ml,2,
Ratio,10'4/s/M,2,
% bound fraction,%,2,
Max rev,,2,
ED delta20,,2,
Kdiss,10^-4M,2,
Cmax,%ID,2,
ED delta5,,2,
permeability,ug ml-1,2,
Max reversing rate,%,2,
Activity,10'-7/M/s,2,
Reaction time,,2,
ED1/3,M,2,
Reactivation,,2,
t1/2,uM,2,
Ratio,mg/g,2,
SBP,,2,
t1/2_ratio,,2,
x fold,100uM,2,
AUMC,ug.hr/L,2,
Ratio,CC/OC,2,
Colonic weight,mg cm-1,2,
tR,,2,
Ratio,10^4/s/M,2,
Kd,umol/dm3,2,
tCmax,min,2,
Ratio,U M-1 s-1,2,
Activity,mmHg s-1,2,
Max fall in MAP,,2,
Cmax,U,2,
Ratio,m M-1 min-1,2,
Ratio,mL/min.umol,2,
DA level,pg 5ul-1,2,
DBP,,2,
permeability,omegacm2,2,
permeability,nmol/cm2/hr,2,
Kd,/uM/s,2,
ED,nM,2,
Kd,10^-10mol/L,2,
rel k,,2,
reduction in CL_renal,%,2,
Max delta,,2,
Activity,10'-3/s,2,
Ratio ki,,2,
Ratio pIC50,hr,2,
K/10e4,M-1,2,
Rate,nM (mg of protein)-1,2,
Ki,10'-3/min,2,
Clp,M min-1 kg-1,2,
SA,%,2,
ED50,KgAi/ha,2,
KD2,nM,2,
relative signal,relative signal,2,
Max delta FC,,2,
Max delta MABP,,2,
Ratio,10'4/M/min,2,
Kdiss,10^-7M,2,
ED10,nmol/Kg,2,
Ratio,10'-4/min.mol%'-4,2,
solubility,10^-3mg/ml,2,
qKD,nM,2,
ED 50,mg kg-1 day-1,2,
solubility,10'-4mg/ml,2,
Max plasma level,uM,2,
Co,ug ml-1,2,
Activity,10'-4M,2,
Max mean weight loss,%,2,
Ratio IC50/EC50,10'6No_unit,2,
Max delta MAP,,2,
Ca2+ excretion,uM day-1,2,
SLI,,2,
Papp,10'-6m/s,2,
SNGFR,nl min-1,2,
Bile flow,ml hr-1,2,
MTD,mg kg-1 day-1,2,
Ki,10^8M,2,
RVCF,%,2,
Cmax,ug hr ml-1,2,
Max fold increase,,2,
Survivors,day,2,
AUC,uM kg-1,2,
LD80,mmol/Kg,2,
MED,nmol/Kg,2,
LD90,g/hm2,2,
ID50,umol/kg/h,2,
Vmax,10'-6mol/min/ug,2,
Vmax,10'-6mM/min,2,
C5 min,nM,2,
ID50,uM/ml,2,
Resorption,,2,
EC5x,,2,
CPA,,2,
Radioactive absorption,%,2,
Absorption,mg kg-1,2,
Difference,,2,
Ki,10^2 nM,2,
MTD,uM/ml,2,
Report,,2,
Mean KD,M,2,
Accumulation,mU ml-1,2,
Mean activity,,2,
Ka,10^-5M,2,
Ka,10^-4/s,2,
Cmax,ng.hr/g,2,
Accumulated counts/30,,2,
Ka,10'7/M.s,2,
Ac,,2,
Absorption,ul min-1,2,
LD90,mg kg-1,2,
Papp,10'-6cm,2,
MED,mg/kg/hr,2,
Cmax_PTH,pg/ml,2,
AUC,uM.h/L,2,
Activity,abs/uL,2,
LD50 x 1/40,,2,
MBC,mg kg-1,2,
Vmax,10'-7cpm/min,2,
MED,pmol/hr,2,
C24,ng mL-1,2,
MED,ug/Kg/min,2,
NcoR1_recruitment,,2,
Dose,ug/embryo,2,
Affinity constant,l M-1,2,
Tumor area,,2,
Vmax,/abs/min,2,
PS,,2,
Ratio,10^6/s/M,2,
LD50 x 1/20,,2,
Glucuronidation rate,,2,
MED,uM/g,2,
LD80,mM,2,
ID50,pKi,2,
C50g,mg/L,2,
log(1/C),ug ml-1,2,
ID90,M,2,
C6h,ng ml-1,2,
ID90,ng/ml,2,
ILS,hr,2,
Vmax,10^-5M/min,2,
ILS,day,2,
Delta BP,,2,
Dose,pM kg-1,2,
LD50 x 1/10,,2,
CL/F,g/hr/kg,2,
Toxic,mg kg-1,2,
Accumulation,nM/mg of dry wt,2,
Ka,10'4mol/L,2,
ED50,10'-3micromol/ml,2,
ED200,ug ml-1,2,
Activity,10'2CFU/ml,2,
Ka,10^4M,2,
pKa_decrease,,2,
pKa_B3,,2,
Remaining rate,,2,
Drug uptake,ng.hr/g,2,
Ka,10^3/min,2,
-Log K B,,2,
Acid output,m equiv [H+] l-1,2,
Radioactivity in urine,% of dose,2,
Cmax,ng,2,
Range,%,2,
Relative peroxidation,,2,
Activity,nM min-1,2,
Rate,M-1 s-1,2,
Radiolabel recovery,hr,2,
Drug uptake,nM/mg,2,
MTD,umol,2,
Ki slope,,2,
AUMC,ng/mL.hr^2,2,
EC50,ug.hr/ml,2,
SPB,%,2,
ED50,nM kg,2,
Ri,nM,2,
KSV,10'4M,2,
Mean,uM,2,
pKb,M,2,
ED25,10'-4M,2,
-Log EC50,,2,
Radiolabel recovery,ugequiv.hr/ml,2,
Ki,10'7nM,2,
Cmin ss,ng/mL,2,
Ki,10'8/M/min,2,
Activation,mU ml-1,2,
ED200,umol/Kg,2,
CSF levels,uM,2,
Kapp,10'4/M/s,2,
BC,,2,
Ka,10'1/M,2,
Ka,10'-5M,2,
Ka,10'-5/RU/s,2,
Ki,nM-1 min-1,2,
BBC,uM,2,
RTG,,2,
ED50,10'-11 ug/ml,2,
pInhibition,%,2,
ED50,10'-13 ug/ml,2,
Cytostatic concentration,ug ml-1,2,
KT4,,2,
KSV,10^6/M,2,
Mean day,,2,
MST,range,2,
Absoption,,2,
Cells arrested,,2,
Renal clearance,L.h-1,2,
MTD/16,mg kg-1,2,
Compound recovery,microg.hr/mL,2,
Cmax,nM g-1,2,
Kapp,10'-6M,2,
(kcat/KM)/kuncat,M-1,2,
Kapp,10'-4/M,2,
Relative stimulation index,%,2,
pKiL,,2,
Radioactivity in urine,%,2,
pKiH,,2,
Ka app,uM,2,
Drug uptake,nCi/cc,2,
Ka,micromol/min,2,
-Delta G obs,kCal mol-1,2,
Clp,ng hr ml-1,2,
Ratio,10^6No_unit,2,
K,10'2/M,2,
t1/2,ug ml-1,2,
Polymorphonuclear cells,,2,
CLb,ml/hr,2,
Cmax_ratio,(null),2,
EU,g-1,2,
Ea,,2,
A50,mg Kg-1,2,
AUClast,nM/min,2,
K,10'4/mol,2,
Ct,mmol/g,2,
Kq,10'7No_unit,2,
MIC98,ug ml-1,2,
Activity,10^10/M,2,
DOPA accumulation,%,2,
log(1/K),,2,
Drugabsorption,mg/hr,2,
Survival after 30 days,,2,
Activity,10^2pg/ml,2,
Css-4w,pg/mL,2,
log(activity),PFU/ml,2,
Css-48h,pg/mL,2,
EIC50,uM,2,
K,10'6/min,2,
Substrate activity,mM,2,
Pmax,,2,
ABC,mmHg.hr,2,
Survivial / total,,2,
Efficacy,No. of mice tumor free,2,
Poct,,2,
Effective molarity,,2,
Survival time,min,2,
Kq,10^14L/mol/s,2,
LOAEL,ng/ml,2,
Min ID,uM kg-1,2,
AUC_ratio,,2,
Css-12w,pg/mL,2,
AUClast,hr.ug/g,2,
AUCt,ug ml-1,2,
K,10^-5/nM/min,2,
log10EID50/g,,2,
Kinetic_solubility,ug/ml/min,2,
Kinetic_solubility(app),,2,
Media area,10e3 um2,2,
K app x10e6,,2,
Block of activity,%,2,
K,L/min.mmol,2,
AUCt,nmol/g.min,2,
ED75,mg/kg/day,2,
K ACT,M-1 s-1,2,
K 0.5,,2,
Blockade effect,,2,
Kkmax,10'-3 log10CFU/ml/hr,2,
ED75,uM,2,
Sleep time,,2,
CLr,l/hr,2,
Drug uptake,ug.hr/ml,2,
Km,10'-3mol/mol,2,
Activity,pA2,2,
Ct,ug/L,2,
Specific activity,uM min-1mg-1,2,
ED90,%,2,
AUCt,mg.hr/kg,2,
Cmax,pg/g,2,
Activity,pEC50,2,
Km,Me-3,2,
MIW,,2,
Blockage,%,2,
Km,10'-5M/min,2,
ED80,mg/kg/day,2,
Activity,10'9CFU,2,
K,mole fraction,2,
K,ms,2,
Sni,,2,
EIR,,2,
K,10'9/M,2,
Ratio,ml/min/nmol,2,
AUCt/dose,microg.hr/mL,2,
Activity,mg/hr/dl,2,
Kinact,10^3/s,2,
K second,M-1 s-1,2,
Drug uptake,uM/g,2,
K inact,nM,2,
K x10e-5,,2,
Cell permeation,,2,
AUCt/dose,uM.hr.kg/mg,2,
K inact,1/minute,2,
ED50,umol/ml,2,
Average uterine weight,,2,
Activity,mg/min/dl,2,
CMT,,2,
"K(p,uu,brain)",nM,2,
K inact,U s-1,2,
Mean time to death,day,2,
MMC,,2,
K,10'9/s,2,
Kinact,10^-5/s,2,
Protective dose,uM,2,
2aPTT,10'-4M,2,
Protective dose,mg kg-1,2,
Quench,%,2,
MLD,10^-8mol,2,
Average tumor weight,g,2,
Mean tumor delay,day,2,
pA2 app,,2,
Bioavailability Increase,%,2,
ED50,ug/L,2,
Mean tumor atency,day,2,
EC50,ug kg-1,2,
QH,ml/hr.kg,2,
p10 MIC,,2,
2T11,,2,
pA2,mg kg-1,2,
Serum LH level,mg ml-1,2,
Seizure stage,,2,
K inact,mM,2,
AUClast,ng/g.hr,2,
K,10'7/s/microM,2,
log(activity),CFU/g,2,
Stenosis,%,2,
K,10^-4No_unit,2,
Kp,nm/s,2,
AUClast,uM.min/ml,2,
K,10^-3/nM/min,2,
AUClast,pmol.min/mg,2,
AUClast,pmol.min,2,
Sublethal dose,mg kg-1,2,
AUClast,nmol.hr/g,2,
Stability of BSR,%,2,
Activity,mg hr-1 kg-1,2,
Staining,%,2,
CLint,uL/(min.pmol),2,
log(activity),%,2,
Stimulation index,%,2,
Cardiac contractile force,g,2,
Kinact,10^-1/min,2,
Sedative dose,mg kg-1,2,
Log10 cfu,/ml,2,
Kp,10^-4cm/hr,2,
K ass app,l uM-1,2,
K,10'6/mol,2,
MIC=<50,ug ml-1,2,
A0.5,mM,2,
Stroke work,g,2,
Stroke volume,ml,2,
K,10'6Lmol,2,
Activity,10^-5/s,2,
Blood pressure,mM,2,
Clonic,,2,
Cmax_tumor,nmol/L,2,
Specific binding per mg of protein,fM mg-1,2,
Stability,nM/min/mg,2,
Rate,nl min-1,2,
Kapp,nM,2,
Kapp,10^7/M,2,
Kapp,10^6/M,2,
Ki,/min/M,2,
Kbapp,10'-7M,2,
Drug uptake,cps/ml,2,
Relative binding affinity,nM,2,
Rate of [Ca+2] increase,nM min-1,2,
Activity,10'-9/min,2,
Kcat,mol/dm3,2,
D,10^-20No_unit,2,
Ke,M,2,
Rate of hydrolysis,nM min-1,2,
D,10^-10m2/s,2,
Relative Vmax,%,2,
Rate,nM min-1 (mg of protein)-1,2,
Rate,pM min-1,2,
EF90,,2,
Rate,pM min-1 (mg of protein)-1,2,
Drug uptake,AU/min,2,
permeability,10'-6cm/s,2,
Activity,(pM of product) min-1 (mg of protein)-1,2,
Rate of recovery,s-1,2,
KbS,uM,2,
Bacterial counts,,2,
Relative cytotoxic activity,,2,
Rate constant,s-1,2,
Rate constant,mM,2,
Kf,M-1,2,
Bactericidal,ug ml-1,2,
Kb,10^3L/mol,2,
Kgmax,10'-3 log10CFU/ml/hr,2,
%LBF,%,2,
Rate acceleration,,2,
BIC,uM,2,
Ke selectivity ratio,,2,
Rate of hydride transfer,,2,
Ke(app),,2,
Ratio,10'8/M/min,2,
solubility,ugA/ml,2,
Ratio,10'7/M/min,2,
Ratio AUC(inf),,2,
Activity,10'-5/s,2,
Kd,10^4/M/s,2,
Ratio CC50/EC50,10'5No_unit,2,
Max inhibition concentration,uM,2,
Kd,10^-8mol/L,2,
Kd,10^-6 mol/L,2,
Activity,10'-5/min,2,
Activity,mmol/L.min,2,
DeltaCp,kcal/mol.K,2,
t1/2,nanoseconds,2,
Ratio EC50,uM,2,
Ratio,10^-3/uM/min,2,
Activity,10'-5g,2,
Kd,10^6/M,2,
Kc,M,2,
Ke(app),/M/min,2,
% of kinase activity,%,2,
Kel,10'-3/hr,2,
Drug uptake,mg%,2,
Compound Recovery,%,2,
Relative antiandrogenic activity,,2,
D,10'-7cm2/sec,2,
t0.9,day,2,
Activity,10'-9No_unit,2,
Cmax,kg/L,2,
Ratio,/nM/s,2,
Kcat/Km,ug ml-1,2,
Ratio,ng/kg,2,
Kd,M-1,2,
DBP15,ug kg-1,2,
Kcat/Km,10'6/Ms,2,
Drug uptake,dpm/ml,2,
Max weight loss,,2,
K,10^8/M/s,2,
ED90,KgAi/ha,2,
ED90,g/ha,2,
K,10^9No_unit,2,
K,10^6No_unit,2,
Concentration,ug 100ml-1,2,
Pro/Min/Enz,M,2,
CLz/F,l/hr.kg,2,
CLz/F,L/kg/hr,2,
logEmax,,2,
Kobs,10^-3/s,2,
K,10^6/M.s,2,
Activity,mg/min/kg,2,
KSV,10^6L/mol,2,
AUEC,,2,
Production,ng (g of tissue)-1,2,
Km,uM kg-1,2,
Specific radioactivity,,2,
K,10^3/Ms,2,
EDP,mmHg,2,
Metabolic rate,nmol/min*mg of protein,2,
Metabolic rate,%,2,
Ct,nmol/mg,2,
CLt/F,uL/min,2,
K,10^3/M.s,2,
Mem Rec,%,2,
ED90,mg/L,2,
MIC>99,ng/ml,2,
Stability,mg/dl,2,
Median tumor,day,2,
CLz/F,L.hr/kg,2,
CLz/F,L/Kg,2,
Koff,1/nM.1/min,2,
Drug uptake,fmol/min,2,
BQL,,2,
permeability,cm/hr,2,
Max,nM,2,
Cmax,mg,2,
Max PI,,2,
Kcat/Km,microM/min,2,
Activity,ml min-1 kg-1,2,
Activity,/min/nM,2,
Kdiss,10^2/M/s,2,
Activity,/min/M,2,
Max BSR,%,2,
Reduced_Cyp7a1_gene_exp,,2,
Reduced_Serpine1_gene_exp,,2,
Reduced_Srebf1_gene_exp,,2,
Reduced_circadian_oscillation,,2,
Kcat/Km,10^-6/nM/s,2,
Cmax,microM.hr,2,
ED100,MPK,2,
ED100,mg Kg-1,2,
Ratio,/mM.s,2,
Reduction in arterial blood pressure,,2,
Kcat/Km,10'-4/M/s,2,
Kcat/Km,10'2 uM/s,2,
permeability,10^-3cm/min,2,
% injected dose/cm3,%,2,
D,kHz,2,
permeability,10^4cm2/sec,2,
Cmin_ratio,,2,
Activity,/M/min,2,
Kcat/Km,10'-5/s/uM,2,
Rel brain exposure,,2,
Drug uptake,fmol/uL,2,
Activity,10'-8No_unit,2,
BSR,uM kg-1,2,
Kds,nM,2,
Drug uptake,Gy/MBq,2,
Anti-Factor Xa activity,mg,2,
MST,g,2,
Vmax,%/min,2,
Drug recovery,ng/ml,2,
Elevation,%,2,
Survivors,ug ml-1,2,
K,10'-8/s,2,
Efflux,,2,
Survivors at day 28,,2,
MIC90,%,2,
Susceptibility,nM hr-1 (mg of protein)-1,2,
Non-specific binding,,2,
Pm,mg/ml,2,
Css,mg/L,2,
Degree of cross resistance,,2,
Kr,min-1,2,
Vmax/Km,U/mg,2,
HED,mg kg-1,2,
Synergy,%,2,
Bmax,fM mg-1 protein,2,
AUC/dose,uM.hr.kg,2,
Vmax / Km,uM min-1 (ug of protein)-1,2,
koff,nM-1 min-1,2,
K,10'-4M,2,
Vmax/Km,/nM.min,2,
No. resp animals / Total,/ 5,2,
Vmax/Km,/M,2,
Min oral dose,,2,
ACAT activity,%,2,
kp,min-1,2,
ACR,,2,
Bmax,pM g-1,2,
K,10'-2/Ms,2,
HF2,,2,
T max,ug ml-1,2,
AUC/dose,nmol/ml.hr,2,
AUC/dose,nmol.hr/g,2,
kon,1/M1/S,2,
Vmax/Km,pmol/microM,2,
Alpha Ki,uM,2,
CL,hr/L/kg,2,
Vmax/Km,10'-4L/min,2,
Activity,10^3pg/ml,2,
T50,,2,
Vmax(app),abs/hr,2,
Creatinine_CL,min/ml/hr,2,
kik0/Ki,uM-1 min**-2,2,
Drugexcretion,%molar,2,
Concentration in Brain,uM,2,
K,1/sM,2,
Activity,10^3L/mol,2,
Cardiac output,,2,
Activity,pmolequiv,2,
Activity,ppm/g/hr,2,
Activity,rat,2,
CL,L.h-1,2,
ka,10^3/M/s,2,
Plasma levels,uM,2,
ka,10^6/M/s,2,
T3,,2,
Molar equivalence bound,,2,
VmaxH,pmol/min/mg,2,
T-cell binding,,2,
CL,L.h/kg,2,
Drugexcretion,/hr,2,
T1/2,l kg-1,2,
keq,,2,
CL,L (min mg)-1,2,
CL,/s,2,
Emesis_ED,,2,
Vmax(app),10'-4abs/s,2,
Molarity,M,2,
AUC,hr/ng.ml,2,
DPM,,2,
Change in body weight,,2,
Elimination,,2,
BmaxH,nmol/mg,2,
K,/min/M,2,
Plasma insulin,uU ml-1,2,
Intinsic activity,%,2,
Activity,cpm/min,2,
Cr leakage,,2,
VmaxL,pmol/min/mg,2,
AUC/dose,ng h/ mL,2,
Kuncat,M-1 min-1,2,
Intake,%,2,
AUC/dose,nM.hr/ml,2,
Amount,,2,
Volume,ml min-1 kg-1,2,
TD10,mg kg-1,2,
Inhibitory ratio,,2,
MIC,%v/v,2,
Brain conc,ng/g,2,
TF/P,,2,
Log k,obs,2,
BmaxL,nmol/mg,2,
MI,uM,2,
Drug recovery,mg,2,
Loss of activity,%,2,
Activity,mM/min,2,
Drugexcretion,umol,2,
CLH,ug/ml/hr,2,
MIC,10'-2nmol,2,
Plasma [14C] cholesterol,dpm dl-1,2,
Insulin lowering effect,%,2,
Inhibitory zone,,2,
kR,,2,
Intact,,2,
CLT,,2,
Drugexcretion,hr,2,
Inverse agonism,%,2,
Allodynia score,,2,
AUC/dose,ng.hr.kg/ml/mg,2,
LBF,ml/min.kg,2,
gammaCMC,,2,
Exhal+B1718ation of 14CO2,%,2,
LC10,mgAi/L,2,
AUC,mU min dl-1,2,
DTH,10e-3mm,2,
Drugexcretion,umol/hr,2,
Average gross pathology scores+/- SE,,2,
EC2,,2,
Plasma Ca2+,mg dl-1,2,
Excess MST,%,2,
k2/Ks,M-1 s-1,2,
OD max,,2,
Decrease of spontaneous firing rate,M,2,
Volume,mm**3,2,
Vmax,uM min-1 (ug of protein)-1,2,
Excreted glucose,mg,2,
Plasma,mM,2,
EC50,10^2 ug/ml,2,
Bone damage score,,2,
Plasma Level,uM,2,
CL,(mg/kg)/(ng/ml)/hr,2,
EC50,10^-4microM,2,
Inhibition concentration,uM,2,
AD50,ug brain-1,2,
ODC activity,,2,
Volume distribution,l,2,
Exhalation of 14CO2,% of dose,2,
Heart rate,mmHg,2,
Inhibition at 1uM,%,2,
Body weight gain,g,2,
EC50,10^-2microM,2,
Activity,10^5/mm3,2,
TED,,2,
CL,%ID,2,
Excretion,,2,
AUC/dose,%,2,
K,/nM.min,2,
T/C (tumor vol),%,2,
kDPPH,,2,
Log P/Log D,,2,
Vmax,pmol/(min.ug),2,
Log Poct N,,2,
Volume of urine,,2,
Occ,ng/ml,2,
LC50,microg/dm2,2,
LC50,gAi/L,2,
k'',,2,
LC30,ppm,2,
TPR,,2,
AUC nom,uM*h*kg/mg,2,
Inhibition,min-1,2,
EC50,10'9PFU,2,
TMED,,2,
LC50,10'-2ppm,2,
Log Pdod N,,2,
Inhibition,pmol,2,
Cell cycle effect,,2,
Imax,ug ml-1,2,
Concentration_plasma,ug ml-1,2,
MAC,mg kg-1,2,
Of tumors,%,2,
Hg,,2,
Duration of peak action,min,2,
Vmax,mol/min/L,2,
Vmax,mol/min,2,
Highest nontoxic dose,,2,
Activity,ug/min.kg,2,
Off-rate,min,2,
AED,mg kg-1,2,
Activity,10^8(p/s/cm^2/sr)/(uW/cm^2),2,
Cl,ml min-1,2,
FPT msad,mg kg-1,2,
Group performance time,s,2,
Brain levels,uM,2,
F,ng/ml,2,
EC50,10^-1microM,2,
k(on)/k(off),,2,
AUC inf,nM l-1 hr-1,2,
Growth rate,,2,
Vmax,pM assay-1 hr-1,2,
Log Poct Z,,2,
Growth zone,,2,
OT,,2,
Drug level,,2,
Inhibition,(ul of blood) (2ml BALF)-1,2,
Exudate,ml,2,
CI90,,2,
OT interval,,2,
Extraction ratio,,2,
Drug excretion,uM,2,
Drug excretion,pmol,2,
LC50,pg,2,
Activity,fmol/ug,2,
TTC,min,2,
Activity,dg/ml,2,
Induction of catalepsy,,2,
Damage score,0-10,2,
Infusion rate,uM min-1 kg-1,2,
Vmax,pmol/min.ug,2,
FB,,2,
Brain level,ng ml-1,2,
Cp(f),nmol/ml,2,
H2 activity,,2,
AUC nom,uM h kg/mg,2,
Drug excretion,nmol,2,
Vmax,pmol/min/ml,2,
FC,10'7No_unit,2,
AUC,mg ml-1,2,
Permeability index,Pi,2,
Change in blood glucose,%,2,
FE,%,2,
Activity,dyn/mg,2,
Peff,10^-5cm/s,2,
Vmax(app),abs/min,2,
C,,2,
Therapeutic index,14 day,2,
LC99,ppm,2,
C,ng ml-1,2,
Activity,mBq,2,
AUC,umol/l.min,2,
Peff,cm/s,2,
Peff,10^-8cm/s,2,
Increase in [Ca+2],,2,
MFC90,,2,
k cat/Km,1/(M*min),2,
Increase in cAMP,fold,2,
Activity,ug g-1,2,
k cat/Kuncat,M-1 s-1,2,
FI50,ppm,2,
Change in DA synthesis,%,2,
Activity,mCi animal-1,2,
Duration of action,mg kg-1,2,
CLH,mL/mg/kg,2,
Vz,L/hr/kg,2,
Cell death,,2,
Creatinine_CL,ml/min.kg,2,
Mobilization,,2,
Bmax,pmol/ml,2,
MIC,ug cm**-3,2,
Critical micelle concentration,uM,2,
LC15,mg/L,2,
Change in density of uterine gland,,2,
DUR,mg kg-1,2,
k cat,uM min-1mg-1,2,
Brdu positive,%,2,
Occulations,,2,
Growth inhibition,uM,2,
EC50,10'5pM,2,
Therapeutic dose,mg kg-1,2,
Vss,k,2,
AUC Npo,uM.h/dose,2,
Occ90,uM,2,
Occlusion time,min,2,
Tick action,%,2,
Drug metabolism,uM.hr,2,
Decrease in life span,day,2,
IUP AD50,ug kg-1,2,
Hk,,2,
C0,ug.hr/ml,2,
IT50,hr,2,
Time,pS,2,
Time,uM,2,
Cp,ug/g,2,
grade,,2,
FRP,,2,
k cat,1/min,2,
CLH,L/hr/mg,2,
AUC,hr.ug/g,2,
LD10,g/hm2,2,
Activity,ug/min/cm2,2,
Attacks,%,2,
AUC N,,2,
Drug degradation,10'-3nmol/min,2,
CI,l min-1,2,
Tc,,2,
Inhibition (alpha = 0.01),%,2,
Cmax,ul ml-1,2,
k cat/Km,mM s-1,2,
Average GI50,,2,
ionization,%,2,
Growth inhibiton,%,2,
Brain/Plasma,%,2,
Activity,dpm (mg of protein)-1,2,
AUC,microM.hr'2,2,
Therm_solubility,ug,2,
IZ,cm2,2,
Vmax,umol.min,2,
inhibition (at 100uM),%,2,
EC50,10^3ug/ml,2,
AUC,uM.min/ml,2,
NOAEL,ug ml-1,2,
Total binding,,2,
Vmax,U mg-1,2,
EC50,10'-2 ug/cm2,2,
Animals,,2,
NOAEL,ug/kg,2,
MAD,10'-3microL,2,
NOAEL,ug/kg/day,2,
Tonic,,2,
Tonic seizures,,2,
Activity,umol/min/g,2,
EC1000,,2,
fEC85,ng/ml,2,
LD50,gAe/L,2,
AUC,ug min g-1,2,
Drug metabolism,pmol/mg/min,2,
AHA,,2,
Anogenital distance,mM,2,
LD50,pmol,2,
Tmax,ug.hr/ml,2,
MED90,,2,
LD50,ml,2,
fCmax/dose,nM,2,
Papp,uM,2,
CFU,10'9/g,2,
MED50,ug/kg,2,
CFU,10'7/ml,2,
AUC,ug h ml-1 kg-1,2,
AUC,ug .hr/g,2,
Total glomeruli,,2,
LD50,ng/ml,2,
CFU,10'7/g,2,
Dose,nM mouse-1,2,
MAD,10'-6microL,2,
NOL,mM,2,
Total CL,L/hr,2,
MED99.9,,2,
INH,10'-4M,2,
PC50,nM,2,
PC50,microg/cm2,2,
AUC,ng min,2,
VRT,ha2,2,
APPTT,uM,2,
Activity_index,mm,2,
IC50,10^-3mg/ml,2,
Utreotropic effect,,2,
Activity,PFU/ml,2,
Anticonulsant activity,mg kg-1,2,
Level,ng dl-1,2,
GH,%,2,
AUC,nM hr-1 ml-1,2,
IC50,10^4 uM,2,
Vdss,kg/L,2,
VFT,,2,
Light transmission,,2,
PC95,,2,
IC50,10'6uM,2,
fCmin,ug ml-1,2,
fCmin,uM,2,
I50,M kg-1,2,
Activity,kiloU/hr,2,
Anti-analgesic,,2,
IC50,10'8nM,2,
Control S/T,,2,
MBEC,mg/L,2,
IC50,10'6pM,2,
P-value,,2,
V0,mg/ml/hr,2,
PC95,microg/cm2,2,
IC50,10'3pM,2,
VDR affinity,,2,
Dose,mg rat-1,2,
Hydrolysis rate constant,s-1,2,
PD 50,mg kg-1,2,
Transporter production rate (r),fM mg-1 day-1,2,
Cmax (Ratio),uM,2,
ID50,mg kg-1 b.i.d.,2,
I14,uM,2,
Treatment,ng ml-1,2,
Vmax,10'-4 uM/s,2,
Vmax,10'-3umol/min/U,2,
deltapH,,2,
ID50,fM,2,
Triglyceride level,%,2,
Vmax,10'-3deltaA/s,2,
PTD50,,2,
ID50,10'-8mol/L,2,
MBC,ng/ml,2,
ID100,mg kg-1,2,
Optimum T/C,%,2,
ID50,mg kg-1 day-1,2,
Transporter deg rate const (k),day-1,2,
AUC,ug/g.min,2,
Weight change of AP-S,mg,2,
MBC,ug cm**-3,2,
TC50,ng/ml,2,
ID30,10'-5M,2,
Affinity,uM,2,
PR,%,2,
I50,10'2mol/L,2,
Weight ratio,,2,
Affinity,M-1 s-1,2,
Vm,10'-5m3/mol,2,
PPB,ug ml-1,2,
Choline uptake,,2,
dpm bound to protein,,2,
PT,min,2,
LL,,2,
C6h,ug ml-1,2,
Apoptotic cells,%,2,
INH,umol/L,2,
fc max,mg/L,2,
LD33,mg kg-1,2,
Gross kill,,2,
Activity,10^9CFU,2,
Onset time,s,2,
Paw swelling,,2,
Time of peak action,min,2,
fpKi,,2,
Time spent,s,2,
Time to 30% BSR,min,2,
Time to max. BSR,s,2,
fp,,2,
Fa,hr.ng/ml,2,
Time to righting,min,2,
Activity,g/cm3,2,
Days to tumor doubling,,2,
CFU,10^5/g,2,
g/30min,,2,
IO,,2,
fm,,2,
INH,mol,2,
Tissue weight,g,2,
LD40,mmol/Kg,2,
fc max,,2,
Arterial occlusion,%,2,
AUC,ug/L,2,
INH,ngequiv,2,
Activity,A% min-1,2,
Tmax,ng.hr/ml,2,
AUC,ug.hr/ml/day,2,
NOAEL,nmol/Kg,2,
Fabs,/hr,2,
fLOAEL,uM,2,
AUC,hr.ng/L,2,
AUC,ug/g,2,
IC50,10^-8nmol,2,
Contractile force,,2,
EC,ng/ml,2,
POE score,,2,
IC,mg kg-1,2,
Fu,10'-5No_unit,2,
Antidiuretic activity,%,2,
CC50,mol,2,
Cp,fmol/uL,2,
Fungicidal,%,2,
No. of active/no. of tested,,2,
Log,1/M MIC,2,
AUC,0-tIdc,2,
AUC,0-infinity,2,
MEC,10'-6 mol/L,2,
Level,fM mg-1,2,
XL50,,2,
IC100,10'-4M,2,
Vdss,ng/ml,2,
MEC,mg kg-1,2,
LV,,2,
AUC,mmHg,2,
ICL50,,2,
CA activity,(ml of NaOH) min-1,2,
PPB,pmol,2,
Tumor inhibition,%,2,
ID/g femur,,2,
Fos,%,2,
Cp,microg.hr/mL,2,
MEC,nmol/Kg,2,
CFU,10'2/ml,2,
CFU,/uL,2,
E50,,2,
deltaS,KJ/(mol.K),2,
Activity,Kcal/kg/hr,2,
Tumor volume reduction,%,2,
ICdATP-50,uM,2,
Drug metabolism,fmol/mg,2,
Ya,,2,
Level,mg g-1,2,
Urinary volume,ml min-1,2,
IC50,microg/cm3,2,
Unchanged NDEA,% of dose,2,
CC50,10^3 uM,2,
Anti-emetic,,2,
Oxytocic activity,,2,
delta logPoct-dod,,2,
Gross log kill,,2,
Parent remaining at time,%,2,
CLH,/min/uL,2,
Enoyl-CoA hydratase,uM min-1mg-1,2,
CLH,umol/min/ml,2,
Concentration of max response,M,2,
HC>=50,ug ml-1,2,
IC50,10^-6nmol,2,
kIAM',,2,
Plasma conc,ng/ml,2,
Left atrial pressure,mmHg,2,
IC50 ratio,%,2,
Latency time,min,2,
LambdaZ,/min,2,
delta Log Doct-dod 7.4,,2,
Carotid flow reduction,%,2,
IC50,ucm/s,2,
Drug metabolism,g/mol,2,
LZ,/hr,2,
IC,nmol/ml,2,
Last therapy day,%,2,
Vi,ml/kg,2,
IC50L,uM,2,
Control,uM kg-1,2,
IC50/EC50,,2,
No. active,,2,
C0(unbound),uM,2,
Antifertility activity,,2,
Worm reduction,,2,
Activity,10^4L/mol,2,
PKb,,2,
Vd,Kg,2,
Vd,L/1.73 m2,2,
Vd,L/hr,2,
"[A]T,L",/mol.dm'3,2,
EC25(unbound),ng/ml,2,
GR50,uM,2,
Correct responses,%,2,
P50,mM,2,
[3H] thymidine cpm/dish,,2,
PA,ml/s/g,2,
CCIC50,,2,
Vbeta,kg-1,2,
MCC,ucm,2,
AUC,nM l-1 hr-1,2,
alphat1/2(app),hr,2,
alphat1/2,,2,
"[A]T,L",10'-8 /no of units.cm'3,2,
Activity,U (g of tissue)-1,2,
Vdss,%,2,
IC20,10'-3M,2,
Level,nmol ofpHB/min/mgof protein,2,
Level,pg ml-1,2,
Activity,kg/kg,2,
Vdss,hr,2,
GI,cm/day,2,
Cdyn,% delta,2,
Uterus to blood ratio,,2,
EC30,10'-9M,2,
AUC,%.hr,2,
VRT(t),hr,2,
Activity,kBq/ml,2,
Vd/F,g/Kg,2,
GR50,gAe/L,2,
Dose range,uM kg-1,2,
GR50,ppb,2,
EC30,10'-8M,2,
Vc/F,L/hr/kg,2,
Vagus,,2,
No change,,2,
Fraction excreted unchanged,%,2,
LV DRxHR,%,2,
AUC,pmolÂ·min/mg,2,
Affinity,M,2,
Vinact,min-1,2,
Dose elevation,,2,
Turns/1st,,2,
deltaS,,2,
LV dP/dt,%,2,
AUC,mmHg.day,2,
alphaKi,,2,
deltaH,cal/mol.K,2,
No effect dose,,2,
CL free,nmol/min/mg,2,
ALT/GPT,l,2,
AUC,pmol.min/mg,2,
Cavg,ng/dL,2,
No. of culturesactive/total,,2,
IC40,uM,2,
AUC,(umol/L).min,2,
Variation,,2,
PB,pmol/mg.hr,2,
CDOG,,2,
Vascular relaxation,,2,
Dose normalized clearance,L/hr,2,
PB,nmol,2,
Vd/F,ml,2,
IC35,uM,2,
MBC99.9,mg/ml,2,
EC100,10'-5M,2,
PB,nmol/mg,2,
Kapp,10'4M,1,
Ki,10'11mM,1,
Kapp,10'3L/mol,1,
Activation,uM,1,
Kapp,10'5/M/s,1,
Relative potency,nM,1,
Relative peroxidation,%,1,
Activ ity,%,1,
Activ ity,,1,
Range of MIC,ug ml-1,1,
Ki,10'2/M/min,1,
Kapp,10'-7M,1,
Ki,10'22mM,1,
Kact,mV,1,
Kapp,10'5L/mol,1,
Kact,/s,1,
Ki,10'5/M/s,1,
T/C @ 20mg/kg,%,1,
Ki,10'5/M,1,
Ka,mM,1,
Activity,10'10L/mol/s,1,
Plasma_leptin,%,1,
Liphophilicity,sigma pi,1,
T/C @ 30mg/kg,%,1,
IC50,10'-13 ug/ml,1,
Level in serum,mM l-1,1,
AUC,ng.Eq/ml,1,
IC50,10^-4mg/ml,1,
Acid output,(equiv of [H+]) 2hr-1,1,
IC50,10'7nM,1,
Level in serum,mg dl-1,1,
IC50,10'5uM,1,
Life span,%,1,
V1,ml,1,
AUC,ng ml kg-1,1,
Anticancer activity,,1,
VV,,1,
CCID50,PuM,1,
VSV,,1,
IC50,/uM/s,1,
AUC,ng/L,1,
IC50,10'-11uM,1,
IC50,10'-4umol/L,1,
IC50,10'13nM,1,
IC50,10'16 uM,1,
Anticoagulant activity,mg kg-1 hr-1,1,
IC50,10'20 uM,1,
V2,ml,1,
Radiolabel recovery,ugequiv/ml,1,
Rate,ul min-1,1,
Acid hydrolysis,mol/mol,1,
Kel,min,1,
Drug uptake,microg.hr/mL,1,
Ki,/min,1,
Kb,10'6/mol,1,
IC50,10^-5mg/ml,1,
Cz,ug ml-1,1,
DC50,mmol/L,1,
Remained,%,1,
Relative inactivation,,1,
Kb,10^-5L/mol,1,
Kb,10^1/M,1,
Kb,10^2/M,1,
Kb,10^3/M,1,
Kb,10^7L/mol,1,
Relative contractile potency,,1,
Rate constant,M s-1,1,
Ke,10^-5M,1,
Ka,10^5/M.s,1,
Ki,10^-2/min,1,
Ka,10'-7M,1,
BBB Impermeable,,1,
BBB,hr,1,
Ka,/nM/min,1,
Ka,/nM,1,
Relative bioavailability,nM ml-1,1,
Kbapp,10'4/M,1,
Activity,10'12L/mol/s,1,
Kc,min-1,1,
DCmax,%,1,
Relative weight loss,%,1,
Ka,10^7/M/s,1,
Ka,10^7/M.s,1,
Ki,10^-12M,1,
Ka,10^5/Ms,1,
Range,ug ul-1,1,
Relative oncentration,uM,1,
Kapp,10'7/M/s,1,
Basal glucose,mg dl-1,1,
Rate of reduction,,1,
Kcat,umol/min/nmol,1,
Rate of metabolism,pM/mg/minute,1,
Activity,%mg,1,
Kcat,10^4/s,1,
Relative Vmax/Km,rel,1,
Kcat,10'7/s,1,
Kcat,10'2/s,1,
Rate of formation,,1,
Activit y,,1,
Kcat,/hr,1,
Drug uptake,mg/L.hr,1,
Kel,L/Kg,1,
Activity,PbU,1,
PAP,mM,1,
AUC,ng.h-1.ml-1,1,
PCaco-2,cm s-1,1,
Ulcer incidence,,1,
Cp,mM,1,
UV,ml kg-1,1,
PPB,mg/ml,1,
PPB,mM,1,
Cp,microg.min/mL,1,
PPB,L/hr/kg,1,
PPB,%ID,1,
ID/animal,%,1,
CAC,mg/ml,1,
PLT,10E3/mm3,1,
CC,uM,1,
CC10,,1,
IC90,PuM,1,
Cp,mg/min/kg,1,
Tumour inhibition,,1,
IC90,Gy,1,
Turnover,ug ml-1,1,
IC90,%,1,
Twitch tension,,1,
IC60,10'-2 ug/ml,1,
CC50,10'10uM,1,
PIC seizure,,1,
Lethal dose,ng ml-1,1,
IC50,mg/kg/day,1,
IC50,microA,1,
IC50,uL/ml,1,
Clearance,l kg-1,1,
IC50,ug/kg,1,
Ka,/min,1,
Untreated control,,1,
IC50,ug cm**-2,1,
Uptake,% injected dose cm**-3,1,
Antidiuretic activity,IU mg-1,1,
IC50,uM.hr,1,
Uptake,nM 3s-1 (mg of protein)-1,1,
Activity,M-1,1,
CC50,ucm,1,
Activity,Osm/kg,1,
IC50,nmol/min,1,
Lethal toxicity,mg kg-1,1,
Anticonvulsant activityAnticonvulsant activity,,1,
IC50,ng/mg,1,
IC50,nM/g,1,
Cp,M,1,
Cp,L/Kg,1,
PD50,pmg kg-1,1,
Clearance,l hr-1,1,
PD50,mg/ml,1,
IC75,mg kg-1,1,
Cp,mg kg-1,1,
Antihypertensive,,1,
Locomotor,Counts,1,
IC25,ug ml-1,1,
CD50,mg/ml,1,
IC25,PuM,1,
Vd,ml/mg,1,
Decrease in RFU,uM,1,
Clast,ug.hr/ml,1,
Vd app,L,1,
Vd area,mg kg-1,1,
Vd(app),L,1,
Vd(app),L/hr,1,
IC15,nM,1,
AUC,ng hr g-1,1,
Vdss,L/hr.Kg,1,
IC15,10'-7M,1,
P50C,mmHg,1,
Ccontrol,%,1,
IC5,ng/ml,1,
Antibody titer,log-2,1,
IC50,10^5uM,1,
Uterine activity,,1,
PD' 2,,1,
Level,nmol of pHB/min/mg of protein,1,
EC10,,1,
AUC,nM/L.hr,1,
IC50,mg/cm3,1,
CC90,nM,1,
Antihypertensive activity,mg kg-1,1,
LV dp/dt,%,1,
EBD20,,1,
EAUC50,ug.hr/ml,1,
Activity,L/Kg,1,
U/P,,1,
Ratio,10^5No_unit,1,
Activity,L/hr,1,
Drug metabolism,mg,1,
Level,mg/gof liver,1,
Variation of edema volume,%,1,
Vc/F,L/hr,1,
IC40,nm,1,
IC40,mM,1,
PB,equiv,1,
PActivity,,1,
Vasopressor activity,mg,1,
PAO activity,pM min-1 mg-1,1,
IC33,uM,1,
Cbrain,ng g-1,1,
IC30,10'-8M,1,
Liver catalase,mg of protein,1,
BBB,10'-3cm/min,1,
Reduction in blood pressure,%,1,
Cmax,ng/10^6â¯cells,1,
KdSPR,uM,1,
Kdiss,10^-8M,1,
Kcat/Km,10^2/M/s,1,
Kcat/Km,10^1/M/s,1,
Reduced food intake,%,1,
Kcat/Km,10^-4/nM/s,1,
Kcat/Km,10^-4/M/s,1,
Kcat/Km,10^-3/M/s,1,
Kcat/Km,10'7M/s,1,
BP increase,AUD30min,1,
Kdiss,microM/s,1,
Kcat/Km,10'5/Ms,1,
Reduction in arterial blood pressure,%,1,
BP increase,%,1,
Reduction in movement,,1,
Activity,10'-8 ug/ml,1,
Kcat/Km,10'4/M/min,1,
Reduction in respiratoryvolume,ml,1,
Kcat/Km,10'3/M.s,1,
Kcat/Km,10'2/Ms,1,
Kdiss,nM,1,
Reduction of prostate weight,%,1,
Ratio,%ID,1,
BSA binding,,1,
Kcat/Km,10^8/M/s,1,
Recovery rate,,1,
Ratio,10'-6cm/min,1,
Ratio,10'7/s/M,1,
Ratio,10^3No_unit,1,
Ratio,10^3/mM/s,1,
Ratio,mg kg-1,1,
Kd,microL/min/mg,1,
Ratio,microL/min/mg,1,
Kdiss,/hr,1,
Kdiss,10'-6/s,1,
Ratio,10'5/min/M,1,
Ratio CC50/EC50,10^10No_unit,1,
Ratio,10'6/s/M,1,
Ratio,umolequiv/umol,1,
Activity,10'-3nmol,1,
Activity,10'-3umol/min,1,
Kd,10^6uM,1,
Ratio,ms,1,
Ratio,mole fraction,1,
Ratio,ml/min/umol,1,
Drug uptake,L/Kg,1,
Kd,M-1 s-1,1,
Ratio,ml g-1,1,
Activity,10'-5nmol,1,
Ke,10^-4M,1,
Relation,%,1,
Relative,uM,1,
Rate of rotation,turns 5min-1,1,
KL,M,1,
BP change,,1,
Kd,10'7/M/s,1,
Kd,10'-29M,1,
BP (ED50),%,1,
Kd,10'-5 cm/s,1,
Kdiss,10^-5M,1,
Activity,10'-1/M/s,1,
Ratio,1/M1/s,1,
Kd,10'-7/s,1,
Activity,10'-1 ug/ml,1,
KI50,,1,
Kd,10'-11/M,1,
Ki/Km,nM,1,
Activity,10^-3/s,1,
Potency Ratio,,1,
Kq,10'10L/mol/s,1,
K,10^-2/M/s,1,
K,10^-12/min,1,
K,10^-11/min,1,
Activity,10^-3No_unit,1,
Ultrafiltration,,1,
AUClast,ngequiv.hr/g,1,
Kd,10'-2(1/s),1,
D50,nM,1,
Activity,/10^6mm3,1,
Kdiss,10^-3M,1,
Reduction in heart rate,%,1,
Kcat/Km,uM,1,
Kd,/nM/min,1,
Recovered in bile,%,1,
Activity,10'-3 ug/ml,1,
Ratio,10'-6/nM/s,1,
Ratio of distribution,,1,
Ratio,10'-5/min.mol%'-4,1,
Ratio,10'-5/M/s,1,
Kdiss,10^-2/Ms,1,
Kd,10'5/M,1,
Kd,10'-10L/mol,1,
Activity,10'-2M,1,
Ratio,10'-2/s,1,
Kd,10'1/s,1,
RatioGI50,10'4No_unit,1,
Activity,10'-1microM,1,
Activity,10'-10s,1,
Ratio_Cmax_brain/plasma,,1,
Kd,10'-9L/mol,1,
Kd,10'-9/M,1,
Kdiss,10^-6M,1,
Kd,microM/s,1,
KdSPA,mM,1,
Ki comp,mM,1,
Activity,10'-6No_unit,1,
Ka,10^4/M.s,1,
Ki,10^-4microM,1,
Ka,10^2/M/s,1,
Ki,10^-9/min,1,
Ka,10^2/M,1,
Replacement,%,1,
Ka,10^1/M,1,
Cmax,ng kg-1,1,
Rescued neurons,,1,
Ka,10^1 uM,1,
Ka,10^-7M,1,
Ka,10^-7/M,1,
Activity,10'2pg/ml,1,
Cmax,ng.hr,1,
Drug uptake,ng/cm2/h,1,
Ki,10^2/M/s,1,
Ka,10'2L/mol,1,
Binding,mg kg-1,1,
Ki,ml/min/g,1,
Ki,PuM,1,
Ka,10'4 /uL,1,
Ki,Kg,1,
Radioactivity remained,%,1,
Ka,10^4/s,1,
Ka,10'2/Ms,1,
Ka,10'10M,1,
Cytocidal effect,%,1,
Cmax,ng/10^6â¯cells in 4â¯h,1,
Activity,10'4/M,1,
KSV,10^5L/mol,1,
Ki inact,min-1,1,
Drug uptake,%ID/mg/ml,1,
Ka,10'1/M/s,1,
Ki obs / [I],M-1 s-1,1,
KSV,10'4/mol,1,
BBB,,1,
AbA/analogue ratio,,1,
KSV,10'-5M,1,
Ka,10'10L/mol/s,1,
KSV,10'-4M,1,
Ki' uncomp,mM,1,
KSV,10'-4L/M,1,
BAV,,1,
Clp,ml mg-1 kg-1,1,
KS,uM,1,
Clp,ml hr-1,1,
"Ki,app",nM,1,
KNa,M-1,1,
BBB,%,1,
Ka,10'6/Ms,1,
Resistance ratio,,1,
Ki,10^6/M/s,1,
Kdiss,10^-1M,1,
Kd,10^-1M,1,
Kdiss,10^-1/s,1,
Kdiss,10^-10M,1,
Ratio Ki,10'-5No_unit,1,
Ratio Ki,10'-7No_unit,1,
Ratio Ki,10'4No_unit,1,
Ratio Ki,10'7No_unit,1,
Kd,10^-17M,1,
Kd,10^-15M,1,
Ratio Ki,10^-6No_unit,1,
Ratio IC50/EC50,10'3No_unit,1,
Kd,10^-2M,1,
Kd,10^3/M/s,1,
Kd,10^4/M,1,
Ratio CC50/EC50,10^5No_unit,1,
Kd1,,1,
Ratio,10^8/M/s,1,
Ratio,CPP/GLY,1,
Kd2,,1,
Ratio,KB 7d-1,1,
Ratio,10^4No_unit,1,
Ratio,M,1,
Ratio IC50/EC50,10'7No_unit,1,
Kdiss,10'-7M,1,
Ki,10^4/M/s,1,
Ratio EC50,10^-5No_unit,1,
Cytotoxic endpoint,,1,
Ka,10'7/Ms,1,
Ka,10'8M,1,
Ka,10'7(1/Ms),1,
Clp,l kg-1,1,
Kcat/Km,/min.uM,1,
Activity,/10^3mm3,1,
Kd,10^3 uM,1,
Ratio EC50,10^-2No_unit,1,
Ratio EC50,10^-4No_unit,1,
Ratio EC50,10^-6No_unit,1,
Activity,10'-4g,1,
Kd,10^-52M,1,
Ratio ED50/MIC50,,1,
Activity,10'-5 mol/L,1,
Kd,10^-4/M,1,
Ratio IC50,10^-3No_unit,1,
Ratio,10'3/s/M,1,
Activity,10'-7 cm/s,1,
Ratio IC50,10^4No_unit,1,
Ratio IC50,nM,1,
Kd,10^3/M,1,
Unchanged NDEA,%,1,
ID60,mg kg-1,1,
IC50 reduction,,1,
Toxicity index,,1,
Cp,pg/ml,1,
LD50,ug/uL,1,
ILS (Sur),%,1,
AUC,uM.hr.kg,1,
ID50,10'-1microM,1,
Incorporated,,1,
Increase,ml min-1,1,
Kuncat,min-1,1,
Kup,ml/min,1,
Activity,10^4/M/s,1,
Activity,10^4CFU/mg,1,
Plasma concentration,ug equiv ml-1,1,
Body temperature,,1,
L,%,1,
Activity,10^4CFU/ml,1,
Plasma concentration,%,1,
Injected dose (g),%,1,
Plasma clearance,mg.ml-1,1,
Drugexcretion,ug ml-1,1,
Body weight,kg,1,
Injected,,1,
Kuncat,M-1 s-1,1,
Initial inhibition,ug ml-1,1,
Papp,10^-6cm2/s,1,
ILA,,1,
AUC,uM.hr/mg,1,
Papp,microg/cm3,1,
INH,/min,1,
Cp,uM/g,1,
INCC50,ug ml-1,1,
INCC50,%,1,
INCC50,,1,
IN,,1,
ILSmaxOD,,1,
Papp,uL/min.mg,1,
LD50,ng/kg,1,
Papp,nanometer/sec,1,
Papp,microg/cm2,1,
LD60,mg kg-1,1,
Papp,cm2/sec,1,
LD50,po,1,
Activity,Ci/mmol,1,
AUC,uN h kg/mg,1,
Toxicity,number of dead animals,1,
ID90,nM,1,
Papp,10'-9cm/s,1,
LD70,ug ml-1,1,
IFN gamma concentration,pg ml-1,1,
LD50,mg-1 kg-1,1,
Plasma clearance,hkg,1,
Plasma clearance,Clp,1,
Initial heart rate,,1,
Drugexcretion,Da,1,
Plasma_IL-6,%,1,
T1/2,uM,1,
T1/2 beta,,1,
Bmax2,,1,
T1/2 h/min,,1,
Drugexcretion,ml/min.kg,1,
Drugexcretion,ml/hr/kg,1,
Drugexcretion,mg/day,1,
T>IC50,uM,1,
Clerance,l hr-1 kg-1,1,
Inhibition_index,10'27No_unit,1,
Bmax1,fM (mg of protein)-1,1,
T50,ug,1,
T4,,1,
Bmax2,fM (mg of protein)-1,1,
Clinical reference,,1,
T1/2 iv,,1,
Jmax,pmol/min/mg,1,
T1/2 h/s,,1,
Ks,10^6/M,1,
Performance,,1,
Plasma,ng ml-1,1,
T1/2,mg kg-1,1,
Plasma_NEFA,%,1,
Plasma clearance,,1,
Plasma clearance,mg kg-1,1,
TCID50,log10/ml,1,
Body weight change,,1,
AUC/dose,min.g/L,1,
LA,,1,
Change,uM kg-1,1,
Drugexcretion,umol/L,1,
Inhibitory dose,mg kg-1,1,
Cp(f)ss,nM,1,
LBF,L/hr,1,
LBF,L/hr/kg,1,
Drugexcretion,ng,1,
Creatinine_CL,mg/dl,1,
Intraperitoneal score,,1,
Intrinsic,,1,
T/C @ 50mg/kg,%,1,
Bmax,sites cell-1,1,
Plasma_insulin,%,1,
Bmax1,,1,
Plasma_glucose,%,1,
T/C value,,1,
AUC/dose,ng/hr.ml,1,
Plasma_cholesterol,%,1,
Total acid output,,1,
C5 min,ug ml-1,1,
LC50,10^5uM,1,
Cp,nmol/Kg,1,
INH,10'6/M/s,1,
INH,10'4/M/s,1,
INH,10'-9mol/L,1,
INH,10'-8mol/kg,1,
Topical dosage,M,1,
LD50,10'-8M,1,
LD100,ng,1,
Time of dosing before antigen challenge.,hr,1,
Paw volume,ml,1,
LCC99,uM,1,
Therm_solubility,10'-1mol/L,1,
LCC99.9,uM,1,
Activity,10^7CFU,1,
Imax,ng/ml,1,
Activity,10^7CFU/g,1,
LD,g,1,
Imax,min,1,
Activity,10^7cm/s,1,
C(24h),mcg/mL,1,
Drug metabolism,uM/g,1,
Peak effect,%,1,
IZ/AAR / AAR/LV,%,1,
IZ/AAR / AAR/LV,,1,
Tmin,min,1,
INH,10^-10mol/L,1,
Tmin,day,1,
Parasite_Clearance_time,,1,
Stabilty,months,1,
IP,nm/s,1,
LD100,ug/kg,1,
C10,,1,
Parasites,,1,
Tissue levels,,1,
LD30,mg kg-1,1,
Tissue swelling,uM g-1,1,
INH,ug/kg,1,
INH,pmol,1,
Parasite_Clearance,,1,
LD50,g,1,
INH,L/hr/kg,1,
INH,E^1%,1,
Tm shift degreeC,degrees C,1,
Activity,10^9CFU/ml,1,
INH,E^-1%,1,
AUC,ug min/mL,1,
LD50,10'2umol/kg,1,
Tmax,ng/ml,1,
INH,10^-8mol/L,1,
Tmax/dose,hr,1,
C0,ng ml-1,1,
C0,ng.hr,1,
Ti,,1,
PVCs,,1,
Papp,10'-3cm/s,1,
Transcriptional activity,,1,
Anxiolytic activity,,1,
Clearance_blood,Not_given,1,
ID50,microg/cm2,1,
ID50,ug/hr.kg,1,
LDH,U g-1,1,
Clearance,ml min-1,1,
ID50,mg kg-1 day-1 b.i.d.,1,
LDH50,uM,1,
LDLO,mg kg-1,1,
LD95,,1,
C90,,1,
ID50,10'-9mol/L,1,
Antipsychotic,,1,
ID50,10'-7mol/L,1,
E2,,1,
CA,,1,
ID50,10'-3microM,1,
ID50,10'-3M,1,
ID50,10'-2microM,1,
ID50,mg/kg/hr,1,
Anxiolytic affect,,1,
ID50,pM,1,
Paw weight increase,,1,
Time,10'11min,1,
C0(unbound),ng/ml,1,
Asorbance,,1,
Activity,10^8CFU/ml,1,
LD10,umol/L,1,
LD10,ug/uL,1,
INH,10'-7mol/kg,1,
AUC,ug/mg/day,1,
Time after dose,,1,
Cp,ug/hr.ml,1,
Cp,umol,1,
Peak GH,ug l-1,1,
Decreace in BP,mM,1,
Peak concentration,%,1,
LD10,ug ml-1,1,
Duration of block,,1,
INH,10'-7mol/L,1,
LD50,microM/g,1,
ID50,ug kg-1 min-1,1,
ID50,pug ml-1,1,
ID50,pmg kg-1,1,
ID50,pg kg-1,1,
Papp,10'-6/s,1,
Cp(f)max,uM,1,
Pharmacokinetic,%,1,
CC50,10'7uM,1,
Vdss,ml/hr/kg,1,
Anti-arhythmic,,1,
P Increase,,1,
EC10x,,1,
Vmax,mOD/minute,1,
AUC,mg.hr,1,
Vmax,pmol/min/U,1,
Vmax,pmol/min/cm2,1,
Heme loss,nM,1,
Vmax,uM g-1,1,
Vmax,uM hr-1,1,
Cav(ss),nmol.L-1,1,
Vmax,uM mg-1,1,
Decrease of spontaneous firing rate,,1,
Halucinogenic activity,,1,
CL,(ml/min)/kg,1,
Half duration,,1,
EC16,M,1,
CL,/hr,1,
Log Poct A,,1,
EC16,uM,1,
OD,M,1,
HSF release,,1,
Log geometric mean,ppfu mg-1,1,
Ventricular tachycardia,,1,
Drug metabolism,fmol/ug,1,
CFR,mg kg-1,1,
Log,(degrees C)-1,1,
IC100,mg/kg/day,1,
Vdss(app),l,1,
Vdss(app),ml/min.kg,1,
IC100,mM,1,
Vdu,,1,
CFC20,,1,
P,pcm s-1,1,
Vel rem,%,1,
Velocity,,1,
Activity,U/ml/min,1,
IC05,,1,
Virucidal,ng/ml,1,
I5,uM,1,
Vm,uM ml-1,1,
Decrease in arterial blood pressure,%,1,
Decrease in arterial blood pressure,,1,
Vm,rel,1,
I50,10'5mol/L,1,
Log EC50(uM),,1,
I7,uM,1,
Clast,ng/mL.hr,1,
Oxidation,%,1,
Vmax / Km,ml min-1 mg-1,1,
Vmax(app),nM/min,1,
Vmax(app),pmol/mg/min,1,
Vmax,nmol/min/ml,1,
Vmax,nanomol/min,1,
Anabolic activity,,1,
Vmax,pM hr-1 mg-1,1,
EC14,M,1,
Occ50,uM/g,1,
Vmax,pM 0.5hr-1,1,
Hepatic blood flow,L.h.Kg-1,1,
Log Kill,,1,
Vmax,mM/hr,1,
Log Ki,uM.hr/L,1,
Vmax,nmol/min/kg,1,
Log Ke,M-1,1,
CI,10^-5No_unit,1,
CI,10'7No_unit,1,
CI,10'6No_unit,1,
Vmax,nmol/cm2/s,1,
Occ90,ng/ml,1,
ID100,M,1,
Drug metabolism,mM,1,
P-450 loss,nM,1,
IC50H,uM,1,
CC50,10'5uM,1,
Occupancy,mg kg-1,1,
Log KZ,,1,
Degree of activation,,1,
CI50,ug ml-1,1,
Amine formed,,1,
Log of inhibitory zone,mM,1,
CL,hr,1,
Vmax/Km,10'-4min,1,
Vmax/Km,10'-5L/min,1,
Vmax/Km,10'-5min,1,
Vmax/Km,10'3/M/s,1,
Vmax (uM),%,1,
Log Pn,cyh,1,
CIp,mg kg-1,1,
"Onset for sleep, min",,1,
Vmax,nM/hr,1,
Analgesicactivity,,1,
Log IC50(uM),,1,
Histamine release,,1,
Log K4,,1,
Of viability,%,1,
CFU,ml,1,
CFU/ml,10'3/ml,1,
CFU/ml,10'4/ml,1,
Log KB,,1,
CFU/ml,10'7/ml,1,
Vdss,ml/mg,1,
Activity,U/min/ml,1,
TR,min,1,
P (Ei),Ei,1,
Increase in MAP,%,1,
Activity,10^5PFU/g,1,
Activity,10^5CFU,1,
AUC glu reduction(mM x min),%,1,
LC50,10'-4ppm,1,
Bound,,1,
Brain,ng g-1,1,
Activity,10^5/Ms,1,
Brain,weight,1,
LBF,ml/hr,1,
LBF,ml/min.Kg,1,
Pka2,,1,
PkB,,1,
LC10,ppm,1,
TG,mg kg-1 diet,1,
TG 2X lag,,1,
LC100,,1,
LC100,mg/L,1,
AUC(0-24) normalised,(nmol.h.L-1)/(mg/kg),1,
Inhibition at 10nM,%,1,
TGI,10^5uM,1,
Photoxic reaction,mg,1,
Inhibition,c.p.m. 50ul-1,1,
LC95,ug/g,1,
Activity,10^6/100microL,1,
Terminal t1/2,hr,1,
Permeability,nm/s,1,
Peroxidase rate,,1,
LC50,p.p.m.,1,
Permeability limited,,1,
Infection score mean,,1,
TT,nM,1,
Cp(f),nmol/L,1,
Average bile flow,ml hr-1,1,
LC50,ug.cm'-2,1,
Brain levels,nM,1,
Increases,%,1,
LC50,10'5uM,1,
Terminal elimination t1/2,hr,1,
Increased,%,1,
Permeability,nM/s,1,
AUC Npo,,1,
Increase in heart rate,beats min-1,1,
TdeltaS,10^2kJ/mol,1,
Increase in heart rate,%,1,
Cp(T),ug ml-1,1,
Increase in heart rate,,1,
Temperature change,(degrees C)-1,1,
Increase in blood pressure,,1,
Cmax,ug/ml.hr,1,
Inhibition,cm,1,
Cp(f)/dose,nM/mg/kg,1,
Hypnosis duration,,1,
Vmax,10'3mmol/min/mg,1,
I30,uM,1,
I13,uM,1,
I10,M,1,
Oral activity,ml min-1,1,
Oral activity,%,1,
Vmax,L/Kg,1,
Drug metabolism,10'-4/s,1,
Optimal dosage,,1,
Hypoglycemic,,1,
Drug metabolism,10'-2/s,1,
Vmax,10'-8M/s,1,
Hydrolysis rate constant,t/2,1,
CFU,10^6/g,1,
Opsin shift activity,,1,
Vmax,deltaOD/hr,1,
Anesthesia duration,,1,
Vmax,10'7U/min,1,
Anti-HIV activity,,1,
AUC,min.ng/g,1,
I42,uM,1,
Vdss,mg/L,1,
Vmax,10'-8cpm/min,1,
Vmax,10'-7mol/s,1,
LC50,10'-13 ug/ml,1,
T/C @ 40mg/kg,%,1,
TID20,mg kg-1,1,
Boron incorporation,ug,1,
Brain level,nM,1,
Brain level,,1,
LC25,ppm,1,
Brain concentration,uM,1,
Inhibition,umol,1,
Phototoxicity,mg kg-1,1,
Inhibition (500 ÂµM),%,1,
Brain level,%,1,
LOAEL,ml/kg,1,
Vmax,10'-6mol/s,1,
Cp,ml/kg,1,
I28,uM,1,
I23,M,1,
I20,uM,1,
Vmax,10'-2umol/min/U,1,
Antagonist efficacy,%,1,
I16,uM,1,
Oral dose,mg kg-1,1,
Drug metabolism,10^-2/s,1,
Vmax,10'-6deltaA/s,1,
AUClast,ng/hr,1,
MIC,ucm,1,
K,10^-1(1/Ms),1,
-Log Kb,,1,
logP,c.p.m.,1,
pKa BZ,,1,
pKa BN,,1,
pKa AZ,,1,
pKa AN,,1,
MTD,mg/g,1,
NBT reduction,%,1,
MLD50,,1,
Maximal activation,uM,1,
EC50,10'8PFU,1,
WCC90,ug ml-1,1,
HD40,mg kg-1,1,
Max delta BP,mg kg-1 p.o.,1,
No. of rats died,,1,
CL,min.ug/ml,1,
EC50,nM kg-1,1,
Edema,uM,1,
Cl-,,1,
M.A.D,,1,
CL,min,1,
Edema inhibition,,1,
ED50,uM ear-1,1,
EC50,nM g-1,1,
pKa E2,,1,
pEC50,uM,1,
logP,10'-2No_unit,1,
fCmax,ng/g,1,
deltaS,kcal/mol,1,
EC37,%,1,
MHC,10'-5M,1,
CLH,ml/min/10^6cells,1,
pKP,,1,
Activity,ug.hr/ml,1,
MHC,10'-6M,1,
fCmax,nmol/L,1,
2x PT,,1,
2X PT,,1,
-Log LC50,,1,
MITC95,,1,
ED35,ng,1,
Cmin,nmol/L,1,
F,ml/min.kg,1,
k1,,1,
fCmax,nmol/ml,1,
MEC,nmol/L,1,
MTD,ng,1,
pKa(1),,1,
MED50,uM,1,
Delta IOP,,1,
Activity,pg/uL,1,
Change in systolic pressure,,1,
CL,micromol.hr/L/mg/kg,1,
Max reduction,mg kg-1,1,
Cl,ml hr-1,1,
MAD,10'-2microL,1,
Chemosensitizing activity,mg l-1,1,
CO,uM,1,
pka,M-1,1,
ppKb,,1,
AUC,hr.nmol/g,1,
WCC99.9,uM,1,
Diuretic activity,(m equiv [Na+]) kg-1,1,
Cmax_triphosphate,uM,1,
CL,lL/min/million,1,
EC50,10'10PFU,1,
CL,kg-1 hr-1,1,
ED,umol/Kg,1,
CL,ml,1,
ED 50,,1,
Change of body weight,,1,
Activity,pg/dl,1,
Activity,fM,1,
ED Arec,,1,
Max contractile activity,mg,1,
kobs,,1,
pinhibition,%,1,
kmax/KS,M-1 s-1,1,
EC90,mg/ml,1,
EC90,microM,1,
Activity,dyn.s.cm'-5.10'4,1,
Vss,L/m2,1,
solubility,10'-1mg/ml,1,
EC50,mmol/Kg,1,
ECMax,uM,1,
pBBB,10'-3cm/s,1,
Cmedia,ug of B g-1,1,
Activity,ul g-1,1,
tCmax,hr,1,
ECmax,mg kg-1,1,
Vss/F,,1,
MAD,10'-4microL,1,
Vss/F,L,1,
ECmax,ng/ml,1,
Activity,pg/ug,1,
pBBB,cm/s,1,
solubility,10'-1mol/L,1,
Ea,kcal/mol,1,
Diuretic activity,(m equiv [Na+]) 5hr-1 kg-1,1,
food intake,g mouse-1 day-1,1,
kmax,s-1,1,
Effllux,min-1,1,
deltaS,J/mol,1,
MEC,pM,1,
Max cAMP,,1,
Diameter of inhibition zone,diameter mm,1,
Food intake,g 5mice-1 5days-1,1,
duration of action,hr,1,
MHC,10'-4M,1,
Concentration,PuM,1,
ED60,mM,1,
pH50,,1,
EC50H,nM,1,
max activation,pmol/mg/min,1,
Mean effective dose,,1,
pH,ml 4hr-1,1,
1/2Kcat/Km,M-1 s-1,1,
max activation,pmol,1,
ED50,10'1 ug/ml,1,
Fmean,%,1,
ED58,,1,
pGI50,uM,1,
Concentration,mequiv/L,1,
ED50,10'-8mol,1,
Fluoroscence,,1,
fAUC/dose,hr.Kg/L,1,
Fold IC50,,1,
CL/F,(mg/kg)/(microg/ml)/hr,1,
MED,mmol/Kg,1,
MTC,%,1,
MEC2.0,uM,1,
Fluorescence,,1,
ED50,DIUR,1,
MED,ug min-1 kg-1,1,
EC50,ucm/s,1,
Cmin,ng/g,1,
mequiv of Na+/kg,,1,
ED50,10'-1umol/L,1,
MED,g/Kg,1,
ED70,ug/kg,1,
Median,%,1,
ED75,,1,
-TdeltaS,J/mol.K,1,
ED5,umol/Kg,1,
ED50 / ED50 (taxol),nM,1,
CLH,ml/mg,1,
ALP_CHANGE_TO,,1,
Activity,nM/g,1,
Net cell kill,,1,
MLD,ug/kg,1,
deltaTm,Â°C,1,
Net body weight delta,g,1,
MLC,mg/ml,1,
MEC1.5,uM,1,
MEC2.0,nM,1,
Activity,ug cm**-2 hr-1,1,
ED50,10^-5 ug/ml,1,
Activity,l hr-1 kg-1,1,
Conc_brain,,1,
EC70,mg kg-1,1,
Activity,pKa,1,
Cmin,ug/g,1,
ED25,ug ml-1,1,
Control,ng ml-1,1,
2xAPTT,,1,
Fu,%ID,1,
ED25,pmg kg-1 day-1,1,
MEC,g/ml,1,
Delta non HDL-C,%,1,
No effective/ no. tested,,1,
k12,/hr,1,
MTD,ug/m2/day,1,
deltaA,degrees C,1,
Fu,nmol/Kg,1,
CL,umol/min/mg,1,
3.3,uM,1,
Dmax,%,1,
Fu,microg.hr/mL,1,
deltaG,10^2kJ/mol,1,
Control,pfu/ml,1,
Change of weight,g mouse-1,1,
Activity,micromol/dl,1,
AD50,umol/Kg,1,
FC,10'-4No_unit,1,
CL-renal,mL/min,1,
AD90,ug/kg,1,
f %t > MIC,%,1,
fAUClast,uM.hr,1,
CL(app),L/min,1,
fAUC,mg/L,1,
fAUC,nM,1,
EC50L,nM,1,
CL-renal,L/hr,1,
MST,MST,1,
Med tumor area,mg,1,
eduction,%,1,
Cholesterol,mg kg-1 diet,1,
APA,ms,1,
Activity,nM/10e6,1,
pK3',,1,
deltaH,10'4cal/mol,1,
deltaH,10^3kJ/mol,1,
fCmax,umol/L,1,
1/Km,10'2/M,1,
Control,mg kg-1,1,
Dissociation,,1,
CS50,,1,
Activity,mg/kg/hr,1,
WBC,10E3/mm3,1,
K,10'8Lmol,1,
GTPshift,,1,
MIC,M-1,1,
permeability,10'-6cm2/s,1,
MIC,IU/ml,1,
Change in corpora lutea,,1,
Margin before onset of tachycardia,mg kg-1,1,
MBIC100,ug ml-1,1,
Activity,mN,1,
Emesis_ED,mg kg-1,1,
fc max,mg L-1,1,
DeltaBP,,1,
Concentration in serum,,1,
Control current,,1,
Activity,uCi/ml,1,
Emax,ug/kg,1,
ERH,nM,1,
AD,,1,
% dose,%,1,
ED50,ug animal-1,1,
CMI,ug ml-1,1,
EC50,mM/L,1,
% inhibition in bone-marrow,%,1,
EC24,uM,1,
ED50,nM animal-1,1,
AD50,day,1,
Control at the dose of 5.0microg/mouse,%,1,
ED100,ug day-1 kg-1,1,
EC25(unbound),nM,1,
Activity,pM/min/ml,1,
CLr,L/hr,1,
CL/F,ug.hr/ml,1,
[3H] thymidinecpm/dish,,1,
Concentration,ug min-1 kg-1,1,
AT1 affinity,,1,
ED15,%,1,
Delta beats/min,,1,
Dose/g,,1,
MIC,10^-6 uM,1,
10E2 K1,min-1,1,
CL_renal,l/h,1,
Cmax_triphosphate,pmol/10^6cells,1,
Margin before onset of hypokalemia,mg kg-1,1,
ED50,mg/cm2,1,
% of Control Agonist Response,%,1,
ED14.5,ug/kg,1,
permeability,10'-6/s,1,
A ctivity,,1,
Adverse effect,,1,
Efficacy,mg/dl,1,
AUBC,ng.hr/ml,1,
Glucose lowering relative to positive control,%,1,
MIC,ucm/s,1,
Glucose lowering ob/ob dose,mg kg-1,1,
permeability,microg/cm2,1,
AUC,10^6nM,1,
AD100,mg kg-1,1,
% inhibition in liver,%,1,
permeability,cm/min,1,
ED50,ml/kg,1,
ED100,mg,1,
HD50,umol/Kg,1,
EC50,10'-2mol%,1,
EmaxL,%,1,
Activity,um3.um2/day,1,
Catalase rate,,1,
Alpha Ki,,1,
Max IOP reduction,,1,
AUC,L/hr.Kg,1,
Control at the dose of 50.0microg/mouse,%,1,
Weight increase,%,1,
Concentration,ug of B/ml,1,
washout,%,1,
ED100,M,1,
Activity,mmol.h/L,1,
EmaxH,%,1,
Cmax/Tmax,hr,1,
Glucose,mg dl-1,1,
log(activity),/min,1,
AC30,%,1,
permeability,pmol/min,1,
Drug,nM (mg of protein)-1,1,
MIC,ug.hr/ml,1,
Activity,ml/cm,1,
kinact,uM,1,
AE score,%,1,
No_cures,,1,
Co,ng ml-1,1,
EC91,nM,1,
EC90,nmol/L,1,
ED10,,1,
Agonism inflection point,nM,1,
Molar ratio,,1,
k cat,*10e-3,1,
permeability,nmol/sec,1,
Weight change,T-C,1,
Weight (mg/g),%,1,
Displacement,nM,1,
Max MBP,,1,
NOAEL,ng/kg,1,
Glucose level,%,1,
AC30,,1,
ED50,mmol,1,
Concentration in Brain,,1,
ED100,pmol,1,
permeability,ug/cm2.hr,1,
ET-1 level,pg ml-1,1,
AC50,hr.nmol/L,1,
Effective dose,ug kg-1,1,
EC98,uM,1,
t1/2,microsec,1,
EC98.6,nM,1,
Loss of activity,,1,
CL,mg kg-1,1,
CL,mL.min,1,
Activity,log10pfu/g,1,
CL,mg/kg/microM.hrs,1,
% Inhibition of Control Agonist Response,%,1,
No. of survivors,48h,1,
solubility,10'-7mol,1,
solubility,10'-8mol,1,
Lowering activity,,1,
Emax,10'-1/hr,1,
MIC97,ug ml-1,1,
EC200,,1,
solubility,10'3ug/ml,1,
MNTD,mg,1,
log Pe,10^-6 cm/s,1,
log(1/ID50),uM,1,
MIC95,mg/L,1,
Dispacement,%,1,
log Kp,10'-6 cm/s,1,
AC50,g/dl,1,
log(1/IC50),mM,1,
solubility,10'-2g,1,
Cholesterol,,1,
Drug degradation,10'-5/s,1,
CL,mg/hr/kg,1,
solubility,ug/kg,1,
MPC,ng/ml,1,
NOAEL,mg Kg-1,1,
Min lytic concentration,,1,
hSlo current,,1,
EC50,10'-3 ug/cm2,1,
NOAEL,mg,1,
t1/2,ug.hr/ml,1,
EC99,mg/ml,1,
Eggs,,1,
t1/2eff,,1,
Effective dose,M,1,
Drug degradation,10'-6/hr,1,
EC50,mgAi,1,
AC50,mg,1,
MPA,,1,
t1/2(app),,1,
Activity,ng/min/dl,1,
Change non HDL-C,,1,
ECG,,1,
Vp/F,L/hr,1,
A0.5,,1,
Gastric emptying,,1,
XI50,nM,1,
Delta SBP,,1,
Activity,pg.hr/ml,1,
AUC,0-tldc,1,
MBC99,mM,1,
MIC=<90,uM,1,
Gain,,1,
ER/PR,,1,
Gastric lesions,,1,
pCB,,1,
Activity,mean,1,
% inhibition in spleen,%,1,
permeability,10^-6cm/min,1,
ka,10^5L/mol,1,
permeability,10^-6m/s,1,
Max APD95,%,1,
permeability,10^-8cm/s,1,
Generalization,,1,
Mean maximumtemp drop,degrees C,1,
CMC,umol/dm3,1,
2PT,nM,1,
Concentration of Cl-,m equiv 6hr-1 kg-1,1,
XL50,nM,1,
AlDH activity,nM min-1,1,
CL_biliary,%,1,
g/mouse,,1,
Max inhibition,uM,1,
solubility,ppb,1,
solubility,mmol/ml,1,
EC99,ng/ml,1,
MIC82,uM,1,
AC50,g,1,
solubility,ug,1,
Control level,ng ml-1,1,
CL_biliary,ml/min.kg,1,
Activity,deltalog10/ml,1,
MBC99,ug ml-1,1,
EC50,10'-6microg/cm2,1,
EC99.6,uM,1,
Volume reduction,%,1,
DeltaCp,,1,
t1/2/dose,hr,1,
135,nM,1,
Min concentration,,1,
Monomer,%,1,
EC50,10'-2mg/ml,1,
Gastric concentration,,1,
ED50,10'-13mol,1,
CL_renal,mL/min/1.73 m2,1,
N/D,,1,
K,10'11/M,1,
Kin,10'-5ml/s/g,1,
Cures@ 20mg/kg,,1,
Kin,min-1,1,
Cures@ 10mg/kg,,1,
K3,s-1,1,
Activity,10'6PFU,1,
K2,mM,1,
K1,s-1,1,
SUV,nCi/cc,1,
KA,10'8/M,1,
SUVmax,kBq/cm3,1,
Activity,10'6log10CFU/ml,1,
Kinact,/M/s,1,
AUMC,,1,
Cures,day,1,
Saldiuretic activity,(m equiv) 6hr-1 kg-1,1,
Saline control,,1,
Activity,10'7/M,1,
Kinact,10'-5/s,1,
Kinact,10'-7/s,1,
K-1,1/min,1,
K+2/Ki,,1,
Kinact,10'-8/s,1,
Kin,10'-3ml/s/g,1,
RBC,10E6/mm3,1,
Cures@ 40 mg/kg,,1,
Drugabsorption,ml/hr/kg,1,
Css min,ng/mL,1,
K,10'10/M,1,
Css min,mcg/mL,1,
Pm,10^-6 cm/s,1,
AUC/dose,uM.hr/ml,1,
Pm,ucm/s,1,
K,10'-6/hr,1,
K,10'-7/M,1,
K,10'-7/nM/min,1,
Kq,10'6No_unit,1,
K,10'-8No_unit,1,
RBC,10e-6ul-1,1,
K,10'1/M/s,1,
K,10'1/mol/s,1,
AUC/dose,uM/hr/Kg/mg,1,
Survivors,mg kg-1,1,
K,10'1/s,1,
Bmax,fM bound (mg of protein)-1,1,
K,10^7No_unit,1,
Km app,rel,1,
Ct,uM/L,1,
RBC,10e3 ul-1,1,
K+2,,1,
Kinact,10'-9M,1,
KinX,hr-1,1,
"K(p,uu,brain)",%,1,
RC50,10'-5mg/ml,1,
SEC50,10'-8M,1,
SEC50,10'-10M,1,
SDS,,1,
KA,uM l-1,1,
KB,10'3/M,1,
SD90,,1,
Binding constant,1/M,1,
Kinact,10'2/M/s,1,
Kinact,10'2/s,1,
Protection,mg kg-1,1,
KA,10^8/M,1,
Drug uptake,ug.min/g,1,
Bleeding time,uM,1,
Ctau,ug ml-1,1,
Activity,10'9/ml,1,
K act,nM,1,
Sleep latency,%,1,
K act,M-1 s-1,1,
Kiuc,10'3nM,1,
Prolonged QT,,1,
K H,%,1,
Second order,M s-1,1,
KA,10^4/M,1,
Kin,/min,1,
KD hydro,,1,
Cures@ 40mg/kg,,1,
KA,10^-3/M,1,
KH,M,1,
AUMCt,ug.hr2/L,1,
KH,%,1,
"S20,w",s,1,
Ki/ki,uM,1,
Activity,10'5L/mol,1,
KD non ionic,mM,1,
Ki0,nM,1,
KBp,,1,
AUMC,ug.hr2/L,1,
REM latency,,1,
KB1,,1,
SC50,ng/ml,1,
KB,mg kg-1,1,
SCW reduction,%,1,
RD500,ug kg-1,1,
DIZ,ug ml-1,1,
Killed,%,1,
Cures@ 80 mg/kg,,1,
KA,10^-4/M,1,
K,10'10/s,1,
Kq,10^14/M/s,1,
pED50,mg kg-1,1,
K,10'1mol/dm3/s,1,
Pressure response,%,1,
Kobs,uM,1,
Stability,%/min,1,
Pressor response,,1,
K,10^3No_unit,1,
K,10^3L/mol,1,
Pressor activity,%,1,
AUCss(tau) normalised,(nmol.h.L-1)/(mg/kg),1,
Kon,10e3* M-1 s-1,1,
Ct,pg/ml,1,
AUClast/dose,ug.hr/ml,1,
Average score,%,1,
Stability,microg.min/mL,1,
K,10^-5/min,1,
AUClast,ug.min/g,1,
K,10^-6No_unit,1,
DNA single strand breaks,,1,
K,10^-8/M/s,1,
Potentiation inflection point,uM,1,
Bmax,10'-6pmol,1,
Kp,ml/min/g,1,
K,10^10No_unit,1,
K,10^2/M,1,
Spontaneous reperfusion,%,1,
K,10^5/min/M,1,
K,10^5/s,1,
Kq,10'13/mol/s,1,
K,10'7L/mol,1,
K,10'7/mol,1,
Activity,10^-11M,1,
Stimulation,uM,1,
Stimulatory activity,%,1,
Stimulatory effect,nM min-1 (mg of protein)-1,1,
Activity,10^-5No_unit,1,
K,10'6/nM/min,1,
Kq,10'11L/mol.s,1,
Kq,10'12L/mol.s,1,
Blood volume,HB g ml-1,1,
K,10^5No_unit,1,
Activity,10^-6M,1,
K,10'5/mol,1,
Kq,10'14/M/s,1,
Kq,10'4L/mol,1,
Kq,10'4No_unit,1,
Suppression of parasitemia,,1,
Drug uptake(free),ug/g,1,
K,10^-3No_unit,1,
Activity,10'9CFU/ml,1,
Stability,pM/mg/hr,1,
Kp,10^-5cm/hr,1,
K,10^2/M/min,1,
K,10^2/Ms,1,
K,10'-5L/mol,1,
Ks,10'4/M,1,
AUC/dose,ngequiv.hr/ml/mg,1,
Bmax,pg/mm2,1,
T/C,g,1,
T/C,log10,1,
Cell density,cells ml-1,1,
Plasma_triglyceride,%,1,
Bmax,pmol/g,1,
Platelet count,10e3 ul-1,1,
K,10'-53No_unit,1,
Average peak Concn,ug ml-1,1,
K,10'-10No_unit,1,
Activity,10^-9M,1,
Survival,10'3CFU/ml,1,
Activity,10^1/mm2,1,
K,10'3mol/dm3/s,1,
K,10'3/s/M,1,
Bmax,fM,1,
Activity,10^2CFU/ml,1,
Survival dose,,1,
K,10'2/M/min,1,
Activity,10^3/M,1,
K,/s/microM,1,
K,10'-11M,1,
K,10^2No_unit,1,
Bmax,fmol/ug,1,
K,10^1/M/s,1,
Kmax,/hr,1,
K,10'4/s/M,1,
AUClast,nM,1,
Synergistic effect,,1,
Cmax,ug m-1 min-1,1,
K,10'-51No_unit,1,
K,10'-5/s/nM,1,
K,10'-5/hr,1,
Systolic blood pressure,SBP,1,
K,10'-3No_unit,1,
T-cell,,1,
Kr,nM,1,
K,10'-3/M/s,1,
K,10'-2M,1,
K,10'-2/s/M,1,
K,10'-2/nM/min,1,
Drugabsorption,pmol,1,
Pm,/ml,1,
T max,mg kg-1,1,
K,10'-18No_unit,1,
K,10'-12/min,1,
K B,nM,1,
Smax,IU/ml/hr,1,
Km,/min,1,
K,nM/min,1,
Dose per organ,,1,
log10CFU/ml,mg/L,1,
k cat,hr-1,1,
Actvity,,1,
CL,nM/min/mg,1,
fKi,uM,1,
% reduction,%,1,
pWeight change,,1,
CLt/F,,1,
EC50,PuM,1,
Delta F75,,1,
MCC50,mM,1,
MTT,hr,1,
AD50,ng,1,
% reduction,,1,
MC100,uM,1,
MPE,uM,1,
fMEC,ng/ml,1,
MIC,10^-3micromol/ml,1,
Enoyl-CoA hydratase,uM min-1 (mg of protein)-1,1,
EC80,mgAi,1,
MTT,mg/ml,1,
Activity,pM/min/mg,1,
MC100,ug ml-1,1,
GI clearence,,1,
nKa,mM-1,1,
CL,ug/ml/hr,1,
Change in ovarian follicular atresia,,1,
n/N,/ 7,1,
CLH,uL,1,
delta T,K,1,
ED90,kg/ha,1,
EC50,10^-6 uM,1,
GC200 [d],%,1,
Cmax/dose,nmol,1,
NOL,mg kg-1,1,
Median toxicity,mg kg-1,1,
k2/Ki,,1,
Fez,%,1,
APD95,,1,
G1,,1,
NOL,ug kg-1,1,
Compound recovery,ug ml-1,1,
MEC,10'-7M,1,
EC50,ug hr ml-1,1,
ED50,umol/g,1,
Cmin(1),nmol.L-1,1,
MEC,10'-8M,1,
Cmax/dose,ngequiv/ml/mg,1,
[Ca2+],nM,1,
MIC,10'4pg/ml,1,
MLC,pug ml-1,1,
ED2,uM,1,
CTD50,ug ml-1,1,
CL,ng/min/kg,1,
Mortality ratio,,1,
CMC,mmol/dm3,1,
Activty,%,1,
Equieffective dose,,1,
%AUC,%,1,
%Bound_Albumin,%,1,
CLH,umol/min/kg,1,
%Cleared,%,1,
pRatio,,1,
CL,ng/ml/hr,1,
GI75,nM,1,
GI50/EC50,uM,1,
CLt/F,L/hr,1,
average log GI50,M,1,
Cmin(ss),nmol.L-1,1,
Mortality,nM,1,
CLH,mg/kg/min,1,
ED90,1/mg.1/kg.1/day,1,
MLC,ml/min.kg,1,
MED,M,1,
Activity,uM kg-1 s.c.,1,
Cl,l hr-1,1,
MIC=>90,mg/ml,1,
CTD50,mM,1,
kOH-,,1,
Compound in urine,%,1,
ED2,Na2,1,
fMEC,nM,1,
GR control,%,1,
MIC,10'-4nmol,1,
%Remaining,%,1,
EFF+/-SD,%,1,
alphaKi,mM,1,
Dose non renally cleared,%,1,
pMax,%,1,
fIC80,nM,1,
beta t1/2,%,1,
k3/ki,,1,
CLH,umol/min/g,1,
behavioral observation,,1,
GI50,PuM,1,
No. of axonal branchpoints/cell,,1,
GI50,10^3nM,1,
GI50,10'-8cm/s,1,
GI tolerance,,1,
MRC,mg kg-1,1,
30 day survival/total,,1,
EC70,ng/ml,1,
pKb(app),,1,
Drug uptake,uM/L,1,
Selectivity in binding,,1,
AUCt/dose,ng.hr/ml/mg,1,
QH,ml/min,1,
Selectivity index,Monkey,1,
QH,L/min,1,
Kinact,10^-2microM,1,
Kinact,10^-4/min,1,
QH,L/Kg,1,
K inact/Ki,10e4 M-1 s-1,1,
QA,,1,
K cat/Km,1/M.s,1,
Curative Index,%,1,
Activity,10'7PFU/ml,1,
Protein,,1,
Protein bound,%,1,
AUCt/dose,,1,
K inact,M-1 min-1,1,
K cat/Km,1/M*s,1,
Kinact,mV,1,
Drug uptake,uM/ml,1,
Kinact,10^4nM,1,
Kinact,10^4/s,1,
K obs,mM,1,
Selectivity Index,uM,1,
Cumulative dose,mM kg-1,1,
K,M-2,1,
Prolongation,,1,
Km,10'-4M/min,1,
K,10^9/M/min,1,
Specific incorporation,,1,
K,10e4min-1,1,
Specific binding,,1,
Km,ng/ml,1,
Specific activity,uM Pi/min/mg protein,1,
Activity,10'8/ml,1,
Km,min-1,1,
K,fM,1,
K obs / s,,1,
Prolactin release,ng mg-1 hr-1,1,
AUCt,ml/min.kg,1,
Blood Pressure,,1,
K,microM/s,1,
Progressed tumors,,1,
HDL-C change,,1,
K cat,1/sM,1,
Drug transport,%ID,1,
Kinact,10'4nM,1,
AUCt/dose,ngequiv.hr/ml/mg,1,
K inact/I,M-1 s-1,1,
Selectivity ratio,uM,1,
fCmin,ng/ml,1,
pDelta IOP,mmHg,1,
k3/K1,uM,1,
MTL,,1,
GI,10'-7M,1,
ED20,ug/kg,1,
pMEC,,1,
GI,10'-6M,1,
EC50,pnM,1,
GI,%/hr,1,
ED97,,1,
EC70,uM,1,
APD95,uM,1,
ED50,mg g-1 day-1,1,
Cmax/dose,ng/ml/mg,1,
k21,/hr,1,
Full inhibition,uM,1,
Fu,umol/L,1,
CLH,uL/hr,1,
delta Vmax,%,1,
ED25,10'-9M,1,
Activity,mCi/M,1,
EC50,10'6pM,1,
APD,%,1,
Cmin(80hr),pg/mL,1,
AFLCl,ms,1,
Average weight gain,,1,
MRT,ng/ml,1,
Cataleptic effect,,1,
BNa,,1,
ED19.5,ug/kg,1,
Activity,kJ/cm2,1,
logD,,1,
CPmax,ng ml-1,1,
Change in entry latency,,1,
CL,uM.hr,1,
Compound recovery,ml/hr,1,
CPmax,,1,
Activity,kT/e,1,
GI,ng/ml,1,
logD7.5,,1,
CL,ug/hr,1,
5-HT Level,%,1,
Contractility,mg kg-1,1,
ED25,10'-11M,1,
CL,ug.hr/ml,1,
MDH Reactivation,,1,
%max,ng/ml,1,
EC50,10'-1ppm,1,
FRP at 10microM,%,1,
EAUC50,ng.hr/ml,1,
